



US012391933B2

(12) **United States Patent**
Busser et al.

(10) **Patent No.:** US 12,391,933 B2
(45) **Date of Patent:** Aug. 19, 2025

(54) **TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPY**

(71) Applicant: **CELLECTIS**, Paris (FR)

(72) Inventors: **Brian Busser**, New York, NY (US);
Philippe Duchateau, Draveil (FR);
Alexandre Juillerat, New York, NY (US); **Laurent Poirot**, Paris (FR);
Julien Valton, New York, NY (US)

(73) Assignee: **CELLECTIS**, Paris (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **18/540,309**

(22) Filed: **Dec. 14, 2023**

(65) **Prior Publication Data**

US 2024/0141293 A1 May 2, 2024

Related U.S. Application Data

(62) Division of application No. 16/340,222, filed as application No. PCT/EP2017/076798 on Oct. 19, 2017, now Pat. No. 11,873,511.

(60) Provisional application No. 62/410,187, filed on Oct. 19, 2016.

(30) **Foreign Application Priority Data**

Oct. 27, 2016 (DK) PA201670840

(51) **Int. Cl.**

C12N 5/0783 (2010.01)
A61K 35/17 (2025.01)
A61K 40/11 (2025.01)
A61K 40/30 (2025.01)
A61K 40/31 (2025.01)
A61K 40/36 (2025.01)
A61K 40/42 (2025.01)
C12N 5/078 (2010.01)
C12N 9/22 (2006.01)
C12N 15/90 (2006.01)

(52) **U.S. Cl.**

CPC *C12N 9/22* (2013.01); *A61K 40/11* (2025.01); *A61K 40/30* (2025.01); *A61K 40/31* (2025.01); *A61K 40/36* (2025.01); *A61K 40/4203* (2025.01); *A61K 40/4212* (2025.01);
C12N 5/0634 (2013.01); *C12N 5/0638* (2013.01); *C12N 15/907* (2013.01); *A61K 2239/48* (2023.05);
C12N 2510/00 (2013.01); *C12N 2750/14143* (2013.01); *C12N 2830/008* (2013.01)

(58) **Field of Classification Search**

CPC C12N 9/22; C12N 5/0634; C12N 5/0636;

C12N 5/0638; C12N 15/907; C12N 2510/00; C12N 2750/14143; C12N 2830/008; A61K 39/4611; A61K 39/4631; A61K 39/4636; A61K 39/4637; A61K 39/46403; A61K 39/464413; A61K 2239/48; C07K 14/7051; C07K 2319/03

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

10,166,255 B2	1/2019	Moriarity et al.
2013/0315884 A1	11/2013	Galletto et al.
2016/0272999 A1	9/2016	Duchateau et al.
2016/0361359 A1	12/2016	Valton et al.
2017/0065636 A1	3/2017	Moriarity et al.

FOREIGN PATENT DOCUMENTS

WO	WO-2014191128 A1	*	12/2014	A61K 35/17
WO	2015075195 A1		5/2015		
WO	2016124765 A1		8/2016		
WO	WO-2017023803 A1	*	2/2017	A61K 35/00

OTHER PUBLICATIONS

Fesnak, A.D., June, C.H. and Levine, B.L., 2016. Engineered T cells: the promise and challenges of cancer immunotherapy. *Nature reviews cancer*, 16(9), pp. 566-581. (Year: 2016).*

Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M. and Brentjens, R.J., 2012. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. *Blood, The Journal of the American Society of Hematology*, 119(18), pp. 4133-4141. (Year: 2012).*

Austin, J.W., Lu, P., Majumder, P., Ahmed, R. and Boss, J.M., 2014. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. *The Journal of Immunology*, 192(10), pp. 4876-4886. (Year: 2014).*

(Continued)

Primary Examiner — Christopher M Babic

Assistant Examiner — Masudur Rahman

(74) *Attorney, Agent, or Firm* — ARRIGO, LEE,
GUTTMAN & MOUTA-BELLUM LLP

(57) **ABSTRACT**

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

15 Claims, 16 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**OTHER PUBLICATIONS**

Chu et al., Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL/6 Cas9 transgenic mouse line, PNAS, Nov. 1, 2016 , vol. 113, No. 44, 12514-12519.

Sather et al., Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template, Sci Transl Med. Sep. 30, 2015; 7(307):1-29.

Wang et al., Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors, Nat Biotechnol. Dec. 2015 ; 33(12): 1256-1263.

Rongvaux et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proceedings of the National Academy of Sciences. 2011, 108(6), 2378-83.

Willinger et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proceedings of the National Academy of Sciences. Feb. 8, 2011; 108(6): 2390-5. (Year: 2011).

Willinger et al. Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends in immunology, 2011, 32(7), 321-7.

Fesnak et al. Engineered T cells: the promise and challenges of cancer immunotherapy. Nature reviews cancer, 2016, 16(9), 566-81.

Chmielewski et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res, 2011, 71, 5697-706.

Pegram et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood, The Journal of the American Society of Hematology. 2012, 119(18), 4133-41.

Austin et al. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. The Journal of Immunology, 2014, 192(10), 4876-86.

Bally et al. Genetic and epigenetic regulation of PD-1 expression. The Journal of Immunology. 2016, 196(6), 2431-7.

Tsai et al. Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors, Oncoimmunology, 2016, 5(5), e1122158.

* cited by examiner




Figure 1




Figure 2




Figure 3



A**B**

Figure 4




Figure 5




Figure 6




Figure 7

Endogenous CD25 expression

+ TALEN® TRAC and TALEN® CD25




Figure 8



A**B**

Figure 9




Figure 10




Figure 11




Figure 12





Figure 13

B



A




Figure 14



B**A**

Figure 15



A**B**

Figure 16

TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPY

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 16/340,222 filed on Apr. 8, 2019, which is a U.S. Natl. Stage of International Application PCT/EP2017/076798 filed Oct. 19, 2017, which claims the benefit of U.S. provisional application 62/410,187 filed Oct. 19, 2016, and Danish Application PA201670840 filed Oct. 27, 2016.

REFERENCE TO SEQUENCE USING SUBMITTED ELECTRONICALLY

The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on Dec. 13, 2023, is named D12016-11US2_SL.xml and is 215,538 bytes in size.

FIELD OF THE INVENTION

The invention pertains to the field of adaptive cell immunotherapy. It aims to enhance the functionality of primary immune cells against pathologies that develop immune resistance, such as tumors, thereby improving the therapeutic potential of these immune cells. The method of the invention provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are up or downregulated upon immune cells activation, upon tumor microenvironment or life threatening inflammatory conditions or promoters that are insensitive to immune cells activation. The invention also provides with sequence-specific endonuclease reagents and donor DNA vectors, such as AAV vectors, to perform such targeted insertions at said particular loci. The method of the invention contributes to improving the therapeutic potential and safety of engineered primary immune cells for their efficient use in cell therapy

BACKGROUND OF THE INVENTION

Effective clinical application of primary immune cell populations including hematopoietic cell lineages has been established by a number of clinical trials over a decade against a range of pathologies, in particular HIV infection and Leukemia (Tristen S. J. et al. (2011) Treating cancer with genetically engineered T cells. *Trends in Biotechnology*. 29(11):550-557).

However, most of these clinical trials have used immune cells, mainly NK and T-cells, obtained from the patients themselves or from compatible donors, bringing some limitations with respect to the number of available immune cells, their fitness, and their efficiency to overcome diseases that have already developed strategies to get around or reduce patient's immune system.

As a primary advance into the procurement of allogeneic immune cells, universal immune cells, available as "off-the-shelf" therapeutic products, have been produced by gene editing (Poirot et al. (2015) Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies *Cancer Res.* 75: 3853-64). These univer-

sal immune cells are obtainable by expressing specific rare-cutting endonuclease into immune cells originating from donors, with the effect of disrupting, by double strand-break, their self-recognition genetic determinants.

Since the emergence of the first programmable sequence-specific reagents by the turn of the century, initially referred to as Meganucleases (Smith et al. (2006) A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. *Nucl. Acids Res.* 34 (22):e149), different types of sequence-specific endonucleases reagents have been developed offering improved specificity, safety and reliability.

TALE-nucleases (WO2011072246), which are fusions of a TALE binding domain with a cleavage catalytic domain have been successfully applied to primary immune cells, in particular T-cells from peripheral blood mononuclear cell (PBMC). Such TALE-nucleases, marketed under the name TALEN®, are those currently used to simultaneously inactivate gene sequences in T-cells originating from donors, in particular to produce allogeneic therapeutic T-Cells in which the genes encoding TCR (T-cell receptor) and CD52 are disrupted. These cells can be endowed with chimeric antigen receptors (CAR) for treating cancer patients (US2013/0315884). TALE-nucleases are very specific reagents because they need to bind DNA by pairs under obligatory heterodimeric form to obtain dimerization of the cleavage domain Fok-1. Left and right heterodimer members each recognizes a different nucleic sequences of about 14 to 20 bp, together spanning target sequences of 30 to 50 bp overall specificity.

Other endonucleases reagents have been developed based on the components of the type II prokaryotic CRISPR (Clustered Regularly Interspaced Short palindromic Repeats) adaptive immune system of the bacteria *S. pyogenes*. This multi-component system referred to as RNA-guided nuclease system (Gasiunas, Barrangou et al. 2012; Jinek, Chylinski et al. 2012), involves members of Cas9 or Cpf1 endonuclease families coupled with a guide RNA molecules that have the ability to drive said nuclease to some specific genome sequences (Zetsche et al. (2015). Cpf1 is a single RNA-guided endonuclease that provides immunity in bacteria and can be adapted for genome editing in mammalian cells. *Cell* 163:759-771). Such programmable RNA-guided endonucleases are easy to produce because the cleavage specificity is determined by the sequence of the RNA guide, which can be easily designed and cheaply produced. The specificity of CRISPR/Cas9 although stands on shorter sequences than TAL-nucleases of about 10 pb, which must be located near a particular motif (PAM) in the targeted genetic sequence. Similar systems have been described using a DNA single strand oligonucleotide (DNA guide) in combination with Argonaute proteins (Gao, F. et al. DNA-guided genome editing using the *Natronobacterium gregoryi* Argonaute (2016) doi:10.1038/nbt.3547).

Other endonuclease systems derived from homing endonucleases (ex: I-Onu1, or I-CreI), combined or not with TAL-nuclease (ex: MegaTAL) or zing-finger nucleases have also proven specificity, but to a lesser extend so far.

In parallel, novel specificities can be conferred to immune cells through the genetic transfer of transgenic T-cell receptors or so-called chimeric antigen receptors (CARs) (Jena et al. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. *Blood*. 116:1035-1044). CARs are recombinant receptors comprising a targeting moiety that is associated with one or more signaling domains in a single fusion molecule. In general, the binding moiety of a CAR consists of an antigen-binding domain of

a single-chain antibody (scFv), comprising the light and heavy variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully. The signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains. First generation CARs have been shown to successfully redirect T cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity in vivo. Signaling domains from co-stimulatory molecules including CD28, OX-40 (CD134), ICOS and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T cells. CARs have successfully allowed T cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors.

Recently engineered T-cells disrupted in their T-cell receptor (TCR) using TALE-nucleases, endowed with chimeric antigen receptor (CAR) targeting CD19 malignant antigen, referred to as "UCART19" product, have shown therapeutic potential in at least two infants who had refractory leukemia (Leukaemia success heralds wave of gene-editing therapies (2015) *Nature* 527:146-147). To obtain such UCART19 cells, the TALE-nuclease was transiently expressed into the cells upon electroporation of capped mRNA to operate TCR gene disruption, whereas a cassette encoding the chimeric antigen receptor (CAR CD19) was introduced randomly into the genome using a retroviral vector.

In this later approach, the steps of gene inactivation and of expressing the chimeric antigen receptor are independently performed after inducing activation of the T-Cell "ex-vivo".

However, engineering primary immune cells is not without any consequences on the growth/physiology of such cells. In particular one major challenge is to avoid cells exhaustion/anergy that significantly reduces their immune reaction and life span. This is more likely to happen when the cells are artificially activated ahead of their infusion into the patient. It is also the case when a cell is endowed with a CAR that is too reactive.

To avoid these pitfalls, the inventors have thought about taking advantage of the transcriptional regulation of some key genes during T-cell activation to express exogenous genetic sequences increasing the therapeutic potential of the immune cells. The exogenous genetic sequences to be expressed or co-expressed upon immune cell activation are introduced by gene targeted insertion using sequence-specific endonuclease reagents, so that their coding sequences are transcribed under the control of the endogenous promoters present at said loci. Alternatively, loci that are not expressed during immune cell activation can be used as "safe-harbor loci" for the integration of expression cassettes without any adverse consequences on the genome.

These cell engineering strategies, as per the present invention, tend to reinforce the therapeutic potential of primary immune cells in general, in particular by increasing their life span, persistence and immune activity, as well as by limiting cell exhaustion. The invention may be carried out on primary cells originating from patients as part of autologous treatment strategies, as well as from donors, as part of allogeneic treatment strategies.

SUMMARY OF THE INVENTION

Non-homologous end-joining (NHEJ) and homology-directed repair (HDR) are the two major pathways used to

repair in vivo DNA breaks. The latter pathway repairs the break in a template-dependent manner (HDR naturally utilizes the sister chromatid as a DNA repair template). Homologous recombination has been used for decades to precisely edit genomes with targeted DNA modifications using exogenously supplied donor template. The artificial generation of a double strand break (DSB) at the target location using rare-cutting endonucleases considerably enhances the efficiency of homologous recombination (e.g. 10 U.S. Pat. No. 8,921,332). Also the co-delivery of a rare-cutting endonuclease along with a donor template containing DNA sequences homologous to the break site enables HDR-based gene editing such as gene correction or gene insertion. However, such techniques have not been widely used in 15 primary immune cells, especially CAR T-cells, due to several technical limitations: difficulty of transfecting DNA into such types of cells leading to apoptosis, immune cells have a limited life span and number of generations, homologous recombination occurs at a low frequency in general.

So far, sequence specific endonuclease reagents have been mainly used in primary immune cells for gene inactivation (e.g. WO2013176915) using the NHEJ pathway.

In a general aspect, the present invention relies on performing site directed gene editing, in particular gene insertion 25 (or multi gene insertions) in a target cell in order to have the integrated gene transcription be under the control of an endogenous promoter.

In a general aspect the invention relies on performing gene editing in primary immune cells to have integrated 30 genes transcription be under the control of an endogenous promoter while maintaining the expression of the native gene through the use of cis-regulatory elements (e.g. 2A cis-acting hydrolase elements) or of internal ribosome entry site (IRES) in the donor template.

In a general aspect the invention relies, as non-limiting examples, on controlling the expression, in primary T-cells, of chimeric antigen receptors (CAR), of critical cytokines to drive an anti-tumor response, of stimulatory cytokines to increase proliferative potential, of chemokine receptors to encourage trafficking to the tumor, or of different protective or inhibitory genes to block the immune inhibition provided by the tumor. Indeed, one major advantage of the present invention is to place such exogenous sequences under control of endogenous promoters, which transcriptional activity 45 is not reduced by the effects of the immune cells activation.

By contrast to previous method for engineering therapeutic immune cells, where for instance an exogenous coding sequence was integrated and expressed at the TCR locus for constitutive gene expression, the inventors have integrated coding sequence at loci, which are specifically transcribed 50 during T-cells activation, preferably on a CAR dependent fashion.

In one aspect, the invention relies on expressing a chimeric antigen receptor (CAR) at selected gene loci that are 55 upregulated upon immune cells activation. The exogenous sequence(s) encoding the CAR and the endogenous gene coding sequence (s) may be co-transcribed, for instance by being separated by cis-regulatory elements (e.g. 2A cis-acting hydrolase elements) or by an internal ribosome entry site (IRES), which are also introduced. For instance, the exogenous sequences encoding a CAR can be placed under transcriptional control of the promoter of endogenous genes that are activated by the tumor microenvironment, such as HIF1a, transcription factor hypoxia-inducible factor, or the 60 aryl hydrocarbon receptor (AhR), which are gene sensors respectively induced by hypoxia and xenobiotics in the close environment of tumors.

The present invention is thus useful to improve the therapeutic outcome of CAR T-cell therapies by integrating exogenous genetic attributes/circuits under the control of endogenous T-cell promoters influenced by tumor microenvironment (TME). TME features, including as non-limiting examples, arginine, cysteine, tryptophan and oxygen deprivation as well as extracellular acidosis (lactate build up), are known to upregulate specific endogenous genes. Pursuant to the invention, upregulation of endogenous genes can be "hijacked" to re-express relevant exogenous coding sequences to improve the antitumor activity of CAR T-cells in certain tumor microenvironment.

In preferred embodiments, the method of the invention comprises the step of generating a double-strand break at a locus highly transcribed under tumor microenvironment, by expressing sequence-specific nuclease reagents, such as TALEN, ZFN or RNA-guided endonucleases as non-limiting examples, in the presence of a DNA repair matrix preferably set into an AAV6 based vector. This DNA donor template generally includes two homology arms embedding unique or multiple Open Reading Frames and regulatory genetic elements (stop codon and polyA sequences) referred to herein as exogenous coding sequences.

In another aspect, said exogenous sequence is introduced into the genome by deleting or modifying the endogenous coding sequence(s) present at said locus (knock-out by knock-in), so that a gene inactivation is combined with transgenesis.

Depending on the locus targeted and its involvement in immune cells activity, the targeted endogenous gene may be inactivated or maintained in its original function. Should the targeted gene be essential for immune cells activity, this insertion procedure can generate a single knock-in (KI) without gene inactivation. In the opposite, if the targeted gene is deemed involved in immune cells inhibition/exhaustion, the insertion procedure is designed to prevent expression of the endogenous gene, preferably by knocking-out the endogenous sequence, while enabling expression of the introduced exogenous coding sequence(s).

In more specific aspects, the invention relies on up-regulating, with various kinetics, the target gene expression upon activation of the CAR signalling pathway by targeted integration (with or without the native gene disruption) at the specific loci such as, as non-limiting example, PD1, PDL1, CTLA-4, TIM3, LAG3, TNFa or IFNg.

In an even more specific aspect, it is herein described engineered immune cells, and preferably primary immune cells for infusion into patients, comprising exogenous sequences encoding IL-15 or IL-12 polypeptide(s), which are integrated at the PD1, CD25 or CD69 endogenous locus for their expression under the control of the endogenous promoters present at these loci.

The immune cells according to the present invention can be [CAR]^{positive}, [CAR]^{negative}, [TCR]^{positive}, or [TCR]^{negative}, depending on the therapeutic indications and recipient patients. In one preferred aspect, the immune cells are further made [TCR]^{negative} for allogeneic transplantation. This can be achieved especially by genetic disruption of at least one endogenous sequence encoding at least one component of TCR, such as TRAC (locus encoding TCRalpha), preferably by integration of an exogenous sequence encoding a chimeric antigen receptor (CAR) or a recombinant TCR, or component(s) thereof.

According to a further aspect of the invention, the immune cells are transfected with an exogenous sequence coding for a polypeptide which can associate and preferably interfere with a cytokine receptor of the IL-6 receptor

family, such as a mutated GP130. In particular, the invention provides immune cells, preferably T-cells, which secrete soluble mutated GP130, aiming at reducing cytokine release syndrome (CRS) by interfering, and ideally block, interleukine-6 (IL-6) signal transduction. CRS is a well-known complication of cell immunotherapy leading to auto immunity that appears when the transduced immune cells start to be active in-vivo. Following binding of IL-6 to its receptor IL-6R, the complex associate with the GP130 subunit, initiating signal transduction and a cascade of inflammatory responses. According to a particular aspect, a dimeric protein comprising the extracellular domain of GP130 fused to the Fc portion of an IgG1 antibody (sgp130Fc) is expressed in the engineered immune cells to bind specifically soluble IL-R/IL-6 complex to achieve partial or complete blockade of IL-6 trans signaling. The present invention thus refers to a method for limiting CRS in immunotherapy, wherein immune cells are genetically modified to express a soluble polypeptide which can associate and preferably interfere with a cytokine receptor of the IL-6 receptor family, such as sgp130Fc. According to a preferred aspect, this sequence encoding said soluble polypeptide which can associate and preferably interfere with a cytokine receptor of the IL-6 receptor family, is integrated under control of an endogenous promoter, preferably at one locus responsive to T-cells activation, such as one selected from Tables 6, 8 or 9, more especially PD1, CD25 or CD69. Polynucleotide sequences of the vectors, donor templates comprising the exogenous coding sequences and/or sequences homologous to the endogenous loci, the sequences pertaining to the resulting engineered cells, as well as those permitting the detection of said engineered cells are all part of the present disclosure.

In a general aspect the invention relies, as non-limiting examples, on controlling the expression of components of biological "logic gates" ("AND" or "OR" or "NOT" or any combination of these) by targeted integration of genes. Similar to the electronic logic gates, cellular components expressed at different loci can exchange negative and positive signals that rule, for instance, the conditions of activation of an immune cell. Such component encompasses as non-limiting examples positive and negative chimeric antigen receptors that may be used to control T-cell activation and the resulting cytotoxicity of the engineered T-cells in which they are expressed.

According to a preferred embodiment, the invention relies on introducing the sequence specific endonuclease reagent and/or the donor template containing the gene of interest and sequences homologous to the target gene by transfecting ssDNA (oligonucleotides as non-limiting example), dsDNA (plasmid DNA as non-limiting example), and more particularly adeno-associated virus (AAV) as non-limiting example.

The invention also relates to the vectors, donor templates, reagents and resulting engineered cells pertaining to the above methods, as well as their use in therapy.

BRIEF DESCRIPTION OF THE FIGURES AND TABLES

FIG. 1: Strategies for engineering hematopoietic stem cells (HSCs) by introducing exogenous sequences at specific loci under transcriptional control of endogenous promoters specifically activated in specific immune cell types. The figure lists examples of specific endogenous genes, at which loci the exogenous coding sequence(s) can be inserted for expression in the desired hematopoietic lineages as per the present invention. The goal is to produce ex-vivo engineered

HSCs to be engrafted into patients, in order for them to produce immune cells in-vivo, which will express selected transgenes while they get differentiated into a desired lineage.

FIG. 2: Schematic representation of the donor sequences used in the experimental section to insert IL-15 exogenous coding sequence at the CD25 and PD1 loci and also the anti-CD22 CAR exogenous coding sequence at the TRAC locus. A: donor template (designated IL-15m-CD25) designed for site directed insertion of IL-15 at the CD25 locus for obtaining co-transcription of CD25 and IL-15 polypeptides by the immune cell. Sequences are detailed in the examples. B: donor template (designated IL-15m-PD1) designed for site directed insertion of IL-15 at the PD1 locus for obtaining transcription of IL-15 under the transcriptional activity of the promoter of PD1 endogenous gene. The PD1 right and Left border sequences can be selected so as to keep the PD1 endogenous coding sequence intact or disrupted. In this later case, PD1 is knocked-out while IL-15 is Knocked-in and transcribed. C: donor template designed for site directed insertion of a chimeric antigen receptor (ex: anti-CD22 CAR) into the TCR locus (ex: TRAC). In general, the left and right borders are chosen so as to disrupt the TCR in order to obtain [TCR]^{neg}[CAR]^{pos} engineered immune cells suitable for allogeneic transplant into patients.

FIG. 3: Flow cytometry measures of the frequency of targeted integration of IL-15m at either the PD1 or CD25 locus by using respectively PD1 or CD25 TALEN®, in a context where an anti-CD22 CAR is also integrated at the TRAC locus using TRAC TALEN®. These results show efficient targeted integration of both the CAR anti-CD22 at the TRAC locus together and the IL-15 coding sequence at the PD1 or CD25 loci. A: mock transfected primary T-cells. B: primary T-cells transfected with the donor sequences described in FIGS. 1 (B and C) and specific TALEN® for the double integration at the TCR and PDI loci. C: primary T-cells transfected with the donor sequences described in FIG. 1 (A and C) and specific TALEN® for the double integration at the TCR and CD25 loci.

FIG. 4: Schematic representation of the exogenous sequences used in the experimental section to transfet the primary immune cells to obtain the results shown in FIGS. 5 and 6.

FIGS. 5 and 6: Flow cytometry measures for LNGFR expression among viable T-cells transfected with donor templates of FIG. 4 and specific TALEN® (TCR and CD25), upon antiCD3/CD28 non-specific activation (Dynabeads®) and upon CAR dependent tumor cell activation (raji tumor cells). As shown in FIG. 6, LNGFR expression was specifically induced in [CAR anti-CD22]^{positive} cells upon CAR/tumor engagement.

FIGS. 7 and 8: Flow cytometry measures for CD25 expression among viable T-cells transfected with donor templates of FIG. 4 and specific TALEN® (TCR and CD25) upon antiCD3/CD28 non-specific activation (Dynabeads®) and Tumor cell activation (raji tumor cells). As shown in FIG. 8, CD25 expression was specifically induced in [CAR anti-CD22]^{positive} cells upon CAR/tumor engagement.

FIG. 9: Schematic representation of the exogenous sequences used in the experimental section to transfet the primary immune cells to obtain the results shown in FIGS. 11 and 12.

FIGS. 10 and 11: Flow cytometry measures for LNGFR expression among viable T-cells transfected with donor templates of FIG. 9 and specific TALEN® (TCR and PD1) upon antiCD3/CD28 non-specific activation (Dynabeads®) and Tumor cell activation (raji tumor cells). As shown in

FIG. 11, LNGFR expression was specifically induced in [CAR anti-CD22]^{positive} cells upon CAR/tumor engagement.

FIG. 12: Flow cytometry measures for endogenous PD1 expression among viable T-cells transfected with donor templates of FIG. 9 upon antiCD3/CD28 non-specific activation (Dynabeads®) and Tumor cell activation (raji tumor cells) with and without using TALEN® (TCR and PD1). PD1 was efficiently Knocked-out by TALEN treatment (8% remaining expression of PD1 out of 54%).

FIG. 13: Diagram showing IL-15 production in [CAR]^{positive} (CARm) and [CAR]^{negative} engineered immune cells according to the invention transfected with the donor template described in FIG. 2 (B) and TALEN® for insertion of IL-15 exogenous coding sequences into the PD1 locus. IL15, which transcription was under control of endogenous PD1 promoter, was efficiently induced upon antiCD3/CD28 non-specific activation (Dynabeads®) and Tumor cell activation (raji tumor cells) and secreted in the culture media.

FIG. 14: Graph showing the amount of IL-15 secreted over time (days) post activation by the immune cells engineered according to the invention. A: Cells engineered by integration of the IL-15 coding sequence at the CD25 locus using the DNA donor templates described in FIGS. 2A (IL-15m_CD25) and/or 2C (CARm). B: Cells engineered by integration of the IL-15 coding sequence at the PD1 locus using the DNA donor templates described in FIGS. 2B (IL-15m_PD1) and/or 2C (CARm). Integrations at both loci show similar IL-15 secretion profiles. Secretion of IL-15 is significant increased by tumor specific activation of CAR.

FIG. 15: Graph reporting number of Raji-Luc tumor cells expressing CD22 antigen (luciferase signal) over time in a survival assay (serial killing assay) as described in Example 2. The immune cells (PBMCs) have been engineered to integrate IL-15 coding sequences at the PD1 (A) or CD25 locus (B) and to express anti-CD22-CAR at the TCR locus (thereby disrupting TCR expression). In this assay, tumor cells are regularly added to the culture medium, while being partially or totally eliminated by the CAR positive cells. The re-expression of IL-15 at either PD1 or CD25 cells dramatically helps the elimination of the tumor cells by the CAR positive cells.

FIG. 16: Schematic representation of the donor sequences used in the experimental section to insert at the PD1 locus the exogenous sequences encoding IL-12 and gp130Fc. A: donor template (designated IL-12m-PD1) designed for site directed insertion of IL-12a and IL-12b coding sequences (SEQ ID NO:47 and 48) at the PD1 locus for obtaining co-transcription of IL-12a and IL-12b, while disrupting PD1 endogenous coding sequence. The right and left border sequences homologous to the PD1 locus sequences are at least 100 pb long, preferably at least 200 pb long, and more preferably at least 300 pb long and comprising SEQ ID NO:45 and 46. Sequences are detailed in Table 5. B: donor template (designated gp130Fc-PD1) designed for site directed insertion of gp130Fc coding sequences (SEQ ID NO:51) for obtaining transcription at the PD1 locus under PD1 promoter, while disrupting PD1 endogenous coding sequence. The right and left border sequences homologous to the PD1 locus sequences are at least 100 pb long, preferably at least 200 pb long, and more preferably at least 300 pb long and comprising SEQ ID NO:45 and 46. Sequences are detailed in Table 5.

Table 1: ISU domain variants from diverse viruses.

Table 2: Amino acid sequences of FP polypeptide from natural and artificial origins.

Table 3: List of genes involved into immune cells inhibitory pathways, which can be advantageously modified or inactivated by inserting exogenous coding sequence according to the invention.

Table 4: sequences referred to in example 1.

Table 5: sequences referred to in example 2.

Table 6: List of human genes that are up-regulated upon T-cell activation (CAR activation sensitive promoters), in which gene targeted insertion is sought according to the present invention to improve immune cells therapeutic potential.

Table 7: Selection of genes that are steadily transcribed during immune cell activation (dependent or independent from T-cell activation).

Table 8: Selection of genes that are transiently upregulated upon T-cell activation.

Table 9: Selection of genes that are upregulated over more than 24 hours upon T-cell activation.

Table 10: Selection of genes that are down-regulated upon immune cell activation.

Table 11: Selection of genes that are silent upon T-cell activation (safe harbor gene targeted integration loci).

Table 12: List of gene loci upregulated in tumor exhausted infiltrating lymphocytes (compiled from multiple tumors) useful for gene integration of exogenous coding sequences as per the present invention.

Table 13: List of gene loci upregulated in hypoxic tumor conditions useful for gene integration of exogenous coding sequences as per the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Unless specifically defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled artisan in the fields of gene therapy, biochemistry, genetics, and molecular biology.

All methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, with suitable methods and materials being described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will prevail. Further, the materials, methods, and examples are illustrative only and are not intended to be limiting, unless otherwise specified.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press, Inc., New York), specifically, Vols. 154 and 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (D. Goeddel,

ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

The present invention is drawn to a general method of preparing primary immune cells for cell immunotherapy involving gene targeted integration of an exogenous coding sequence into the chromosomal DNA of said immune cells. According to some aspects, this integration is performed in such a way that said coding sequence is placed under the transcriptional control of at least one promoter endogenous to said cells, said endogenous promoter being preferably not a constitutive promoter, such as the one transcribing T-cell receptor alpha constant (TRAC—NCBI Gene ID #28755) A constitutive promoter as per the present invention is for instance a promoter that is active independently from CAR activation—ex: when T-cells are not yet activated.

Improving the Therapeutic Potential of Immune Cells by Gene Targeted Integration

Gene editing techniques using polynucleotide sequence-specific reagents, such as rare-cutting endonucleases, have become the state of the art for the introduction of genetic modifications into primary cells. However, they have not been used so far in immune cells to introduce exogenous coding sequences under the transcriptional control of endogenous promoters.

The present invention aims to improve the therapeutic potential of immune cells through gene editing techniques, especially by gene targeted integration.

By "gene targeting integration" is meant any known site-specific methods allowing to insert, replace or correct a genomic sequence into a living cell. According to a preferred aspect of the present invention, said gene targeted integration involves homologous gene recombination at the locus of the targeted gene to result the insertion or replacement of at least one exogenous nucleotide, preferably a sequence of several nucleotides (i.e. polynucleotide), and more preferably a coding sequence.

By "sequence-specific reagent" is meant any active molecule that has the ability to specifically recognize a selected polynucleotide sequence at a genomic locus, preferably of at least 9 bp, more preferably of at least 10 bp and even more preferably of at least 12 pb in length, in view of modifying said genomic locus. According to a preferred aspect of the invention, said sequence-specific reagent is preferably a sequence-specific nuclease reagent.

By "immune cell" is meant a cell of hematopoietic origin functionally involved in the initiation and/or execution of innate and/or adaptative immune response, such as typically CD3 or CD4 positive cells. The immune cell according to the present invention can be a dendritic cell, killer dendritic cell, a mast cell, a NK-cell, a B-cell or a T-cell selected from the group consisting of inflammatory T-lymphocytes, cytotoxic T-lymphocytes, regulatory T-lymphocytes or helper T-lymphocytes. Cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and from tumors, such as tumor infiltrating lymphocytes. In some embodiments, said immune cell can be derived from a healthy donor, from a patient diagnosed with cancer or from a patient diagnosed with an infection. In another embodiment, said cell is part of

11

a mixed population of immune cells which present different phenotypic characteristics, such as comprising CD4, CD8 and CD56 positive cells.

By "primary cell" or "primary cells" are intended cells taken directly from living tissue (e.g. biopsy material) and established for growth in vitro for a limited amount of time, meaning that they can undergo a limited number of population doublings. Primary cells are opposed to continuous tumorigenic or artificially immortalized cell lines. Non-limiting examples of such cell lines are CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44 cells; K-562 cells, U-937 cells; MRC5 cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells; Molt 4 cells. Primary cells are generally used in cell therapy as they are deemed more functional and less tumorigenic.

In general, primary immune cells are provided from donors or patients through a variety of methods known in the art, as for instance by leukapheresis techniques as reviewed by Schwartz J. et al. (Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue (2013) *J Clin Apher.* 28(3):145-284).

The primary immune cells according to the present invention can also be differentiated from stem cells, such as cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells (HSC) and induced pluripotent stem cells (iPS).

By "nuclease reagent" is meant a nucleic acid molecule that contributes to an nuclease catalytic reaction in the target cell, preferably an endonuclease reaction, by itself or as a subunit of a complex such as a guide RNA/Cas9, preferably leading to the cleavage of a nucleic acid sequence target.

The nuclease reagents of the invention are generally "sequence-specific reagents", meaning that they can induce DNA cleavage in the cells at predetermined loci, referred to by extension as "targeted gene". The nucleic acid sequence which is recognized by the sequence specific reagents is referred to as "target sequence". Said target sequence is usually selected to be rare or unique in the cell's genome, and more extensively in the human genome, as can be determined using software and data available from human genome databases, such as ensembl.org/index.html.

"Rare-cutting endonucleases" are sequence-specific endonuclease reagents of choice, insofar as their recognition sequences generally range from 10 to 50 successive base pairs, preferably from 12 to 30 bp, and more preferably from 14 to 20 bp.

According to a preferred aspect of the invention, said endonuclease reagent is a nucleic acid encoding an "engineered" or "programmable" rare-cutting endonuclease, such as a homing endonuclease as described for instance by Arnould S., et al. (WO2004067736), a zing finger nuclease (ZFN) as described, for instance, by Umov F., et al. (Highly efficient endogenous human gene correction using designed zinc-finger nucleases (2005) *Nature* 435:646-651), a TALE-Nuclease as described, for instance, by Mussolini et al. (A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity (2011) *Nucl. Acids Res.* 39(21):9283-9293), or a MegaTAL nuclease as described, for instance by Boissel et al. (MegaTALS: a rare-cleaving nuclease architecture for therapeutic genome engineering (2013) *Nucleic Acids Research* 42 (4):2591-2601).

12

According to another embodiment, the endonuclease reagent is a RNA-guide to be used in conjunction with a RNA guided endonuclease, such as Cas9 or Cpf1, as per, inter alia, the teaching by Doudna, J., and Charpentier, E., (The new frontier of genome engineering with CRISPR-Cas9 (2014) *Science* 346 (6213):1077), which is incorporated herein by reference.

According to a preferred aspect of the invention, the endonuclease reagent is transiently expressed into the cells, meaning that said reagent is not supposed to integrate into the genome or persist over a long period of time, such as be the case of RNA, more particularly mRNA, proteins or complexes mixing proteins and nucleic acids (eg: Ribonucleoproteins).

In general, 80% the endonuclease reagent is degraded by 30 hours, preferably by 24, more preferably by 20 hours after transfection.

An endonuclease under mRNA form is preferably synthesized with a cap to enhance its stability according to techniques well known in the art, as described, for instance, by Kore A. L., et al. (Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization (2009) *J Am Chem Soc.* 131 (18):6364-5).

In general, electroporation steps that are used to transfect immune cells are typically performed in closed chambers comprising parallel plate electrodes producing a pulse electric field between said parallel plate electrodes greater than 100 volts/cm and less than 5,000 volts/cm, substantially uniform throughout the treatment volume such as described in WO/2004/083379, which is incorporated by reference, especially from page 23, line 25 to page 29, line 11. One such electroporation chamber preferably has a geometric factor (cm^{-1}) defined by the quotient of the electrode gap squared (cm^2) divided by the chamber volume (cm^3), wherein the geometric factor is less than or equal to 0.1 cm^{-1} , wherein the suspension of the cells and the sequence-specific reagent is in a medium which is adjusted such that the medium has conductivity in a range spanning 0.01 to 1.0 milliSiemens. In general, the suspension of cells undergoes one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the cells in the chamber is substantially uniform.

Due to their higher specificity, TALE-nuclease have proven to be particularly appropriate sequence specific nuclease reagents for therapeutic applications, especially under heterodimeric forms—i.e. working by pairs with a "right" monomer (also referred to as "5'" or "forward") and 'left' monomer (also referred to as "3'" or "reverse") as reported for instance by Mussolini et al. (TALEN® facilitate targeted genome editing in human cells with high specificity and low cytotoxicity (2014) *Nucl. Acids Res.* 42(10): 6762-6773).

As previously stated, the sequence specific reagent is preferably under the form of nucleic acids, such as under DNA or RNA form encoding a rare cutting endonuclease a subunit thereof, but they can also be part of conjugates involving polynucleotide(s) and polypeptide(s) such as so-called "ribonucleoproteins". Such conjugates can be formed with reagents as Cas9 or Cpf1 (RNA-guided endonucleases) or Argonaute (DNA-guided endonucleases) as recently respectively described by Zetsche, B. et al. (Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System (2015) *Cell* 163(3): 759-771) and by Gao F. et al. (DNA-guided genome editing using the *Natronobacterium*

13

gregoryi Argonaute (2016) *Nature Biotech*), which involve RNA or DNA guides that can be complexed with their respective nucleases.

“Exogenous sequence” refers to any nucleotide or nucleic acid sequence that was not initially present at the selected locus. This sequence may be homologous to, or a copy of, a genomic sequence, or be a foreign sequence introduced into the cell. By opposition “endogenous sequence” means a cell genomic sequence initially present at a locus. The exogenous sequence preferably codes for a polypeptide which expression confers a therapeutic advantage over sister cells that have not integrated this exogenous sequence at the locus. A endogenous sequence that is gene edited by the insertion of a nucleotide or polynucleotide as per the method of the present invention, in order to express a different polypeptide is broadly referred to as an exogenous coding sequence. The method of the present invention can be associated with other methods involving physical of genetic transformations, such as a viral transduction or transfection using nanoparticles, and also may be combined with other gene inactivation and/or transgene insertions.

According to one aspect, the method according to the invention comprises the steps of:

providing a population of primary immune cells;
introducing into a proportion of said primary immune cells:

i) At least one nucleic acid comprising an exogenous nucleotide or polynucleotide sequence to be integrated at a selected endogenous locus to encode at least one molecule improving the therapeutic potential of said immune cells population;

ii) At least one sequence-specific reagent that specifically targets said selected endogenous locus, wherein said exogenous nucleotide or polynucleotide sequence is inserted by targeted gene integration into said endogenous locus, so that said exogenous nucleotide or polynucleotide sequence forms an exogenous coding sequence under transcriptional control of an endogenous promoter present at said locus.

According to one aspect of the method, the sequence specific reagent is a nuclease and the targeted gene integration is operated by homologous recombination or NHEJ into said immune cells.

According to a further aspect of the invention, said endogenous promoter is selected to be active during immune cell activation and preferably up-regulated. More specifically, the invention is drawn to a method for preparing engineered primary immune cells for cell immunotherapy, said method comprising:

providing a population of primary immune cells;
introducing into a proportion of said primary immune cells:

i) At least one exogenous nucleic acid comprising an exogenous coding sequence encoding at least one molecule improving the therapeutic potential of said immune cells population;

ii) At least one sequence-specific nuclease reagent that specifically targets a gene which is under control of an endogenous promoter active during immune cell activation;

wherein said coding sequence is introduced into the primary immune cells genome by targeted homologous recombination, so that said coding sequence is placed under the transcriptional control of at least one endogenous promoter of said gene.

By “improving therapeutic potential” is meant that the engineered immune cells gain at least one advantageous

14

property for their use in cell therapy by comparison to their sister non-engineered immune cells. The therapeutic properties sought by the invention maybe any measurable one as referred to in the relevant scientific literature.

5 Improved therapeutic potential can be more particularly reflected by a resistance of the immune cells to a drug, an increase in their persistence in-vitro or in-vivo, or a safer/more convenient handling during manufacturing of therapeutic compositions and treatments.

10 In general said molecule improving the therapeutic potential is a polypeptide, but it can also be a nucleic acid able to direct or repress expression of other genes, such as interference RNAs or guide-RNAs. The polypeptides may act directly or indirectly, such as signal transducers or transcriptional regulators.

15 According to one embodiment of the present method, the exogenous sequence is introduced into the endogenous chromosomal DNA by targeted homologous recombination. Accordingly, the exogenous nucleic acid introduced into the immune cell comprises at least one coding sequence(s), along with sequences that can hybridize endogenous chromosomal sequences under physiological conditions. In general, such homologous sequences show at least 70%, preferably 80% and more preferably 90% sequence identity with the endogenous gene sequences located at the insertion locus. These homologous sequences may flank the coding sequence to improve the precision of recombination as already taught for instance in U.S. Pat. No. 6,528,313. Using available software and on-line genome databases, it is possible to design vectors that includes said coding sequence (s), in such a way that said sequence(s) is (are)

20 introduced at a precise locus, under transcriptional control of at least one endogenous promoter, which is a promoter of an endogenous gene. The exogenous coding sequence(s) is 25 (are) then preferably inserted “in frame” with said endogenous gene. The sequences resulting from the integration of the exogenous polynucleotide sequence(s) can encode many different types of proteins, including fusion proteins, tagged protein or mutated proteins. Fusion proteins allow adding new functional domains to the proteins expressed in the cell, such as a dimerization domain that can be used to switch-on or switch-off the activity of said protein, such as caspase-9 switch. Tagged proteins can be advantageous for the detection of the engineered immune cells and the follow-up of the 30 patients treated with said cells. Introducing mutation into proteins can confer resistance to drugs or immune depletion agents as further described below.

35 Conferring Resistance to Drugs or Immune Depletion Agents
40 According to one aspect of the present method, the exogenous sequence that is integrated into the immune cells genomic locus encodes a molecule that confers resistance of 45 said immune cells to a drug.

45 Examples of preferred exogenous sequences are variants 50 of dihydrofolate reductase (DHFR) conferring resistance to folate analogs such as methotrexate, variants of inosine monophosphate dehydrogenase 2 (IMPDH2) conferring resistance to IMPDH inhibitors such as mycophenolic acid (MPA) or its prodrug mycophenolate mofetil (MMF), variants 55 of calcineurin or methylguanine transferase (MGMT) conferring resistance to calcineurin inhibitor such as FK506 and/or CsA, variants of mTOR such as mTORmut conferring resistance to rapamycin and variants of Lck, such as Lckmut conferring resistance to Imatinib and Gleevec.

60 The term “drug” is used herein as referring to a compound or a derivative thereof, preferably a standard chemotherapy agent that is generally used for interacting with a cancer cell,

thereby reducing the proliferative or living status of the cell. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents (e.g., cyclophosphamide, ifosfamide), metabolic antagonists (e.g., purine nucleoside anti-metabolite such as clofarabine, fludarabine or 2'-deoxyadenosine, methotrexate (MTX), 5-fluorouracil or derivatives thereof), antitumor antibiotics (e.g., mitomycin, adriamycin), plant-derived antitumor agents (e.g., vincristine, vindesine, Taxol), cisplatin, carboplatin, etoposide, and the like. Such agents may further include, but are not limited to, the anti-cancer agents TRIMETHOTRUXATE™ (TMTX), TEMOZOLOMIDE™, RALTRITREXED™, S-(4-Nitrobenzyl)-6-thioinosine (NBMPR), 6-benzylguanidine (6-BG), bis-chloronitrosourea (BCNU) and CAMPTOTH-ECIN™, or a therapeutic derivative of any thereof.

As used herein, an immune cell is made “resistant or tolerant” to a drug when said cell, or population of cells is modified so that it can proliferate, at least in-vitro, in a culture medium containing half maximal inhibitory concentration (IC₅₀) of said drug (said IC₅₀ being determined with respect to an unmodified cell(s) or population of cells).

In a particular embodiment, said drug resistance can be conferred to the immune cells by the expression of at least one “drug resistance coding sequence”. Said drug resistance coding sequence refers to a nucleic acid sequence that confers “resistance” to an agent, such as one of the chemotherapeutic agents referred to above. A drug resistance coding sequence of the invention can encode resistance to anti-metabolite, methotrexate, vinblastine, cisplatin, alkylating agents, anthracyclines, cytotoxic antibiotics, anti-immunophilins, their analogs or derivatives, and the like (Takebe, N., S. C. Zhao, et al. (2001) “Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene”. *Mol. Ther.* 3(1): 88-96), (Zielske, S. P., J. S. Reese, et al. (2003) “In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.” *J. Clin. Invest.* 112 (10): 1561-70) (Nivens, M. C., T. Felder, et al. (2004) “Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase” *Cancer Chemother Pharmacol* 53(2): 107-15), (Bardenheuer, W., K. Lehmberg, et al. (2005). “Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells”. *Leukemia* 19(12): 2281-8), (Kushman, M. E., S. L. Kabler, et al. (2007) “Expression of human glutathione S-transferase P1 confers resistance to benzo[a]pyrene or benzo[a]pyrene-7,8-dihydrodiol mutagenesis, macromolecular alkylation and formation of stable N2-Gua-BPDE adducts in stably transfected V79MZ cells co-expressing hCYP1A1” *Carcinogenesis* 28(1): 207-14).

The expression of such drug resistance exogenous sequences in the immune cells as per the present invention more particularly allows the use of said immune cells in cell therapy treatment schemes where cell therapy is combined with chemotherapy or into patients previously treated with these drugs.

Several drug resistance coding sequences have been identified that can potentially be used to confer drug resistance according to the invention. One example of drug resistance coding sequence can be for instance a mutant or modified form of Dihydrofolate reductase (DHFR). DHFR is an enzyme involved in regulating the amount of tetrahydrofolate in the cell and is essential to DNA synthesis. Folate

analogs such as methotrexate (MTX) inhibit DHFR and are thus used as anti-neoplastic agents in clinic. Different mutant forms of DHFR which have increased resistance to inhibition by anti-folates used in therapy have been described. In 5 a particular embodiment, the drug resistance coding sequence according to the present invention can be a nucleic acid sequence encoding a mutant form of human wild type DHFR (GenBank: AAH71996.1), which comprises at least one mutation conferring resistance to an anti-folate treatment, such as methotrexate. In particular embodiment, mutant form of DHFR comprises at least one mutated amino acid at position G15, L22, F31 or F34, preferably at positions L22 or F31 (Schweitzer et al. (1990) “Dihydrofolate reductase as a therapeutic target” *Faseb J* 4(8): 2441-52; 10 International application WO94/24277; and U.S. Pat. No. 6,642,043). In a particular embodiment, said DHFR mutant form comprises two mutated amino acids at position L22 and F31. Correspondence of amino acid positions described herein is frequently expressed in terms of the positions of the 15 amino acids of the form of wild-type DHFR polypeptide. In a particular embodiment, the serine residue at position 15 is preferably replaced with a tryptophan residue. In another particular embodiment, the leucine residue at position 22 is preferably replaced with an amino acid which will disrupt binding of the mutant DHFR to antifolates, preferably with uncharged amino acid residues such as phenylalanine or tyrosine. In another particular embodiment, the phenylalanine residue at positions 31 or 34 is preferably replaced with a small hydrophilic amino acid such as alanine, serine or glycine.

Another example of drug resistance coding sequence can also be a mutant or modified form of ionisine-5'-monophosphate dehydrogenase II (IMPDH2), a rate-limiting enzyme in the de novo synthesis of guanosine nucleotides. The 20 mutant or modified form of IMPDH2 is a IMPDH inhibitor resistance gene. IMPDH inhibitors can be mycophenolic acid (MPA) or its prodrug mycophenolate mofetil (MMF). The mutant IMPDH2 can comprises at least one, preferably two mutations in the MAP binding site of the wild type human IMPDH2 (Genebank: NP_000875.2) leading to a significantly increased resistance to IMPDH inhibitor. Mutations in these variants are preferably at positions T333 and/or S351 (Yam, P., M. Jensen, et al. (2006) “Ex vivo selection and expansion of cells based on expression of a 25 mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells” *Mol. Ther.* 14(2): 236-44)(Jonnalagadda, M., et al. (2013) “Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.” *PLoS One* 8(6): e65519).

Another drug resistance coding sequence is the mutant form of calcineurin. Calcineurin (PP2B—NCBI: ACX34092.1) is an ubiquitously expressed serine/threonine protein phosphatase that is involved in many biological processes and which is central to T-cell activation. Calcineurin is a heterodimer composed of a catalytic subunit (CnA; three isoforms) and a regulatory subunit (CnB; two isoforms). After engagement of the T-cell receptor, calcineurin dephosphorylates the transcription factor NFAT, allowing it 30 to translocate to the nucleus and active key target gene such as IL2. FK506 in complex with FKBP12, or cyclosporine A (CsA) in complex with CyPA block NFAT access to calcineurin’s active site, preventing its dephosphorylation and thereby inhibiting T-cell activation (Brewin et al. (2009) “Generation of EBV-specific cytotoxic T cells that are 35 resistant to calcineurin inhibitors for the treatment of post-transplantation lymphoproliferative disease” *Blood* 114(23):

4792-803). In a particular embodiment, said mutant form can comprise at least one mutated amino acid of the wild type calcineurin heterodimer a at positions: V314, Y341, M347, T351, W352, L354, K360, preferably double mutations at positions T351 and L354 or V314 and Y341. In a particular embodiment, the valine residue at position 341 can be replaced with a lysine or an arginine residue, the tyrosine residue at position 341 can be replaced with a phenylalanine residue; the methionine at position 347 can be replaced with the glutamic acid, arginine or tryptophane residue; the threonine at position 351 can be replaced with the glutamic acid residue; the tryptophane residue at position 352 can be replaced with a cysteine, glutamic acid or alanine residue, the serine at position 353 can be replaced with the histidine or asparagines residue, the leucine at position 354 can be replaced with an alanine residue; the lysine at position 360 can be replaced with an alanine or phenylalanine residue. In another particular embodiment, said mutant form can comprise at least one mutated amino acid of the wild type calcineurin heterodimer b at positions: V120, N123, L124 or K125, preferably double mutations at positions L124 and K125. In a particular embodiment, the valine at position 120 can be replaced with a serine, an aspartic acid, phenylalanine or leucine residue; the asparagines at position 123 can be replaced with a tryptophan, lysine, phenylalanine, arginine, histidine or serine; the leucine at position 124 can be replaced with a threonine residue; the lysine at position 125 can be replaced with an alanine, a glutamic acid, tryptophan, or two residues such as leucine-arginine or isoleucine-glutamic acid can be added after the lysine at position 125 in the amino acid sequence. Correspondence of amino acid positions described herein is frequently expressed in terms of the positions of the amino acids of the form of wild-type human calcineurin heterodimer b polypeptide (NCBI: ACX34095.1).

Another drug resistance coding sequence is O(6)-methylguanine methyltransferase (MGMT—UniProtKB: P16455) encoding human alkyl guanine transferase (hAGT). AGT is a DNA repair protein that confers resistance to the cytotoxic effects of alkylating agents, such as nitrosoureas and temozolamide (TMZ). 6-benzylguanine (6-BG) is an inhibitor of AGT that potentiates nitrosourea toxicity and is co-administered with TMZ to potentiate the cytotoxic effects of this agent. Several mutant forms of MGMT that encode variants of AGT are highly resistant to inactivation by 6-BG, but retain their ability to repair DNA damage (Maze, R. et al. (1999) “Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment” *J. Pharmacol. Exp. Ther.* 290(3): 1467-74). In a particular embodiment, AGT mutant form can comprise a mutated amino acid of the wild type AGT position P140. In a preferred embodiment, said proline at position 140 is replaced with a lysine residue.

Another drug resistance coding sequence can be multi-drug resistance protein (MDR1) gene. This gene encodes a membrane glycoprotein, known as P-glycoprotein (P-GP) involved in the transport of metabolic byproducts across the cell membrane. The P-Gp protein displays broad specificity towards several structurally unrelated chemotherapy agents. Thus, drug resistance can be conferred to cells by the expression of nucleic acid sequence that encodes MDR-1 (Genebank NP_000918).

Another drug resistance coding sequence can contribute to the production of cytotoxic antibiotics, such as those from ble or mcrA genes. Ectopic expression of ble gene or mcrA

in an immune cell gives a selective advantage when exposed to the respective chemotherapeutic agents bleomycine and mitomycin C (Belcourt, M. F. (1999) “Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA”. *PNAS*. 96(18):10489-94).

Another drug resistance coding sequence can come from genes encoded mutated version of drug targets, such as mutated variants of mTOR (mTOR mut) conferring resistance to rapamycin such as described by Lorenz M. C. et al. (1995) “TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin” *The Journal of Biological Chemistry* 270, 27531-27537, or certain mutated variants of Lck (Lckmut) conferring resistance to Gleevec as described by Lee K. C. et al. (2010) “Lck is a key target of imatinib and dasatinib in T-cell activation”, *Leukemia*, 24: 896-900.

As described above, the genetic modification step of the method can comprise a step of introduction into cells of an exogenous nucleic acid comprising at least a sequence encoding the drug resistance coding sequence and a portion of an endogenous gene such that homologous recombination occurs between the endogenous gene and the exogenous nucleic acid. In a particular embodiment, said endogenous gene can be the wild type “drug resistance” gene, such that after homologous recombination, the wild type gene is replaced by the mutant form of the gene which confers resistance to the drug.

Enhancing Persistence of the Immune Cells In-Vivo

According to one aspect of the present method, the exogenous sequence that is integrated into the immune cells genomic locus encodes a molecule that enhances persistence of the immune cells, especially in-vivo persistence in a tumor environment.

By “enhancing persistence” is meant extending the survival of the immune cells in terms of life span, especially once the engineered immune cells are injected into the patient. For instance, persistence is enhanced, if the mean survival of the modified cells is significantly longer than that of non-modified cells, by at least 10%, preferably 20%, more preferably 30%, even more preferably 50%.

This especially relevant when the immune cells are allo-geic. This may be done by creating a local immune protection by introducing coding sequences that ectopically express and/or secrete immunosuppressive polypeptides at, or through, the cell membrane. A various panel of such polypeptides in particular antagonists of immune checkpoints, immunosuppressive peptides derived from viral envelope or NKG2D ligand can enhance persistence and/or an engraftment of allogeneic immune cells into patients.

According to one embodiment, the immunosuppressive polypeptide to be encoded by said exogenous coding sequence is a ligand of Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4 also known as CD152, GenBank accession number AF414120.1). Said ligand polypeptide is preferably an anti-CTLA-4 immunoglobulin, such as CTLA-4a Ig and CTLA-4b Ig or a functional variant thereof.

According to one embodiment, the immunosuppressive polypeptide to be encoded by said exogenous coding sequence is an antagonist of PD1, such as PD-L1 (other names: CD274, Programmed cell death 1 ligand; ref. UniProt for the human polypeptide sequence Q9NZQ7), which encodes a type I transmembrane protein of 290 amino acids consisting of a Ig V-like domain, a Ig C-like domain, a hydrophobic transmembrane domain and a cytoplasmic tail of 30 amino acids. Such membrane-bound form of PD-L1 ligand is meant in the present invention under a native form (wild-type) or under a truncated form such as, for instance,

by removing the intracellular domain, or with one or more mutation(s) (Wang S et al., 2003, *J Exp Med.* 2003; 197(9): 1083-1091). Of note, PD1 is not considered as being a membrane-bound form of PD-L1 ligand according to the present invention. According to another embodiment, said immunosuppressive polypeptide is under a secreted form. Such recombinant secreted PD-L1 (or soluble PD-L1) may be generated by fusing the extracellular domain of PD-L1 to the Fc portion of an immunoglobulin (Haile S T et al., 2014, *Cancer Immunol. Res.* 2(7): 610-615; Song M Y et al., 2015, *Gut.* 64(2):260-71). This recombinant PD-L1 can neutralize PD-1 and abrogate PD-1-mediated T-cell inhibition. PD-L1 ligand may be co-expressed with CTLA4 Ig for an even enhanced persistence of both.

According to another embodiment, the exogenous sequence encodes a polypeptide comprising a viral env immusuppressive domain (ISU), which is derived for instance from HIV-1, HIV-2, SIV, MoMuLV, HTLV-I, -II, MPMV, SRV-1, Syncitin 1 or 2, HERV-K or FELV.

The following Table 1 shows variants of ISU domain from diverse virus which can be expressed within the present invention.

described by Margalit A. et al. (2003) "Chimeric β 2 micro-globulin/CD3 ζ polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8+ T cells" *Int. Immunol.* 15 (11): 1379-1387.

According to one embodiment, the exogenous sequence encodes NKG2D ligand. Some viruses such as cytomegaloviruses have acquired mechanisms to avoid NK cell mediated immune surveillance and interfere with the NKG2D pathway by secreting a protein able to bind NKG2D ligands and prevent their surface expression (Welte, S. A et al. (2003) "Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein". *Eur. J. Immunol.*, 33, 194-203). In tumors cells, some mechanisms have evolved to evade NKG2D response by secreting NKG2D ligands such as ULBP2, MICB or MICA (Salih H R, Antropius H, Gieseke F, Lutz S Z, Kanz L, et al. (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. *Blood* 102: 1389-1396)

According to one embodiment, the exogenous sequence encodes a cytokine receptor, such as an IL-12 receptor.

TABLE 1

ISU domain variants from diverse viruses														Virus origin	SEQ ID NO
ISU Amino acids sequences															
Amino acid positions															
1	2	3	4	5	6	7	8	9	10	11	12	13	14	Origin	SEQ ID NO
L	Q	A	R	I/V	L	A	V	E	R	Y	L	K/R/Q	D	HIV-1	SEQ ID NO: 68
L	Q	A	R	V	T	A	I	E	K	Y	L	K/A/Q	D/H	HIV-2	SEQ ID NO: 69
L	Q	A	R	L	L	A	V	E	R	Y	L	K	D	SIV	SEQ ID NO: 70
L	Q	N	R	R	G	L	D	L	L	F	L	K	E	MoMuLV	SEQ ID NO: 71
A	Q	N	R	R	G	L	D	L	L	F	W	E	Q	HTLV-I, -II	SEQ ID NO: 72
L	Q	N	R	R	G	L	D	L	L	T	A	E	Q	MPMV, SRV-1	SEQ ID NO: 73
L	Q	N	R	R	A	L	D	L	L	T	A	E	R	Syncitin 1	SEQ ID NO: 74
L	Q	N	R	R	G	L	D	M	L	T	A	A	Q	Syncitin 2	SEQ ID NO: 75
L	A	N	Q	I	N	D	L	R	Q	T	V	I	W	HERV-K	SEQ ID NO: 76
L	Q	N	R	R	G	L	D	I	L	F	L	Q	E	FELV	SEQ ID NO: 77

According to another embodiment, the exogenous sequence encodes a FP polypeptide such as gp41. The following Table 2 represents several FP polypeptide from natural and artificial origins.

IL-12 is a well known activator of immune cells activation (Curtis J. H. (2008) "IL-12 Produced by Dendritic Cells Augments CD8+ T Cell Activation through the Production of the Chemokines CCL1 and CCL171". *The Journal of Immunology.* 181 (12): 8576-8584.

TABLE 2

Amino acid sequences of FP polypeptide from natural and artificial origins									SEQ ID NO
FP Amino acids sequences									
Amino acid positions									
1	2	3	4	5	6	7	8	9	Origin NO
G	A	L	F	L	G	F	L	G	HIV-1 gp41 SEQ ID NO: 78
A	G	F	G	L	L	L	G	F	Synthetic SEQ ID NO: 79
A	G	L	F	L	G	F	L	G	Synthetic SEQ ID NO: 80

According to another embodiment, the exogenous sequence encodes a non-human MHC homolog, especially a viral MHC homolog, or a chimeric β 2m polypeptide such as

According to one embodiment the exogenous sequence encodes an antibody that is directed against inhibitory peptides or proteins. Said antibody is preferably be secreted under soluble form by the immune cells. Nanobodies from shark and camels are advantageous in this respect, as they are structured as single chain antibodies (Muyldermans S. (2013) "Nanobodies: Natural Single-Domain Antibodies" *Annual Review of Biochemistry* 82: 775-797). Same are also deemed more easily to fuse with secretion signal polypeptides and with soluble hydrophilic domains.

The different aspects developed above to enhance persistence of the cells are particularly preferred, when the exogenous coding sequence is introduced by disrupting an endogenous gene encoding P2m or another MHC component, as detailed further on.

Enhancing the Therapeutic Activity of Immune Cells

According to one aspect of the present method, the exogenous sequence that is integrated into the immune cells

21

genomic locus encodes a molecule that enhances the therapeutic activity of the immune cells.

By "enhancing the therapeutic activity" is meant that the immune cells, or population of cells, engineered according to the present invention, become more aggressive than non-engineered cells or population of cells with respect to a selected type of target cells. Said target cells generally belong to a defined type of cells, or population of cells, preferably characterized by common surface marker(s). In the present specification, "therapeutic potential" reflects the therapeutic activity, as measured through in-vitro experiments. In general sensitive cancer cell lines, such as Daudi cells, are used to assess whether the immune cells are more or less active towards said cells by performing cell lysis or growth reduction measurements. This can also be assessed by measuring levels of degranulation of immune cells or chemokines and cytokines production. Experiments can also be performed in mice with injection of tumor cells, and by monitoring the resulting tumor expansion. Enhancement of activity is deemed significant when the number of developing cells in these experiments is reduced by the immune cells by more than 10%, preferably more than 20%, more preferably more than 30%, even more preferably by more than 50%.

According to one aspect of the invention, said exogenous sequence encodes a chemokine or a cytokine, such as IL-12. It is particularly advantageous to express IL-12 as this cytokine is extensively referred to in the literature as promoting immune cell activation (Colombo M. P. et al. (2002) "Interleukin-12 in anti-tumor immunity and immunotherapy" *Cytokine Growth Factor Rev.* 13(2):155-68).

According to a preferred aspect of the invention the exogenous coding sequence encodes or promote secreted factors that act on other populations of immune cells, such as T-regulatory cells, to alleviate their inhibitory effect on said immune cells.

According to one aspect of the invention, said exogenous sequence encodes an inhibitor of regulatory T-cell activity is a polypeptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), and more preferably is a cell-penetrating peptide inhibitor of FoxP3, such as that referred as P60 (Casares N. et al. (2010) "A peptide inhibitor of FoxP3 impairs regulatory T cell activity and improves vaccine efficacy in mice." *J Immunol* 185(9):5150-9).

By "inhibitor of regulatory T-cells activity" is meant a molecule or precursor of said molecule secreted by the T-cells and which allow T-cells to escape the down regulation activity exercised by the regulatory T-cells thereon. In general, such inhibitor of regulatory T-cell activity has the effect of reducing FoxP3 transcriptional activity in said cells.

According to one aspect of the invention, said exogenous sequence encodes a secreted inhibitor of Tumor Associated Macrophages (TAM), such as a CCR2/CCL2 neutralization agent. Tumor-associated macrophages (TAMs) are critical modulators of the tumor microenvironment. Clinicopathological studies have suggested that TAM accumulation in tumors correlates with a poor clinical outcome. Consistent with that evidence, experimental and animal studies have supported the notion that TAMs can provide a favorable microenvironment to promote tumor development and progression. (Theerawut C. et al. (2014) "Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment" *Cancers (Basel)* 6(3): 1670-1690). Chemokine ligand 2 (CCL2), also called monocyte chemoattractant protein 1 (MCP1—NCBI NP_002973.1), is a small cytokine that belongs to the CC chemokine family, secreted by macrophages, that produces chemoattraction on monocytes, lym-

22

phocytes and basophils. CCR2 (C-C chemokine receptor type 2—NCBI NP_001116513.2), is the receptor of CCL2. Enhancing Specificity and Safety of Immune Cells

Expressing chimeric antigen receptors (CAR) have become the state of the art to direct or improve the specificity of primary immune cells, such as T-Cells and NK-cells for treating tumors or infected cells. CARs expressed by these immune cells specifically target antigen markers at the surface of the pathological cells, which further help said immune cells to destroy these cells in-vivo (Sadelain M. et al. "The basic principles of chimeric antigen receptor design" (2013) *Cancer Discov.* 3(4):388-98). CARs are usually designed to comprise activation domains that stimulate immune cells in response to binding to a specific antigen (so-called positive CAR), but they may also comprise an inhibitory domain with the opposite effect (so-called negative CAR)(Fedorov, V. D. (2014) "Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells" *Cancer Journal* 20 (2):160-165. Positive and negative CARs may be combined or co-expressed to finely tune the cells immune specificity depending of the various antigens present at the surface of the target cells.

The genetic sequences encoding CARs are generally introduced into the cells genome using retroviral vectors that have elevated transduction efficiency but integrate at random locations. Here, according to the present invention, components of chimeric antigen receptor (CAR) car be introduced at selected loci, more particularly under control of endogenous promoters by targeted gene recombination.

According to one aspect, while a positive CAR is introduced into the immune cell by a viral vector, a negative CAR can be introduced by targeted gene insertion and vice-versa, and be active preferably only during immune cells activation. Accordingly, the inhibitory (i.e. negative) CAR contributes to an improved specificity by preventing the immune cells to attack a given cell type that needs to be preserved. Still according to this aspect, said negative CAR can be an apoptosis CAR, meaning that said CAR comprise an apoptosis domain, such as FasL (CD95—NCBI: NP_000034.1) or a functional variant thereof, that transduces a signal inducing cell death (Eberstadt M; et al. "NMR structure and mutagenesis of the FADD (Mort1) death-effector domain" (1998) *Nature*. 392 (6679): 941-5).

Accordingly, the exogenous coding sequence inserted according to the invention can encode a factor that has the capability to induce cell death, directly, in combination with, or by activating other compound(s).

As another way to enhance the safety of us of the primary immune cells, the exogenous coding sequence can encodes molecules that confer sensitivity of the immune cells to drugs or other exogenous substrates. Such molecules can be cytochrome(s), such as from the P450 family (Preissner S et al. (2010) "SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions". *Nucleic Acids Res* 38 (Database issue): D237-43), such as CYP2D6-1 (NCBI—NP_000097.3), CYP2D6-2 (NCBI—NP_001020332.2), CYP2C9(), CYP3A4 (NCBI—NP_000762.2), CYP2C19 (NCBI—NP_000760.1) or CYP1A2 (NCBI—NP_000752.2), conferring hypersensitivity of the immune cells to a drug, such as cyclophosphamide and/or isophosphamide.

According to a further aspect of the invention, an exogenous sequence is introduced in the immune cells for its expression, especially in vivo, to reduce IL-6 or IL-8 trans signalling in view of controlling potential Cyokine Release Syndrome (CRS).

23

Such an exogenous sequence can encode for instance antibodies directed against IL-6 or IL-8 or against their receptors IL-6R or IL-8R.

According to a preferred aspect said exogenous sequence can encode soluble extracellular domain of GP130, such as one showing at least 80% identity with SEQ ID NO:61.

Such soluble extracellular domain of GP130 is described for instance by Rose-John S. [The Soluble Interleukine Receptor Advanced Therapeutic Options in Inflammation (2017) *Clinical Pharmacology & Therapeutics*, 102(4):591-598] can be fused with fragments of immunoglobulins, such as sgp130Fc (SEQ ID NO:62). As stated before, said exogenous sequence can be stably integrated into the genome by site directed mutagenesis (i.e. using sequence specific nucleic acid reagents) and be placed under the transcriptional activity of an endogenous promoter at a locus which is active during immune cell activation, such as one listed in Tables 6, 8 or 9, and preferably up-regulated upon CAR activation or being CAR dependent.

According to a more preferred embodiment, the exogenous sequence is introduced into a CAR positive immune cell, such as one expressing an anti-CD22 CAR T-cell polynucleotide sequence such as SEQ ID NO:31. According to some more specific embodiments, said exogenous sequence coding for a polypeptide which can associate, and preferably interfere, with a cytokine receptor of the IL-6 receptor family, such as said soluble extracellular domain of GP130, is integrated at a PD1, CD25 or CD69 locus. As per the present invention, the endogenous sequence encoding PD1 locus is preferably disrupted by said exogenous sequence.

The invention thus provides with a method for treating or reducing CRS in cell immunotherapy, wherein cells or a therapeutic composition thereof are administered to patients, said cells being genetically modified to secrete polypeptide(s) comprising a soluble extracellular domain of GP130, sGP130Fc, an anti-IL-6 or anti-IL-6R antibody, an anti-IL-8 or anti-IL8R antibody, or any fusion thereof.

Examples of preferred genotypes of the engineered immune cells are:

[CAR]^{positive}[GP130]^{positive}
 [CAR]^{positive}[GP130]^{positive}
 [CAR]^{positive}[TCR]^{negative}[GP130]^{positive}[PD1]^{negative}
 [CAR]^{positive}[TCR]^{negative}[GP130]^{positive}[PD1]^{negative}
 [CAR]^{positive}[GP130]^{positive}[CD25]^{negative}
 [CAR]^{positive}[TCR]^{negative}[GP130]^{positive}[CD25]^{negative}

Improving the Efficiency of Gene Targeted Insertion in Primary Immune Cells Using AAV Vectors

The present specification provides with donor templates and sequence specific reagents as illustrated in the figures that are useful to perform efficient insertion of a coding sequence in frame with endogenous promoters, in particular PD1 and CD25, as well as means and sequences for detecting proper insertion of said exogenous sequences at said loci.

The donor templates according to the present invention are generally polynucleotide sequences which can be included into a variety of vectors described in the art prompt to deliver the donor templates into the nucleus at the time the endonuclease reagents get active to obtain their site directed insertion into the genome generally by NHEJ or homologous recombination,

Specifically, the present invention provides specific donor polynucleotides for expression of IL-15 (SEQ ID NO:59) at the PD1 locus comprising one or several of the following sequences:

24

Sequence encoding IL-15, such as one presenting identity with SEQ ID NO:50;

Upstream and downstream (also referred to left and right) sequences homologous to the PD1 locus, comprising preferably polynucleotide sequences SEQ ID NO:45 and SEQ ID NO:46;

optionally, a sequence encoding soluble form of an IL-15 receptor (sIL-15R), such as one presenting identity with SEQ ID NO:50;

optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of IL-12 (SEQ ID NO:58) at the PD1 locus comprising one or several of the following sequences:

Sequence encoding IL-12a, such as one presenting identity with SEQ ID NO:47;

Upstream and downstream (also referred to left and right) sequences homologous to the PD1 locus, comprising preferably polynucleotide sequences SEQ ID NO:45 and SEQ ID NO:46;

optionally, a sequence encoding IL-12b, such as one presenting identity with SEQ ID NO:48;

optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of soluble GP130 (comprising SEQ ID NO:61) at the PD1 locus comprising one or several of the following sequences:

Sequence encoding soluble GP130, preferably a soluble gp130 fused to a Fc, such as one presenting identity with SEQ ID NO:62;

Upstream and downstream (also referred to left and right) sequences homologous to the PD1 locus, comprising preferably polynucleotide sequences SEQ ID NO:45 and SEQ ID NO:46;

optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of IL-15 (SEQ ID NO:59) at the CD25 locus comprising one or several of the following sequences:

Sequence encoding IL-15, such as one presenting identity with SEQ ID NO:50;

Upstream and downstream (also referred to left and right) sequences homologous to the CD25 locus, comprising preferably polynucleotide sequences SEQ ID NO:43 and SEQ ID NO:44;

optionally, a sequence encoding soluble form of an IL-15 receptor (sIL-15R), such as one presenting identity with SEQ ID NO:50;

optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of IL-12 (SEQ ID NO:58) at the CD25 locus comprising one or several of the following sequences:

Sequence encoding IL-12a, such as one presenting identity with SEQ ID NO:47;

Upstream and downstream (also referred to left and right) sequences homologous to the CD25 locus, comprising preferably polynucleotide sequences SEQ ID NO:43 and SEQ ID NO:44;

optionally, a sequence encoding IL-12b, such as one presenting identity with SEQ ID NO:48; optionally, at least one_2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of soluble GP130 (comprising SEQ ID NO:61) at the CD25 locus comprising one or several of the following sequences:

Sequence encoding soluble GP130, preferably a soluble gp130 fused to a Fc, such as one presenting identity with SEQ ID NO:62;

Upstream and downstream (also referred to left and right) sequences homologous to the CD25 locus, comprising preferably polynucleotide sequences SEQ ID NO:43 and SEQ ID NO:44;

optionally, at least one_2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A). As illustrated in the examples herein, the inventors have significantly improved the rate of gene targeted insertion into human cells by using AAV vectors, especially vectors from the AAV6 family.

One broad aspect of the present invention is thus the transduction of AAV vectors in human primary immune cells, in conjunction with the expression of sequence specific endonuclease reagents, such as TALE endonucleases, more preferably introduced under mRNA form, to increase homologous recombination events in these cells.

According to one aspect of this invention, sequence specific endonuclease reagents can be introduced into the cells by transfection, more preferably by electroporation of mRNA encoding said sequence specific endonuclease reagents, such as TALE nucleases.

Still according to this broad aspect, the invention more particularly provides a method of insertion of an exogenous nucleic acid sequence into an endogenous polynucleotide sequence in a cell, comprising at least the steps of transducing into said cell an AAV vector comprising said exogenous nucleic acid sequence and sequences homologous to the targeted endogenous DNA sequence, and

Inducing the expression of a sequence specific endonuclease reagent to cleave said endogenous sequence at the locus of insertion.

The obtained insertion of the exogenous nucleic acid sequence may result into the introduction of genetic material, correction or replacement of the endogenous sequence, more preferably "in frame" with respect to the endogenous gene sequences at that locus.

According to another aspect of the invention, from 10^5 to 10^7 preferably from 10^6 to 10^7 , more preferably about $5 \cdot 10^6$ viral genomes are transduced per cell.

According to another aspect of the invention, the cells can be treated with proteasome inhibitors, such as Bortezomib to further help homologous recombination.

As one object of the present invention, the AAV vector used in the method can comprise a promoterless exogenous coding sequence as any of those referred to in this specification in order to be placed under control of an endogenous promoter at one loci selected among those listed in the present specification.

As one object of the present invention, the AAV vector used in the method can comprise a 2A peptide cleavage site followed by the cDNA (minus the start codon) forming the exogenous coding sequence.

As one object of the present invention, said AAV vector comprises an exogenous sequence coding for a chimeric antigen receptor, especially an anti-CD19 CAR, an anti-CD22 CAR, an anti-CD123 CAR, an anti-CS1 CAR, an anti-CCL1 CAR, an anti-HSP70 CAR, an anti-GD3 CAR or an anti-ROR1 CAR.

The invention thus encompasses any AAV vectors designed to perform the method herein described, especially vectors comprising a sequence homologous to a locus of insertion located in any of the endogenous gene responsive to T-cell activation referred to in Table 4.

Many other vectors known in the art, such as plasmids, episomal vectors, linear DNA matrices, etc. . . . can also be used following the teachings to the present invention.

As stated before, the DNA vector used according to the invention preferably comprises: (1) said exogenous nucleic acid comprising the exogenous coding sequence to be inserted by homologous recombination, and (2) a sequence encoding the sequence specific endonuclease reagent that promotes said insertion. According to a more preferred aspect, said exogenous nucleic acid under (1) does not comprise any promoter sequence, whereas the sequence under (2) has its own promoter. According to an even more preferred aspect, the nucleic acid under (1) comprises an Internal Ribosome Entry Site (IRES) or "self-cleaving" 2A peptides, such as T2A, P2A, E2A or F2A, so that the endogenous gene where the exogenous coding sequence is inserted becomes multi-cistronic. The IRES of 2A Peptide can precede or follow said exogenous coding sequence.

Preferred vectors of the present invention are vectors derived from AAV6, comprising donor polynucleotides as previously described herein or illustrated in the experimental section and figures. Examples of vectors according to the invention comprise or consist of polynucleotides having identity with sequences SEQ ID NO:37 (matrix for integration of sequence coding for IL-15 into the CD25 locus), SEQ ID NO:38 (matrix for integration of sequence coding for IL-15 into the PD1 locus) SEQ ID NO:39 (matrix for integration of sequence coding for IL-12 into the CD25 locus) and SEQ ID NO:40 (matrix for integration of sequence coding for IL-12 into the PD1 locus).

Gene Targeted Integration in Immune Cells Under Transcriptional Control of Endogenous Promoters

The present invention, in one of its main aspects, is taking advantage of the endogenous transcriptional activity of the immune cells to express exogenous sequences that improve their therapeutic potential.

The invention provides with several embodiments based on the profile of transcriptional activity of the endogenous promoters and on a selection of promoter loci useful to carry out the invention. Preferred loci are those, which transcription activity is generally high upon immune cell activation, especially in response to CAR activation (CAR-sensitive promoters) when the cells are endowed with CARs.

Accordingly, the invention provides with a method for producing allogeneic therapeutic immune cells by expressing a first exogenous sequence encoding a CAR at the TCR locus, thereby disrupting TCR expression, and expressing a second exogenous coding sequence under transcriptional activity of an endogenous locus, preferably dependent from either:

CD3/CD28 activation, such as dynabeads, which is useful for instance for promoting cells expansion;
CAR activation, such as through the CD3zeta pathway, which is useful for instance to activate immune cells functions on-target;

Transcriptional activity linked to the appearance of disease symptom or molecular marker, which is useful for instance for activating the cells in-situ in ill organs. Cell differentiation, which is useful for conferring therapeutic properties to cells at a given level of differentiation or to express protein into a particular lineage (see FIG. 1), for instance at the time hematopoietic cells gain their immune functions; or/and TME (Tumor microenvironment), which is useful for redirect cells activity and their amplification to specific tumor conditions (hypoxia, low glucose . . .), or for preventing exhaustion and/or sustaining activation; CRS (cytokine release syndrome), which is useful to mitigate adverse events related to CAR T-cell activity

The inventors have established a first list of endogenous genes (Table 6) which have been found to be particularly appropriate for applying the targeted gene recombination as per the present invention. To draw this list, they have come across several transcriptome murine databases, in particular that from the Immunological Genome Project Consortium referred to in Best J. A. et al. (2013) "Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation" *Nat. Immunol.* 14(4):404-12., which allows comparing transcription levels of various genes upon T-cell activation, in response to ovalbumin antigens. Also, because very few data is available with respect to human T-cell activation, they had to make some extrapolations and analysis from these data and compare with the human situation by studying available literature related to the human genes. The selected loci are particularly relevant for the insertion of sequences encoding CARs. Based on the first selection of Table 6, they made subsequent selections of genes based on their expected expression profiles (Tables 7 to 10).

On another hand, the inventors have identified a selection of transcriptional loci that are mostly inactive, which would be most appropriate to insert expression cassette(s) to express exogenous coding sequence under the transcriptional control of exogenous promoters. These loci are referred to as "safe harbor loci" as those being mostly transcriptionally inactive, especially during T-Cell activation. They are useful to integrate a coding sequence by reducing at the maximum the risk of interfering with genome expression of the immune cells.

Gene Targeted Insertion Under Control of Endogenous Promoters that are Steadily Active During Immune Cell Activation

A selection of endogenous gene loci related to this embodiment is listed in Table 7.

Accordingly the method of the present invention provides with the step of performing gene targeted insertion under control of an endogenous promoter that is constantly active during immune cell activation, preferably from of an endogenous gene selected from CD3G, Rn28s1, Rn18s, Rn7sk, Actg1, β2m, Rpl18a, Pabpc1, Gapdh, Rpl17, Rpl19, Rplp0, Cfl1 and Pfn1.

By "steadily active" means that the transcriptional activity observed for these promoters in the primary immune cell is not affected by a negative regulation upon the activation of the immune cell.

As reported elsewhere (Acuto, O. (2008) "Tailoring T-cell receptor signals by proximal negative feedback mechanisms". *Nature Reviews Immunology* 8:699-712), the promoters present at the TCR locus are subjected to different negative feedback mechanisms upon TCR engagement and thus may not be steadily active or up regulated during for the method of the present invention. The present invention has

been designed to some extend to avoid using the TCR locus as a possible insertion site for exogenous coding sequences to be expressed during T-cell activation. Therefore, according to one aspect of the invention, the targeted insertion of the exogenous coding sequence is not performed at a TCRalpha or TCRbeta gene locus.

Examples of exogenous coding sequence that can be advantageously introduced at such loci under the control of steadily active endogenous promoters, are those encoding or positively regulating the production of a cytokine, a chemokine receptor, a molecule conferring resistance to a drug, a co-stimulation ligand, such as 4-1BRL and OX40L, or of a secreted antibody.

Gene Integration Under Endogenous Promoters that are Dependent from Immune Cell Activation or Dependent from CAR Activation

As stated before, the method of the present invention provides with the step of performing gene targeted insertion under control of an endogenous promoter, which transcriptional activity is preferably up-regulated upon immune cell activation, either transiently or over more than 10 days.

By "immune cell activation" is meant production of an immune response as per the mechanisms generally described and commonly established in the literature for a given type of immune cells. With respect to T-cell, for instance, T-cell activation is generally characterized by one of the changes consisting of cell surface expression by production of a variety of proteins, including CD69, CD71 and CD25 (also a marker for Treg cells), and HLA-DR (a marker of human T cell activation), release of perforin, granzymes and granzylisin (degranulation), or production of cytokine effectors IFN-γ, TNF and LT-alpha.

According to a preferred embodiment of the invention, the transcriptional activity of the endogenous gene is up-regulated in the immune cell, especially in response to an activation by a CAR. The CAR can be independently expressed in the immune cell. By "independently expressed" is meant that the CAR can be transcribed in the immune cell from an exogenous expression cassette introduced, for instance, using a retroviral vector, such as a lentiviral vector, or by transfecting capped messenger RNAs by electroporation encoding such CAR. Many methods are known in the art to express a CAR into an immune cell as described for instance by (REF.)

Said endogenous gene whose transcriptional activity is up-regulated are particularly appropriate for the integration of exogenous sequences to encode cytokine(s), such as IL-12 and IL-15, immunogenic peptide(s), or a secreted antibody, such as an anti-IDO1, anti-IL10, anti-PD1, anti-PDL1, anti-IL6 or anti-PGE2 antibody.

According to a preferred embodiment of the invention, the endogenous promoter is selected for its transcriptional activity being responsive to, and more preferably being dependent from CAR activation.

As shown herein, CD69, CD25 and PD1 are such loci, which are particularly appropriate for the insertion of expression of an exogenous coding sequences to be expressed when the immune cells get activated, especially into CAR positive immune cells.

The present invention thus combines any methods of expressing a CAR into an immune cell with the step of performing a site directed insertion of an exogenous coding sequence at a locus, the transcriptional activity of which is responsive to or dependent from the engagement of said CAR with a tumor antigen. Especially, the method comprises the step of introducing into a CAR positive or Recombinant TCR positive immune cell an exogenous

sequence encoding IL-12 or IL-15 under transcriptional control of one promoter selected from PD1, CD25 and CD69 promoters.

In particular, CAR positive cells can obtain by following the steps of co-expressing into an immune cell, preferably a primary cell, and more preferably into a primary T-cell, at least one exogenous sequence encoding a CAR and another exogenous sequence placed under an endogenous promoter dependent, which transcriptional activity is dependent from said CAR, such a PD1, CD25 or CD71.

The expression "dependent from said CAR" means that the transcriptional activity of said endogenous promoter is necessary increased by more than 10%, preferably by more than 20%, more preferably by more than 50% and even more preferably more than 80%, as a result of the engagement of the CAR with its cognate antigen, in a situation where, in general, the antigens are exceeding the number of CARs present at the cell surface and the number of CARs expressed at the cell surface is more than 10 per cell, preferably more than 100, and more preferably more than 1000 molecules per cells.

The present invention thus teaches the expression of a CAR sequence, preferably inserted at the TCR locus and constitutively expressed, whereas another exogenous sequence integrated at another locus is co-expressed, in response to, or dependent from, the engagement of said CAR with its cognate antigen. Said another locus is for instance CD25, PD1 or CD71 or any loci being specifically transcribed upon CAR activation.

In other words, the invention provides the co-expression of a CAR and at least one exogenous coding sequence, the expression of said exogenous sequence being under control of an endogenous promoter the transcriptional activity of which is influenced by the CAR activity, this being done in view of obtaining engineered immune cells offering a better immune response.

As previously described, this can be performed by transfecting the cells with sequence-specific nuclease reagents targeting the coding regions of such loci being specifically CAR dependent, along with donor templates comprising sequences homologous to said genomic regions. The sequence specific nuclease reagents help the donor templates to be integrated by homologous recombination or NHEJ.

According to a preferred embodiment, the exogenous coding sequence is integrated in frame with the endogenous gene, so that the expression of said endogenous gene is preserved. This is the case for instance with respect to CD25 and CD69 in at least one example of the experimental section herein.

According to a preferred embodiment, the exogenous sequence disrupts the endogenous coding sequence of the gene to prevent its expression of one endogenous coding sequence, especially when this expression has a negative effect on the immune cell functions, as it the case for instance with PD1 in the experimental section herein.

According to an even more preferred embodiments, the exogenous coding sequence, which disrupts the endogenous gene sequence is placed in frame with the endogenous promoter, so that its expression is made dependent from the endogenous promoter as also shown in the experimental section.

The present invention is also drawn to the polynucleotide and polypeptide sequences encoding the different TAL-nucleases exemplified in the present patent application, especially those permitting the site directed insertion at the CD25 locus (SEQ ID NO:18 and 19), as well as their respective target and RVD sequences.

The present invention also encompasses kits for immune cells transfection comprising polynucleotides encoding the sequence-specific endonuclease reagents and the donor sequences designed to integrate the exogenous sequence at the locus targeted by said reagents. Examples of such kits are a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN®) and an AAV vector comprising an exogenous sequence encoding IL-12, a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN®) and an AAV vector comprising an exogenous sequence encoding IL-15, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN®) and an AAV vector comprising an exogenous sequence encoding IL-12, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN®) and an AAV vector comprising an exogenous sequence encoding IL-15, a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN®) and an AAV vector comprising an exogenous sequence encoding soluble gp130, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN®) and an AAV vector comprising an exogenous sequence encoding soluble gp130, and any kits involving endonuclease reagents targeting a gene listed in table 6, and a donor matrix for introducing a coding sequence referred to in the present specification.

According to one aspect of the invention, the endogenous gene is selected for a weak up-regulation. The exogenous coding sequence introduced into said endogenous gene whose transcriptional activity is weakly up regulated, can be advantageously a constituent of an inhibitory CAR, or of an apoptotic CAR, which expression level has generally to remain lower than that of a positive CAR. Such combination of CAR expression, for instance one transduced with a viral vector and the other introduced according to the invention, can greatly improve the specificity or safety of CAR immune cells

Some endogenous promoters are transiently up-regulated, sometimes over less than 12 hours upon immune cell activation, such as those selected from the endogenous gene loci Spata6, Itga6, Rcbtb2, Cdld1, St8sia4, Itgae and Fam214a (Table 8). Other endogenous promoters are up-regulated over less than 24 hours upon immune cell activation, such as those selected from the endogenous gene loci IL3, IL2, Ccl4, IL21, Gp49a, Nr4a3, Lirb4, Cd200, Cdkn1a, Gzmc, Nr4a2, Cish, Ccr8, Lad1 and Crabp2 (Table 9) and others over more than 24 hours, more generally over more than 10 days, upon immune cell activation. Such as those selected from Gzmb, Tbx21, Plek, Chek1, Slamf7, Zbtb32, Tigit, Lag3, Gzma, Wee1, IL12rb2, Eea1 and DtU (Table 9).

Alternatively, the inventors have found that endogenous gene under transcriptional control of promoters that are down-regulated upon immune cell activation, could also be of interest for the method according to the present invention. Indeed they have conceived that exogenous coding sequences encoding anti-apoptotic factors, such as of Bcl2 family, BcIXL, NF- κ B, Survivin, or anti-FAP (fibroblast activation protein), such as a constituent of a CAR anti-FAP, could be introduced at said loci. Said endogenous gene under transcriptional control of promoters that are down-regulated upon immune cell activation can be more particularly selected from Slc6a19, Cd55, Xkrx, Mtum, H2-Ob, Cnr2, Itgae, Raver2, Zbtb20, Arrb1, Abca1, Tet1, Sic16a5 and Ampd3 (Table 10)

31

Gene Integration Under Endogenous Promoters Activated Under Tumor Microenvironment (TME) Conditions

One aspect of the present invention more particularly concerns methods to prevent immune cells exhaustion in tumor microenvironment (TME) conditions. Immune cells often get exhausted in response to nutrient depletion or molecular signals found in the microenvironment of tumors, which helps tumor resistance. The method comprises the steps of engineering immune cells by integrating exogenous coding sequences under control of endogenous promoters which are up-regulated under arginine, cysteine, tryptophan and oxygen deprivation as well as extracellular acidosis (lactate build up).

Such exogenous sequences may encode chimeric antigen receptors, interleukins, or any polypeptide given elsewhere in this specification to bolster immune cells function or activation and/or confer a therapeutic advantage.

The inventors have listed a number of loci which have been found to be upregulated in a large number of exhausted tumor infiltrating lymphocytes (TIL), which are listed in tables 12 and 13. The invention provides with the step of integrating exogenous coding sequences at these preferred loci to prevent exhaustion of the immune cells, in particular T-cells, in tumor microenvironment.

For instance, the exogenous sequences encoding a CAR can be placed under transcriptional control of the promoter of endogenous genes that are activated by the tumor microenvironment, such as HIF1a, transcription factor hypoxia-inducible factor, or the aryl hydrocarbon receptor (AhR). These gene are sensors respectively induced by hypoxia and xenobiotics in the close environment of tumors.

The present invention is thus useful to improve the therapeutic outcome of CAR T-cell therapies by integrating exogenous coding sequences, and more generally genetic attributes/circuits, under the control of endogenous T-cell promoters influenced by tumor microenvironment (TME).

Pursuant to the invention, upregulation of endogenous genes can be “hijacked” to re-express relevant exogenous coding sequences to improve the antitumor activity of CAR T-cells in certain tumor microenvironment

Gene Targeted Insertion and Expression in Hematopoietic Stem Cells (HSCs)

One aspect of the present invention more particularly concerns the insertion of transgenes into hematopoietic stem cells (HSCs).

Hematopoietic stem cells (HSCs) are multipotent, self-renewing progenitor cells from which all differentiated blood cell types arise during the process of hematopoiesis. These cells include lymphocytes, granulocytes, and macrophages of the immune system as well as circulating erythrocytes and platelets. Classically, HSCs are thought to differentiate into two lineage-restricted, lymphoid and myelo-erythroid, oligopotent progenitor cells. The mechanisms controlling HSC self-renewal and differentiation are thought to be influenced by a diverse set of cytokines, chemokines, receptors, and intracellular signaling molecules. Differentiation of HSCs is regulated, in part, by growth factors and cytokines including colony-stimulating factors (CSFs) and interleukins (ILs) that activate intracellular signaling pathways. The factors depicted below are known to influence HSC multipotency, proliferation, and lineage commitment. HSCs and their differentiated progeny can be identified by the expression of specific cell surface lineage markers such as cluster of differentiation (CD) proteins and cytokine receptors into hematopoietic stem cells.

32

Gene therapy using HSCs has enormous potential to treat diseases of the hematopoietic system including immune diseases. In this approach, HSCs are collected from a patient, gene-modified ex-vivo using integrating retroviral vectors, and then infused into a patient. To date retroviral vectors have been the only effective gene delivery system for HSC gene therapy. Gene delivery to HSCs using integrating vectors thereby allowing for efficient delivery to HSC-derived mature hematopoietic cells. However, the gene-modified cells that are infused into a patient are a polyclonal population, where the different cells have vector proviruses integrated at different chromosomal locations, which can result into many adverse mutations, which may be amplified due to some proliferative/survival advantage of these mutations (Powers and Trobridge (2013) “Identification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies” *J Stem Cell Res Ther* S3:004. doi:10.4172/2157-7633.S3-00).

HSCs are commonly harvested from the peripheral blood after mobilization (patients receive recombinant human granulocyte-colony stimulating factor (G-CSF)). The patient's peripheral blood is collected and enriched for HSCs using the CD34+ marker. HSCs are then cultured ex vivo and exposed to viral vectors. The ex vivo culture period varies from 1 to 4 days. Prior to the infusion of gene-modified HSCs, patients may be treated with chemotherapy agents or irradiation to help enhance the engraftment efficiency. Gene-modified HSCs are re-infused into the patient intravenously. The cells migrate into the bone marrow before finally residing in the sinusoids and perivascular tissue. Both homing and hematopoiesis are integral aspects of engraftment. Cells that have reached the stem cell niche through homing will begin producing mature myeloid and lymphoid cells from each blood lineage. Hematopoiesis continues through the action of long-term HSCs, which are capable of self-renewal for life-long generation of the patient's mature blood cells, in particular the production of common lymphoid progenitor cells, such as T cells and NK cells, which are key immune cells for eliminating infected and malignant cells.

The present invention provides with performing gene targeted insertion in HSCs to introduce exogenous coding sequences under the control of endogenous promoters, especially endogenous promoters of genes that are specifically activated into cells of a particular hematopoietic lineage or at particular differentiation stage, preferably at a late stage of differentiation. The HSCs can be transduced with a poly-nucleotide vector (donor template), such as an AAV vector, during an ex-vivo treatment as referred to in the previous paragraph, whereas a sequence specific nuclease reagent is expressed as to promote the insertion of the coding sequences at the selected locus. The resulting engineered HSCs can be then engrafted into a patient in need thereof for a long term in-vivo production of engineered immune cells that will comprise said exogenous coding sequences. Depending on the activity of the selected endogenous promoter, the coding sequences will be selectively expressed in certain lineages or in response to the local environment of the immune cells in-vivo, thereby providing adoptive immunotherapy.

According to one preferred aspect of the invention, the exogenous coding sequences are placed under the control of promoters of a gene, which transcriptional activity is specifically induced in common lymphoid progenitor cells, such as CD34, CD43, Flt-3/Flik-2, IL-7 R alpha/CD127 and Neprilysin/CD10.

More preferably, the exogenous coding sequences are placed under the control of promoters of a gene, which transcriptional activity is specifically induced in NK cells, such as CD161, CD229/SLAMF3, CD96, DNAM-1/CD226, Fc gamma RII/CD32, Fc gamma RII/RIII (CD32/CD16), Fc gamma RIII (CD16), IL-2 R beta, Integrin alpha 2/CD49b, KIR/CD158, NCAM-1/CD56, NKG2A/CD159a, NKG2C/CD159c, NKG2D/CD314, NKp30/NCR3, NKp44/NCR2, NKp46/NCR1, NKp80/KLRF1, Siglec-7/CD328 and TIGIT, or induced in T-cells, such as CCR7, CD2, CD3, CD4, CD8, CD28, CD45, CD96, CD229/SLAMF3, DNAM-1/CD226, CD25/AL-2 R alpha, L-Selectin/CD62L and TIGIT.

The invention comprises as a preferred aspect the introduction of an exogenous sequence encoding a CAR, or a component thereof, into HSCs, preferably under the transcriptional control of a promoter of a gene that is not expressed in HSC, more preferably a gene that is only expressed in the hematopoietic cells produced by said HSC, and even more preferably of a gene that is only expressed in T-cells or NK cells.

Conditional CAR Expression in HSCs to Overpass the Thymus Barrier

A particular aspect of the present invention concerns the in-vivo production by the above engineered HSCs of hematopoietic immune cells, such as T-cells or NK-cells, expressing exogenous coding sequences, in particular a CAR or a component thereof.

One major bar of the production of hematopoietic CAR positive cells by engineered HSCs, for instance, is the rejection of the CAR positive cells by the immune system itself, especially by the thymus.

The blood-thymus barrier regulates exchange of substances between the circulatory system and thymus, providing a sequestered environment for immature T cells to develop. The barrier also prevents the immature T cells from contacting foreign antigens (since contact with antigens at this stage will cause the T cells to die by apoptosis).

One solution provided by the present invention is to place the sequences encoding the CAR components in the HSCs under the transcriptional control of promoters which are not significantly transcribed into the hematopoietic cells when they pass through the thymus barrier. One example of a gene that offers a conditional expression of the CAR into the hematopoietic cells with reduced or no significant transcriptional activity in the thymus is LCK (Uniprot P06239).

According to a preferred aspect of the invention the exogenous sequence encoding a CAR, or a component thereof, is introduced into the HSC under the transcriptional control of a gene that is described as being specifically expressed in T-cells or NK cells, preferably in these types of cells only.

The invention thereby provides with a method of producing HSCs comprising an exogenous coding sequences to be expressed exclusively in selected hematopoietic lineage(s), said coding sequences encoding preferably at least one component of a CAR or of an antigen in order to stimulate the immune system.

More broadly, the invention provides with a method of engineering HSCs by gene targeted insertion of an exogenous coding sequences to be selectively expressed in the hematopoietic cells produced by said HSCs. As a preferred embodiment, said hematopoietic cells produced by said engineered HSCs express said exogenous coding sequences in response to selected environmental factors or in-vivo stimuli to improve their therapeutic potential.

Combining Targeted Sequence Insertion(s) in Immune Cells with the Inactivation of Endogenous Genomic Sequences

One particular focus of the present invention is to perform gene inactivation in primary immune cells at a locus, by integrating exogenous coding sequence at said locus, the expression of which improves the therapeutic potential of said engineered cells. Examples of relevant exogenous coding sequences that can be inserted according to the invention have been presented above in connection with their positive effects on the therapeutic potential of the cells. Here below are presented the endogenous gene that are preferably targeted by gene targeted insertion and the advantages associated with their inactivation.

According to a preferred aspect of the invention, the insertion of the coding sequence has the effect of reducing or preventing the expression of genes involved into self and non-self recognition to reduce host versus graft disease (GVHD) reaction or immune rejection upon introduction of the allogeneic cells into a recipient patient. For instance, one of the sequence-specific reagents used in the method can reduce or prevent the expression of TCR in primary T-cells, such as the genes encoding TCR-alpha or TCR-beta.

As another preferred aspect, one gene editing step is to reduce or prevent the expression of the 182m protein and/or another protein involved in its regulation such as C2TA (Uniprot P33076) or in MHC recognition, such as HLA proteins. This permits the engineered immune cells to be less alloreactive when infused into patients.

By "allogeneic therapeutic use" is meant that the cells originate from a donor in view of being infused into patients having a different haplotype. Indeed, the present invention provides with an efficient method for obtaining primary cells, which can be gene edited in various gene loci involved into host-graft interaction and recognition.

Other loci may also be edited in view of improving the activity, the persistence of the therapeutic activity of the engineered primary cells as detailed here after
Inactivation of Checkpoint Receptors and Immune Cells Inhibitory Pathways:

According to a preferred aspect of the invention, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of a protein involved in immune cells inhibitory pathways, in particular those referred to in the literature as "immune checkpoint" (Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy, *Nature Reviews Cancer*, 12:252-264). In the sense of the present invention, "immune cells inhibitory pathways" means any gene expression in immune cells that leads to a reduction of the cytotoxic activity of the lymphocytes towards malignant or infected cells. This can be for instance a gene involved into the expression of FOXP3, which is known to drive the activity of Tregs upon T cells (moderating T-cell activity).

"Immune checkpoints" are molecules in the immune system that either turn up a signal (co-stimulatory molecules) or turn down a signal of activation of an immune cell. As per the present invention, immune checkpoints more particularly designate surface proteins involved in the ligand-receptor interactions between T cells and antigen-presenting cells (APCs) that regulate the T cell response to antigen (which is mediated by peptide-major histocompatibility complex (MHC) molecule complexes that are recognized by the T cell receptor (TCR)). These interactions can occur at the initiation of T cell responses in lymph nodes (where the major APCs are dendritic cells) or in peripheral tissues or tumours (where effector responses are regulated). One important family of membrane-bound ligands that bind

both co-stimulatory and inhibitory receptors is the B7 family. All of the B7 family members and their known ligands belong to the immunoglobulin superfamily. Many of the receptors for more recently identified B7 family members have not yet been identified. Tumour necrosis factor (TNF) family members that bind to cognate TNF receptor family molecules represent a second family of regulatory ligand-receptor pairs. These receptors predominantly deliver co-stimulatory signals when engaged by their cognate ligands. Another major category of signals that regulate the activation of T cells comes from soluble cytokines in the microenvironment. In other cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on APCs. A2aR, adenosine A2a receptor; B7RP1, B7-related protein 1; BTLA, B and T lymphocyte attenuator; GAL9, galectin 9; HVEM, herpesvirus entry mediator; ICOS, inducible T cell co-stimulator; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; LAG3, lymphocyte activation gene 3; PD1, programmed cell death protein 1; PDL, PD1 ligand; TGF β , transforming growth factor- β ; TIM3, T cell membrane protein 3.

Examples of further endogenous genes, which expression could be reduced or suppressed to turn-up activation in the engineered immune cells according the present invention are listed in Table 3.

For instance, the inserted exogenous coding sequence(s) can have the effect of reducing or preventing the expression, by the engineered immune cell of at least one protein selected from PD1 (Uniprot Q15116), CTLA4 (Uniprot P16410), PPP2CA (Uniprot P67775), PPP2CB (Uniprot

P62714), PTPN6 (Uniprot P29350), PTPN22 (Uniprot Q9Y2R2), LAG3 (Uniprot P18627), HAVCR2 (Uniprot Q8TDQ0), BTLA (Uniprot Q7Z6A9), CD160 (Uniprot 095971), TIGIT (Uniprot Q495A1), CD96 (Uniprot P40200), CRTAM (Uniprot 095727), LAIR1 (Uniprot Q6GTX8), SIGLEC7 (Uniprot Q9Y286), SIGLEC9 (Uniprot Q9Y336), CD244 (Uniprot Q9BZWC), TNFRSF1B (Uniprot Q14763), TNFRSF10A (Uniprot Q00220), CASP8 (Uniprot Q14790), CASP10 (Uniprot Q92851), CASP3 (Uniprot P42574), CASP6 (Uniprot P55212), CASP7 (Uniprot P55210), FADD (Uniprot Q13158), FAS (Uniprot P25445), TGFBRII (Uniprot P37173), TGFBRI (Uniprot Q15582), SMAD2 (Uniprot Q15796), SMAD3 (Uniprot P84022), SMAD4 (Uniprot Q13485), SMAD10 (Uniprot B7ZSB5), SKI (Uniprot P12755), SKIL (Uniprot P12757), TGIF1 (Uniprot Q15583), IL10RA (Uniprot Q13651), IL10RB (Uniprot Q08334), HMOX2 (Uniprot P30519), IL6R (Uniprot P08887), IL6ST (Uniprot P40189), EIF2AK4 (Uniprot Q9P2K8), CSK (Uniprot P41240), PAG1 (Uniprot Q9NWQ8), SIT1 (Uniprot Q9Y3P8), FOXP3 (Uniprot Q9BZS1), PRDM1 (Uniprot Q60636), BATF (Uniprot Q16520), GUCY1A2 (Uniprot P33402), GUCY1A3 (Uniprot Q02108), GUCY1B2 (Uniprot Q8BXH3) and GUCYB3 (Uniprot Q02153). The gene editing introduced in the genes encoding the above proteins is preferably combined with an inactivation of TCR in CAR T cells.

Preference is given to inactivation of PD1 and/or CTLA4, in combination with the expression of non-endogenous immunosuppressive polypeptide, such as a PD-L1 ligand and/or CTLA-4 Ig (see also peptides of Table 1 and 2).

TABLE 3

List of genes involved into immune cells inhibitory pathways		
Pathway		Genes that can be inactivated In the pathway
Co-inhibitory receptors	CTLA4 (CD152) PDCD1 (PD-1, CD279) CD223 (lag3) HAVCR2 (tim3) BTLA(cd272) CD160(by55) IgSF family LAIR1(cd305) SIGLECs CD244(2b4) Death receptors TRAIL FAS Cytokine signalling TGF-beta signaling IL10 signalling IL6 signalling Prevention of TCR signalling Induced Treg Transcription factors controlling exhaustion Hypoxia mediated tolerance	CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22 PDCD1 LAG3 HAVCR2 BTLA CD160 TIGIT CD96 CRTAM LAIR1 SIGLEC7 SIGLEC9 CD244 TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7 FADD, FAS TGFBRII, TGFBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1 IL10RA, IL10RB, HMOX2 IL6R, IL6ST CSK, PAG1 SIT1 FOXP3 PRDM1 BATF GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3

Inhibiting Suppressive Cytokines/Metabolites

According to another aspect of the invention, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of genes encoding or positively regulating suppressive cytokines or metabolites or receptors thereof, in particular TGFbeta (Uniprot:P01137), TGFbR (UniprotP37173), IL10 (Uniprot:P22301), IL10R (Uniprot: Q13651 and/or Q08334), A2aR (Uniprot: P29274), GCN2 (Uniprot: P15442) and PRDM1 (Uniprot: 075626).

Preference is given to engineered immune cells in which a sequence encoding IL-2, IL-12 or IL-15 replaces the sequence of at least one of the above endogenous genes.

Inducing Resistance to Chemotherapy Drugs

According to another aspect of the present method, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of a gene responsible for the sensitivity of the immune cells to compounds used in standard of care treatments for cancer or infection, such as drugs purine nucleotide analogs (PNA) or 6-Mercaptopurine (6MP) and 6 thio-guanine (6TG) commonly used in chemotherapy. Reducing or inactivating the genes involved into the mode of action of such compounds (referred to as "drug sensitizing genes") improves the resistance of the immune cells to same.

Examples of drug sensitizing gene are those encoding DCK (Uniprot P27707) with respect to the activity of PNA, such a clorofarabine et fludarabine, HPRT (Uniprot P00492) with respect to the activity of purine antimetabolites such as 6MP and 6TG, and GGH (Uniprot Q92820) with respect to the activity of antifolate drugs, in particular methotrexate.

This enables the cells to be used after or in combination with conventional anti-cancer chemotherapies.

Resistance to Immune-Suppressive Treatments

According to another aspect of the present invention, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of receptors or proteins, which are drug targets, making said cells resistant to immune-depletion drug treatments. Such target can be glucocorticoids receptors or antigens, to make the engineered immune cells resistant to glucocorticoids or immune depletion treatments using antibodies such as Alemtuzumab, which is used to deplete CD52 positive immune cells in many cancer treatments.

Also the method of the invention can comprise gene targeted insertion in endogenous gene(s) encoding or regulating the expression of CD52 (Uniprot P31358) and/or GR (Glucocorticoids receptor also referred to as NR3C1— Uniprot P04150).

Improving CAR Positive Immune Cells Activity and Survival

According to another aspect of the present invention, the inserted exogenous coding sequence can have the effect of reducing or preventing the expression of a surface antigen, such as BCMA, CS1 and CD38, wherein such antigen is one targeted by a CAR expressed by said immune cells.

This embodiment can solve the problem of CAR targeting antigens that are present at the surface of infected or malignant cells, but also to some extent expressed by the immune cell itself.

According to a preferred embodiment the exogenous sequence encoding the CAR or one of its constituents is integrated into the gene encoding the antigen targeted by said CAR to avoid self-destruction of the immune cells.

Engineered Immune Cells and Populations of Immune Cells

The present invention is also drawn to the variety of engineered immune cells obtainable according to one of the method described previously under isolated form or as part of populations of cells.

According to a preferred aspect of the invention the engineered cells are primary immune cells, such as NK cells or T-cells, which are generally part of populations of cells that may involve different types of cells. In general, population deriving from patients or donors isolated by leukapheresis from PBMC (peripheral blood mononuclear cells).

According to a preferred aspect of the invention, more than 50% of the immune cells comprised in said population are TCR negative T-cells. According to a more preferred aspect of the invention, more than 50% of the immune cells comprised in said population are CAR positive T-cells.

The present invention encompasses immune cells comprising any combinations of the different exogenous coding sequences and gene inactivation, which have been respectively and independently described above. Among these combinations are particularly preferred those combining the expression of a CAR under the transcriptional control of an endogenous promoter that is steadily active during immune cell activation and preferably independently from said activation, and the expression of an exogenous sequence encoding a cytokine, such as IL-2, IL-12 or IL-15, under the transcriptional control of a promoter that is up-regulated during the immune cell activation.

Another preferred combination is the insertion of an exogenous sequence encoding a CAR or one of its constituents under the transcription control of the hypoxia-inducible factor 1 gene promoter (Uniprot: Q16665).

The invention is also drawn to a pharmaceutical composition comprising an engineered primary immune cell or immune cell population as previously described for the treatment of infection or cancer, and to a method for treating a patient in need thereof, wherein said method comprises:

preparing a population of engineered primary immune cells according to the method of the invention as previously described;

optionally, purifying or sorting said engineered primary immune cells;

activating said population of engineered primary immune cells upon or after infusion of said cells into said patient.

Activation and Expansion of T Cells

Whether prior to or after genetic modification, the immune cells according to the present invention can be activated or expanded, even if they can activate or proliferate independently of antigen binding mechanisms. T-cells, in particular, can be activated and expanded using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. T cells can be expanded in vitro or in vivo. T cells are generally expanded by contact with an agent that stimulates a CD3 TCR complex and a co-stimulatory molecule on the surface of the T cells to create an activation signal for the T-cell. For example, chemicals such as calcium ionophore A23187, phorbol 12-myristate 13-acetate (PMA), or mitogenic lectins like phytohemagglutinin (PHA) can be used to create an activation signal for the T-cell.

As non-limiting examples, T cell populations may be stimulated in vitro such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-

CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , IL-4, IL-7, GM-CSF, -10, -2, IL-15, TGF β , and TNF- or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptopethanol. Media can include RPMI 1640, A1M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% CO₂). T cells that have been exposed to varied stimulation times may exhibit different characteristics.

In another particular embodiment, said cells can be expanded by co-culturing with tissue or cells. Said cells can also be expanded in vivo, for example in the subject's blood after administrating said cell into the subject.

Therapeutic Compositions and Applications

The method of the present invention described above allows producing engineered primary immune cells within a limited time frame of about 15 to 30 days, preferably between 15 and 20 days, and most preferably between 18 and 20 days so that they keep their full immune therapeutic potential, especially with respect to their cytotoxic activity.

These cells form a population of cells, which preferably originate from a single donor or patient. These populations of cells can be expanded under closed culture recipients to comply with highest manufacturing practices requirements and can be frozen prior to infusion into a patient, thereby providing "off the shelf" or "ready to use" therapeutic compositions.

As per the present invention, a significant number of cells originating from the same Leukapheresis can be obtained, which is critical to obtain sufficient doses for treating a patient. Although variations between populations of cells originating from various donors may be observed, the number of immune cells procured by a leukapheresis is generally about from 10⁸ to 10¹⁰ cells of PBMC. PBMC comprises several types of cells: granulocytes, monocytes and lymphocytes, among which from 30 to 60% of T-cells, which generally represents between 10⁸ to 10⁹ of primary T-cells from one donor. The method of the present invention generally ends up with a population of engineered cells that reaches generally more than about 10⁸ T-cells, more generally more than about 10⁹ T-cells, even more generally more than about 10¹⁰ T-cells, and usually more than 10¹¹ T-cells.

The invention is thus more particularly drawn to a therapeutically effective population of primary immune cells,

wherein at least 30%, preferably 50%, more preferably 80% of the cells in said population have been modified according to any one the methods described herein. Said therapeutically effective population of primary immune cells, as per the present invention, comprises immune cells that have integrated at least one exogenous genetic sequence under the transcriptional control of an endogenous promoter from at least one of the genes listed in Table 6.

Such compositions or populations of cells can therefore be used as medicaments; especially for treating cancer, particularly for the treatment of lymphoma, but also for solid tumors such as melanomas, neuroblastomas, gliomas or carcinomas such as lung, breast, colon, prostate or ovary tumors in a patient in need thereof.

The invention is more particularly drawn to populations of primary TCR negative T-cells originating from a single donor, wherein at least 20%, preferably 30%, more preferably 50% of the cells in said population have been modified using sequence-specific reagents in at least two, preferably three different loci.

In another aspect, the present invention relies on methods for treating patients in need thereof, said method comprising at least one of the following steps:

- (a) Determining specific antigen markers present at the surface of patients tumors biopsies;
- (b) providing a population of engineered primary immune cells engineered by one of the methods of the present invention previously described expressing a CAR directed against said specific antigen markers;
- (c) Administrating said engineered population of engineered primary immune cells to said patient,

Generally, said populations of cells mainly comprises CD4 and CD8 positive immune cells, such as T-cells, which can undergo robust in vivo T cell expansion and can persist for an extended amount of time in-vitro and in-vivo.

The treatments involving the engineered primary immune cells according to the present invention can be ameliorating, curative or prophylactic. It may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment. By autologous, it is meant that cells, cell line or population of cells used for treating patients are originating from said patient or from a Human Leucocyte Antigen (HLA) compatible donor. By allogeneic is meant that the cells or population of cells used for treating patients are not originating from said patient but from a donor.

In another embodiment, said isolated cell according to the invention or cell line derived from said isolated cell can be used for the treatment of liquid tumors, and preferably of T-cell acute lymphoblastic leukemia.

Adult tumors/cancers and pediatric tumors/cancers are also included.

The treatment with the engineered immune cells according to the invention may be in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.

According to a preferred embodiment of the invention, said treatment can be administrated into patients undergoing an immunosuppressive treatment. Indeed, the present invention preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent. In this aspect, the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the patient.

41

The administration of the cells or population of cells according to the present invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.

The administration of the cells or population of cells can consist of the administration of 10^4 - 10^9 cells per kg body weight, preferably 10^5 to 10^8 cells/kg body weight including all integer values of cell numbers within those ranges. The present invention thus can provide more than 10, generally more than 50, more generally more than 100 and usually more than 1000 doses comprising between 10^8 to 10^8 gene edited cells originating from a single donor's or patient's sampling.

The cells or population of cells can be administrated in one or more doses. In another embodiment, said effective amount of cells are administrated as a single dose. In another embodiment, said effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions within the skill of the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.

In another embodiment, said effective amount of cells or composition comprising those cells are administrated parenterally. Said administration can be an intravenous administration. Said administration can be directly done by injection within a tumor.

In certain embodiments of the present invention, cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efalizumab treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycoplenolic acid, steroids, FR901228, cytokines, and irradiation. These drugs inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin) (Henderson, Naya et al. 1991; Liu, Albers et al. 1992; Bierer, Hollander et al. 1993). In a further embodiment, the cell compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or anti-

42

bodies such as OKT3 or CAMPATH. In another embodiment, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery.

When CARs are expressed in the immune cells or populations of immune cells according to the present invention, the preferred CARs are those targeting at least one antigen selected from CD22, CD38, CD123, CS1, HSP70, ROR1, GD3, and CLL1.

The engineered immune cells according to the present invention endowed with a CAR or a modified TCR targeting CD22 are preferably used for treating leukemia, such as acute lymphoblastic leukemia (ALL), those with a CAR or a modified TCR targeting CD38 are preferably used for treating leukemia such as T-cell acute lymphoblastic leukemia (T-ALL) or multiple myeloma (MM), those with a CAR or a modified TCR targeting CD123 are preferably used for treating leukemia, such as acute myeloid leukemia (AML), and blastic plasmacytoid dendritic cells neoplasm (BPDCN), those with a CAR or a modified TCR targeting CS1 are preferably used for treating multiple myeloma (MM).

The present invention also encompasses means for detecting the engineered cells of the present invention comprising the desired genetic insertions, especially by carrying out steps of using PCR methods for detecting insertions of exogenous coding sequences at the endogenous loci referred to in the present specification, especially at the PD1, CD25, CD69 and TCR loci, by using probes or primers hybridizing any sequences represented by SEQ ID NO:36 to 40.

Immunological assays may also be performed for detecting the expression by the engineered cells of CARs, GP130, and to check absence or reduction of the expression of TCR, PD1, IL-6 or IL-8 in the cells where such genes have been knocked-out or their expression reduced.

Other Definitions

Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue.

Amino acid substitution means the replacement of one amino acid residue with another, for instance the replacement of an Arginine residue with a Glutamine residue in a peptide sequence is an amino acid substitution.

Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine. For the degenerated nucleotides, r represents g or a (purine nucleotides), k represents g or t, s represents g or c, w represents a or t, m represents a or c, y represents t or c (pyrimidine nucleotides), d represents g, a or t, v represents g, a or c, b represents g, t or c, h represents a, t or c, and n represents g, a, t or c.

"As used herein, "nucleic acid" or "polynucleotides" refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain

reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Nucleic acids can be either single stranded or double stranded.

The term “endonuclease” refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA molecule, preferably a DNA molecule. Endonucleases do not cleave the DNA or RNA molecule irrespective of its sequence, but recognize and cleave the DNA or RNA molecule at specific polynucleotide sequences, further referred to as “target sequences” or “target sites”. Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 10 base pairs (bp) in length, more preferably of 14-55 bp. Rare-cutting endonucleases significantly increase homologous recombination by inducing DNA double-strand breaks (DSBs) at a defined locus thereby allowing gene repair or gene insertion therapies (Pingoud, A. and G. H. Silva (2007). Precision genome surgery. *Nat. Biotechnol.* 25(7): 743-4).

By “DNA target”, “DNA target sequence”, “target DNA sequence”, “nucleic acid target sequence”, “target sequence”, or “processing site” is intended a polynucleotide sequence that can be targeted and processed by a rare-cutting endonuclease according to the present invention. These terms refer to a specific DNA location, preferably a genomic location in a cell, but also a portion of genetic material that can exist independently to the main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting example. As non-limiting examples of RNA guided target sequences, are those genome sequences that can hybridize the guide RNA which directs the RNA guided endonuclease to a desired locus.

By “mutation” is intended the substitution, deletion, insertion of up to one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty, twenty five, thirty, forty, fifty, or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide sequence. The mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA.

By “vector” is meant a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. A “vector” in the present invention includes, but is not limited to, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non chromosomal, semi-synthetic or synthetic nucleic acids. Preferred vectors are those capable of

autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available. Viral vectors 5 include retrovirus, adenovirus, parvovirus (e. g. adenoassociated viruses (AAV), coronavirus, negative strand RNA viruses such as orthomyxovirus (e. g., influenza virus), rhabdovirus (e. g., rabies and vesicular stomatitis virus), paramyxovirus (e. g. measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e. g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e. g., vaccinia, smallpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, 10 lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).

As used herein, the term “locus” is the specific physical 25 location of a DNA sequence (e.g. of a gene) into a genome. The term “locus” can refer to the specific physical location of a rare-cutting endonuclease target sequence on a chromosome or on an infection agent’s genome sequence. Such a locus can comprise a target sequence that is recognized 30 and/or cleaved by a sequence-specific endonuclease according to the invention. It is understood that the locus of interest of the present invention can not only qualify a nucleic acid sequence that exists in the main body of genetic material (i.e. in a chromosome) of a cell but also a portion of genetic material that can exist independently to said main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting examples.

The term “cleavage” refers to the breakage of the covalent 40 backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result 45 of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.

“identity” refers to sequence identity between two nucleic 50 acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid 55 sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two 60 sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting. For example, polypeptides having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific 65 polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated.

The term "subject" or "patient" as used herein includes all members of the animal kingdom including non-human primates and humans.

The above written description of the invention provides a manner and process of making and using it such that any person skilled in this art is enabled to make and use the same, this enablement being provided in particular for the subject matter of the appended claims, which make up a part of the original description.

Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.

Having generally described this invention, a further understanding can be obtained by reference to certain specific examples, which are provided herein for purposes of illustration only, and are not intended to limit the scope of the claimed invention.

EXAMPLES

Example 1: AAV Driven Homologous Recombination in Human Primary T-Cells at Various Loci Under Control of Endogenous Promoters with Knock-Out of the Endogenous Gene

Introduction

Sequence specific endonuclease reagents, such as TALEN® (Collectis, 8 rue de la Croix Jarry, 75013 PARIS) enable the site-specific induction of double-stranded breaks (DSBs) in the genome at desired loci. Repair of DSBs by cellular enzymes occurs mainly through two pathways: non-homologous end joining (NHEJ) and homology directed repair (HDR). HDR uses a homologous piece of DNA (template DNA) to repair the DSB by recombination and can be used to introduce any genetic sequence comprised in the template DNA. As shown therein, said template DNA can be delivered by recombinant adeno-associated virus (rAAV) along with an engineered nuclease such as TALEN® to introduce a site-specific DSB.

Design of the Integration Matrices

1.1. Insertion of an Apoptosis CAR in an Upregulated Locus with Knock-Out of the Endogenous PD1 Gene Coding Sequence

The location of the TALEN target site has been designed to be located in the targeted endogenous PDCD1 gene (Programmed cell death protein 1 referred to as PD1—Uniprot #Q15116). The sequence encompassing 1000 bp upstream and downstream the TALEN targets is given in SEQ ID NO:1 and SEQ ID NO:2. Target sequences of the TALEN (SEQ ID NO:3 and SEQ ID NO:4) is given in SEQ ID NO:5. The integration matrix is designed to be composed of a sequence (300 bp) homologous to the endogenous gene upstream of the TALEN site (SEQ ID NO:1), followed by a 2A regulatory element (SEQ ID NO:6), followed by a sequence encoding an apoptosis inducing CAR without the start codon (SEQ ID NO:7), followed by a STOP codon (TAG), followed by a polyadenylation sequence (SEQ ID NO:8), followed by a sequence (1000 bp) homologous to the endogenous gene downstream of the TALEN site (SEQ ID NO:2). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

1.2 Insertion of an Interleukin in an Upregulated Locus with Knock-Out of the Endogenous Gene

The location of the TALEN target site is designed to be located in the targeted endogenous PDCD1 gene (Pro-

grammed cell death protein 1, PD1). The sequence encompassing 1000 bp upstream and downstream the TALEN targets is given in SEQ ID NO:1 and SEQ ID NO:2. Target sequences of the TALEN (SEQ ID NO:3 and SEQ ID NO:4) is given in SEQ ID NO:5. The integration matrix is designed to be composed of a sequence (300 bp) homologous to the endogenous gene upstream of the TALEN site (SEQ ID NO:1), followed by a 2A regulatory element (SEQ ID NO:6), followed by a sequence encoding an engineered

10 single-chained human IL-12 p35 (SEQ ID NO:9) and p40 (SEQ ID NO:10) subunit fusion protein, followed by a STOP codon (TAG), followed by a polyadenylation sequence (SEQ ID NO:8), followed by a sequence (1000 bp) homologous to the endogenous gene downstream of the TALEN site (SEQ ID NO:2). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

1.3 Insertion of an Apoptosis CAR in a Weakly Expressed Locus without Knocking Out the Endogenous Gene—N-Terminal Insertion

The location of the TALEN target site is designed to be located as close as possible to the start codon of the targeted endogenous LCK gene (LCK, LCK proto-oncogene, Src family tyrosine kinase [*Homo sapiens* (human)]). The 25 sequence encompassing 1000 bp upstream and downstream the start codon is given in SEQ ID NO:11 and SEQ ID NO:12. The integration matrix is designed to be composed of a sequence (1000 bp) homologous to the endogenous gene upstream of the start codon, followed by a sequence encoding an apoptosis inducing CAR containing a start codon (SEQ ID NO:13), followed by a 2A regulatory element (SEQ ID NO:8), followed by a sequence (1000 bp) homologous to the endogenous gene downstream of the start codon (SEQ ID NO:12). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

1.4 Insertion of an Apoptosis CAR in a Weakly Expressed Locus without Knocking Out the Endogenous Gene—C-Terminal Insertion

The location of the TALEN target site is designed to be located as close as possible to the stop codon of the targeted endogenous LCK gene (LCK, LCK proto-oncogene, Src family tyrosine kinase [*Homo sapiens* (human)]). The sequence encompassing 1000 bp upstream and downstream 40 the stop codon is given in SEQ ID NO:14 and SEQ ID NO:15. The integration matrix is designed to be composed of a sequence (1000 bp) homologous to the endogenous gene upstream of the stop codon, followed by a 2A regulatory element (SEQ ID NO:8), followed by a sequence encoding an apoptosis inducing CAR without the start codon (SEQ ID NO:7), followed by a STOP codon (TAG), followed by a sequence (1000 bp) homologous to the endogenous gene downstream of the stop codon (SEQ ID NO:15). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

Expression of the Sequence-Specific Nuclease Reagents in the Transduced Cells

TALEN® mRNA is synthesized using the mMessage mMachine T7 Ultra kit (Thermo Fisher Scientific, Grand Island, NY) as each TALEN is cloned downstream of a T7 promoter, purified using RNeasy columns (Qiagen, Valencia, CA) and eluted in "cytoporation medium T" (Harvard Apparatus, Holliston, MA). Human T-cells are collected and activated from whole peripheral blood provided by ALL-65 CELLS (Alameda, CA) in X-Vivo-15 medium (Lonza, Basel, Switzerland) supplemented with 20 ng/ml human IL-2 (Miltenyi Biotech, San Diego, CA), 5% human AB

serum (Gemini Bio-Products, West San Francisco, CA) and Dynabeads Human T-activator CD3/CD28 at a 1:1 bead:cell ratio (Thermo Fisher Scientific, Grand Island, NY). Beads are removed after 3 days and 5×10^6 cells are electroporated with 10 μ g mRNA of each of the two adequate TALEN® using Cytopulse (BTX Harvard Apparatus, Holliston, MA) by applying two 0.1 mS pulses at 3,000 V/cm followed by four 0.2 mS pulses at 325 V/cm in 0.4 cm gap cuvettes in a final volume of 200 μ L of “cytoporation medium T” (BTX

Harvard Apparatus, Holliston, Massachusetts). Cells are immediately diluted in X-Vivo-15 media with 20 ng/mL IL-2 and incubated at 37°C with 5% CO₂. After two hours, cells are incubated with AAV6 particles at 3×10 \equiv viral genomes (vg) per cell (37°C, 16 hours). Cells are passaged and maintained in X-Vivo-15 medium supplemented with 5% human AB serum and 20 ng/mL IL-2 until examined by flow cytometry for expression of the respective inserted gene sequences.

TABLE 4

Sequences referred to in example 1			
Sequence name	Ref. sequences	Polynucleotide or polypeptide sequences	
PD1 left homology	SEQ ID NO: 1	CCAAGCCCTGACCCCTGGCAGGCATATGTTTCAAGGAGGTCTTGTCTTGGGA GCCAGGGTCGGGGCCCCGTGTCTGTCACATCCGAGTCATGGCCAT CTCGTCTCTGAAGCATCTTGTGAGCTCTAGTCCCCACTGTCTTGCTGG AAATCTGGAGGCCACTGCCCCTGCCCAGGGCAGCAATGCCATACC ACGTGGTCCCAGCTCCGAGCTTGTCTCAAAGGGGCAAAGACTGAGC CTGAGCCTGCCAAGGGGCACACTCCTCCAGGGCTGGGTCTCATGGG CAGCCCCCACCCACCCACCCAGGTTAACCTCCCTGTGCAAGGAGATGC AGACAGGACCAAGGCCAGGATGCCAAGGGCTGGGGATGGGT AGCCCCAACAGCCCTTCTGGGGAACTGGCTCAACGGGGAAAGGG GTGAAGGCTTTAGTAGGAATCAGGGGACCCAAGTCAGAGCAGGTG CTTGTGCAAGGCTGCAGCTCACAGTAAGGGAAAGAGGCTCTGAGTGG GGCCAGTGCCATCCGGGTGGCAGGCCAGCAGAGACTTCTCAAT GACATTCCAGCTGGGTGCCCTTCCAGGCCCTTGCTGCCAGGGATG TGAGCAGGTGCCGGGGAGGCTTGTGGGGCCACCCAGCCCTTCAC CTCTCTCCATCTCAGACTCCCAAGGCCAGGGCTGGGACCCCCACCTTC TCCCCAGCCCTGCTGGTGGCTGAGGCAAGGGGACAACGCCACCTTCAC AGCTTCTCCAAACATCGAGGAGCTTGTGCTAAACTGGTACCGCATGAGC CCCAGCAACCAGCAGGACAAGCTGGCCGCTTCCCGAGGACCGAGCCA GCCGGCCAGGACTGCCCTCCGTGACACAACGTGCCAACGGCGT ACTTCCACATGAGCGTGGTCAGGGCCCGGCCAATGACAGCGGAC GCCTGCAGGAGAGCTCAGGGTCAAGGGTCTGGTGGCTGGGAGGCTGG GCAGGGTGGAGCTGAGCTGAGCCAGGGCAGCCAGGGCTGGTGGAGTCTC GATCAGGAGCTCCAGGTCTGAGCCGCTCTGGGTGGTGTCCCCTCTGCACAG GATCAGGAGCTCCAGGTCTGAGCCGCTCTGGGTGGTGTCCCCTCTGCACAG GGCTCTGCTCTGACCTCTGGGAAATGGTGACCGGCATCTGTCTCTAGCT CTGGAAGCACCCAGCCCTCTAGTCTGCCCTCACCCCTGACCTGACCC CACCCCTGACCCCGTCCAAACCCCTGACCTTGTGCCCTTCAGAGAGAAGG GCAGAAGTGCCACAGGCCACCCAGGCCACCCCTCACCCAGGCCAGGGCCA GTTCCAAACCTCTGGTGGTGGTGTCTGGCCGCTCTGGGAGGCTGG TGCTGCTAGCTCTGGTCTGGCGTCACTGCTCCCGGCCACGAGGTA ACGTCACTCCAGCCCTCGGCCCTGCCCTGCCCTAACCTGCTGGCGCCCT CACTCCCGCCCTCCCTCCACCCCTCACCCAGGCCACCCCTCCCC ATCTCCCGCCAGGCTCAAGTCCCTGATGAAGGCCCCCTGGACTAAAGCCCC CACCTAGGAGCACGGCTCAGGGTGGCCTGGTGACCCCAAGTGTGTTCT CTGCAAGGACAATAGGAGCCAGGGCACCAGGCCAGCCCTGGTGAGTCTC ACTCTTCTGCACTGACTCTGCTCTCCCTGGGTGGGAGAGGT GGAGGAAGGAGCTGGGACACAGGCCCTGCAAGGACTCACATTCTATTATA GCCAGGACCCACCTCCCAAGGCCACAGGCCACACCTCAATCCCTAAAGC CATGATCTGGGCCCCAGCCACCTCGCGTCTCCGGGGTGCCCGGCCA TGTGTGCTGCTGCGTCTCCAGGGTGCTGGCCACCGCTGTG CGCCTGCGTCTCTGGGGTGCCCGGCCACATATGTGCC	
PD1 right homology	SEQ ID NO: 2	GCTCTGCCAGAGCTCAGGGTACAGGTGCGGCCCTGGAGGGCCCGGG GCAGGGTGGAGCTGAGCCGCTCTGGGTGGTGTCCCCTCTGCACAG GATCAGGAGCTCCAGGTCTGAGCCGAGGCCACCCCGAGCTCAGTCCAG GGCTCTGCTCTGACCTCTGGGAAATGGTGACCGGCATCTGTCTCTAGCT CTGGAAGCACCCAGCCCTCTAGTCTGCCCTCACCCCTGACCTGACCC CACCCCTGACCCCGTCCAAACCCCTGACCTTGTGCCCTTCAGAGAGAAGG GCAGAAGTGCCACAGGCCACCCAGGCCACCCCTCACCCAGGCCAGGGCCA GTTCCAAACCTCTGGTGGTGGTGTCTGGCCGCTCTGGGAGGCTGG TGCTGCTAGCTCTGGTCTGGCGTCACTGCTCCCGGCCACGAGGTA ACGTCACTCCAGCCCTCGGCCCTGCCCTGCCCTAACCTGCTGGCGCCCT CACTCCCGCCCTCCCTCCACCCCTCACCCAGGCCACCCCTCCCC ATCTCCCGCCAGGCTCAAGTCCCTGATGAAGGCCCCCTGGACTAAAGCCCC CACCTAGGAGCACGGCTCAGGGTGGCCTGGTGACCCCAAGTGTGTTCT CTGCAAGGACAATAGGAGCCAGGGCACCAGGCCAGCCCTGGTGAGTCTC ACTCTTCTGCACTGACTCTGCTCTCCCTGGGTGGGAGAGGT GGAGGAAGGAGCTGGGACACAGGCCCTGCAAGGACTCACATTCTATTATA GCCAGGACCCACCTCCCAAGGCCACAGGCCACACCTCAATCCCTAAAGC CATGATCTGGGCCCCAGCCACCTCGCGTCTCCGGGGTGCCCGGCCA TGTGTGCTGCTGCGTCTCCAGGGTGCTGGCCACCGCTGTG CGCCTGCGTCTCTGGGGTGCCCGGCCACATATGTGCC	
PD1_T3C-L2	SEQ ID NO: 3	ATGGGCATCTAAAAAGAAACGTAAAGGTACATGCATATGCCGATCTACG CACCTCGGCTACAGCAGGAGCAACAGGAGAAAGATCAAACCGAACGGTT GTTGACACTGGCCACACAGGCCACAGGCCACTGTCGGCCACGGTTTACA CACCGGCACATCGTGTGTTAAGCCAACACCCGGCAGCGTCTAGGGACCG CGCTGTCAAGTATCAGGACATGATCGCAGCGTGTGCCAGAGGGACACAG AAGGGATCTGGGCTGGGAAACAGTGTGCTCCGGCGCACGCCCTCTGGA GGCCTTGCTCACGGTGGGGAGAGTGTGAGGGTCCACCGTTACAGTTGG ACACAGGCAACTCTCAAGATTGCAAAACGTGCGCCGTCAGCGCAGTG GAGGCAGTGCATGGCGCAATGCACTGACGGGTGCCCGCTCAACTT GACCCCGAGCAAGTGGTGGCTATGCTCTCCAGCTGGGGAAAGCAG GCCCTGGAGAACGCTGGCCCTCTCCAGTGTCTGGCCAGGCTCACCGGA CTGACCCCTGAAACAGGTGGGCAATTGCTCACACGACGGGGCAAGCA GGCACTGGAGACTGTCCAGCGGTGCTGCCCTGCTCTGCCAGGCCACG GACTCACTCTGAGCAGGTGCGGCCATTGCCAGGCCACGATGGGGAAA CAGGCTCTGGAGAACGGCTGCGCCTCTCCAGTGTGCTGGCCAGGCTCAT GGGCTGACCCACAGCAGGTGCGCATTGCCAGTAAAGCGGGGGGG AGCAGGCCCTGAAACAGTGCAGAGGCTGCTGCCGCTCTGTGCAAGCA CACGGCCCTGACACCCGAGCAGGTGGTGGCCATGCCCTCTCATGACGGGG CAAGCAGGCCCTTGAGAGCAGTGCAGAGACTGTGCCCCGTGTTGTGTCAG CCACGGGGTGAACACCCAGGGTGGTCATGCCAGCAATGGCGGG GGAAGCAGGCCCTGAGACCGTGCAGCGGTTGCTCCAGTGTGCA	

TABLE 4 - continued

		Sequences referred to in example 1
Sequence name	Ref. sequences	Polynucleotide or polypeptide sequences
		GGCACACGGACTGACCCCTCAACAGGTGGTCGAATGCCAGCTACAAGG GCGGAAAGCAGGCTCTGGAGACAGTGCAGCGCCTCTGCCGTGCTGTG CAGGCTCAGCGACTGACACCACAGCAGGGTGGTCGCCATGCCAGTAACGG GGCGGCAAGCAGGCTTTGGAGACGCTCAGAGACTCTTCCCCGTCCTT GCCAGGCCACGGGTTGACACCTCAGCAGGTGCTGCCATTGCCCTAAC AACGGGGCAAGCAGGCCCTCGAAACTGTGCAAGGGCTGCTGCCGTGCT GTGAGGGCTCATGGGCTGACACCCAGCAGGAGGTGCTGCCATTGCCCTA ACAACGGGCAAACAGGCACTGGAGACCGTCAAAAGGCTGCTGCCCGT CCTCTGCCAACGCCACGGGCTACTCCACAGCAGGTGGCCATTGCCCTC AAACATGGCGGAAGCAGGCCCTGGAGACTGTGCAAGGCTGCTCCCT GTGCTCTGCCAGGACACCGGACTGACCCCTCAGCAGGTGGTCGCCATTG TTCCAACAAAGGGGAAAGCAGGCCCTCGAAACCGTGCAAGGCCCTCTCC CAGTGTGCTGCCAGGACATGCCCTCACACCGAGCAAGTGGTGGCTATC GCCAGGCCACGAGGGAAAGCAGGCTCTGGAGACCGTGCAGAGGCTGC TGCCTGTCCTGTGCCAGGCCACGGGCTACTCCAGACAGGTGCTGCCA TCGCGAGTCATGAGGGGAAAGCAGGCCCTTGAGACAGTCCAGCAGG GCTGCGAGTCCTTGCAGGCTCACGGCTTGACTCCAGGAGCAGTCAGG CATTCGCTCAAACATTGGGGCAACAGGCCCTGGAGACAGTCAGGCC TGCTGCCCTGGTGTGCTGCCAGGCTTGAGACACCCAGCAGGCTGTC GCCATTGCCCTAATGGCGGGAGACCGCTTGAGAGAGCATTGTC CCAGTATTCGCGCTGATCGGGCTTGGCGCGTTGACCAACGACCACT CGTCGCCTGGCTGCCCTGGCGCGTCTGCGCTGGATGCAAGTGGCTA AGGGATTGGGATCTCATGGCCTTCCAGCTGGTGAAGTCCGAGCTG GAGGAGAAGAAATCCGAGTTGAGGACAAAGCTGAAGTACGTGCCCCAC AGTACATCGAGCTGATCGAGATGCCCGAACAGCACCCAGGACCGTATC CTGGAGATGAGGTGATGGAGTTCTCATGAAGGTGACGGCTACAGGG GCAAGCCTGGCGCTCCAGGAAGGCCACGGCGCCATCTACACCGTG GGCTCCCTCGAATCGACTACGGCGTGTGGACACCAAGGCCCTACTCGG CGGCTACACCTGCCATGCCAGGCCAGCAATGCAAGGTAAGTGGCT AGGAGAACAGACAGAACAGCACATCAACCCAAACGAGTGGTGGAA GGTGTACCCCTCCAGCTGACCGAGTTCAAGTCTGTGCTGCCGCA CTTAAGGGCAACTACAAGGCCAGCTGACCCAGGCTGACCCACATCCA ACTGCAACGGCGCCGCTGCTGCCGTGGAGGAGCTCTGATCGGGCGA GATGATCAAGGCCGACCCCTGACCTGGAGGAGGTGAGGAGGAAGTTC AACACGGCAGATCAACTCGCGGCCACTGATAA
PD1T3R	SEQ ID NO : 4	ATGGGCATCCTAAAAAGAACGTAAGGTATCGATATGCCATCTACG CACGCTGGTACAGCCACCGAGAACAGGAGAACGATCAAACGAAGGTC GTTGACAGTGGCGCAGCACACAGGAGCAGTGTGGCCACGGGTTACA CACCGCAGCATCGTTAGGCAACACCCGGCAGCGTTAGGGACCGT CGCTGCTCAATATCAGGACATGATGCCAGCGTTGCCAGAGGCCACACG AAGGATCGTGGCTCGCAAACAGTGTCCGGCGCAGCGCTCTGGA GGCTTGCTCACGGTGGGGAGAGTTGAGAGGTCCACCGTTACAGTTG ACACAGGCCACTTCAAGATTGCAAAACCTGCGCCGTGACCCAGTG GAGGCAGTGCATGCAATGCCAGGCTGACTGACGGGTGCCGCTCAACT GACCCCGAGCAAGTGTGCAATGCCAGGCCATGATGGAGGAAGCAA GCCCTCGAAACCGTGCAGCGGTTGCTCTGTGCTCTGCCAGGCCACGGC CTTACCCCTCAGCAGGTGGCATCGCAAGTAACGGAGGAGAAAGCA AGCCTGGAGACAGTGCAGCGCCTGTTGCCGTGCTGCCAGGCCACACG GCCCTCACACCCAGACAGGCTGTGCCATTGCCCTCCATGACGGGGAAA CAGGCTCTGGAGACCGTCCAGAGGCTGCTGCCGCTCTGTCAAGTCAC GGCTGACTCCCAAACAAACTGGTGCCTAATGGCGGGGGAA GCAGGCACTGGAAACAGTGTGCAAGACTGTCCTGTGCTTGGCAAGCTC ATGGGTTGACCCCCAAACAGGTGCTGTGCTATTGCCCTAAACGGGGGG AAGCAGGCCCTTGAGACTGTGCAAGGGCTGTTGCCAGTGTGTCAGGC TCACGGGCTCACTCCACACAGGTGGTCCAATTGCCAGCAACGGCGCG GAAAGCAAGCTTGGAAACCGTCAACGCCCTCTGCCGTGCTGTGAGG CTCATGGCTGACACCAACAAACAGTGTGCCATGCCAGTAATAATGCC GGGAAACAGGCTCTTGAGACCGTGCAGAGGCTGCTCCAGTGTCTGCC GGCACACGGCTGACCCCGAGCAGGTGGCTATGCCAGCAATATTG GGGGCAAGCAGGCCCTGGAAACAGTCCAGGCCCTGCTGCCAGTGTGTTG CAGGCTCACGGGCTCACTCCCCAGCAGGTGCTGCCAATGCCCTCAACGG CGGAGGGAGCAGGCTCTGGAGACCGTGCAGAGACTGCTGCCGCTCTGT GCCAGGCCACGGACTCACACCGTCAACAGTGTGCTGCCATTGCCCTCACG ATGGGGCAACAGGCCCTGGAGACAGTGCAGCGGCTGTTGCCGTGTTG TGCAAGGCCAGGGCTGACTCTCAACAAAGTGGTGCCTGCCATGCCCTAAAT GGCGCGGAAAACAAGCTGGAGACAGTGCAGAGGTGCTGCCGCT TCTGCCAAGGCCACGGCTGACTCCCCAACAGGTGCTGCCATTGCCAGCA ACAACGGAGGAAGCAGGCTCTCGAAACACTGTGCAAGCGGCTGCTTCCCTGTG CTGTGTCAGGCTCATGGGCTGACCCCGAGCAAGTGGTGGCTATTGCCCT AATGGAGGCAAGCAAGGCCCTGGAGACAGTCCAGAGGTGCTGCCATGCCAGTA GTGCAAGGCCACGGCTCACACCCAGCAGGTGCTGCCATGCCAGTA ACAACGGGGCAACAGGATTGGAAACCGTCCAGCGCCTGCTTCCAGTG CTCTGCCAGGCACACGGACTGACACCCGAACAGGTGGTGCCTGCCATTGCACTC CCATGATGGGGCAAGCAGGCCCTGGAGACCGTGCAGAGACTCCTGCCA

TABLE 4 - continued

Sequences referred to in example 1		
Sequence name	Ref. sequences	Polynucleotide or polypeptide sequences
		GTGTTGTGCGCAAGCTCACGGCCTCACCCCTCAGCAAGTCGTGCCATGCC TCAAACGGGGGGGGCGCGCTGCACGGAGAGCATGTTGCCAGTTATC TCGCCCTGATCCGGCGTGTGGCTGGAGCTGGCAACGACCACTCGTCGCCCT GGCTGCGCTCGGGGGCTCTGGCTGGAGCTGGAGATGAAAAAGGGATTG GGGATCTATCAGCGTTCCAGCTGGTAAGTCGAGCTGGAGAAGA GAAATCCGAGTTGAGGACAAGCTGAAGTACGTGCCCCACGAGTACATCG AGCTGATCGAGATGCCCGGAACGACCCAGGACCGTATCTGGAGATG AAGGTGATGGAGTTCTCATGAAGGTGTACGGCTACAGGGCAAGCACCT GGCGCGCTCAGGAAGGCCACGGCGCATCTACACCGTGGCTCCCG TCGACTACGGCGTATCGTGACCAAGGCCTACTCCGGCGGTACAAAC CTGGCCATCGGCCAGGCCAACGAAATGCAAGGGTACGTGGAGGAGAAC AGACCGAGAACAGCACATCAACCCAAACGAGTGGTGAAGGTGACCC TCCACGCGTACCGAGTTCAAGTTCTGTCGTTGCGGCACTTCAAGGGC AACTACAAGGCCAGCTGACCAAGCTGAACCACATCACCACATGCAACGG CGCCGTGCTGTCGGAGGAGCTCTGATCGGGGGGAGATGATCAAG GCCGCACCCGACCCCTGAGGGAGGTGAGGAGGAAGTCAACAACGGCG AGATCAACTTCGCGGCCACTGATAA
PD1-T3	SEQ ID NO: 5	TACCTCTGTGGGCCATCTCCCTGGCCCCAAGGCGCAGATCAAAGAGA
2A-element	SEQ ID NO: 6	TCCGGTGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGA ATCCGGGCC
apoptosis CAR (without start codon)	SEQ ID NO: 7	GCTTGTGCGCTGACTGCCTTGCTGCTTCACTTGCTCTGTTGACGCCG CAAGACCCGAGGTCAAGCTCAGGAAGGGACCGAGGCTGGTGGCC TAGTCAGTCACTGAGCGTCACTTGACCGCTCAGGGCGTGTCTGCC TTAGGGCGTGGCTGGATCAGACGCCAACGAGGAAGGGACTGGAGTGG CTGGCGTCACTGCGGAGGAGACTACCTACTACAAACAGGCCCTGAA GAGCAGGCTGACCATCATTAAAGGACAACCTCAAGTCCCAGGTCTTGAA AATGAACAGCCTGCAGACTGATGACACTGCCATCTACTACTGCGCAAGCA TTACTACTACGGGGCAGCTACGCTATGGACTACTGGGGCAGGGACCT CTGTCACAGTGTCAAGTGGCGAGGAGGAGTGGCGAGGGGGAGTG GGGGGGCGGCAGGCACATCGAGATGACCAACACATCCAGCCTCTCC GCCTCTGGCGACAGAGTGACAATCAGCTGCCGGCAGTCAGGACAT CAGCAAGTATCTCAATTGGTACCCAGCAGAAACAGACGGGAGTGAAT TGCTGATCTACACACATCCAGGTGCACTCAGGAGTCCCCAGCAGGTTT CCGGCTCCGGCTCCGGAGCAGATTACAGTCTGACCATTTCAACCTGGAGC AGGAGGATATTGCCACATACTTTGCCAGCAAGGAAACACTGCCCATA CCTCTGGCGAGGACAAACACTGGAGATTACTCGGTGGATCCCGAGGCC AAATCTCTGACAAAACACACATGCCAACCTGCCCCAGCACCTCCGTG GCCGGCCCTGAGTGTCTCTTCCCCAAAACCAAGGACACCCATG ATCGCCCGGACCCCTGAGGTCACTGCGTGGTGGACGTGAGCCACGA GGAGGCTGGAGTCAAGTCAACTGGTACCTGGAGGCGTGGAGGTGCA AATGCCAAGAACAGCCGGAGGAGCAGTACAACAGCACGTACCGTG TGGTCAGGCTCTCACCGTCTGACCAAGGACTGGCTGAATGGCAAGGAG TACAAGTGAAGGTGTCACAAAGCCCTCCAGCCCCATCGAGAAAAC CATCTCCAAGCCAAGGGCAGCCCCGAGAACACAGGGTACACCTTG CCCCATCCGGATGAGCTGACCAAGAACAGGTGAGCTGACCTGCGCTG GTCAAGGCTTCTACCCAGCGACATCGCGTGGAGTGGAGAGCAATGG GCAACCGGAGAACACTACAAGAACACGCCCTCCGTGCTGGACTCCGAC GCTCTTCTCCCTACACCAAGCTCACCGTGGACAAAGGCAGGTGGCAGC AGGGGAACGTGTTCTCATGCTCGTGTGATGAGGCCCTGACAATCACT ATACCCAGAAATCTGACTCTGAGCCAGGAAGAAGGATAATTGGGG TGGCTTGCTCTCTTGCCAATTCCACTAATTGTTGGTGAAGAGAA AGGAAGTCAAGAAAACATCGAGAACAGCACAGAAAGGAAAACCAAGGTT TCATGAATCTCAACCTTAAATCTGAAACAGTGGCAATTAAATTATCTGAT GTTGACTTGAAGTAAATATCACCATTGCTGGAGTCACTGACACTAAGT CAAGTAAAGGCTTGTGAGGAAATGGTGTCAATGAAGCCAAATAGA TGAGATCAAGAATGACAATGTCAGACAGCAGAACAGAAAGTTAAC TGCTCGTAATTGGCATCAACTCATGGAAAGAAGAACGCGTGTGACACAT TGATGGAGATCTAAAAAGGCAATTCTGTACTCTGCAAGGAAATTC AGACTATCATCTCAAGGACATTACTAGTGAATCAGAAAATTCAAACCTCA GAAATGAAATCCAGAGCTTGGTCGA
BGH polyA	SEQ ID NO: 8	TCTAGAGGGCCGTTAACCCGCTGATCAGCCTGACTGTGCCCTAGT TGCCAGCCATCTGTGTTGCCCTCCCCGTGCCCTGACCCGAG GTGCCACTCCACTGCTCTTCTCTAAATAAATGAGGAAATTGCACTGCGATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGCAGGACAG CAAGGGGGGAGGATGGGAAGACAATAGCAGGCTGCTGGGATGCGGT GGGCTCTATGACTAGTGGCGAATT
Interleukin-12 subunit alpha	SEQ ID NO: 9	MCPARSLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNML QKARQTLFYPCTSEEIDHEDITDKTSTVEACLPLELKNECLNSRETSF ITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLMDPKRQIFLD

TABLE 4 - continued

		Sequences referred to in example 1	
Sequence name	Ref. sequences	Polynucleotide or polypeptide sequences	
		QNMLAVI DELMQALNFNSETVPQKSSLEEPDFYKT KI KLCILLHAFRIRAVT IDRVM SYLNAS	
Interleukin-12 subunit beta	SEQ ID NO: 10	MCHQQLVISWFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDT PEEDGITWTLDQSSEVLGSGKTLTIQVKFEGDAGQYTCHKGGEVLSHSLLLHK KEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSR GSSDPQGVTCGAATLSEAERVRGDNKEYEVSVEQEDSACPAAEESLPIEVMV DAVSPKLYENYTSSFFIRDIKPDPPKNLQLPKLNRSRQVEVSWEYPDTWSTPH SYFSLTFCVQVQGKS KREKKDRVTDKTSATVICRKNA SISVRAQDRY YSSSSWS EWASVPCS	
Lck left homology	SEQ ID NO: 11	GGGATAGGGGTGCCTCTGTGTGTGAGAGTGTGTGTAGG GTGTGTATGTATAGGGTGTGTGAGGTGTGTGTGAGAGTGTGTGAGAGTGTGTGGCAGAAATAGACTCGCGAGGTGGATTTCATCTGTATGTGAAAGGT CTGGAATGATGGTACATTAAACTTGGAGGACAGCGCTTCAAGCCTCT GAGGAGCAGCCCCTAGAGAAGGGAGGAGCTGCAGGGACTCCGGGGCTTCA AAGTGAGGGCCCACTCTCTTCAAGGCAAACAGGCACACATTATACCTT TATCTATGGAGTTCTGCTTGTGTTTCATCAGACAAAAAATTTCACGTCTAAA ACAGGCCAATAAACAAAAAAAGTTAGCACAACAGAGTCACTGGAGG GTTTCTGCTGGGAGAACAGCAGGGCTTGTGAAGGAACCCGTGTGAGAT GACTGTGGCTGTGAGGGGAACAGCGGGCTTGTGAGGTGACTTCG GGAGCAGAACCTCTTCTCAGCCTCCCTCAGCTAGACAGGGGAATTATAAT AGGAGGTGTGGCTGCACACTCTCCAGTAGCTAGGGAGGGCTGTGATAAGTC AGGTCTCCAGGGTGGGAAAGTGTGTGTCATCTCTAGGAGGTGGTCTCCC CCAACACAGGGTACTGGCAGAGGGAGGGAGGGCAGAGGCAGGA AGTGGTAACACTAGACTAACAAAGGTGCTGTGGGGTTGGCCATCCAG GTGGGAGGGTGGGCTTAGGGCTCAGGGGGCTGTGAAATTACTTGTA GCCTGAGGGCTCAGAGGGAGCACGGCTGGAGCTGGGACCCCCCTATT TT AGCTTTCTGCTGGTGAATGGGATCCAGGATCTACAATCTCAGGT ACTTTGGAACTTTCCAGGGCAAGGCCCATATATCTGATGTGGGAG CAGATCTGGGGGAGCCCTTCAGCCCCCTTCCATTCCCTCAGGGAC	
Ick right homology	SEQ ID NO: 12	GGCTGTGGCTGCAGCTCACACCGGAAGATGACTGGATGGAAAACATCGA TGTGTGTGAGAACTGCCATTATCCCATAGTCCACTTGATGGCAAGGGCA CGGTAAGAGGGCAGACAGGGCCTGGTGAAGGGAGTTGGGTAGAGAAT GCAACCCAGGAGAAAGAAATGACCGAGCACTACAGGCCCTGAAAGAATA GAGTGGCCCTCTCCCTGAAATACAGAAAGGAAAAGAGGGCCAGAGGAGG GGAAGGGAACTCTCTAAGATCACAGAAAGTAGTTGTTAAACTCAGGA TAACATCTAACACAGGCTGGAGAGGCTGAGAGCAGAGCAGGGGGAGG GGGCAGGGCTGACCCATCTCTGCTTCTGACCCCACCCCTCATCCCCA CTCCACAGCTGCTCATCCAAATGGCTCTGAGTGGGGACCCACTGGTA CCTACGAAGGCTCCAATCCGGGCTTCCCTGACTGCAAGGTGACCCAGGC AGCAGGGCTGAAAGACAAGGCTGCGGATCCCTGGCTGGCTTCCAC CTCTCCCCAACCTACTTCTCCCGGTCTGCCCTCTGGTCCCCAACCTGT AACTCAGGCTTCCGCCATCCCAGCTGGTTCTCCCTGATGCCCTTGTCTTACAGACAACTCTGTTATCGCTCTGCACAGCTATGACCCCTCTCAGAC GGAGATCTGGGTTTGAGAAGGGGGACAGCTCCGCATCTGGAGCAGT GAGTCCCTCTCCACCTTGCTCTGGGGAGCTCCGTGAGGGAGCGGCGATCT CCAGCAGGGCAGGCCCTCTGGGGCTTGCAGCAGCTCGGGTGGGCCGC CTTGGGACAAAATTGAGGCTCACTTCTGAGCCAGGGTGGGGAG GCTGGCTTAAGGGGTTGGAGGGGCTTGTAGGGAGGGTCTCAGGTGAGC GCTGAGCGACCAACTGACCCACCTCCGCTGGCGCAGGAGCGGCAGTG	
apoptosis CAR (with start codon)	SEQ ID NO: 13	ATGGCTTGCTGTCAGTCCTGCTGCTCTTCACTTGCTCTGTTGCACG CCGAAGACCCGAGGTCAAGCTCCAGGAAAGCGGACCAGGGCTGGTGGC CCCTAGTCAGTCAGTCAGTCAGTCAGCAGGCCAACAGGAAGGGACTGGAG CGATTACGGCGTGAAGCTGGATCAGACAGGCCAACAGGAAGGGACTGGAG TGGCTGGGCGTCACTGGGGAGGGAGACTACCTACTAACACAGCGCCCT GAAGAGCAGGCTGACCACATCATTAGGACAACCTCAAGTCCAGGTCTTCT GAAAATGAACAGCTGCAACTGATGACACTGCCATCTACTACTGCGCCAA GCATTAACACTACGGGGCAGCTACGCTATGGACTACTGGGGAGGGGG ACCTCTGTCACAGTCAAGTGCGGGAGGGAGGTGGGGAGGGGAA GTGGGGGGCGGGAGCGACATCCAGATGACCCAGACAAACATCCAGCCTC TCCGCTCTCTGGGGAGAGCTGACAACTCAGCTGCCGGCAGTCAGGA CATCAGCAAGTATCTCAATTGGTACCGAGCAAACAGCAGGGACAGTGA AATTGCTGATCTACACACATCAGGCTGCACTCAGGAGTCCCCAGAGGT TTTCGGCTCCGGCTCCGGAGCAGATTACAGTCTGACCAATTCCAACTGG AGCAGGAGGATATTGCCACATACTTTGCGAGCAAGGCAACACTCTGCCCT ATACCTTCCGGGGAGGCACAAAATGGAGATTACTCGGTGGATCCCGAG CCCAATCTCTGACAAAATCACACATGCCAACCGTGCCAACCTCCC GTGGCGGGCCGTAGTGTCTCTTCCCCCAAACCAAGGACACCCCTC ATGATGCCCGGACCCCTGAGGTACATCGCTGGTGGTGGACCTGAGCCA CGAGGACCCCTGAGGTCAAGTCAACTGGTACGTGGACGGCGTGGAGGTG CATAATGCAAGACAAAGCCGGGGAGGAGCAGTACAACAGCACGTACC GTGTGGTCAAGCTCCTCACCGTCTGCACAGGACTGGCTGAATGGCAAG	

TABLE 4 - continued

Sequences referred to in example 1		
Sequence name	Ref. sequences	Polynucleotide or polypeptide sequences
		GAGTACAAGTGCAAGGTGCCAACAAAGCCCTCCCAGCCCCCATCGAGAA AACCATCTCAAAGCCAAGGGCAGCCCCGAGAACCAACAGGTGTACACCC TGCCCCCATCCCGGGATGAGCTGACCAAGAACCAACAGGTGTACCTGC CTGGTCAAAGGCTTCTATCCAGCGACATGCCGTGGAGTGGAGAGCAA TGGGCAACCGAGAACAACTACAAGACCAACGCCCTCCCGTGTGGACTCG ACGGCTCCTCTCTACAGCAAGCTACCGTGGACAAGAGCAGGTGG AGCAGGGGAACGTGTTCTCATGCTCCGTGATGCACTGAGCCCTGACAAT CACTATACCCAGAAATCTGAGTCTGAGCCAGGCAAGAAGGATATTG GGGTGGCTTCCTCTTGCCTAACTTAATTGTTGGGTGAAGA GAAAGGAAGTACAGAAAATCGAGAAACAGAAAGGAAACCAAGG TTCTCATGAATCTCAAACCTTAAATCCTGAAACAGTGGCAATAAATTATCT GATGTTGACTTGAGTAAATATACCAACTATTGCTGGAGTCATGACACTA AGTCAGTAAAGGCTTGTGAGAAAGATGGTGTCAATGAGCCAAAT AGATGAGATCAAGAATGACAATGTCCAAGACACAGCAGAACAGAAAGTTC AACTGCTTCTGAAATGGCATCAACTTCACTGGAAAGAAAGCAGTGT ACATTGATTGAGATCTCAAAAAAGCCAATCTTGACTCTTGAGAGAAA ATTCAAGACTATCATCCTCAAGGACATTACTAGTGAACAGAAAATTCAAC TTCAGAAATGAAATCCAGAGCTTGGTCGA
Lck left homology	SEQ ID NO: 14	CTCATACAATTCTATGAGGTAGGAACAGTTATTTACTCTATTTCCAATA AGGAAACTGGGCTCGCCCAAGGTTCCACAACAACTAACATGTTGATTATTGA GCATTTAATTACACCAGGGAAAGCAGGTTGTGGTGTGCACCTGTTG CAGCTATTAGGAGGCTGAGGTGAAAGGATCACTGAACGGAGGAGTCA AATTGCAATGTGCTATGATTGTCCTGTGAACAGCTGCTGCACTCCAGCC TGGGCAACATAGTGGAGATCTTAAACATTTTTAAGTAAATAAT CAGGTGGGACGGTGGCTCACGCCGTAACTCCAGCAGCTTGGGAGGCTGA GGGGGGCGGATCACCTGAGGTCAAGGCTGAGGAGTCAAGACAGCAGAACAT GGAGAACCCGCTCTACTAAAAAAATACAAAATTAGCTTGGCTGGTGG CATGCTGAAATCCAGCTACTCGAGAACGCTGAGGCAGGAGATTGTTG AACCTGGGAGGTGGAGGTGCGGTGAGCCGAGATCGCACCAATTGCACTCC AGCCTGGGACAAAGAGTGAATTGCATCTCAAAAAAAAGAAAAGGAA ATAATCTATACCAAGGCACTCAAGTGGTGTGACTGATATTCAACAAGTACC TCTAGTGTGACCTTACCATGATGAAGACCAAGATTCTTGGATTGGTGC TCACACTGTGCCAGTTAAATATCCGAACATTACCCCTGCTGTGGCTTCC AGTGCCTGACCTTGTCTTACCCATCAACCCGTAAGGGATGACCAAC CCGAGGGTGAATTCAAGACCTGGAGCGAGGCTACCGCATGGTGCCTG CAACTGTCCAGAGGAGCTGACCAACTCATGAGGCTGTGCTGGAGGAGC GCCAGAGGACCGCCCACCTTGACTACCTGCCAGTGTGCTGGAGGAC TTCTCACGGCCACAGAGGGCCAGTACCGCCTCAGCCT
Ick right homology	SEQ ID NO: 15	GAGGCCCTTGAGAGGCCCTGGGTTCTCCCCCTTCTCTCAGCCTGACTTG GGGAGATGGAGTTCTGTGCCATAGTCACATGCCATATGACACATGGAC TCTGCACATGAATCCACCCACATGTGACACATATGCACTTGTGTCTGTAC ACGTGTCCTGTAGTTGCGTGGACTCTGCACATGTCTGTACATGTGTAGCC TGTGATGATGTCTTGGACACTGTACAAGGTACCCCTTCTGGCTCTCCCA TTCTCTGAGACCAAGAGAGAGGGAGAACGCTGGGATTGACAGAACGCT TCTGCCACACTTTCTCTCAGATCATCAGAACGTTCTCAAGGGCC AGGACTTTATCAATACCTCTGTGCTCTCTGGTGCCTGGCTGGCAC ACATCAGGGAGTCAATAAATGTCGTGATGACTGTTGACATCTTGT GTCCACTCTTGTGGGTGGCAGTGGGGTTAAGAAAATGGTAATTAGGT CACCTTGAGTTGGGTGAAGATGGAGTGGATGTTGAGCTGGAGGCTCT GCAGACCCCTCAATGGACAGTGTCTCACCCCTCCCAAGGATTC GGGTGACTCTCACCTGGAAATCCCTAGGGAAATGGGTGCGCTCAAAGGACCT TCCTCCCTTACATAAAAGGGCAACAGCATTCTTACTGATTCAGGGCTATA TTGACCTCAGATTGTTTTTAAGGCTAGTCAAATGAAGCGCGGGAA TGGAGGAGGAACAAATAATCTGTAACATCCTCAGATTTTTTTT GAGACTGGGCTCACTTTCATCCAGGCTGGAGTGCAGTCGATGATCAC GGCTCACTGTAGCCCTCAACCTCTCAGCTCAAATGCTCCCTGCTCAGCC TCCCGAGTACCTGGGACTACTTCTTGAGGCCAGGAATTCAAGAACAGAG TAAGATCCTGGTCTCCAAAAAAAGTTTAA

Example 2: TALEN®-Mediated Double Targeted Integration of IL-15 and CAR Encoding Matrices in T-Cells

Materials

X-vivo-15 was obtained for Lonza (cat #BE04-418Q), IL-2 from Miltenyi Biotech (cat #130-097-748), human serum AB from Seralab (cat #GEM-100-318), human T activator CD3/CD28 from Life Technology (cat #11132D), QBEND10-APC from R&D Systems (cat #FAB7227A), vioblue-labeled anti-CD3, PE-labeled anti-LNGFR, APC-labeled anti-CD25 and PE-labeled anti-PD1 from Miltenyi (cat #130-094-363, 130-112-790, 130-109-021 and 130-104-892 respectively) 48 wells treated plates (CytoOne, cat #CC7682-7548), human IL-15 Quantikine ELISA kit from R&D systems (cat #S1500), ONE-Glo from Promega (cat #E6110). AAV6 batches containing the different matrices were obtained from Virovek, PBMC cells were obtained from Allcells, (cat #PB004F) and Raji-Luciferase cells were obtained after Firefly Luciferase-encoding lentiviral particles transduction of Raji cells from ATCC (cat #CCL-86).

Methods

2.1-Transfection-Transduction

The double targeted integration at TRAC and PD1 or CD25 loci were performed as follows. PBMC cells were first thawed, washed, resuspended and cultivated in X-vivo-15 complete media (X-vivo-15, 5% AB serum, 20 ng/mL IL-2). One day later, cells were activated by Dynabeads human T activator CD3/CD28 (25 uL of beads/1E⁶ CD3 positive cells) and cultivated at a density of 1E⁶ cells/mL for 3 days in X-vivo complete media at 37° C. in the presence of 5% CO₂. Cells were then split in fresh complete media and transduced/transfected the next day according to the following procedure. On the day of transduction-transfection, cells were first de-beaded by magnetic separation (EasySep), washed twice in Cytoporation buffer T (BTX Harvard Apparatus, Holliston, Massachusetts) and resuspended at a final concentration of 28E⁶ cells/mL in the same solution. Cellular suspension was mixed with 5 µg mRNA encoding TRAC TALEN® arms (SEQ ID NO:16 and 17) in the presence or in the absence of 15 µg of mRNA encoding arms of either CD25 or PD1 TALEN® (SEQ ID NO:18 and 19 and SEQ ID NO:20 and 21 respectively) in a final volume of 200 µL. TALEN® is a standard format of TALE-nucleases resulting from a fusion of TALE with Fok-1. Transfection was performed using Pulse Agile technology, by applying two 0.1 mS pulses at 3,000 V/cm followed by four 0.2 mS pulses at 325 V/cm in 0.4 cm gap cuvettes and in a final volume of 200 µL of Cytoporation buffer T (BTX Harvard Apparatus, Holliston, Massachusetts). Electroporated cells were then immediately transferred to a 12-well plate containing 1 mL of prewarm X-vivo-15 serum-free media and incubated for 37° C. for 15 min. Cells were then concentrated to 8E⁶ cells/mL in 250 µL of the same media in the presence of AAV6 particles (MOI=3E⁵ vg/cells) comprising the donor matrices in 48 wells regular treated plates. After 2 hours of culture at 30° C., 250 µL of Xvivo-15 media supplemented by 10% AB serum and 40 ng/ml IL-2 was added to the cell suspension and the mix was incubated 24 hours in the same culture conditions. One day later, cells were seeded at 1E⁶ cells/mL in complete X-vivo-15 media and cultivated at 37° C. in the presence of 5% CO₂.

2.2-Activation-Dependent Expression of ΔLNGFR and Secretion of IL15

Engineered T-cells were recovered from the transfection-transduction process described earlier and seeded at 1E⁶ cells/mL alone or in the presence of Raji cells (E:T=1:1) or

Dynabeads (12.5 uL/1E⁶ cells) in 100 µL final volume of complete X-vivo-15 media. Cells were cultivated for 48 hours before being recovered, labeled and analyzed by flow cytometry. Cells were labeled with two independent sets of antibodies. The first sets of antibodies, aiming at detecting the presence of ΔLNGFR, CAR and CD3 cells, consisted in QBEND10-APC (diluted 1/10), vioblue-labeled anti CD3 (diluted 1/25) and PE-labeled anti-ΔLNGFR (diluted 1/25). The second sets of antibodies, aiming at detecting expression of endogenous CD25 and PD1, consisted in APC-labeled anti-CD25 (diluted 1/25) and vioblue-labeled anti PD1 (diluted 1/25).

The same experimental set up was used to study IL-15 secretion in the media. Cells mixture were kept in co-culture for 2, 4, 7 and 10 days before collecting and analyzing supernatant using an IL-15 specific ELISA kit.

2.3-Serial Killing Assay

To assess the antitumor activity of engineered CAR T-cells, a serial killing assay was performed. The principle of this assay is to challenge CAR T-cell antitumor activity everyday by a daily addition of a constant amount of tumor cells. Tumor cell proliferation, control and relapse could be monitored via luminescence read out thanks to a Luciferase marker stably integrated in Tumor cell lines.

Typically, CAR T-cells are mixed to a suspension of 2.5×10⁵ Raji-luc tumor cells at variable E:T ratio (E:T=5:1 or 1:1) in a total volume of 1 mL of Xvivo 5% AB, 20 ng/uL IL-2. The mixture is incubated 24 hours before determining the luminescence of 25 uL of cell suspension using ONE-Glo reagent. Cells mixture are then spun down, the old media is discarded and substituted with 1 mL of fresh complete X-vivo-15 media containing 2.5×10⁵ Raji-Luc cells and the resulting cell mixture is incubated for 24 hours. This protocol is repeated 4 days.

EXPERIMENTS AND RESULTS

This example describes methods to improve the therapeutic outcome of CAR T-cell therapies by integrating an IL-15/soluble IL-15 receptor alpha heterodimer (IL15/sIL15ra) expression cassette under the control of the endogenous T-cell promoters regulating PD1 and CD25 genes. Because both genes are known to be upregulated upon tumor engagement by CAR T-cells, they could be hijacked to re-express IL-IL15/sIL15ra only in vicinity of a tumor. This method aims to reduce the potential side effects of IL15/sIL15ra systemic secretion while maintaining its capacity to reduced activation induced T-cell death (AICD), promote T-cell survival, enhance T-cell antitumor activity and to reverse T-cell anergy.

The method developed to integrate IL15/sIL15ra at PD1 and CD25 loci consisted in generating a double-strand break at both loci using TALEN in the presence of a DNA repair matrix vectorized by AAV6. This matrix consists of two homology arms embedding IL15/sIL15ra coding regions separated by a 2A cis acting elements and regulatory elements (stop codon and polyA sequences). Depending on the locus targeted and its involvement in T-cell activity, the targeted endogenous gene could be inactivated or not via specific matrix design. When CD25 gene was considered as targeted locus, the insertion matrix was designed to knock-in (KI) IL15/sIL15ra without inactivating CD25 because the protein product of this gene is regarded as essential for T-cell function. By contrast, because PD1 is involved in T-cell inhibition/exhaustion of T-cells, the insertion matrix was designed to prevent its expression while enabling the expression and secretion of IL15/sIL15ra.

To illustrate this approach and demonstrate the feasibility of double targeted insertion in primary T-cells, three different matrices were designed (FIGS. 2A, 2B and 2C). The first one named CARm represented by SEQ ID NO:36 was designed to insert an anti-CD22 CAR cDNA at the TRAC locus in the presence of TRAC TALEN® (SEQ ID NO:16 and 17). The second one, IL-15_CD25m (SEQ ID NO:37) was designed to integrate IL15, sIL15 α and the surface marker named Δ LNGFR cDNAs separated by 2A cis-acting elements just before the stop codon of CD25 endogenous coding sequence using CD25 TALEN® (SEQ ID NO:18 and 19). The third one, IL-15_PD1m (SEQ ID NO:38), contained the same expression cassette and was designed to integrate in the middle of the PD1 open reading frame using PD1 TALEN® (SEQ ID NO:20 and 21). The three matrices contained an additional 2A cis-acting element located upstream expression cassettes to enable co-expression of IL15/sIL15 α and CAR with the endogenous gene targeted.

We first assessed the efficiency of double targeted insertion in T-cells by transducing them with one of the AAV6 encoding IL15/sIL15 α matrices (SEQ ID NO:41; pCLS30519) along with the one encoding the CAR and subsequently transfected the corresponding TALEN®. AAV6-assisted vectorization of matrices in the presence of mRNA encoding TRAC TALEN® (SEQ ID NO:22 and 23) and PD1 TALEN® (SEQ ID NO:24 and 25) or CD25 TALEN® (SEQ ID NO:26 and 27) enabled expression of the anti CD22 CAR in up to 46% of engineered T-cells (FIG. 3).

To determine the extent of IL15m integration at CD25 and PD1 locus, engineered T-cells were activated with either antiCD3/CD28 coated beads or with CD22 expressing Raji tumor cells. 2 days post activation, cells were recovered and analyzed by FACS using LNGFR expression as IL15/sIL15 α secretion surrogate (FIGS. 4 and 5). Our results showed that antiCD3/CD28 coated beads induced expression of Δ LNGFR by T-cells containing IL-15m_CD25 or IL-15m_PD1, independently of the presence of the anti CD22 CAR (FIG. 4A-B). Tumor cells however, only

induced expression of Δ LNGFR by T-cell treated by both CARm and IL-15m. This indicated that expression of Δ LNGFR could be specifically induced through tumor cell engagement by the CAR (FIGS. 5 and 6).

As expected the endogenous CD25 gene was still expressed in activated treated T-cells (FIGS. 7 and 8) while PD1 expression was strongly impaired (FIG. 12).

To verify that expression of Δ LNGFR correlated with secretion of IL15 in the media, T-cells expressing the anti-CD22 CAR and Δ LNGFR were incubated in the presence of CD22 expressing Raji tumor cells (E:T ratio=1:1) for a total of 10 days. Supernatant were recovered at day 2, 4, 7 and 10 and the presence of IL15 was quantified by ELISA assay. Our results showed that IL15 was secreted in the media only by T-cells that were co-treated by both CARm and IL15m matrices along with their corresponding TALEN® (FIG. 13). T-cell treated with either one of these matrices were unable to secrete any significant level of IL15 with respect to resting T-cells. Interestingly, IL-15 secretion level was found transitory, with a maximum peak centered at day 4 (FIG. 14).

To assess whether the level of secreted IL-15 (SEQ ID NO:59) could impact CAR T-cell activity, CAR T-cell were co-cultured in the presence of tumor cells at E:T ratio of 5:1 for 4 days. Their antitumor activity was challenged everyday by pelleting and resuspended them in a culture media lacking IL-2 and containing fresh tumor cells. Antitumor activity of CAR T-cell was monitored everyday by measuring the luminescence of the remaining Raji tumor cells expressing luciferase. Our results showed that CAR T-cells co-expressing IL-15 had a higher antitumor activity than those lacking IL15 at all time points considered (FIG. 15).

Thus, together our results showed that we have developed a method allowing simultaneous targeted insertions of CAR and IL15 cDNA at TRAC and CD25 or PD1 loci. This double targeted insertion led to robust expression of an antiCD22 CAR and to the secretion of IL15 in the media. Levels of secreted IL15 were sufficient to enhance the activity of CAR T-cells.

TABLE 5

Sequences referred to in example 2.			
SEQ ID	Name	Polypeptide sequence	RVD sequence
16 TALEN right TRAC		MGDPKKRKVIDPYDVPDYAIDIADLRLGYSQQQKKEKIKPKVRSTVA QHHEALVGHGFTHAHIVALSQHPAALGTAVAKYQDMIAALPEATHEAV GVGKQWSGARALEALTAVAGELRGPPPLQQLDTGOLLKTAKRGGVTA VHAWRNALTGAPLNLTQPOVVIAISNGGGKQALETVQRLLPVLCQA LTPQQVVAIASNNGGKQALETVQRLLPVLCQAHLTPQQVVAIASN GKQALETVQRLLPVLCQAHLTPEQVVIAISHDGKQALETVQRLLPV CQAHLGLPEQVVIAISHDGKQALETVQRLLPVLCQAHLGLPEQV SHDGKQALETVQRLLPVLCQAHLGLTPEQVVIAISNIGGKQALETV LPVLCQAHLGLTPEQVVIAISHDGKQALETVQRLLPVLCQAHLGLP VVAIASNIGGKQALETVQALLPVLCQAHLTPQQVVAIASNNGGKQALE TVQRLLPVLCQAHLGLTPEQVVIAISNIGGKQALETVQALLPVLCQA LTPQQVVAIASNNGGKQALETVQRLLPVLCQAHLGLTPEQVVIAISN QALETVQALLPVLCQAHLGLTPQQVVAIASNNGGKQALETVQRLLPV QAHGLTPEQVVIAISHDGKQALETVQRLLPVLCQAHLGLTPQQVVA NGGGRPALESIVQLSRPDPAALALTNDHLVALACLGGRPALDAVKKL GDP1RSQSLVKSELEEKKSELRHKLKVYPHEYIELIEIARNSTQDRILEMK VMEFFPMKVGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGY NLPIQQADEMQRVYVEENQTRNKHINPNEWWKVYPSVTEFKFLFVSGH FKGNYKAQLTRLNHTNCNGAVLSVEELLIGGEMIAGTLTLEEVRKFN NGEINFAAD	NG-NN-NG-HD- HD-HD-NI-HD-NI- NN-NI-NG-NI-NG- HD-NG#

TABLE 5-continued

Sequences referred to in example 2.

17	TALEN Left TRAC	MGDPKKKRKVIDKETAAAKFERQHMDSIDIADLRTLGYSQQQQEIKPK VRSTVAQHNEALVGHGFTAHIALSQHPAALGTAVKYQDMIAALPEA THEAVGVGKQWSGARALEALLTVAEGLRGPPQLDTGQLLKIAKRGGV TAVEAHWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQRLLPVL CQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPEQVVAI ASHDGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASNIGGKQALETVQ LLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTP CQVVAIASHDGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQ LETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVL CQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASN GGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASNIGGKQALETVQRLLP VLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCAQAHGLTPEQV AIAASNIGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASHDGGKQALETV QRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLT PQQVVAIASNGGGRPALESIVQLSRPDPAALALTNDHLVALACLGGRP ALDAVKKGGLDPIRSQSLVKSLEEKSELRHKLKYVPHYEIELIEIARNS TQDRILEMKVMEFFMKVYGRKGHLGGSRKPDGAIYTVGSPIDYGVIVD TKAYSGGYNLPIGQADEMORYVEENQTRNKHINPNEWWKVYPSSVTE FKFLFVSGHFKGNYKAQLTRLNHTINCNGAVSVEELLIGGEMIKAGTLT LEEVRRKFNNGEINFAAD	HD - NG - HD - NI - NN - HD - NG - NN - NN - NG - NI - HD - NI - HD - NN - NG #
18	TALEN right CD25	MGDPKKKRKVIDYDYPDVPAIDIAIDLRTLGYSQQQQEIKPKVIRSTVA QHHEALVGHGFTAHIALSQHPAALGTAVKYQDMIAALPEATHEAIV GVGKQWSGARALEALLTVAEGLRGPPQLDTGQLLKIAKRGGVTAVEA VHAWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQALLPVLCQAHGL LTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGG GKQALETVQRLLPVLCAQAHGLTPEQVVAIASHDGGKQALETVQRLLPVL CQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIAS ASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQ RLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTP PQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQ ALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQ AHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIAS ASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRL PVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPEQV VVAIASNGGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASNIGGKQALETV QALLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLT PEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGKQ ALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQ AHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASN GGGRPALESIVQLSRPDPSGSGGDPISRSQLVKSLEEKSELRH KLKYVPHYEIELIEIARNSTQDRILEMKVMEFFMKVYGRKGHLGGSRK PDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMORYVEENQTRNK HINPNEWWKVYPSSVTEFKLFVSGHFKGNYKAQLTRLNHTINCNGAV LSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD	NN - NG - NG - HD - NG - NG - NG - NG - NN - NN - NG - NG - NG - NG - HD - NG #
19	TALEN left CD25	MGDPKKKRKVIDYDYPDVPAIDIAIDLRTLGYSQQQQEIKPKVIRSTVA QHHEALVGHGFTAHIALSQHPAALGTAVKYQDMIAALPEATHEAIV GVGKQWSGARALEALLTVAEGLRGPPQLDTGQLLKIAKRGGVTAVEA VHAWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQALLPVLCQAHGL LTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGG GKQALETVQRLLPVLCAQAHGLTPEQVVAIASHDGGKQALETVQRLLPVL CQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIAS ASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASYGGKQALETVQ RLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTP PQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQ ALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQ HGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASHD GGKQALETVQRLLPVLCAQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVA IASNGGGRPALESIVQLSRPDPAALALTNDHLVALACLGGRPALDK KGLGDPISRSQLVKSLEEKSELRHKLKYVPHYEIELIEIARNSTQDRIL	NI - HD - NI - NN - NN - NI - NN - NN - NI - NI - NN - NI - NN - NG - NI - NG #
20	TALEN right PD1	MGDPKKKRKVIDYDYPDVPAIDIAIDLRTLGYSQQQQEIKPKVIRSTVA QHHEALVGHGFTAHIALSQHPAALGTAVKYQDMIAALPEATHEAIV GVGKQWSGARALEALLTVAEGLRGPPQLDTGQLLKIAKRGGVTAVEA VHAWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQALLPVLCQAHGL LPEQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASHDGG KQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVL CQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCAQAHGLTPQQVVAIAS ASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASYGGKQALETVQ RLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTP PQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQ ALETVQRLLPVLCAQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQ HGLTPQQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPEQVVAIASHD GGKQALETVQRLLPVLCAQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCAQAHGLTPQQVVA IASNGGGRPALESIVQLSRPDPAALALTNDHLVALACLGGRPALDK KGLGDPISRSQLVKSLEEKSELRHKLKYVPHYEIELIEIARNSTQDRIL	KL - HD - HD - NG - HD - NG - YK - NG - NN - NN - NN - NN - HD - HD - NI - NG #

TABLE 5-continued

Sequences referred to in example 2.					
SEQ	ID	Sequence	Polynucleotide sequence		
21	TALEN Left PD1	EMKVMEEFFMKVYGYRGKHLGGSRKPDGAIYTGVGSPIDYGIVI DTKAYS GGYNLPQGADEMORYVEENQTRNKHINPNEWWKVYPSSVTEFKPLFV SGHFKGNYKAQLTRLNHIITNCNGAVLSVEELLIGGEMIKAGTLTLEEVVR KFNNGEINFAAD	MGDPKKKRKV1DKE TAAAKF ERQHMDSIDIA LRTL GYSQQQ EKIKPK VRSTVAQHHEALVGHGHTHAI VALS QH PA ALGTV AVK YQDMIA ALPEA THEA IVGVG KQW SGAR ALE ALLT VAGEL RGP PLQ DLTG QL KIA KRGGV TA VEAV HAWRN ALT GAPL NL TPE QVVA IAS H DGK Q ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS ASHDG GK Q ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RLL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NI GG KQ ALET VQ ALL PVL CQ HGLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS DGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QV VVA IAS NGG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ ALET V QRL PVL CQAH GLT P QVVA IAS HDG KQ ALET VQ RL PVL CQAH GLT P QVVA IAS NGG KQ PALES IVA QLSRP DP ALA AL TNHD LVAL AC LG GRP ALDA VK GKL GDPI SRS QLV KSE LE EKK SLE RL HKL KY VP HEY I E I ARNS TQDR I LEMK VM EFFF MKVYGYRGKHLGGSRKPDGAI YTGV SPIDY GVIVD TKAY SGGY NL PI QGA DEMORY VEENQ TRNK HIN PNEWW KVYPSS VTE FKFL FVSGH FG NYKA QLTRLN HI ITNCNGAV LSVEELLIGGEMIKAGTLT LEE VRK FNNGE INFAAD	HD - NG - HD - NG - NG - NG - NN - NI - NG - HD - NG - NN - N - NN - HD - NG #	
22	TALEN TRAC pCLS11370	ATGGGGCGATCTTAAAAAGAAAAGCTAAGGTATCGATTACCCATACGATGTTCCAGATTACGCTAT CGATATCGCCGATCTACGCACGCCGCTCGCTACAGCCAGCACAGGAGAACATCAAACCGAA GGTCGTTGCACAGTGCGCAGCACACAGGGACTGGTCGCCACGGTTACACACCGCC ACATCGTTGCCTTAAGCCAACACCCCGCAGCGTTAGGGACCGTCGCTGCAAGTATCAGGACA TGATCGCAGCGCTGGCAAGCAGCGCACACAGGAGACAGGCTGCGCCACCGGTTACACCGCC GGCGCACCGCCTCTGGAGGCCCTGCTCACGGTGGCGGAGAGTGGAGGTCACCGGTTAC GTTGGACACAGGCCAACTTCTCAAGATTGCAAGGAACTGGCGCGTGACCCGAGTGGAGGAGT GCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTGACCCCCCAGCAGGTGGTG CCATGGCCAGCGCAATGGCGCTGGCAAGCAGGCGCTGGAGACGGTCCAGCGCTGTGGCGGT CTGTCGCCAGGCCACGGCTTGAACCCCCCACGGTGTGGCGCATGCCAGCAATAATGGTC CAAGCAGGCCGCTGGAGACGTTGCGCCAGGGCTGTGGCGGTCTGTGCCAGGCCACGGCTTGA CCCCCAGCAGGTGGTGCCATCGCCAGCAATGGCGGTGCAAGCAGGCCGCTGGAGACGGT CCAGCGCTGGCTGTGGCGCTGGCGCATCGCCAGCAACTGGCGGTGCGTGGAGACGGTGGCG TCGCCAGCCACGATGGCGCAAGCAGGCCAGGGCTGGAGACGGTCCAGCGCTGTGGCGTCT TGCCAGGCCACGGCTTGAACCCCAGGGCTGGAGACGGTCCAGCGCTGTGGCGTCT GCAGGCGCTGGAGACGGTCCAGCGCTGTGGCGTGTGGCGCATCGCCAGGCCACGGCTTGA CGGAGCAGGTGGTGGCCATCGCCAGCACTGGCGCAAGCAGGCCAGGGCTGGAGACGGTCCA GCCGGCTGGCCGGCTGTGGCCAGGCCAACGGCTTGAACCCCAGGGAGCAGGTGGTGGCGATCG CCAGCAATATTGGTGGCAAGCAGGCCAGGGCTGGAGACGGTCCAGCGCTGTGGCGTGTGG CAGGCCACGCCATGGCCAGGGCTGGAGACGGTGTGGCCATCGCCAGCAATATTGGTGGCAAG GGCGCTGGAGACGGTCCAGCGCTGTGGCGTGTGGCGCATCGCCAGGCCACGGCTTGA GAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCCAGGGCTGGAGACGGTGCAGGC GCTGTTGGCCGGCTGTGGCCAGGCCAACGGCTTGAACCCCAGGGAGCAGGTGGTGGCGATCGCC GCAATATTGGTGGCAAGCAGGCCAGGGCTGGAGACGGTCCAGCGCTGTGGCGTGTGG GCCCAAGGGCTTGAACCCCAGGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAG GCTGGAGACGGTGCAGCGCTGTGGCGTGTGGCGCATCGCCAGGCCACGGCTTGA AGGTGGTGGCCATCGCCAGCAATGGCGTGGCAAGCAGGCCAGGGCTGGAGACGGTCCAGCGG GTTGGCCGGCTGTGGCCAGGCCAACGGCTTGAACCCCAGGGAGCAGGTGGTGGCCATCGCCAGCA ATATTGGTGGCAAGCAGGCCAGGGCTGGAGACGGTCCAGCGCTGTGGCGTGTGGCGAGGCC CACGGCTTGAACCCCAGGGAGCAGGTGGCTGTGGCGCATCGCCAGCAATATTGGTGGCG GGAGAGCGTCCAGCGCTGTGGCGTGTGGCGCATCGCCAGGCCACGGCTTGA GTGGTGGCCATCGCCAGGCCACGATGGCGCAAGCAGGCCAGGGCTGGAGACGGTCCAGCGG GCCGGCTGGCTGTGGCCAGGCCAACGGCTTGAACCCCAGGGAGCAGGTGGTGGCCATCGCCAGCA GCCGGCGCAGGCCAGGGCTGGAGACGGTCCAGCGCTGTGGCGTGTGGCGTGTGG GCCGGCTTGAACCCCAGGGAGCAGGTGGCTGTGGCGCATCGCCAGCAATATTGGTGGCG TGCAGTGGAAAAGGAGTGGGGATCTATCGCCAGCTGGCTGTGGAGACGGTCCAGGCC GGAGAGAAATCCAGGTTGAGGACAAGCTGAAAGTGTGGAGACGGTCCAGGCC CGAGAGTGGCCGGAAACAGCACCCAGGGAGCAGTCTGGAGATGAAGGTGATGGAGTTCTT GAAGGGTGTACGGCTACAGGGCAAGCACCTGGGGCTGGCTGGAGACGGCAGGCC ACACCGTGGCTCCCCCATCGCACTGGCGTGTGGAGACGGCAGGCC TACAACCTGCCCATCGCCAGGCCAGCAATCGAGGAGTACGTGGAGGAGAACAGACCC GAACAAGCAGCAACACCAACGAGTGGTGGAGGTGACCCCTCCAGCGTACCGAGTCA GTTCTGTTCTGTGGCCGACTTCAAGGGCAACTACAAGGCCAGCTGACCCAGCT CATCCAACATGCAAGGCCAGCGTGTGGCTGGAGGAGCTCTGTGATCGGGCG TCAAGGGCGGACCTGGACCTGGAGGAGGTGAGGAGGAAGTCAACAAAGGGCAGATCAA TCGCGGCCGACTGATAA			

TABLE 5 -continued

Sequences referred to in example 2.

23 TALEN TRAC pCLS11369	ATGGCCGATCTAAAAAGAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTCAGAGACAGCACATGGACAGCATCGATATCGCGATCTACGCACGCTCGGCTACAGCAGCAGCAA CAGGAGAAAGATCAAACCGAAGGTTGTTGACAGTGGCCAGCACCCAGGACTGTTGCGGTTAACGCAACACCCGGCAGCGTTAGGGACCGT CGCTGTCAGTACAGGAGCATGTCGAGCTGGCCAGAGGCACACAGCAAGCGATCGTTGG CGTCCGAAACAGTGGTCCGGCCACGGCTCTGAGGCTTGCTCACGGTGGCCAGAGT TGAGAGGTCCACCGTTACAGTGGACACAGGCAACTTCAGATTGAAAAGCTGGCCGG TGACCGCAGTGGAGGCAGTGCATGGCAATGCACTGACGGGTGCCCGCTCAACTTG ACCCGGAGCAGGTGGCCATGCCAGCCACGATGGGCAAGCAGGGCTGGAGACGG TCCAGGGCTGGCCGGTGTGTCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCC ATCGCCAGCAATGGGGTGGCAACAGGGCTGGAGACGGTCCAGCGCTGTGGCCGTGCT GTGCCAGGCCACGGCTGGCATCGCCAGCACGGCTGGAGACGGTCCAGCGCT AAGCAGGCCTGTGGCGGTGCTGGCCAGGGCTGGAGACGGTCCAGCGCTGGAGC AGGGCTGTGGCGGTGACCCGGAGCAGGTGGTGGCATCGCCAGGCCACGGCTGGAGC GCGCTGGAGACGGTCTGGCCAGGGCTGGAGACGGTCCAGCGCTGGAGACGGTCC CCAGGGCTGTGGCGGTGCTGTGTCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCC TCGGCAGCCACGATGGGGCAAGCAGGGCTGGAGACGGTCCAGCGCTGGTGGCGT TGCAGGGCCACGGCTGGACCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGGCAA GCAGGGCTGGAGACGGTCCAGGGCTGTGCGCTGGTGGCATCGCCAGGCCACGGCTTGAC CCCAGCAGGTGGCGCATCGCCAGCAATGGGGTGGCAAGCAGGGCTGGAGACGGTCC GCGCTGGTGGCGTGTGCGCAGGCCACGGCTGGAGACGGTCCAGCGCTGGAGACGGTCC CTGTTGGCGGTGCTGTGCGAGGCCACGGCTGGAGACGGTCCAGCGCTGGAGACGGTCC CAATAATGGTGGCAAGCAGGGCTGGAGACGGTCCAGCGCTGGAGACGGTCCAGCG CCCACGGCTTGACCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGGCAAGCAG CTGGAGACGGTCCAGGGCTGTGCGCTGGTGGCATCGCCAGGCCACGGCTGGAGACGGTCC GGTGGTGGCATCGCCAGCAATGGGGTGGCAAGCAGGGCTGGAGACGGTCCAGCG TTGGCGGTGCTGTGCGAGGCCACGGCTGGAGACGGTCCAGCGCTGGAGACGGTCCAGCG TGGCGGTGGCAAGCAGGGCTGGAGACGGTCCAGGGCTGTGCGCTGGTGGCATCGCCAG CACGGCTTGACCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGGCAAGCAGGGCT
24 TALEN CD25 pCLS30480	ATGGGCATCTAAAAAGAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTAT CGATATCGCGATCTACGACGCTCGGCTACAGCAGCAGCAACAGGAGAAGATCAAACCGAA GGTCTGGTGCACAGTGGCGCAGCACACAGGGACTGGTGGCCACGGGTTACACAGCGC ACATCGTGTGGCTAACGCAACACCCGGCAGCGTTAGGGACCGTCTGCTCAAGTATCAGGACA TGATCGCAGCGTGGCCAGGGCAGACACGAAGGCTGCTTGCGCTGGCAAACAGTGGTCC GGCGCACGCGCTCTGGAGGCCCTGGCTCACGGTGGCGGGAGAGTTGAGGGTCCACCGTTACA GTTGGACACAGGCCACTCTCAAGATTGCAAACAGTGGCAGGGCTGGAGCGCAGTGGAGGAG GCATGCTGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGACCCCCCAGCAGGGTGG CCATCGCCAGCAATATGGTGGCAAGCAGGGCTGGAGACGGTCCAGGGCTGTGGCGGT CTGTCAGGGCCACGGCTTGACCCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGG CAAGCAGGGCTGGAGACGGTCCAGGGCTGGTGGAGACGGTCTGTCAGGGCCACGGCTTGAC CCCCCAGCAGGTGGCGCATCGCCAGCAATGGGGTGGCAAGCAGGGCTGGAGACGGT CCAGGGCTGTGGCGGTGCTGTGCGCAGGCCACGGCTTGACCCCCAGCAGGGCTGGAGACGG TCGGCAGCCACGATGGGGCAAGCAGGGCTGGAGACGGTCCAGCGCTGGTGGCGT TGCAGGGCCACGGCTGGACCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGGCAA GCAGGGCTGGAGACGGTCCAGGGCTGTGCGCTGGTGGCATCGCCAGGCCACGGCTTGAC CCCAGCAGGTGGCGCATCGCCAGCAATGGGGTGGCAAGCAGGGCTGGAGACGGTCCAGCG GCGCTGGTGGCGTGTGCGCAGGCCACGGCTGGAGACGGTCCAGCGCTGGAGACGGTCC CTGTTGGCGGTGCTGTGCGAGGCCACGGCTGGAGACGGTCCAGCGCTGGAGACGGTCC CAATAATGGTGGCAAGCAGGGCTGGAGACGGTCCAGCGCTGGAGACGGTCCAGCG CCCACGGCTTGACCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGGCAAGCAG CTGGAGACGGTCCAGGGCTGTGCGCTGGTGGCATCGCCAGGCCACGGCTGGAGACGGTCC GGTGGTGGCATCGCCAGCAATGGGGTGGCAAGCAGGGCTGGAGACGGTCCAGCG TTGGCGGTGCTGTGCGAGGCCACGGCTGGAGACGGTCCAGGGCTGGAGACGGTCCAGCG TGGCGGTGGCAAGCAGGGCTGGAGACGGTCCAGGGCTGTGCGCTGGTGGCATCGCCAG CACGGCTTGACCCCCAGCAGGTGGTGGCATCGCCAGCAATGGGGTGGCAAGCAGGGCT

TABLE 5-continued

Sequences referred to in example 2.

GGAGACGCTTCCAGCGCTGTGCCGGTGTGCCCCAGGCCACGGCTTGACCCCGAGCAG
GTGGTGGCCATCAGCGCAGGCACGATGGCCGAAAGCAGGGCTGGAGACGGCTCAGGGCTGTG
GCCGGTGTGCGGCCAGGCCACGGCTTGACCCCTGAGCGTGGGCTATGCCGCAATG
GGCGCCGAGGCCGGCGCTGGAGACGATTGTCGGCCAGTTATCTGCCCTGATCCGAGTGGC
AGCGGAAGTGGCGGGGATCTTATCAGCCGTTCCAGCTGGTAAGTCCGAGCTGGAGGAGAA
GAATTCGGACTTGGGCCAACAGCTGGAACTGGCTCCACGACTATCGACGCTTGAGAT
GCCCGGAAACAGCACCCAGGGCTATCCTGGAGATGAAGGTGATGGAGTTCTCATGAAGGG
GTACGGCTACAGGGCCAAGCACCTGGCGCTCAGGAGGCCAGGCCACGACTATCACACCC
TGGGCTCCCCCATGACTACCGCGTGTACTGGACACCAAGGGCTACTCCGGGGCTACAACCC
TGCCCCATGCCAGGCCAGGGCAAGAATGGAGGTGATGGAGGAGAACCCAGGCCAACACA
CACATCAACCCCAAAGCTGGTAAGGTGTACCCCTCACGGCTTGAGGAGTTCAAGTCTGG
TTCTGTGTCGGCCACTTCAGGGCAACTACAAAGGCCAGCTGACCAGGCTGAACCACATCACC
AACTGCAACAGGCCGCGCTGTGTCGGAGGAGCTCTGATCGCCGGCAGATGATCAAGGG
CGGCCACCTGACCTGGAGGAGGTGAGGAGGAAGTTCACAAACAGGCCAGATCAACTCGGG
CGCAGTATAA

25 TALEN CD25
 pCL30479 ATGGGCGATCTAAAAAGAACGTAAGGTATCGATTACCCATACGATGTTCCAGATTACGCATCGATATCCGGCTACCTCCGGCTACAGCCAGCAGCACACAGGAGAAGATCAAACCGAA
 CGATATCCGGCATCTACGCCACCTCGGCTACAGCCAGCAGCACACAGGAGAAGATCAAACCGAA
 GGTTCTGGTGCAGTGGCGCAGCACCCAGGGACTGGTCGGGACCGGGTTTACACCGCGC
 ACATCGTGGCTTAAGGCCAACCCGGCAGCGTTAGGGACCGTCGCTGAAGTATCAGGACA
 TGATCGCAGCGTGGCCAGAGGCAGACACGAAGCAGTCGTTGGCTCGGAAACAGTGGTCC
 GGCAGCAGCGCTCTGGAGGCCACTCTCAAGATTGCAAAACGGGCTGGCGAGCAGTCACCGGTACCA
 GTTGGGACAGGCCAACTCTCAAGATTGCAAAACGGGCTGGCGAGCAGTCACCGGTACCA
 GCATGCTGGCGCAATGCTACTGAGGGTGGCCCGTCAACTTGAACCCGGCAGCGTGG
 CCATCGCAGCAATATTGGTGGCAAGCAGGCCGCTGGAGACCGTGAGCGCTGTTGCCGGT
 CTGTCGAGGCCACCGGCTTGACCCGGAGCAGGTGGTGGCCATGCCAGCAGATGGGG
 CAAGCAGCGCTGGAGACAGGCTCAGCGGCTGTGGCGGCTGAGCGGCCACCGGCTTGA
 CCCCAGGAGCAGGGTGGCTGGCCATCGCAGCAATATTGGTGGCAAGCAGGCCACCGGCTTGA
 CAGGCCTGTTGCCGGTGTGTGCCAGGCCACCGGCTGACCCCCAGCAGGTGGTGGCCAT
 CGCCAGAATAATGGTGGCAACGAGGCCAGGGCTGGAGACCGTGAGCGCTGTGGCGGTGCTGT
 GCCAGGCCACCGGCTTGACCCGGAGCAGGTGGTGGCCATGCCAGCAATAATGGTGGCA
 CAGGCCTGGAGACGGCTCAGCGGCTGTGGCGGCTGTGTGCCAGGCCACCGGCTTGA
 GGAGCAGGTGGCCATCGCAGCAATATTGGTGGCAAGCAGGCCACCGGCTGAGACGGTGCAGG
 CGCTGTTGCCGGTGTGTGCCAGGCCACCGGCTGACCCCCAGCAGGTGGTGGCCATGCC
 AGCAATAATGGTGGCAAGCAGGCCAGGGCTGGAGACCGGCTGGCAGCGCTGTGGCG
 GGCCACCGGCTTGACCCGGAGCAGGTGGTGGCCATGCCAGCAATAATGGTGGCAAGCAGG
 CGCTGGAGACGGTCCAGCGGCTGTGGCGGCTGTGTGCCAGGCCACCGGCTGACCCGGAG
 CAGGTGGTGGCCATCGCAGCAATAATTGGTGGCAAGCAGGCCACCGGCTGGAGACGGTGCAGGCC
 GTTGGCCGGTGTGTGCCAGGCCACCGGCTGTGGACCCCCAGCAGGTGGTGGCCATGCCAGCA
 ATATTGGTGGCAAGCAGGCCAGGGCTGGAGACGGTGGCCAGGGCTGTGGCGGTGTGCCAGGCC
 CACGGCTTGACCCGGAGCAGGTGGTGGCCATCGCAGCAATAATGGTGGCAAGCAGGCC
 GGAGACGGTCCAGCGGCTGTGGCGGCTGTGTGCCAGGCCACCGGCTGACCCGGAGCAG
 GTGTTGGCCATCGCAGCAATAATTGGTGGCAAGCAGGCCACCGGCTGGAGACGGTGCAGGCC
 GTTGGCCGGTGTGTGCCAGGCCACCGGCTGTGGACCCCCAGCAGGTGGTGGCCATGCCAGCA
 ATATTGGTGGCAAGCAGGCCAGGGCTGGAGACGGTGGCCATCGCAGCAATGGGCTGGCAAGCAGGCC
 GGCTTGACCCGGAGCAGGTGGTGGCCATCGCAGCAATGGGCTGGCAAGCAGGCCAGGGCTGG
 GACGGCTCAGGCCAGGGCTGTGGCGGTGTGGAGACGGCAGGGCTGGACCCCCAGCAGGTGG
 TGGCCATGCCAGCAATAATTGGTGGCAAGCAGGCCAGGGCTGTGGAGACGGTGGCCAGGCC
 GTGCTGTGCCAGGCCACCGGCTTGACCCCTACAGCAGGTGGTGGCCATCGCAGCAATGGG
 CGCAGGCCGGCTGGAGAGCATTGTGGCCAGGTATCTGCCCTGATCGAGTGGCAGCG
 GAAGTGGGGGAGCTCATCGCCTGGAGACGGCTGGAGACGGTGGAGACGGAGAAGAAAAT
 CCGAGTGGAGGCCAACAGTGAAGTACGTGCCCCACAGAGTACATCGAGCTGAGATGCC
 GGAAACAGCAGGCCAGGACCGTATCTGGAGAGTGAAGGTGATGGAGTCTTCATGAAGGTGAC
 GCTACAGGGCAAGCACCTGGCGCTCCAGGAAGGCCAGGGCCATCTACACCGTGGGC
 TCCCCATCGACTACGGCGTGTGCGACCCAAGGGCTACCCGGCTAACACCGTGGC
 ATCGGCCAGGCCAGAACATGCAAGGGTACGTGGAGAGGAACAGACAGGAAACAGACAT
 CAACCCCAAGGAGTGGTGGAGGTGACCCCTCCAGGGTACCGAGTTCAGGTTCTGTG
 GTCCGGGACTTCAAGGGCAACTACAAGGCCAGCTGACCAGGCTGAACCACATCACCAC
 CAACGGGCCGTGTCGTCGAGGAGGCTCTGATCGCCGGAGATGATCAAGGCC
 CCCCTGGAGGAGGTGAGGAGGAAGTCAACACGGCGAGATCAACTTCGCGGCC
 TGATAA

26 TALEN PD1
pCLSP28959 ATGGGCGATCTAAAGAAGACGTAAAGTCATCGATTACCCATACGATGTTCCAGATTACGCATCGATATCGCCGACTCACGCCCTCGGCTACAGCCAGCAGCACACAGGAGAACATCAAACCGAA
GGTTCGTCGACAGTGGCGCAGCACCCGGCAGCGCTTACGGGGACTGGTCGGGACAGGGTTCACACAGGAGAACATCGTGGCTTAAGGCCAACCCGGCAGCGCTTACGGGGACTGGTCGGTCAAGTATCAGGACA
TGATCGCAGCGTTGCCAGAGGGCAGACACGAAGCAGTCGTTGGCTCGGAAACAGTGGTCC
GGCCGACCCGCTCTGGAGCCCTTGCTACGGTGGCGGGAGAGTTGAGAGGTCACCGTTACA
GTTGGACAGGCCAACCTTGCTCAAGATTGCAAAACAGGCTGGCGCTGGCGCAGCCAGTGGAGGCC
GCGATCGATGGCGCAATGCACTGACGGGTGGCCCTCACTTGAACCCCCGGAGCAAGTGGTGG
CTATCGCTTCAAGCTGGGGGAAAGCAGGCCCTGGAGACCGTCCAGGCCCTCTCCAGTG
CTTTCGCAAGGCTCACGGACTGACCCCTGAACAGGTGGCAATTGCTCCTACACAGCGGGGG
CAAGCAGGCCTGGAGACTGTCAGGGCTTGCTCTGGCCAGGGCAACAGGCTTGGAGACCGTCA
CTCTGGAGCAGGCTGTGGCATTCAGGCGCAGGCTGGCTCTGGCCAGGGCAACAGGCTTGGAGACCGT
CAGCGCCTCTCCAGTGTGTGCGAGGCTCATGGGCTGACCCCAACAGCAGGGCTGCGCATT
GCCAGTAACGGCGGGGAAGCAGGCCCTGAACAAACAGTGGAGGGCTGTGGCCCTCTGGT
CCAAGCACAAGGGCTGGACACCCGGAGCAGGTGGGATCGCCTCTCATGAGCGGGCAAGC
AGGGCCCTTGAGCAGTGCAGAGACTGTGTCGGCTGTGTGTCAGGCCACAGGGTTGACACCC

TABLE 5-continued

Sequences referred to in example 2.

AGCAGGTGGTCGCCATGCCAGCAATGGGGGGAAAGCAGGCCCTTGAGACCGTGCAGCGG
TTGCTTCAGTGTGTCAGGCCACAGGACTGACCCCTCAACAGGTGGTGCACATGCCAGC
TACAAGGGGGAAAGCAGGCTGGAGACAGTGGCAGGCCCTCTGGCCGCTGTGTCAGGC
TCACGGACTGACACACAGGGTGGTGCACATGCCAGTAACGGGGGCCAGCAGGCTT
TGGAGACCGTCCAGAGACTCTCCCCGTCTTGGCAGGCCACGGGGTGCACACCTCAGCAGG
TGTGCGCATGCCCTCAACACGGGGCAAGCAGGCCCTCGAACACTGTGCAGAGGCTGCTG
CTCTGTGCTGGCAGGCTCATGGGCTGACACCCCGAGCAGGGTGGGCCATTCCTCAACAC
GCCGGCAACACAGGACTGGAGACGGTGCACGGCTGCGCCCTCTGCAAGGCCACCG
GCTCACTCACAGGGTGGCCATGCCCTCAAACATGGGGGAAGCAGGCCCTGGAGA
CTGTGCAAAGGCTGCTCCCTGTGCTGCCAGGCACACGGACTGACCCCTCAGCAGGTTG
GCAATGCCATCAACACGGGGAAAGCAGGCCCTGAAACACCTGCGAGGCCCTCCCAAGT
GCTGTGCCAGGGACATGGCCATCACCCGGCAAGTGGCTATGCCAGGCCACAGGGAG
GGAGCAGGGCTGGAGACGGTGCAGGGCTGCTGCCCTGTGTCAGGGCCACGGGCTT
ACTCCAGAGCAGGTGTCGCCATGCCAGTCATGATGGGGGAAGCAGGCCCTGGAGACAGT
CCAGGGCTGCTGGAGCTTGGCCAGGTCAGGGCTTCAAGCTGCCAGGAGCTGGGCCAT
TGCCCACAAATGGGGCAACAGGCCCTGGAGACAGTCAGGCCCTCTGGCTTGTG
TCAGGCCACGGCTGACACCCAGCAGGGTGTGCCATTGCTCTAATGGGGGCCAGAGC
CCGGCTTGGAGAGCATGTTGCCAGTTATGCCCTGATCCGGCTGGCCGCTGTGACCA
ACGACCACTCTGGCCCTTGGCTGCCCTGGCCGGCTCTGGCTGGATCAGTAAAACT
GGATTTGGGGATCTTATCAGCGCTTCCAGGGTGAAGTCCAGGGTGGAGGAGAAATCC
GAATTGGGGCAACAGTGAAGTACGTGCCCAAGGATCACATGCCAGTCAGATGCCCG
AACAGCACCAGGACCGTATCTGGAGATGAAGGTGATGGAGTTCTCATGAAGGTGACGG
TACAGGGGCAAGCACCTGGGGCTCCAGGAAGGCCAGGGCCATCTACACCGTGGGCTC
CCCCATCGACTACGGCTGTATCGTGGACACCAAGGGCTACTGGGGCTCAACATGCCCAT
GCCGGCAGGCCAGGAATGCAAGGGTACCTGGAGGAACACGACAGGAACATAAGCACA
ACCCCAACAGTGGTGAAGGTGATCCCTCCAGCGTGCACGGAGTCAAGTCTGTGCTG
CCGGGCACTCAAGGGCAACTACAAGGCCAGCTGACCGAGCTGAACACATCACCACATC
ACGGGCCGTGCTGTCGGAGGAGGCTCTGATCGCCGGAGATGATCAAGGCCGGCAC
CTGACCCCTGGAGGAGGTGAGGAGGAAGTCAACACGGCAGATCAACTTCGCCGGCAGT
ATAA

27 TALEN PD1
pCLSL18792 ATGGGGCATCTAAAAAGAACGTAAGGTATCGATAAGGAGACCGCGCTGCCAAGTTCGAGAGACAGCACATGGACAGCATGCATATCGCCTACGCCAGCTCGGCTACAGCCAGCAGCAA CAGGGAAGATCAACCGAAGGTTCTGTCAGTGGCGCAGCACCGAGGACTGGTCGCGCAGGGTTACACCGCCATACCGTCTGGTAAAGCCACACCCGGCAGCGTCTAGGGACCGT CGCTGTCAGTATCAGGACATGATCGCAGCGTTGCCAGAGGGCAGACACGAAGCAGATCGTGGCGTGGCCAAACAGTGGCTCCAGCTGGAGGAGT TGAGAGGTTCCACCGTTCAGTGGACAGGCCAATCTCAAGTGCAGGAACTTCAGCTGGCCGAGGAGT TGACGGCAGTGGAGGCTGTCATGCATGCCAGTAAGTCAGTGCGGCTCCGGCTCAATTG ACCCCCAGAGCAAGTCGTCGAATGCCAGCATGATGGAGGGAAAGCAAGGCCCTGAAACCGT GCAGCGGTTGCTCTGTCTGCCAGGCCACGGCTTACCCCTCAGCAGGTGGTGGCCCAT CGCAAGTAACGGAGGAAAGCAAGCTTGGAGACAGTCAGCGCCCTGGCCGCTGCTGCTGCCAGGCACACGGCTCAGGCCATTGCTCCCATGACGGGGAAA CAGGCTCTGGAGACCGTCCAGAGGCTGCTGCCGCTCTGTCAAGTCACGGCTCCGGCTACTCC CAACAAGTGGTCGCATGCCCTAATGGGGGGAAAGCAGGACTGGAAACAGTGCAGAG ACTGCTCTCTGTCTTGGCAAGTCATGGTTGACCCCCAACAGGCTGCTGCTTATGCCCTCA AACGGGGGGCAAGGCCCTTGAGACTGTCAGGGCTTGGCCAGTGTGTGTCAGGCTCACGGGCTCAGTCACACAGGTGGCAATTGCCAGCAACGGCGGGAAAGCAAGCTCT TGAAACCGTGCACAGCCTCTGGCCGTGCTGTCAAGGCTATGGCTGACACCACAAAGT CGTGGCCATTCGGAGATAATGGGGAAACAGGCTTGTGACAGCTGCAAGGGCTGCTCC AGTGTCTGCAGGACACGGCTGACGGCTGACGGGGAGCAGGTGGTGTGCTGCAAGCAATTG GGGCCAAGCAGGGCTGGAAACAGTCCAGGCCCTGCTGCCAGTGTCTGGCCAGGCTCACGGG CTCACTCCCAGAGGTGCAATGCCCTCAACGGGGAGGAAGCAGGCTCTGGAGAC CGTGCAGAGACTGTCGCCGTCTGTGCCCCAGGCCAGGACTCACACCTGCAAGGCTGTCGC CATTGCCCTCAGGGGGAAACAGGCCCTGGAGACAGTGCAGGGCTGTGCTGTGTT GTGCCAAGGCCAGGCTTGACTIONTCAGGCTGTCAGGCCCTGGCCATCAATGGGGGGAA ACAAGCTCTGGAGACAGTGCAGAGGTTGCTGCCCTCTGCCAGGCCACGGCTGACTCC CCAACAGGTGTCGCCATTGCCAGCAACCGGGAGGAAGCAGGCTCTGAAACTGTGCCAGG GCTGCTCTCTGTGTCAGGCTCATGGGTGACCCCCGGCAAGTGGTGTCTATGGCTCT TAATGGGGCAAGCAGGCTTGAAGACAGTCAGGCTGTGCTGCCAGGCCA CGGGCTCACACCCAGAGGTGGTCGCATGCCAGTAACACGGGGAAACAGGATTGG AAACCGTCCAGGCCCTGCTTCAGTGTCTGCCAGGACACGGACTGACACCCGACAGGTGG TGGCCATTGCACTCCATGATGGGGCAAGCGGCCCTGGAGACGGTCAAGACTCTGCCA GTGTTGTCAGGCCATCAGGCCCTCACCCCTCAGGCTGTGGCCAGTTATCTGCCCTGATCCGGCTGGCC CGTTGACCAACGCCACCTCTGTGCCCTTGCCCTGCCCTGGGGCTCTGCCGTGGATGCA GTGAAAAGGGATTGGGGATCTTACGGCCCTTCCAGCTGGTGAAGTCCAGGCTGGAGAG AAGAAATCCAGGTGGAGGCAACAGTCAGTGTGCTGCCAGGACATCGCTGCCAGTGTGCTGCCAGGCTGGAGGAGTCAACCCGGAAACAGGACAGTCG ATCCGGGAAACAGCACCCAGGACGTTCTGGAGATGAAGGTGATGGAGTTCTCATGAAG GTGTACGGTACAGGGCAAGCACCTGGCGCTCCAGGAAGCCGACGGCCATCTACAC CGTGGGGTCCCCCATGACTACGGCGTATCTGTCAGGCCACAGGCTACTCCGGGGCTACA ACCTGCCCATGCCAGGCCAGGAATGCAAGGTTGAGTGGAGGAGAACAGACAGGAAC AAGCACATCAACCCCAACAGGTGGAGGTTGACCCCTCAGCGTGAACGGAGTTCAAGTCT CTGTTGTCGCCACTTCAGGGCAACTACAAGGCCAGCTGACCAAGGTGAACACACATC ACCAAACTGCAACAGGCCAGGAGTCTGTCAGGCCACAGGAGATGATCAA GGCGGCCACCTGGCCAGGGAGGTGAGGAGGAAGTTCACAAACGGCAGAGTCAACTCG CGGGCACTGATAA

TABLE 5-continued

TABLE 5 -continued

Sequences referred to in example 2.

	CCCACGGCACCCCCCTCTAGACAAACAGCCAAGAACTGGAACTCACAGCATCCGCCTCCACC AGCGCCAGGTGTTATCCACGGGCCAACAGGCCAACACTGAGGGCAGAGGCAGCTGCTG ACCTCGGGCACGTCGAGGAGAACCCCGGGCCATGGGGCAGGTGCCACCGGCCGCCA TGGACGGGCCGCGCCCTGCTGCTGTTGCTCTGGGGGTGTCCTTGAGGTGCCAAAGGAG GCATCCCCACAGGCCGTACACACAGCGGTGAGTGTGCAAAGCTGCAACCTGGCGA GGGTGTGGGCCAGGCTTGAGGAGCAACAGCGGTGAGTGTGACGCCCTGCCGTGGACAGGGTGA CGTCTCCGACGCTGAGGCGATGACGCCGTGTCGAGGCGTGCCTGCGAGGCGGGCTCGGG CAGAGCATGCGGGCGTGTGAGGCGATGACGCCGTGTCGAGGCGTGCCTGCGAGGAG CTTACAGGATGAGCAGACTGGGCCGTGCGAGGCGTGCCTGCGAGGAGTGCCTGCGAGGAG CTCGTGTCTCCGCCAGGACAACAGAGAACACCTGTGAGGAGTGTGAGTATTGATGCAATTG TGTGATTTATAAGGAAAGTGTGTTTGTGAGGAGTATTGATGCAATTGATGCAATTG TGTGAGGTTACAAGTTTGTGAGTCCAGTGGAGTGTGTTCTGCTGCGCTGCTGCTGAG CTGAGACTGGGTAATGTAAGTGTGTTGAAAAAAATTAAAGGATTTGAGATTTGACATATTG ATGCAATTGAGGAACTGGAGGAAAAAAATTAAAGGATTTGAGATTTGACATATTG GTTCAACACTTGGAAACGGGACTACTAACCTCAGGCTGCTGAGGAGCAGCTGGAGACGT GGAGGAGAACCTGGACCTGGACCCGGCTCTGCAACCATGGATTGGACGGTGCCTGTT CGTGGCAGTGCACAAAGAGTTCACAGTATCACGTGCCCTCCCCATGTCCGTGGAACACGC AGACATCTGGTCAAGAGTACAGCTTGTACTCCAGGGAGCGTACATTGTAACTCTGGTT AAGCGTAAAGCGCACGCTGAGGAGTGCCTGAGGAGTGCCTGAGGAGTGCCTGAG CCACTGGACAACCCCCAGTCTCAATGCAATTGAGACCCCTGCGCTGGTTACAAAGGCCAGC GCCACCCCTCACAGTAACGACGGCAGGGTGACCCACAGCCAGAGGCCCTCCCTCTG GAAAGAGCCGCACTCATCTCCAGCTCAACAAACACAGCCGACAAACAGCAGTATTG TCCCGGCTCCCACTGATGCCCTTCAAAATCACCCTCACAGGAAACACAGAGATAAGCAGTC TGAGTCTCCCACGGCACCCCCCTTCAGACAACAGCAAGAACCTGGAACTCACAGCATCGC CTCCCAACGGCCAGGTGTATCCACAGGGCACAGCGCACACCAGTGGGAGGGCA GCCGCTGACTGGCGCGAGCTGCGAGGAGAACCCCGGGCCATGGGGCAGGTGCCACCGG CCGGCCATGGACGGCCGCGCTGCTGTTGCTGCTGGGGGTGCTCTGGAGGTG CCAAGGAGGAGTGGCCACAGGCTGTCACACACAGCGGTGAGTGTGCAAACGCTGCAAC CTGGGAGGGTGTGGCCACAGGCTGTGGAGGCAACAGACGGTGTGAGGCTGCCGTGGA CAGCGTACCTGGCACGGCCAGCTGGAGGAGGAGCGCAGGGCTGAGCGTGCACCCGAGTGC TGGGGCTCCAGAGCATGTCGCGCCGCTGCTGTTGCTGCTGGGGGTGCTCTGGAGGTG CTACCGCTACTACAGGAGTGGAGACGACTGGGCGTGCAGGGCGTGCCTGGAGGG GCTCGGGCTCGTCTCTGCCAGGACAAGAGAACACCGTGTGCGAGGAGTGCCTGG GGCACGTATTCCGAGGAGGCAACACCGTGGAGGAGCGCAGGGCTGCTGCCGTGAGGAG CACCGAGCGCAGCTCCGAGTGCACAGCTGGGGCGAGCCGAGTGCAGGGAGATCC GGCGCTGGATTACAGGCTCACACCCCCAGAGGGCTCGACAGCACAGCCCCCAGCACCA GGAGGCTGAGGACACCTCCAGAACAAAGACCTCATAGCCAGCACGGTGGAGGTGAGG CAGTGTGGCAGGCTCCAGCCGGGAGGACCCAGGACACCCCTCATCCCTGCT ATTGCTCCATCTGGCTGCTGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT TAGAGGGCCGGTTAACCCGCTGATCAGCCTCGACTGTGCTCTGCTGCTGCTGCT GTTGCCCCTCCCCCTGCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT AAAATGAGGAAATTGCTCATGCCATTGCTGAGTGTGCTGCTGCTGCTGCTGCT GCAGGAGCAGCAAGGGAGGATGGGAAGAACATAGCAGGAGCATGCTGGGGATGG CTATGACTAGTGGGCAATTGGCCAGATCAAAGAGAGGCTGGGGAGAGTCAGGGTGACA GGTGGGGCTCGGAGGCCCCGGGGCAGGGGTGAGCTGAGCCGGTCTGGGGTGG CTCTGCAAGGAGTCAAGGAGCTCAGGGCTGAGGGCAGGGACCCCAAGCTCAGTCAG GCTCTGCTGCACTGGGAATGGTGAACGGGATCTCTGCTCTAGCTCTGGAAAGCAC AGCCCCCTAGTCTGCCCCCACCCCTGACCCCTGACCCCTCACCTGACCCCGTCTAAC GACCTTG
33 Matrice PD1 locus_ IL15 2A_siL15Ra pCLS30513	GACTCCCCAGACAGCCCTGGAAACCCCCCCCACCTCTCCCCAGCCCTGCTGGTGA GGGACAAAGCCACCTTCACCTGAGCTCTCCAAACACATCGGAGAGCTCGCTAAACTGG TACCGCATGAGCCCAAGCAACCAGCGACAAGCTGGCCGCTTCCCGAGGACCGCAGCCA GCCCGGCCAGGACTGCCGCTTCCGTGACACACACTGCCAACAGGGCGTGA CGTGGTCAAGGGCCGGCGAACATGACGCCGACCTACCTCTGTTGGGGCGGTTCTGGCGTGA AACAGACTTGTGAAATTGACCTTCAACTTGGGGAGACGGTGGAGTCAACCCAGGGCC GTACCGGGTCGCCACCATGGACTGGACCTGGATTCCTGCTGCGCTGCTGAG TGCAAGCGCATTGTCATGTCCTTCAATTGGGCTGTTCAAGTGGAGGCTTCTAAACAGAG CAACTGGGTAATGTAAGTGTGTTGAAAAAAATTAAAGGATTTGAGATTTGACATATTG TGCTACTTTATAAGGAAAGTGTGTTACCCCACTGGCAAAAGTAACAGCAATGAGTGC TCTGGAGTTACAAGTTTACTGAGTCCGGAGATGCAAGTATTGATGACAGTAGAAA CTGATCATCTAGAAACACAGTTGCTCTAATGGGAATGTAACAGAAATCTGGATGCAA ATGAGGAGACTGGAGGAAAAAAATTAAAGGATTTGAGATTTGACATATTG GTTCAACACTTGGAAACGGGACTACTAACCTCAGGCTGCTGAGGAGCAGCTGGAG GGAGGAGAACCTGGACCTGGACCCGGCTCTGCAACCATGGATTGGACGGTGC CGTGGCAGTGCACAAAGAGTTCACAGTATCACGTGCCCTCCCCATGTCCGTGGAACACGC AGACATCTGGTCAAGAGTACAGCTTGTACTCCAGGGAGCGTACATTGTAACTCTGGTT AAGCGTAAAGCGCACGCTGAGGAGTGCCTGAGGAGTGCCTGAGGAGTGCCTG CCACTGGACAACCCCCAGTCTCAATGCAATTGAGACCCCTGCGCTGGTTACAAAGGCCAGC GCCACCCCTCACAGTAACGACGGCAGGGTGACCCACAGCCAGAGGCCCTCCCTCTG GAAAGAGCCGCACTCATCTCCAGCTCAACAAACACAGCCGACCAACAGCAGTATTG TCCCGGCTCCCACTGATGCCCTTCAAAATCACCCTCACAGGAAACACAGAGATAAGCAGTC TGAGTCTCCCACGGCACCCCCCTTCAGACAACAGCAAGAACCTGGAACTCACAGCATCGC CTCCCAACGGCCAGGTGTATCCACAGGGCACAGCGCACACCAGTGGGAGGGCA GCCGCTGACTGGCGCGAGCTGCGAGGAGAACCCCGGGCCATGGGGCAGGTGCCACCGG CCGGCCATGGACGGCCGCGCTGCTGTTGCTGCTGGGGGTGCTCTGGAGGTG CCAAGGAGGAGTGGCCACAGGCTGTCACACACAGCGGTGAGTGTGCAAACGCTGCAAC CTGGGAGGGTGTGGCCACAGGCTGTGGAGGCAACAGACGGTGTGAGGCTGCCGTGGA CAGCGTACCTGGCACGGCCAGCTGGAGGAGGAGCGCAGGGCTGCTGCCGTGAGGAG CACCGAGCGCAGCTCCGAGTGCACAGCTGGGGCGAGCCGAGTGCAGGGAGATCC GGCGCTGGATTACAGGCTCACACCCCCAGAGGGCTCGACAGCACAGCCCCCAGCACCA GGAGGCTGAGGACACCTCCAGAACAAAGACCTCATAGCCAGCACGGTGGAGGTG CAGTGTGGCAGGCTCCAGCCGGGAGGACCCAGGACACCCCTCATCCCTGCT ATTGCTCCATCTGGCTGCTGTTGCTGCTGCTGCTGCTGCTGCTGCT TAGAGGGCCGGTTAACCCGCTGATCAGCCTCGACTGTGCTCTGCTGCTGCT GTTGCCCCTCCCCCTGCTGCTCTGCTGCTGCTGCTGCTGCTGCT AAAATGAGGAAATTGCTCATGCCATTGCTGAGTGTGCTGCTGCTGCTGCT GCAGGAGCAGCAAGGGAGGATGGGAAGAACATAGCAGGAGCATGCTGGGGATGG CTATGACTAGTGGGCAATTGGCCAGATCAAAGAGAGGCTGGGGAGAGTCAGGGTGACA GGTGGGGCTCGGAGGCCCCGGGGCAGGGGTGAGCTGAGCCGGTCTGGGGTGG CTCTGCAAGGAGTCAAGGAGCTCAGGGCTGAGGGCAGGGACCCCAAGCTCAGTCAG GCTCTGCTGCACTGGGAATGGTGAACGGGATCTCTGCTCTAGCTCTGGAAAGCAC AGCCCCCTAGTCTGCCCCCACCCCTGACCCCTGACCCCTCACCTGACCCCGTCTAAC GACCTTG
34 Matrice CD25 locus_ IL12a 2A_ IL12b pCLS30520	GTTTATTATTCCTGTTCCACAGCTATTGCTGCCATATAAAACTTAGGCCAGGCACAGTGGCTC ACACCTGTAATCCAGCATTGGAGGGCGAGGGCAGGAGCATCACAGGTCAAGGAGTTCGAG ACCAAGCTGGCCACATAGCAAACCCCCATCTCTACTAAAAATACAAAATTAGCCAGGATGG TGGCGTGTGCACTGGTTAGAGTGGAGGACCAATTGTTGGTGGCGTGTACACATATGACCG TGACTTTGTTACACCACTACAGGAGGAAGAGTAGAAGAACATCGGTTCTGGCGTGA TTGAAATTGGTACCTCTCAAGTTGGCGGGAGACGTGGAGTCCAAACCCAGGGCCATGTGG CCCTGGGTGACGCCCTCCAGGCCACCCCGCCACCTGCCGCCAGGCTGCTGACCGCG

TABLE 5 -continued

Sequences referred to in example 2.

	CTCGCCCTGTGTCCTGCAGTGCCTGCAGCATGTGTCAGCAGCAGCAGCCTCCCTGTGG CTACCCCTGGTCCCTCTGGACACCCTCAGTTGGCAGAACCTCCCGTGGCCACTCCAGACC CAGGAATGTTCCCATGCCCTCACCACTCCCCAAACCTGTGAGGGCGTCAGCACATGCTCCA GAAGGGCAGACAACACTCTAGAATTTCACCTTGCACTCTGTGAGAGATTGATCATGAAAGATA CAAAGATAAAACAGCACAGTGGAGGCTGTTACCATGGAAATAACCAAGAATGAGAGTTG CCTAATTCCAGAGAGACCTCTTCTATAACTAATGGAGATTGGCTGGCCAGAAAAGACCTCT TTTATGATGGCCCTGTGCTTAGTACTATTATGAAAGACTTGAAGATGTACAGTGGAGTTCAA GACCATGAATGCAAAGCTCTGTGAGGAGATCTTAGATCAAACATGCTG GCAGTTATTGATGAGCTTAAGAGGAGATCTGAGACTCTTCTAGATCAA AGGCTGGAGTACTATGTAGAGCTGAGCTGAGGCTGAGGAGATCTTCTAGATCAA ATGTCAGCTGCTGAGGAGATCTGAGCTGAGGCTGAGGAGATCTTCTAGATCAA ATGTCAGCTGCTGAGGAGATCTGAGCTGAGGCTGAGGAGATCTTCTAGATCAA AGGAGTTCAGCTTAACTTCAAGAGGAGCTTCTCATAAACTAATGGAGTTGCTGGCTCCAGAA AGACCTTTTATGATGGCCCTGTGCTTAGTACTATTATGAAAGACTTGAAGATGTACAGGAG GAGGCTAGACCATGAATGCAAGCTTCTGATGGATCTAAGAGGAGACATCTTCTAGATCAA CATGCTGGAGTATTGAGAGCTGAGCTGAGGCTGAGGAGATCTTCAACAGTGTGAGACCTGAG AAATCTCCCTGGAGAACGGATTATAAAACTAAACAGCTGCTACCTCTTCTAGCT TTCAGAATTGGCAGTGAATTGATAGAGTGTGAGCTATCTGAATGCTTCCGGAGCGGAG CTACTAACCTTCAAGCTGCTGAGAGCAGGCTGGAGAGCAGCTGGAGGAGAACCTGGACCTATGTGTC ACCAGCAGTGGTACCTCTGGCTTCTGGGACACCTCAGTTGGCAGTCTCCCTCGTGGCCATATGG GAACTGAAGAAAGATGTTATGCTGAGTAAATTGGAGTTGGTATCCGGATGCCCTGGAGAAATGG TGGCTCTGGCTACCTGTGACACCCCTGAAGAAGATGGTACCTGGACCTGGACAGCAGTG AGGTCTTAGGCTCTGGCAAACCCCTGACCATCAGTCAAAGAGTTGGAGATGCTGCCAGTA CACCTGTACAAAGGAGGGCAGGGTCTAAGGCAATTGCTCTCTGCTGCTCAGTCA GGAAATTGGTCCACTGATATTAAAGGAGCAGAAAGAACCCAAAATAAGACCTTCTAAGATG CGAGGCCAGAATTACTCTGGACCTTCAACCTGCTGGTGGCTGACGACAATCAGTACTGATTG ACATTCACTGCTGAGAGAGTCAGAGGGGACAACAAGGAGTATGAGTACTCAGTGGAGTGCAG GAGGACAGTGCCTGCCAGCTGCTGAGGAGAGTCTGCCATTGAGGTATGGTGGATGCCGT CACAAGCTAAGTGAACCAACTACACCAGCAGCTTCTCATCAGGGACATCATCAAACCTGAC
35 Matrice PD1 locus_IL12a_ 2A_IL12b pCLs30511	GACTCCCCAGAGGCCCTGGAACCCCCCCCACCTCTCCCAGCCCTGCTCGTGGTACCGAA GGGGACAAAGCCACCTTCACCTGCACTGCTTCTCAACACATCGGAGAGCTCGCTGAAACTGG TACCGCATGAGCCCCAGAACAGCACAGGACAAGCTGGCGCTTCCCGAGGACCGCAGCCA GCCCGGCAGGACTGGCGCTTCCGTGTCACACAATGCCAACGGCGTGACTTCCACATGAG CGTGGTCAAGGCCCGCGCAATGACAGCGCACCTACCTCTGCTGGGCGGTCTGGCTG AACAGACTTGAATTTCACCTCTCAAGTGGGGAGACGTGGAGTCAAACCCAGGGCCAT GTGCCCCCTGGGTCAAGCTCCGCCACGCCCTCACCTGCGCCGGCCACAGGTCTGCATC CAGCGGCTGCCCTGGCTTCTGCACTGCTGGCGCTCAGCATGTCAGCGCGCAGGCTCC CTTGTGGCTACCCCTGGCTTCTGGGACACCTCAGTTGGCAGAAAACCTCCCGTGGCCACT CCAGACCCAGGAATGTTCCCATGCCCTCACCACTCCAAAACCTGCTGGGGCGGTGAGCAAC ATGTCAGAGGAGCTTACCTGAGCTGAGGAGATCTGAGAGATTGATCATGA AGATACACAAAGATAAAACAGCACAGTGGGGCTGTTTACATTGGAAATTAAACAGAAAT GAGAGTTCAGCTTAACTTCAAGAGGAGCTTCTCATAAACTAATGGAGTTGCTGGCTCCAGAA AGACCTTTTATGATGGCCCTGTGCTTAGTACTATTATGAAAGACTTGAAGATGTACAGGAG GAGGCTAGACCATGAATGCAAGCTTCTGATGGATCTAAGAGGAGACATCTTCTAGATCAA CATGCTGGAGTATTGAGAGCTGAGCTGAGGCTGAGGAGATCTTCAACAGTGTGAGACCTGAG AAATCTCCCTGGAGAACGGATTATAAAACTAAACAGCTGCTACCTCTTCTAGCT TTCAGAATTGGCAGTGAATTGATAGAGTGTGAGCTATCTGAATGCTTCCGGAGCGGAG CTACTAACCTTCAAGCTGCTGAGAGCAGGCTGGAGAGCAGCTGGAGGAGAACCTGGACCTATGTGTC ACCAGCAGTGGTACCTCTGGCTTCTGGGACACCTCAGTTGGCAGTCTCCCTCGTGGCCATATGG GAACTGAAGAAAGATGTTATGCTGAGTAAATTGGAGTTGGTATCCGGATGCCCTGGAGAAATGG TGGCTCTGGCTACCTGTGACACCCCTGAAGAAGATGGTACCTGGACCTGGACAGCAGTG AGGTCTTAGGCTCTGGCAAACCCCTGACCATCAGTCAAAGAGTTGGAGATGCTGCCAGTA CACCTGTACAAAGGAGGGCAGGGTCTAAGGCAATTGCTCTCTGCTGCTCAGTCA GGAAATTGGTCCACTGATATTAAAGGAGCAGAAAGAACCCAAAATAAGACCTTCTAAGATG CGAGGCCAGAATTACTCTGGACCTTCAACCTGCTGGTGGCTGACGACAATCAGTACTGATTG ACATTCACTGCTGAGAGAGTCAGAGGGGACAACAAGGAGTATGAGTACTCAGTGGAGTGCAG GAGGACAGTGCCTGCCAGCTGCTGAGGAGAGTCTGCCATTGAGGTATGGTGGATGCCGT CACAAGCTAAGTGAACCAACTACACCAGCAGCTTCTCATCAGGGACATCATCAAACCTGAC

TABLE 5 -continued

Sequences referred to in example 2.

36 Inserted matrice TRAC locus CubiCAR CD22 760 nucleotides upstream and downstream)	<p>CACCCAAGAACTTGCAGCTGAAGCCATTAAAGAATTCTGGCAGGTGGAGGTCAAGCTGGGAGT ACCCTGACACTGAGACTTCACATTCTACTTCTCCCTGACATTCTCGGTTCAAGTCCAGGG CAAGAGCAAGAGAAAAAGAAGATAGAGTCTTCACGGACAAGACCTCAGGCCACGGTCACTG CCGCAAAAATGCCAACATTAGCGTGCAGGGCCAGGGACCGCTACTATAGCTCATCTGGAGCGA ATGGGCATCTGTGCCCTGCAGTGAGGGAGGGCAGGGCAGGGCAGCTGCTGACCTGGCGCACGTGAGG AGAACCCCCGGGACATGGGGCAGGGCACCAGGGCAGGGCAGGGCAGCTGAGCAGGGCCGGCTGCT GCTGTGCTTCTGGGGTGTCTCTTGAGGTGCAAGAGGGCATGCCAACAGGCTGTGA CACACACAGCGGTGAGTGTGCAAGCTGCAACTGGCGAGGGTGTGGCCAGCGCTGTG GAGCCAACCAGACCGTGTGAGGCGCTGCGGACAGCGTGAAGTCTCCGAGCTGGTGAGC GCGACCGCAGCGTCAAGCGTGTGAGGAGTGTGGCTGGGCTCCAGAGCATGTCGGCCGT GCGTGGAGGGCGATGACGGCGTGTGCGCTACGGCTACTACCGAGATGAGACGACT GGGCGCTGCCAGGGCTGCCGTGCGAGGGCGCTCGGCCCTCGTGTCTGCCAGG ACAAGCAGAACACCGTGTGAGGGAGTGGCCAGCGCACGTATTCCGACGAGGCAACAC GTGGACCCCGTGCCTGCCCTGCAAGCGTGTGAGGACACCGAGGCGCAGCTCCGAGTGCAC ACGCTGGGCCAGCCGAGTGTGAGGAGATCCCTGGCGTTGGCATCTCCGATCTGGTCCA CAGATATCCAGTACCCCTGAGCTGCCGACTACGCCCTCGGTGAGGGCAGAGGAAGTCTC TAACATGCGGTGACGTGGAGGAGAATCCGGGCCCCGATCGCTCTGCCGTACCGCTCTG CTGCTGCCACTGGCACTGCTGTCACGCTGCTAGGGCGAGGGGAGGGCAGCTGCCCTA CAGCAACCCCGAGCTGTGAGCGGAGGGCGGGAGGGGGAGGGAGGGCAGCTGCC CTGAGCAGAGCGGCCCTGCCCTGGTGAAGCCAAGCAGACACTGTCCCTGACCTGCCCAT CAGCGCGGATTCGGTGAAGCTCAACTCCGCCGCTGGAATTGGATCAGGAGTCCCTCTCG GGGCGTGGAGTGTGGGAGAAGGACATACTATCGTCTAAGTGGTACAAGCAGATTGCGGTGTC TGTGAAGACAGAACATCACACTAACCTGACACCTTCAAGAACATGAGTCTCTGCCAGTGAAT AGCGTGCACACAGAGGACACCGCCGTGACTATTGGCCAGGGAGGTGACCGCCGACCTGGA GGATGCCCTTGACACTGGGGCCAGGGCAATGGTGAAGCTGAGCTCCGGAGGGCGCGAT CTGCGGGAGGAGGAAGTGGGGGGGGAGGTGATATCCAGATGACACAGTCCCCATCTCT CTGAGCGCCCTCGGGCAGAGGTGACAAATCACCTGTAAGGGCTCCAGGACCATCTGGTCT TACCTGAACTGGTATCAGCAGAGGCCGCGCAAGGCCCTAATCTGCTGATCTACCGACAGC TCCCTGAGAGCGGAGTGCACATTCCAGGCTGCTGAGGCCAGAGCAAGGCCACACCAGCCT ACCACTCTAGCTGCCGAGGCCGAGGACTCTGCCACCTACTATTGCCACCGAGCTTATAGCATCC CCCAGACATTGGCCAGGGCAGCTGAGGAGATCAAGTGGATCTGGGATCCGGAAAGCGGAGGG GGCAGCTGCCCTACAGAACCCAGCTGTGAGCGGAGGGCGGGAGCGAGCTGCCA CCCAGGGCACCTTCCAACTGTCACCCAGTGAAGCCAGGCCAGGCAAGGCCACACCAGCCT GTCTTATTCTCAATCTCTGCTGCTCCACCAACCCCGCTCCAAGGCCCTACCC CGCACAACATTGCCCTCCAGCACTCTCACTGCGGCCCTGAGGGCTGCGGCCGCTGCTGG AGGGCAGTGCATACAAGGGCCCTGATTTGCCCTGCGATATTACATCTGGGACCCCTCGC CGCACCTGCGGGTGCTCTCCTCTCCCTGGTATTACCTGTTACCTGAGCGAGGGCGGGAA GAAGCTCTCTACATTAAAGCAGCCCTTCACTGCGGAGTGGCTGAGGAGACCAACCCAGGG GGGTCTCTGGCTGAGGAGGGCTGAGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGG CAGAGGCGCAGATGCCCTCCAGCAAGGGCAGAACAGCTCTACAAAGAGCTTAAACCT CGGGAGGCGCGAAGAATACGAGTGGGATAAGAGAAGGGGGGGGGGGGGGGGGGGGG GGGAGGCGCGAAGAAGACCTCAGGGAGGGCTGTAACACGAGCTGAGGAAGGATAAGAG GGGCAGGCGGAGGACTCAGAGATCGGGATGAGGGAGGGGGGGGGGGGGGGGGGGGG GGGCTTACAGGGGCTGAGCAGGCCAACAGGAGACATACGACGCTTGTACATGAGGC CCTTCCACCCGGGAATAGTCTAGAGGGCCGTTAAACCCGCTGATCAGCCTGACTGTGCC TTCTAGTTGCCAGGCTATCTGTTGCTGCCCTCCCGTGCCTTCTGACCCCTGGAGGTGCC ACTCCCACTGTCTCTTCTAATAAGGAGGAATTGAGCATCGCATTGCTGAGTAGGTGTCATT TATTCTGG ATGCTGGGGATGCCGTGGCTATGACTAGTGGCAATTCCCGTGTACAGCTGAGAGACTC TAAATCAGTGACAGTCTGCTGCTTACAGCAGAACAAAGAATCTGTCACAAA GTAAGGATTCTGATGTTGATATACAGCAGAACAAAGAATCTGCTAGACATGAGGTCTATGGACTTCAG AGCAACAGTGTGCTGCCCTGAGGAAACAAATCTGACTTTGCACTGCAAAAGCCTTCAACA GCATTATCCAGAAGACACCTTCTCCCCAGGCCAGGTAAGGGCAGCTTGGCTAATGATGTC GCTGTTCTGCTTCAGGAATGCCAGGTTGCCAGAGCTCTGGTCAATGATGTC TCCCTGATGGTGTCTGCCCTTATCCATTGCCACAAAACCTCTTTTACTAAGAACAGT GACCTGTTCTGCCAGAGAATGACACGGGAAAAAGCAGATGAAGA </p>
--	--

TABLE 5 -continued

		Sequences referred to in example 2.
37	Inserted matrice CD25 locus _IL15_ 2A_sIL15Ra (60 nucleotides upstream and downstream)	AGTGCTGGCTAGAAACCAAGTGCCTTACTGCATGCACATCATTAGCACAGTTAGTGCTGTTA TTATTCCTGTTCCACAGCTATTGTCGCTCATATAAAAATCTAGGCCAGGCACAGTGGCTCACAC TGTAAATCCCAGCAGCTTGGAGGGCGAGGCAGGACATCACAAAGGTGAGGATTCGAGACAG CCTGGCCACATACAGAAAACCCCATCTCTACTAAAATACAAAAAATTAGCCAGGCATGGTGGGG TGTGCACTGGTTAGAGTGAAGGACACATTTTTGGTGGCGTGTACACATATGACCGTGA TGTGACCTTCAAGTTGGGGAGACGGTGGAGTCAACCCAGGGCCGGTACCGGTC CACCAGTGGACTGGACCTGGATTCTGTTCTCGTGTGCTGTCACAAGAGTGCACAGGGCAT TCATGCTTCATTTGGGCTGTTCTAGTCAGGGCTTCTCAAACAGAACAGCAACTGGGTGA GTAATAAGTGAAGTGGAAAGATCTTAACTATGTCATATTGATGCTACTTTATATA CGGAAAGTGTGATGTCACCCAGTGCAGAACAGAACAGAACAGTGGCTCTGGAGTACA AGTTATTCACTTGAGTCCGGAGATGCAAGTATTGATGATACAGTAGAAAATCTGATCATCTAG CAAACAAACAGTTGCTCTAATGGGAATGTAACAGAACAGAACAGAACAGTGTGAGGA GGGAAAGAAAATTAAGAATTGTCAGAGATTGTCACATTGTCACAGTGGTACA TTCTGGAAGGGAGACTAACTTCAGCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCC TGGAGCTGGGACGGCGCTGCAACCATGGATTGGAGTGGATCTGTTCTGGAGCAGCTG CACAAAGAGTTCACAGTATCACGTGCCCCCTCCCCATGTCGTGAAACAGCAGACATCTGGT CAAGAGCTCACAGCTGACTCCAGGGAGCGGTACATTGTCACCTCTGGTAAAGCTAAAGC GGCAGTCCAGCCTGACGGAGTGGCTGTTGAACAAAGGGCACAGAACAGTGGCCACTGG CCCCAGTCTCAAAATGAGACCCCTGCCCCCTGGTACCAAAAGGGCAGCGCACCCTCCAC AGTAACGACGGCAGGGGTGACCCCCAACAGCCAGAGAGCCTCCCCCTGGAAAAGGCC CAGGTTCATCTCCAGTCAAAACACAGCAGGGCACACAGCAGCAGTATTGTCGGGCTCCC AGCTGATGCTTCAAAATCACCTTCAAGGAAACAGAGATAAGCAGTCAAGTCTCCC CGGCACCCCCCTCTGACACAGCAGGAAAGACTGGAACTCACAGCATCGGCCTCCCACAGC GCCAGGTGTGATCCACAGGGCCACAGCGACACACTGAGGGCAGAGGCGCTGCTGACCT GCGCGCAGCTGAGGGAGAACCCCGGCCATGGGGCAGGTGCCACCGGGCGGCCATGG CGGGCGCAGCTGCTGTTGCTGCTGCTGCTGGGGTGTGGAGGTGGCAAGGGAGGCAT GCCAACAGGGCTGACACACAGGGTGAAGTGTGCTGCAAGGCTGAAACCTGGCGAGGGT GTGGCCACAGGCTTGGAGCCAACAGACGGTGTGAGGCTGCTGGACAGCTGACGTT CTCCGACGTGGTGAAGCGGACCGAGCCGTGCAAGCGCTGCAACCGAGTGGCTGGGCTCCAGA GCATGTCGGCCGCGCTGGCTGAGGGCGATGACGGCGTGTGCGCTACGGCTACTAC CAGGATGAGACGACTGGGGCTGGAGGGCTGGCGTGTGAGGGCGCTGGGCTCG TGTCTCTGGCAGGACAAGCAGAACACCGTGTGCGAGGAGTGGCCACAGGCA ACGAGGCCAACACAGTGGACCCGGTGCCTGCCCCACCGGACACCCTCATCCCTGTATTG CTGGCTGTTGTTGGCTTGTGCTCATAGCTTAAGGCTTAAGGAGTGAAGGAAACCC CTGGCTGTTGTTGGCTTGTGCTCATAGCTTAAGGCTTAAGGAGTGAAGGAAACCC AATTCTGGTAAAGAAGGGGAACAGACAAAGAGTGAAGGCTTAAGGAAATCAAAGGT GCTAAATGGTGCCTGGAGACATCGTTGTGCTGCTGGTTGGAGTCTGAAGTACA TCACAGGACACGGGCAGTGGCAACCTTGTCTATGCCAGCTAGTCCCATCAGAGAGCG CGCTACAGGACACGGGCAGTGGCAACCTTGTCTATGCCAGCTAGTCCCATCAGAGAGCG CATCTTATTTCATGATATGTCATGTCATTAAGCATGAATGGTATGGAACCTCTCC GTAGTATAAGAAAAGTAGTT
38	Inserted matrice PD1 locus _IL15_ 2A_sIL15Ra (60 nucleotides upstream and downstream)	GGTGGCCGGGGAGGCTTGTGGGGCCACCCAGCCCCCTCTCACCCTCTCCATCTCAGAC TCCCCAGACAGGCCCTGGAAACCCCCCACCCTCTCCCGACCCCTGCTGTGGTGA GGACAAAGGCCACCTTCACCTGCACTTCTCAACACATGGAGAGCTGCTAAACTGGTAC CGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCTTCCCGAGGACCGCAGGCC CGGGCAGGACTGCGCTCTGGTACACAACCTGCCAACGGCGTGAATTCCACATGAGCGT GGTCAGGGCCGGCGCAATGACAGCGGCCACCTACCTGTGGGGCGGTTCTGGCGTGA AGACTTGAATTGACCTTCTCAAGTTGGGGAGACGTGGAGTCAACCCAGGGCCGTA CCGGTCCGCCACCATGGACTGGACCTGGATTCTGTCGTGCTGCTACAAGAGTGC ACAGCGGCCATTGCTCATGTCATTTGGCTGTTCTAGTCAGGGCTTCTAAACAGAACAG CTGGGTGAATGATAAGTGAATTGAAAAAATTGAAGATCTTCAATCTATGCAATTGATG TACTTATATACGGAAAGTGTGTTCTGGCTACAGTGGAGTCAAGAACAGAACAGTGG TGGAGTTACAAGTTATTCACTTGAGTCGGAGATGCAAGTATTGATGATACAGTAGAAA ATCTACGCAACAAACAGTTGTTCTCTAATGGGAATGTAACAGAACAGTGGATG TGAGGAACGGGAAAAAAATTAAGAATTGGAGTTGTCAGGTTGTCACATTGTC CATCAACACTCTGGAGCGAGCTACTAACCTCAGCTGCTGAAGCAGGCTGGAGACGT GGAGAACCTGGACCTGGGACCGGCTGCAACCATGGATTGGACGTGGATCTGTTCTCG GGCAGCTGGCACAAGAGTTCACAGTACAGTGGCTCTCCCCCATGTCGGTGGACAGC CATCTGGTCAAGAGCTACAGCTGACTTGTACTCCAGGGAGCGTACATTGTA CGTAAAGGCCGACCTGCAAGGGAGTGGCTGTTGAAACAGGACACAGAGATAAGCAG CTGGACAACCCCCAGTCTCAAATGCTTGTGAGACGGCTGGGCTGGTACCTGG ACCCCTCAAGCTAACAGCGGCCAGGGTGAACAGGCCACAGGCCAGGCC AGAGCCGCAAGCTCATCTCCAGCTCAACACAGCGGCCACACAGCAGCTATTG GGGCTCCAGCTGATGCCCTCAAATCACCTTCAACAGGAACACAGAGATAAGCAG TCCTCCCACGGCACCCCTCTCAGACAACAGGCAAGACTGGGA CACCAGCCGCAAGGTGTGATCCACAGGGCCACAGCGACACCAACTGAGGGCAGGCC GCTGACCTGCGGCGACGCTGGAGGAGAACCCGGGCGCATGGGGCAGGTGCCACCGGCC GCCATGGACGGCGCGCCGTGCTGTTGCTGCTTCTGGGGTGTGCCCCCTGGAGGTGCC GGAGGCATGCCCAAGGGCTGTACACACAGCGGTGAGTGTGCAAGGCTGCA GCGAGGGTGTGGCCAGGCCCTGTGGAGGCAACAGGACCGTGTGAGGCC GTCCTAGAGCATGTCGGCGCGCTGCGTGGAGGCCATGACGCCGTCGCGCTAC GCTACTACCAGGATGAGACGACTGGGCGCTGCGAGGCCGCTGCGAGGGCG

TABLE 5 -continued

Sequences referred to in example 2.

	GGGCCTCGTGTCTCCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCA CGTATTCCGACGAGGCCAACCTGGACCGCTGCCCTGCACCCGTGTGCGAGGACACC GAGGCCAGCTCCGAGTGCACACGCTGGCCGACGCCAGTGCAGGAGATCCCTGGCC GTTGGATTACACGGTCACACCCCCAGAGGGCTGGACAGCACAGCCCCCAGCACCCAGGAG CCTGAGGCACCTCCAGAACAGACCTCATAGGCCAGCACGGTGGCAGGTGGTGAACACAGTG ATGGCAGTCCAGGGCTGGTGAACCCAGGGCAGGACACCCAGAACCTCATCCCCTGCTATTG TCCATCTGGCTGCTGGTGTGGTCTTGCCCTACATAGCTTAAGAGGTGATCTAGAG GGCCGCTTAAACCGCTGATCACCGTCACTGTGCTTCTAGTGTGCGCATCTGTGTTTG CCCCCTCCCGTGCCTCCCTGACCCCTGAAAGGTGCACTCCACTGTCTTCTAATAAAAAT GAGGAATTGATCGCATTGTCAGTGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGGCAAG GACAGCAAGGGGGAGATGGGAAGACAATAGCAGGATGCTGGGGATGCGGTGGCTTAT GACTAGTGGCGAATTGGCGCAGATCAAAGAGACCTGGGGAGAGCTCAGGGTGAAGGT GCGGCTCGGAGGGCCCGGGCAGGGGTGAGCTGAGCCGTCCTGGGGTGGGTGCCCC CTGACAGGATCAGGAGCTCAGGGTGTAGGGTCACTGGGGCAGCTCCAGGGCT CTGCTCTGCACTGGGAATGGTGAACCGGATCTGTGCTCTAGTCTGGCT CCCCTAGTCTGCCCTCACCCCTGACCCCTGACCCCTGACCCGTCATAACCCCTGAC CTTGTGCCCTTCAGAGAGAAGGGCAGAGTGCCCAGGCCACAGCCCCAGGCCCTCACCCAGG
39 Inserted matrice CD25 locus _IL12a_ 2A _IL12b_ (60 nucleotides upstream and downstream)	AGTGCTGGCTAGAACCAAGTGTCTTACTGCATGCACATCATTTAGCACAGTTAGTTGCTGTTA TTATTCCTGTTCCACAGCTATTGTCGCCATATAAAACTTAGGCCAGGCACAGTGGCTCACACC TGTAACTCCAGCACTTGGAAAGGGCGAGGCAGGGCAGATCACAAAGGTGAGGAGTTCGAGACCA CCTGGCCAACATACAAACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCG TGTGCACTGGTTAGGTGAGGCCACATTTTTTGGTCCGCTGTTACACATATGACCGTGA TGTACACCACTACAGGAGGAAGAGTGAAGAACAAATCGGTTCTGGCGTGAACACAGACTTGAA TTTGACCTCTCAAGTGTGGGGAGACGTGGACTCCAACCCAGGGCCATGTGGCCCCCTGG GTCAGCCTCCAGGCCACCGCCCTCACCTGCCGCCCCACAGGGTCTGCACTCCAGGGCTCGCC CTGTCCTCTGCACTGGCCCTCAGTTGGCCAGAACCTCCCGTGGCCACTCCAGAACCCAGGAA TGGTCCCATGCCCTACCACTCCAAAACCTGCTGAGGGCCGTCAGCAACATGCTCCAGAAGG CCAGACAAACTCTGAATTTTACCTTGTGAGGAGATGATCATGAAGATACTCACAAA GATAAAACAGCACAGTGGAGGCCCTGTTACCATTTGGAATTAAAGAAGATGAGGTTGCC ATTCCAGAGAGACCTCTTCATAACTAATGGGAGTTGCCCTGGCTCAGAAAGACCTTTTATG ATGGCCCTGCTGCTTAGTATTATGAAGACTGAGATGTCACCGTGGAGGTCAAGACCA TGAATGCAAGCTCTGATGCTGCTTAAGAGGCCAGACTTCTAGATCAAACATGCTGGCAGT ATTGATGAGCTGATGCAAGGCCCTGAATTCAACAGTGAAGACTGTGCCACAAAATCTCCCTTG AAGAACGGATTTTATAAAACTAAAGCTCTGCTGATACTCTTCTGATGCTTCAAGATTG CAGTGAATTGATAGAGTGTAGCTATCTGAATGCTTCCGGAAGCGGAGCTACTAACCT CCTGCTGAAGCAGCTGGAGACAGGACCTGGACCTATGTCACCCAGTGGT CATCTCTGGTTTCTGGTTTCTGGCATCTCCCTCGTGGCCATATGGGAACACTGAAGAAA GATGTTATGTCGAGAATTGGATGGTATCCGGATGCCCTGGAGAAATGGTGGCTCTACCT GTGACACCCCTGAGAAGAGTGGTACCTGGACCTTGGACCAGAGCAGTGAGGCTCTAGGCT CTGCAAACCCCTGAGAAGAGTGGTACCTGGACCTTGGAGCTGGCCAGTACACCTGTCACAA AGGAGGGAGGTTCTAAGCATTGCTCTTCACAAAAAGGAAGATGCAATTGGTCC ACTGATATTAAAGGACAGAAAGAACCCAAAATAAGACCTTCTAAGATGCGAGGCCAGAA TTATTCTGGACGTTACCTGCTGGTGTGACGACAATCAGTACTGATTGACATTCTAGTGTCA AAAGCAGCAGAGGCTCTGACCCCCAAGGGTGTGCGGAGCTGCTACACTCTCTGCA AGAGAGTCAGAGGGACAACAAAGGAGTATGAGTACTCAGTGGAGTGCAGGAGCAGTGC TGCCAGCTGCTGAGGGAGTCTGCCATTGAGGTCACTGTTGAGTGCAGGCT TACAGCTCATCTGGAGCAGTGGCATCTGTC TATGAAAATACACCAAGCAGCTTCTCATCAGGGACATCATCAAACCTGACCCACCAAGAACT GCAGCTGAGCCATTAAAGAATTCTCGCAGGTGAGGTCACTGGGAGTACCCCTGACACCTG GAGTACTCCACATCTCTACTCTCCCTGACATTCTGCGTCACTGGCCAGGGCAAGAGA GAAAAGAAAGATAGACTCTCACCCAGACCTCAGCCACGGTCACTGCGCCAAAATGCG GCATTAGCGTGCAGGCCAGGGCAGGCCAGCTACTATAGCTCATCTGGAGCAGTGGCATCTGTC CCTCAGTGGAGGCCAGGGCAGGCCAGCTGACCTCGGCCAGCTGGAGGAGAACCCGGGCC CATGGGGGAGGTGGCCACGGGCCGCCATGGAGGGCCGCCCTGCTGTGCTGCT TGGGGGTGCTCTGGAGGTGCAAGGGAGGCTGCCACAGGGCTGTACACACACAGGGT GAGTGTGCAAAGCTGCAACCTGGCGAGGGTGTGGCCAGGCCAGCTTGTGGAGCAGGCCAG CGTGTGTGAGCCCTGCCAGCTGGACAGCTGACGTTCTCCAGCTGAGTGTGAGCCAGGCCGT GCAAGCCGTGCAAGCTGGGCTCAGAGCATGTCGGGCCCTGCGTGGAGGGCGA TGACGCCGTGCGCCTGCGCTACTACCCAGGATGAGACGACTGGGCCCTGCGAGG CGTGCCTGCGCTGTGCGAGGGGGCTCGGGCTCGTGTCTCTGCAAGGACAAGCAGAACACC GTGTGCGAGGAGTGGCCGACGCTTCCAGCAGTACCTGGAGGAGGCCACAGTGGACCC GCCCTGCAAGCTGCGAGGGAGCAGGCCAGCTGGCGAGTGCACACGCTGGGCCAG GCCAGTGGAGGGAGTCCCTGGGGTTGAGTACAGGCTTACAGGCTTACACCCCCAGAGGGCTGG CAGCACAGCCCCCAGCACCCAGGGCCTGAGGCCACCTCCAGAACAGACCTCATAGCAGCA CGGTGGCAGGGTGTGGTGAACCAACTGTGAGGGCAGCTCCAGGGCTGGTGAACCGAGGCC ACCGACAACTCTACCCCTGCTATTGCTCCATCTGGCTGTGGTGTGGCTTGTGG ACATAGCTTCAAGAGGTGAAAACCAAAAGAACAAAGATTCTGGTAAGAACGGGGAAAG ACAACAGAAGTCATGAAGGCCAAAGTGAATCAAAGGTCTAAATGGTGC GTTGTGCTTGCCTGCGTTGGAGCTCTGAGTCACATCACAGGACACGGGAGCTGGCAAC CTTGTCTCTATGCACTGCTAGTCCACAGAGAGCAGGCCACTTCTAAATAGCAATT CGCCTGAGAGAGGGCAAGGGGAAACCCACTAGAAGACTCTCCATCTTATTT TGAATGGTATGGAACTCTCCACCCATTATGAGTATAAAGAAAAGTAGGTT
40 Inserted matrice PD1 locus _IL12a_	GGTGGCCGGGGAGGCTTGTGGGCCACCCAGCCCCCTCTCACCTCTCCATCTCAGAC TCCCCAGACAGGCCCTGAAACCCCCCACCCTCTCCCTGCCCTGCTGGTGAACGAAG GGACAAAGCCACCTCACCTGCACTGGCAGCTTCTCCAACACATCGAGAGCTCGT AAACTGGTAC

TABLE 5 -continued

Sequences referred to in example 2.

2A IL12b (60 nucleotides upstream and downstream)	CGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCGAGGACCGCAGGCC CGGCCAGGACTGGCCCTTCCGTACACAACCTCCAAACGGGGTGAATTCCACATGAGCGT GGTCAGGGCCCGGCCAATGACAGCGGCACCTACACTCTGGGGCCGGTCTGGCGTGAAC AGACTTGAAATTTCGACCTTCTCAAGTTGGCGGGAGACGTGGAGCTCAACCCAGGGCCATGT GGCCCTCTGGGTCAAGCTCCAGGCCACGCCCTCACCTGCCGCCACAGGTCTGCATCCA GCCGCCAGGACTGGTCCCTGGGACCTCAGTTGGCAGAAAACCTCCCGTGGCACTCCA GTGGCTACCCCTGGTCTCTGGACCACTCAGTTGGCAGAAAACCTCCCGTGGCACTCCA GACCCAGGAATGTTCCCATGCCCTACCAACTCCAAAACCTGCTGAGGGCGTCAGAACATG CTCCAGAAGGCCAGACAAAATCTAGAATTTCACCTTCGACTCTGAAAGAGATTGATCATGAAGA TATCACAAAAGATAAAACAGCAGCTGGAGGCTGTGTTACCATGGAATTAAACCAAGAATGAG AGTGCCTAAATTCCAGAGGACCTCTTCAAATAACTATGGGAGTTGCCCTGGCCTCCAGAAAGA CCTCTTTATGATGGCCCTGTGCCCTAGTAGTATTATGAAAGACTTGAAGATGTAACAGGTGGAG TTCAAGACCATGAATGCAAAGCTCTGATGGATCTAACAGGGCAGATCTTCTAGATCAAACAT GCTGCAGTTATTGATGAGCTGTGAGCTGAGACTGTGCCACAAAAAA TCCTCCCTTGAAAGAAGGATTTTATAAAACTAAATCAAGCTCTGCATACTCTTCATGCTTC AGAATTCGGCAGTGAATTGATGAGGCTATCTGAATGTTCCGGAAAGCGGAGCTA CTAATTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCTGGACATGTGTCACC AGCAGTTGGTCATCTCTGGTTTCTGGTCTCTGGCATCTCCCTCGTGGCCATATGGAA CTGAAGAAAGATGTTATGCTGAGAATTGGATTGGTATCCGGATGCCCTGGAGAAATGGTGG TCCCTCACCTGTGACACCCCTGAAAGAAGATGGTATCACCTGGACCTTGAGCAGCGTGGAG TCTTAGGCTCTGCAAACCCCTGACCATCCAAGTCAAAGAGTTGGAGATGCTGCCAGTACAC CTGTCACAAAGGAGGCCAGGTTCTAAGCATTGCTCTGCTGTTCACAAAAGGAAGATGGA ATTGTCAGTGAATTAAAGGACCAAGAAAGAACCCAAAAAAATAGACCTTCTAAGATGCGA GGCAAGAAATTATTGGAGCTTCACTGCTGTTGCTGACGACAATCAGTACTGATTGACA TTCAGTGTCAAAGCAGCAGAGGCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTACA CTCTGCAAGAGAGCTGAGGAGGACACAAGGAGATGAGTACTCAGTGGAGTGCAGGAG GACAGTGTGCCAGCTGCTGAGGAGATCTGGCCATTGAGGTATGGTGGAGTGCCTCAC AAGCTCAAGTATGAAAACATCACACAGCAGCTCTCATCAGGACATCATCAAACCTGACCCAC CCAAGAACTTGCAGTGAAGCCATTAAAGAATTCTGGCAGGTTGGAGGTAGCTGGAGTACCC CTGACACCTGGAGTACTCCACATCTACTTCTCCCTGACATTCTGCGTTCAAGTCCAGGGCAA GAGCAAGAGAGAAAAGAAGATAGGTCTACGGACAGAACGAGGTATGGTGGAGTGCCTGCG CAAAATGCCAGATTAGCTGCCGCCAGGCCAGCTACTATAGCTCATCTGGAGGAAATG GGCATCTGTGCCCTGCACTGGAGGCCAGGCTGCTGACCTGGCGACGTCAGGAGA ACCCGGGCCATGGGGCAGGTGCCACCGCCGCGCATGGACGGGCCGCGCTGCTGCT GTTGCTGCTCTGGGGCTTGGCTGGCAAGGAGGATGCCAGGGCATGCCACAGGCCCTGCTACAC ACACAGCGGTGAGTGTGCAAAGCTGCAACCTGGCGAGGGTGTGGCCAGCCTTGAG CCAACCCAGGCCAGTGTGAGCCCTGCGACAGCGTACGTTCTCCGACGTTGAGCAGCG ACCGAGCCGTGCAAGCCGTGCAACCGAGTGTGCTGGGGCTCCAGACATGTCGGCCGTCG GGAGGCCGATGACCCGCTGCCCCCTGGCTGGAGTACAGGAGTGGAGCAGACTGGC GCTGCAGGGCTGCCGCTGTGCGAGGGCTGGCCCTGGCTGTGTTCTCTGCCAGGACAAG CAGAACACCGTGTGGAGGAGTGGCCGACGGCACTATTCCGACGAGGCAACCCAGTGG CCCGTGCCTGCCCTGCAACCGTGTGCGAGGACACCAGGCCAGCTCCGCGAGTGCACACGCT GGCCGAGCCGAGTGTGAGGGAGTCCCTGGCCCTGGATTACACGGTCCACACCCCGAG GCCCTGGACAGCACACCCCCAACCCAGGCCACTGAGGACCTCCAGAACAAAGACCTCAT AGCAGCACCGTGTGGAGGTGTGACCATCAGTGTGAGGAGTGGCAGCTCCAGCCCTGGT GAGGACACCAGACAACCTCATCCCTGTATTGCTCCATCTGGCTGCTGTGGTTGGT TGTGCTCCTACATGCTCTAAGAGGTGATCTAGAGGGCCGTTAAACCCGCTGATCACGCTC GACTGTGCTCTAGTGTGCAAGCCATCTGTTGCCCCCTCCCCGTGCTTCTTGACCCCTG GAAGGTGCACTCCACTGTGCTTCCCTAAATGAGGAAATGATGTCATGTCATGTCAGT GGTGCATTCTATTCTGGGGGTGGGGCTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGAC AATAGCAGCATGCTGGGATCTGGCTGGCTCTATGACTAGTGGCAATTGGCGAGATCAA AGAGAGCCTGCCGAGAGCTCAGGGTGAACGGTGGCCCTGGAGGGCCCGGGCAGGG TGAGCTGAGCCGGTCTGGGGTGTCCCCTGTCACAGGATCAGGAGCTCAGGGTCG TAGGGCAGGGACCCCCCAGCTCAGGGCTGTGCTGACACTGGGAATGGTACCG GCATCTGTGCTCTAGCTGGAAGCACCCACCCCTGACCTTTGCCCCCTCAGAGAAGGGCAGA GACCTCCACCCCTGACCCCTCAACCCCTGACCTTTGCCCCCTCAGAGAAGGGCAGA AGTGGCCACAGCCCACCCAGCCCCACCCAGGCC
41 upstream TRAC locus polynucleotide sequence	ATGAGATCATGTCCTAACCTGATCCTTGTCCCACAGATATCCAGAACCTGACC CTG
42 downstream TRAC locus polynucleotide sequence	GAAACAGTGAGCCTTGTCTGGCAGTCCAGAGAATGACACGGAAAAAGCAGATG AAGA
43 upstream CD25 locus polynucleotide sequence	AGTGCTGGCTAGAACCAAGTGTCTACTGCATGCACATCATTAGCACAGTTAGTT GCT
44 downstream CD25 locus polynucleotide sequence	GAATGGTATGGAACCTCTCCACCTATATGAGTATAAGAAAAGTAGGTT

TABLE 5 -continued

Sequences referred to in example 2.

45	upstream PD1 locus polynucleotide sequence	GGTGGCCGGGGAGGCCTTGCGGGCCACCCAGCCCCCTCCTCACCTCTCTCCATCTCA
46	downstream PD1 locus polynucleotide sequence	TGCCCTTCCAGAGAGAAGGGCAGAAAGTGCCCACAGCCCACCCAGGCCCTCACCC AGGCC AGGCC
47	IL-12a polynucleotide	ATGTGGCCCTGGTCAGCCTCCAGCCACCAGCCCTCACCTGCCGCGGCCACAG GCGCGCAGCCTCCTCTTGCGCTACCCCTGGCTCCCTGGACACCTCAGTTGGC CAGAACACCTCCGGCTGGCAACTCAGACAGGAAATGTCCTGGCTCAGCATGTGCA CCCCAACCTGCTGGGGCGTCAGCAACATGCTCCAGAAGGGCAGACAAACTCTA GAATTTCACCCCTGCACTCTGAAGAGATTGATCATGAAGATACTACAAAAGATAAAA CCAGCACAGTGGAGGCCCTGTTACCATGGATTAAACAAGAATGAGAGTTGCCAA ATTCCAGAGAGACCTCTTCTATAACTAATGGGAGTTGCTGGCTCCAGAAAGACCT CTTTATGATGGCCCTGCTCTTAGTAGTTATGAAAGACTTGAAGAGTGTACCAAGGT GGAGTTCAAGGACATTAAGTCAAAGCTCTGATGATCTTAAGAGGAGATCTTCT AGATCAAACATGCTGGCAGTTATTGATGAGCTGATGCCAGGGCCCTGAATTCAACAG TGAGACTGTGCCACAAAATCCTCCCTGAAAGAACCGATTTTATAAAAACAAATC AAGCTCTGCATACTCTCATGCTTCAGAATTGGGAGCTGACTATTGATAGAGTGA TGAGCTATCTGAATGCTTCC
48	IL12b polynucleotide	ATGTGTCACCAAGCAGTGGTCATCTTGGTTTCCCTGGTTTCTGGCATCTCCCC TCGTGGCATATGGAAATGAAAGAAGATGTTATGTCGTAGAATTGGATTGGTATC CGGATCCCCCTGGGAAATGTTGCTCCTCACCTGTGACACCCCTGAAGAAGATGGT ATCACTGGACCTGGACCAGAGCAGTGGAGCTTAGGCTCTGGCAAAACCCCTGAC CATCCAAGTCAAAGAGTTGGAGATGCTGCTGGCAAGTACACCTGTGACAAAGGGCG AGGTTCTAACGCCATTGCTCTGCTGCTGCTCACAAAAGGAAGATGGAAATTGGTCCA CTGATATTAAAGGACCAAGAAAGAACCCAAAAAAAGACCTTCTAAGATGCGAGG CCAAGAATTATTCTGGACGTTTACCTGCTGGTGGCTGACGACAATCAGTACTGATT TGACATTCACTGTCAAAGCAGCAGAGGCTCTTGACCCCCAAGGGGTGACGTC GGAGCTGCTACACTCTGCTGAGAGACTCAGGAGGAGACAAAGGAGTATGAGTA CTCAGTGGAGTGCAGGAGACAGTGGCTGCCAGCTGCTGAGGAGACTGCCC ATTGAGGTATGGTGGATGCCGTTCAAGCTCAAGTATGAAACACTACCCAGCAGC TTCTCATCAGGGACATCATCAAACCTGACCCACCCAAGAACACTGCACTGAAAGCA TTAAAGAATTCTCGGCAGGGTCACTGGAGTACCTGACACCTGGAGTAC TCCACATTCTCCTGCACATTCTGCTTCAAGGTCAGGTCCAGGGCAAGAGCAAGAG AGAAAAGAAAAGATGAGTCTTCAGGACAAGACCTCAGGCACCGCTATCTGGCGA AAAATGCCAGATTAGCGTGCAGGGCCACGGACCGCTACTATAGTCATCTGGAGC GAATGGCAGATCTGTCCTGCAGT
49	IL15 polynucleotide	GGCATTCACTGCTTCATTTGGGTGTTTCACTGCGAGGGCTCCATAACAGAACCC AACTGGGTGAATGTAATAAGTGAATTGAAAAAAATTGAAGATCTTATTCAATCTATGC ATATTGAGTCTACTTATATACGAAAGATGATGTCACCCAGTGTGAAAGTAACAGC AATAGTGTCTTCTTGGAGTTACAAGTTATTGACTGAGTCCGGAGATGCAAGT ATTCACTGATACTGAGAAAATCTGATCATCTCACAGCAAACACAGTTGTTCTTAAATG GGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAACCTGGAGGAAAAATTATTA AAGAATTGGCAGAGTTTGTACATATTGTCATCAACACTTCT
50	sIL15ra polynucleotide	ATCACGTGCCCTCCCCCATGTCGTGGAACACGCAGACATCTGGGCAAGAGCTA CAGCTGTACTCCAGGGAGCGGTACATTGTAACTCTGGTTCAAGCGTAAAGCCGG CACGCTCAGCTGAGGGAGTGCCTGTTAACACAAGGCCACGAATGTCGCCACTGGA CAACCCCGACTCTAAATGCTTACAGGACCTGGTTCACCAAAGGGCCAGCG CCACCCCTCCACAGTAAACGCGAGGGTGACCCCAAGCCAGAGGAGCCTCTCC CTTCTGGAAAGAGCCCGCAGCTCATCTCCAGCTAAACACACAGCGGCCACA ACACAGCTATTGTCGGCTCCAGCTGATGCTTCAAAATCACCTTCCACAGGA ACCAAGAGATAAGCAGTCACTGAGTCTCCACGGCACCCCTCTGAGACAACAGC CAAGAACTGGGAACCTCACAGCATCGCCTCCACAGCGGCCAGGTGTATCCAC AGGCCACAGCGACACCACT
51	soluble GP130 polynucleotide	ATGCTGACACTGCAGACTGGCTGGCGAGGCAGTGTATTCTGACTACTGAA TCAACTGGGAACCTGCTGGACCTTGTGGCTACATCAGCCCTGAGTCCCCAGTGGT GCAGCTGCACAGCAACTTCACCGCGTGTGCGTGAAGGAGAAGTGTATGGACT ACTTCACGTGAACGCCAATTATCGTGTGGAAAACCAACCAACTTCACAATCCCAA GGAGCAGTACACCATCATCAATAGGACAGCCAGCTCCGTGACCTTACAGACATCG CCTCCCTGAAACATCCAGCTGACCTGCAATTCTGACATTGCGCAGCTGGAGCAG AACGTGTATGGCATCACCACATCTCTGGCTGCCCTGAGAAGCCTAAGAACCTG AGCTGCATCGTAATGAGGGCAAGAAGATGCGGTGTAGTGGGACGGCGCAGAG AGACACACCTGGAGACAAACTTCACCCCTGAAGTCCGAGTGGGACACACAAGTT GCCGACTGCAAGGGCAAGCGCAGTACCCCAACATCTGTAACCGTGGATTACTCTAC AGTGTATTGTAACATCGAAGTGTGGTGGAGGGCGAGAATGCCCTGGCAAGG TGACCTCCGACCACTCAATTGATCCCGTGTACAAGGTGAAGCCTAACCCACCC ACAATCTGAGCGTCAATTCCAGGGAGCTGTCAGCATCTGAAAGTACAATATCCAGTATCGGACCA CAAACCCATATCAAGAGCGTGAATCTGAAAGTACAATATCCAGTATCGGACCA AGGACGCCCTCACATGGAGGCCAGATCCCTCAGAGGATACCGCAGCACAAGATCC

TABLE 5 -continued

Sequences referred to in example 2.

	TCTTCACCGTGAGGACCTGAAGCCCTCACAGAGTACGTGGATCAGATGT ATGAAAGGAGGACGCCAAGGGCTACTGGAGCGATTGGTCCGAGGGCAGCGCA TCACCATGGACAGGCCCTAAGGCCAGCTCTGGTACAAGATCGATCCAT CCCACACCCAGGGCTATCGCACACTGCAGCTGGACTACAGGGTACCGCTGACAGGTGGAAGTCCC GAGGCCAACGGCAAGATCCCTGGACTACAGGGTACCGCTGACAGGTGGAAGTCCC ACCTGAGAACTACCGTGAATGCCACCAAGCTGACAGTGAACCTGACAAAATGATC GGTACCTGGGACACCTGCACTGAGAAAACCTGGTGGCAAGTCTGACGCCCGGT GCTGACCATCCCTGCGATTTCAGGCCACACACCCAGTGATGGACCTGAGGG CCTTCCAAGGATAATATGCTGTGGGGAGTGGACCACACCTAGAGAGTCCGTG AAGAAGTACATCTGGAGTGTGGTGTGACAAGGCCCCATGTATCACCGA CTGGCAGCAGGAGGACGGCACCCTGACACCCCTGTATGCGCGGCAACCTGGC GAGTCAAGTGTACCTGATCACCGTACACCCCTGTATGCGACAGCGGACCGCTC TCCTGAGAGCATCAAGGCCTACCTGAAGCAGGCCACCAAGCAAGGGACCAACCG TGGGACACAAGGAGTGGCAAGAATGAGGCGCTGCTGGAGTGGGACAGCTGCC TGTGGATGTGAGAACGGCTTACAGGAAATTACACCATTTTATCGCACAATCATC GGCAACGAGACAGCGGTGAATGTGGACAGCTCCACACCGAGTATACTGTCTAG CTGACCTCCGATACACTGTACATGGTGGAGATGGCCGCTATACAGACGAGGGCG GCAAGGATGGCCCCAGTTT	
52	IgE signal sequence	GGTACCGGGTCCGCCACCATGGACTGGACCTGGATTCTGTTCCCTGTGGCTGCTGC TACAAGAGTGCACAGC
53	F2A	GGTTCTGGCGTAAACAGACTTTGAATTTCGACCTTCTCAAGTTGGGGAGACGTG GAGTCCAACCCAGGGCCC
54	P2A	GGAAGCGGAGCTACTAACCTCAGCTGCTGAAGCAGGCTGGAGACGTGGAGGAGA ACCCCTGGACCT
55	T2A	GAGGGCAGAGGCCAGCCTGCTGACCTGCGCGACGTCGAGGAGAACCCCGGGCCC
56	LNGFR	ATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGCCGCGCTGCTGTTG CTGCTCTGGGGGTGTCCTTGAGGTGCGAAGGAGGATGCCACAGGCCCTGT ACACACACAGCGGTGAGTGTGCAAGGCTGCAACCTGGCGAGGGTGTGGCCCA GCCTGTGGAGCCAACACAGCCGTGTGAGGCCGCGCTGGACAGCGTGACGTT CCGAGCTGGTGGCCGAGCCGAGCCGCTGCAAGGCGTGCACCGAGTGTGGCC TCCAGAGCATGTCGGCGCCGTGCGTGGAGGCGATGACGCCGTGTGCGCTGCG CTACCGCTACTACCAAGGATGAGACGACTGGGCGTGCAGGCGTGCCTGCG GAGGCGGGCTCGGCCCTGTGTTCTCTGCCAGGACAAGCAGAACACCGTGTGCG AGGAGTGGCCGAGCCGAGCTTCCGAGGAGCACCGAGCCGAGCTGGACCCGTGCG GCCCTGACCCGTGTGCGAGGAGCACCGAGCCGAGCTCCGCGAGTGCACAGCTGG GCCGAGCCGAGTGGAGGAGATCCCTGGCGTGGATTACAGGTCCACACCC CAGAGGCGTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGA ACAAGACCTCATAGCCAGCACGGTGGCAGGTGTGAGCACAGTGTGGAGCT CCCACCCGTGCTGACCCAGGCCACCCAGAACCTCATCCCTGTCTATTGCTCC ATCTGGCTGCTGTGTTGTGGCTTGTGGCTACATAGCCTCAAGAGGTGA
SEQ ID NO#	Sequence Name	Polypeptide sequence
57	IL-12a polypeptide	MWPPGSASQPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVLVLLDHLSLARNL PVATDPGMPFCLHHSQNLLRAVSNMLQKARQTLFEPYPTSEEIDHEDITKDKTSTVEA CLPBLELTKNESCLNSRETSETIANGSCLASRKTSFMMALCLSSIIYEDLKMVQEFKTMNAK LLMPDKRQIFLDQNMLAVIDELMQLANFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRINA VTIDRVMPSYLNAS
58	IL12b polypeptide	MCHQQLVISWFLVFLASPLVAIWEKKDVYVVELDWYPDAPGEMVLTCDTPPEEDGIT WTLDQSSEVLGSGKTLTIQVKKEPGDAGQYTCHKGGEVLSHSLLLHKKEDGIWSTDILKD QKEPKNKFLRCEAKNYSRFTCWLLTISTDLTSVKSSRGSSDPQGVTCGAATLSAE RVRCGDNKKEYEVSVEQEDSACPAEEESLPIEVMDAVHKLKYENYNTSSFFIRDIICKPDP KNLQLKPLKNSRQVEVSWEYPTDTSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSA TVICRKNAISVRADRYSSSSWEWASVPCS
59	IL15 polypeptide	GIHVFIILGCFSAGLPKTEANWNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVAMKC FLLELQVISLESQDASIHDTVENLIIANNNSLSSNGNVTESGCKECELEEKNIKEFLQSFV HIVQMFINTS
60	sIL15ra polypeptide	ITCPPPMVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTPS LKCIIRDPAVLHQRAPPSTVTAVGTPQPESLSPSGKEPAASSPSSNNTAATTAAIVPGS QLMPSKSPSTGTTEISSHESSHGTPSQTAKNWELTASASHQPPGVYPQGHSDTT
61	soluble gp130	MLTQTLVQALFIFLTTESTGELLDPCGYISPESPVVQLHSNFTAVCVLKEKCMDYFHV NANYIVWKTNHFTIPKEQYTIINRTASSVFTDIAASLNIQLTCNILTGFQLEQNIVYGITIISGL PPEPKPNLSCIVNEGKMKRCEWDGGRETHLETNTFLKSEWATHKFADCKAKRDPTPTSC TVDVYSTVYFVNIEVWVEAENALGVKVTSDHINFDPVYKVPNPNNLVSVINSEELSSILKLT WTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIRCMKE DGKGYWSDWSEEASGITYEDRPSKAPSFWYKIDPSHTQGYRTVQLVWKLPLPFEANGK ILDYEVTLTRWKSHLQNQYTVNATKLTVNLTNDRYLATLTVRNLVGKSDAAVLTIACDFQA

TABLE 5 -continued

Sequences referred to in example 2.

		THPVMDLKAFPKDNMLWVEWTPRESVKYILEWCVLSDLKAPCI TDWQQEDGTVHRTY LRGNLAESKCYLIVTVPVYADGPGSPESIKAYLKQAPPSKGPTVRTKVGKNEAVLEWD QLPVDVQNGFIRNYTIFYRTIIGNETAVNVDSHTEYTLSSLTDLYMVRMAAYTDEGG KDGPEF
62 soluble gp130 fused to a Fc	MLT1QTWLWQALF1FLTTTESTGELLDPCGYISPEPSPVQLHSNFTAVCVLKEKCMDFHV NANY1VWKTNHFT1PKEQYTI1INTTASSVTFDTIASLN1QLTCN1LTFGQLEQNVYGITIISGL PPEPKPNLSC1VNNEGKMRCEWDGGRETHLETNTLKS1EWATHKFADCKAKRDTPTSC TVDYSTVYFVN1EVVVAEANALGKVTSVDHINFDPVYKVPNPNNHLSVINSEELSSILKLT WTNPSIKSV1ILKVN1QYRTKDASTWSQ1PPEDTASTRSSTVQDLKPFTEYVFRIRCME DGKGYWSDSWEASGI1YEDRPSKPSFWYKIDPSHTQGYRTVQLWWKTLPPFEANGK ILDYBVTLTRWKSH1QNYTVNATKLTVNLTNDRYLATLTVRNLVGKSDA1VLTIPACDFQA THPVMDLKAFPKDNMLWVEWTPRESVKYILEWCVLSDLKAPCI TDWQQEDGTVHRTY LRGNLAESKCYLIVTVPVYADGPGSPESIKAYLKQAPPSKGPTVRTKVGKNEAVLEWD QLPVDVQNGFIRNYTIFYRTIIGNETAVNVDSHTEYTLSSLTDLYMVRMAAYTDEGG KDGPEFRSCDKTHTCPCTPAPEAEGPSVFLFPFPKPDTLMSRTPEVTCVVVDVSHED PEVKPNWYDGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESENQGP ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK	
SEQ ID NO#	Sequence Name	Polymer sequence
63	Matrice TRAC locus_CubiCAR CD22 pCLS30056 full sequence	GTGGCACTTTCGGGAAATGTGGCGGAAACCCATTGGTTTATTTCTAAATACA TTCAAATATGTATCGCTCATGAGACAATAACCTGTAAATGCTTCAATAATTGAA AAAGGAAGACTATGAGTATTCAACATTCCGTGTCGCCCTTATCCCTTTTGCAGG ATTTGCCCTCCTTTTGTCAACCAGAACGCTGGTAAAGTAAAGATCTGAGAT GATCAGTGGGTGACAGTGAGCTGGTACATCGAAGCTGGATCTAACAGCGTAAGAT CCTTGAGAGTTTCCCGAAGAACGTTTCCAATGATGAGCAGTCTTTAAAGTCTG CTATGTGGCCGGTATTATCCGTATTGACGCCGGCAAGAGCAACTCGTCGG CATACACTATTCTAGAATGACTTGGTTGAGTACTCACAGTCACAGAAAAGCATCTT ACGGATGGCATGACAGTAAGAGAATTATGAGCTGCTGCCATAACCATGAGTATAAC ACTCGCCGAAACTTACTCTGACAAACGATCGGAGGACCGAAGGAGCTAACCGCTT TTTGCAACACATGGGGATCATGTAACCTGCCCTTGATCGTTGGGAACCGGAGCTGA ATGAAGCCATACCAACGACGAGCGTACACCAAGATGCCGTAGCAATGGCAACA ACGTTGCGAAACTATTAACTGGCAACTACTTACTTAGCTTCCGGCAACAATTAA TAGACTGGATGGAGCGGATAAAATTGAGCAGGACACTCTGCGCTCGGCCCTTCG GCTGGCTGGTTATTGCTGATAAATCTGGAGCCGGTGGCTGGTTCTCGCGTAT CATTCAGCACTGGGCCAGATGTTAAGGCTCCCGTATCGTAGTTAATCACAGA CGGGGAGTCAGGCAACTATGGATGAAACGAAATAGACAGATCGCTGAGATAGGTGCC TCACTGATTAAGGACTTGGTAACCTGACGACCAAGTTACTCATATAACTTGGATTGA TTTAAACATTCTATTAAAGGATCTAGGTGAAGATCTTTGATAATCTCAT GACCAAAATCCCTAACGTGAGTTTCGTCACGTGAGCTAACCCGGTAAAGAAA GATCAAAGGATCTCTTGAGATCTTTCTGCGCGTAACTGCTGCTTGCAACAA AAAAAAACCCGCTAACCGGGTGGTTCTGGCGGATCAAGAGCTACCAACTCTT TTCCCGAAGGTAACCTGGCTCAGCAGAGCGAGTACCAAAATACTGTTCTAGTG TAGCCGTAGTTAGGCCACCACTTCAGAAGACTCTGAGCACGCCATACCTCGCT CTGCTAATCTGTTACCACTGGCTGTCGCACTGGCATAAGTCGTCTTACCG GTTGACTCAAGGACATAGTTACCGGATAAGGGCAGCGCTGGGCTAACCGGG GGTTCGTGACACACGGCCAGCTGGAGCGAACGCTACACCGAAGTGGAGATACCT ACAGCGTGAAGTGGAGAACGCCCCAGCTTCCCGAAGGGAGAACGGGAGCAGG TATCCGGTAAGCGCAGGGTCGGAACAGGAGAGCGCAGAGGGAGCTCCAGGG GAAACGCCCTGTTCTTATAGTCTGCTGGGTTCTGCCACCTCTGACTTGACGCT GATTTTGTGATGCTGTCAGGGGGCGGAGCTATGGAAAAACGCCAGACCG GCCCTTTACGGTTCTGGCTTTGCTGCGCTTGTCACTGGTCTTCTGGCGT TATCCCCTGATTCTGTTGATAACCGTATTACCGCTTGTAGTGAGCTGATACCGCT GCCGAGCAGGTTCCGACTGGAAACCCGAGCTTACACTTATGCTTCCGGCTGTTG TAGCTCACTCATTAGGCACCCAGGGTTTACACTTATGCTTCCGGCTGTTG GTGAGATTGAGCTGAGCGGATAACAAATTCAACAGGAAACAGCTGACCATGATTACG CCAAGCGCTAACCTCAGTAAAGGAAACAAAGCTGTTAATTATGCTGG GCCCTTTCCCATGCTGCCCTACTCTGCGAGGTATATTGCTGGGGTTGGAGA AGATCTTAAATAAAAGAATAAGCAGTATTAAAGTAGCCCTGCTTCAAGCTT CCTCTGAGTGGCAGGCCAGGCTGCGCTGAACTGCTACTGAAATCATGCCCTTG GCCAAGGATGATGAGCTTGTGCTGCCCTGAGTCCAGTCCATCACAGCAGCTGG TTCTAAGGCTATTCCCGTATAAAGCATGAGACCGTGACTTGGCCAGCCCCACAG AGCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGCAAGA GGGAATGAGATCATGCTCTAACCTGATCCTCTGTCCACAGATATCAGTACCC CTACGACGTGCCCCGACTACGCCCTCCGGTGAGGGCAGAGGAAGTCTTCAACATGCG GTGAGCTGGAGGAGAATCCGGGCCGGATCCGGCTCTGCCGTACCGCTCTGCT GCTGCCACTGGCACTGCTGTCAGCTGCTAGGCCGGAGGGGGAGGCAGCTGG CCCTACAGAACCCAGCCTGTGAGCGAGGCCAGCGCCGGAGGGGGT AGCCAGGTGAGCTGCAAGAGGCCCTGGCTGGTGAAGCCAAGCCAGACAC TGTGCTGAGCTGCGCCATCAGCGCGATTCCGTGAGCTCCAATCCGCCCTGG AATTGGATCAGGAGTCCCCCTCTGGGGCTGGAGTGGCTGGGAAGGACATACTA

TABLE 5 -continued

Sequences referred to in example 2.

TCGGTCTAAGTGGTACAACGATTATGCCGTGTCTGTGAAGAGCAGAAATCACAACTCAA
 CCCATGACACCTCCAAGAACATCAGTTCTCTGTCACTGTAATAGCTGACCCAGAGGA
 CACCGCCGTACTATTGCGCCAGGGAGGTGACCCGCGACCTGGAGGTGCCTT
 GACATCTGGGGCAAGGGACAATGGTACCGTGAGCTCGGAGCCGGATCTG
 GCGGAGGAGGAAGTGGGGCGGGGAGTGATATCCAGATGACACAGTCCCCATC
 CTCTGTGGCCCTCGGGCGACAGACTGACAAATCACCTGTAGGGCTCCCAGA
 CCATCTGGTCTTACCTGAACCTGGTATCAGCAGGGCCGGCAAGGCCCTAATCTG
 CTGATCTACCGAGCAGCTCCCTCAGAGCGGAGTGCCATCAGATTCTGGCAG
 GGGCTCCGGCACAGACTTCACCCCTGACCATCTAGCTGCAGGGCAGGACTTCG
 CCACCTATTGGCAGCAGTCTTATAGCATCCCCAGACATTTGGCAGGGCACCA
 AGCTGGAGATCAAGTGGGATCCCCAGGGAGGGAGGCAGCTGCCCTACAG
 CAACCCCAGCCTGTGAGCGAGGGCGCAGGAGCTGCCACCCAGGGCAG
 CTTCTCCAAGCTGTCCACCAACGTGAGGCCAGCCAAGGCCACCACCGCCTGTC
 CTTTATCCAACTTCTCCCTGTGCTCTCCACCAACCCCGCTCCAAAGGCCCTTA
 CCCCGCAGCAACTATTGCGCTCCAGGCCACTCTACTGCGGCTGAGGCCCTGTGCG
 CCCGCTGTGGAGGGCAGTGCATAACAGGGCCTGATTCGCGATATTAA
 CATCTGGCACCCCTCGCCGGCACCTGCGGGGTGCTCTCTCCCTGGTATTA
 CCCGTATTGCGAGCGGGCCGGAGAACAGCTCTACATTTTAAGCAGCCTTCA
 TGGGCCAGCGAGCAACACCAAGAGGAGGATGGGTGTTCTGAGATTCCCTGAG
 GAAGAGGAAGGGGGTGCAGCTGAGGTGAAGTCTCCAGGAGCGCAGATGCC
 CCGCCTATCAACAGGGCAGAACACAGCTCTACACAGAGCTTAACTCGGGAGGGC
 GAAGAATACAGCTGGATAAGAGAACGGGGGGGGGACCCGAGATGGGAGGA
 AGCCCCGGAGGAACCCCTCAGAGGGGCTGTAACAGAGCTGAGAGGATAA
 GATGGCGAGGGCTACTCAGAGTGGGGATGAAGGGGAGCGGGCCGGGAA
 GGGGCACGATGGGCTTACAGGGGCTGAGCACAGCCACAAAGGACACATACGAC
 GCCCTGCACATGCAGGGCTTACCCGGGAATAGCTAGAGGGCCGTTAAC
 CCGCTGATCAGCCTGACTGTGCTTCTAGTTGCGAGGACATCTGTTGGCCCTC
 CCCCTGCTTCTGACCCCTGGAGGTGCACTCCACTGTCCTTCTTAATAAAA
 TGAGGAAATTGCGATGCACTGCTGAGTAGGTGTCATTCTATTCTGGGGGGGG
 GGGGAGGGAGAGCAAGGGGGAGGTTGGGAAGAACATAGCAGGATGCTGGGAG
 GCGGTGGCTCTATGACTAGTGGGAATTCCCGTGTACAGCTGAGGAGACTCTAA
 TCCAGTGAAGTCTGCTGCCATTACCGATTGTTGATTCCTAAACAAATGTCAC
 AAAGTAAGGATTCTGTATGTATACAGACAAAATGTGCTAGACATGAGGCTAT
 GGACTTCAAGAGCAACAGTGTGTCCTGGAGAACAAATGTGACTTTGCACTG
 CAAACGCCCTCAACACACGATTATCCAGAACAGACCCCTCTCCAGGCCAGGTA
 AGGGCAGCTTGGCTCTCGCAGGGCTGTTCTGCTTCAGGAATGGCCAGGTC
 TGCCAGAGCTGCTGCAATGATGTCCTAAACTCTCTGATTGTTGGCTCGCCCT
 ATCCATTGCCACCAAAACCTTTTACTAAGCGATCGCTCCGGTGCCTGAGT
 GGCAGAGGCCACATGCCACAGTCCCCAGAGAAGTTGGGGAGGGCTGGCAAT
 TGAAGGGTGCCTAGAGAAGGTGGCGGGGTAACAGGGAAAGTGTGTCGTG
 ACTGGCTCCGGCTTTCGGAGGGTGGGGAGAACCTGATGTCAGTAGTC
 GCGGTGAACGTTCTTTCGCAACGGGTTGCGCCAGAACACAGCTGAAGCTCG
 AGGGCTCGCATCTCTCCACCCGGCCGCCACTCTGAGGGCCGACATCCA
 CCCCCGTTGAGCTCGCTTCTGCCCTCCGGCTCTGCTGCGCTCTGAACCTGCG
 CGCCGCTAGGTAAAGTCAGGTGAGACCGGGCTTTGCGCTGACCCCTGCTG
 CTTGGAGCCTACCTAGACTCAGCCGCTCTCCACGCTTGCCTGACCCCTGCT
 CAAACTCTACGCTTGTGTTCTGCTGCTGCGCCCTACAGATCCAAGCTGTGAC
 CGGCCTTACCTGAGATCACGGCCACCATGGCTTCTTACCCGGACACCAGCA
 TGCTCTGCTTGGCAGGCGTGGAGATCCAGGGGCACTCCAAACAGGAGAAC
 CCCTAAGACCCAGAACAGCAGGAAGCCACTGGGTGAGGCCCTGAGCAGAAC
 GCAACCCCTGCTGAGGTGATCATGATGGCCATGGCAGACAGCACCA
 CCACTCAACTCTGGTGGCACTGGGCTCCAGGGATGACATTGTGATGCTGAG
 CCAATGACCTACTGGAGAGTGTAGGAGCCTGAGACCATGGCAACATCTACACC
 ACCCAGCACAGGCTGGACCAGGGAGAACCTGCTGGAGATGCTGCTGGT
 GACCTCTGCCAGATCACAATGGGAATGCCCTATGCTGACTGATGCTGTTGGC
 TCCTCACATTGGAGGGAGGGCTGGCTCTTCTCATGCCCTCCACCTGCGCTGAC
 TGATTTGAGACACCCCCATTGCGACGGCTGTGCTACCCAGCAGAAC
 CTCATGGGCTCCATGACCCACAGGGCTGTGCTGGCTTTGCGCTGATCCCTCC
 AACCTCTGGCAACCAATTGTTCTGCTGCGGAGACTGCTGAGAACACATG
 CAGGGCTGCAAGAGGGAGAGACCTGGAGAGAGACTGGACCTGGCCATGCTGG
 GCAATCAGAAGGGTGTATGACTGTCAGAACACTGTGAGATACCTCCAGTGTG
 AGGCTCTGGAGAGAGGACTGGGAGCAGCTCTGGAAACAGCAGTGCCCCCTCA
 GGAGCTGAGGCCAGTCAAGTGTGCTGCAAGACCCCACTTGGGACACCCCTGTT
 CACCCCTGCTGGAGGAGATGGGAGAGGGCAACTAAGGGCAGGCCACTCGAGC
 GCTAGCTGGCAGAGCATGATAAGTACATTGATGAGTTGGACAAACACAACTAGA
 ATGCACTGAAAGGAAATTGCTTATTGTGAAATTGATGCTATTGTTATTGTAAC
 CATTATAAGCTGCAATAACAAAGTTAACACAAATTGCAATTCTATTGTTTCAGG
 TTCAAGGGGAGGTGTGGGAGGTTTTAAAGCAAGTAAAACCTCTACAAATGTTG
 TGGAGGGCGCCCAATTGCCCTATAGTGAGTGTAATACGTGGCTCACTGGC
 CGTCTTTTACAAAGCTGTGACTGGAAAACCTGGCTTACCCAACTTAATGCC
 TGCAGCACATCCCCCTTCGCCACGTGGCTAATAGCGAAGAGGCCACCGAAA
 CGCCCTTCCCAAGTGTGCGCAGGCTGAATGGCGAATGGGAGGCCCTGTAGCG
 CGCCTTAAGCGCGGGGTGTTGGGTTACCGCGCAGCGTGAACCGCTACACTTG
 AGCGCCCTAGCGCCGCTCTTCTGCTTCTCCCTTCTCGCACGTTGCC

TABLE 5 -continued

Sequences referred to in example 2.

GGCTTCCCCGTCAAGCTCTAAATCGGGGCTCCCTTAGGGTTCGATTAGTGC TTACCGCACCTCGACCCAAAAACTTGATTAGGGTATGGTGGCTGTAGTGG CCATAGCCCATAAGCGTTTCGCCCTTGACGTTGGAGTCCACGTTCTTAATA GTGGACTCTTGTCAAACCTGGAACAAACACTAACCCATCTCGTCTATTCTTG TTTATAAGGGATTTCGCCATTGCGCTATTGGTAAAAATGAGCTGATTAAACAA AAATTAAACCGCAATTAAACAAATTAACGCTTACAATTAG	
64 Matrice CD25 locus_IL15_ 2A_sIL15Ra pCLS30519 full sequence	GTTTATTATTCTGTCCACAGCTATTGTCGACATATAAAAACCTAGGCCAGGCACA GTGGCTCACACCTGTAATCCAGCACTTGGAAAGGCCAGGCAGATCACAG GTCAAGGAGTCAGACGCCAGCTGCCAACATAGCAGAAACCCCATCTACTAAAAAT ACAAAATTAGCCAGCATGGTGGCTGTGACTGGTTAGAGTGGAGGCCACATT TTTGGTGCCTGTATTACATATGACCGTGAATTGTTACACCACTACAGGAGAAG AGTAGAAGAACATCGTTCTGGCTGAAACAGACTTGAATTGACCTTCTCAAG TGGGGGAGACGCTGGAGTCCAACCCAGGGGCCGTACCGGGTCCGCCACCATGGA CTGGACCTGGATTCTGTCTCTCGTGTGCTACAAGAGTGCACAGCGGCAATC ATGCTTCAATTGGCTGTTCACTGGAGCTTCAACAGAAGCTGGGGACTGGGG TGAATGTAATAAGTGAATTGAAAAATTGAAGATCTTACATCTATGCATATTGAT GCTACTTTATATACCGAAAGTGAATTGACCCAGTTGCAAAGTAAACAGCAATGAAG TGCTTCTCTGGAGTTCAAGTTACTTGAGTCCGGAGATGCAAGTATTCTCATG ATACAGTAAAAATCTGATCATCTAGCAAACACAGTGTGTTCTCTAATGGGAATGT AACAGAATCTGGATGCAAAGAATGTGAGGAACCTGGAGGAAAAAAATTAAAGAATT TTTCAGAGTTTGATCATATTGTCACATGTCACACTCTCTGAAGCGGAGCT ACTAACCTCAGCCTGCTGAAGCAGCTGGAGACCTGGAGGAGAACCTGGACCTGG GACCGCTCTGCAACATGGATTGGACCTGTTCTCTCTGGAGCTGCCA CAAGAGTTCACAGTATCACGTGCCCTCCCCCATGTCCTGGAAACACGAGACATC TGGTCAAGAGTCAGCTGTGACTCCAGGGGGTACATTGTAACTCTGTTTC AAGCTAAAGCCGACGCTGACGGTCACTGGAGGTGTGAACAAGGCCACGA ATGTCCTTCACTGGACAACCCCACTCTAAATGATTAGAGACCTGCTGGTTTC ACCAAAAGCCAGCGCACCCCTCACAGTAACGACGGCAGGGTGACCCACAGC AGAGGAGCTCTCCCTCTGGAAAGAGCCGAGCTTCATCTCCAGCTCAACAA CACAGCAGCTGGGACACAGAGATAAGCAGTCACTGAGTCTCCACGGCACCCC TCTCAGACAACAGCAAGAACTGGAACTCACAGCATCCGCCCTCACAGCGGCC AGGTGTATCCACAGGGCACAGCGACACCAGTGGGGCAGAGGCAGCTGCTG ACCTGGGAGCGACGCTGAGGAGAACCCCGGGCCATGGGGCAGCTGGCACCAGC CGCGCATGGACGGCGCGCGCTGCTGTGCTGCTCTGGGGTGTCCCTTG GAGGTGCAAGGAGGCATGCCACAGGCTGTACACACAGGGTGTGAGTGT CAAAGCCTGCAACCTGGGGAGGGTGTGGCCAGGCTTGTGGAGCCAACAGAC GTGTGAGGCCCTGCTGAGCTGCTGAGCTTCCAGCTGGAGCTGGAGCGACCG AGCCGTGCAAGCGCTGACCGAGTGCCTGGGGCTCCAGAGCATGTCGGCGCG CGTGGAGGGCGATGACGCCGTGCGCTGCGCTACGGCTACTACAGGAGTGT ACGACTGGCGCTGCGAGGCGTGGCGTGTGCGAGGGGGCTCGGCCCTG TTCTCTGGCAGGACAAGCAGAACACCAGTGTGAGGAGATGCCCGACGG ATTCGGACAGGCCAACACCAGTGGACCCCTGCCCTGCAACCTGTGGAGGA CACCGAGCGCAGCTCCCGAGTCACAGCCTGGGCCAGCGCAGTGCAGG GATCCCTGGCGTTGGATTACACGGTCCACACCCCAAGGGCTGGACAGCACA GCCCCCAAGCACCAGGGCTGAGGACCTCCAGAACAGACCTCATAGCCAGCA CGTGGCAGGTGGTGGACCCAGTGTGGCAGCTCCAGGCCCTGGTGGACCC AGGACACCAGCAACCTCATCTGTCTATTGTCATCTGGCTGTGGTGT GGGTTGTTGGCCTACATGCTTAAGGGTGAACAAAGAACAGAATTTC TTGTAAGAAGCCGGAAACAGAACACAGAACAGTGAAGCCTAACAGTGAATCAA GTGCTAAATGGTCCCGCAGGAGACATCCGTTGTGCTGCTGCTTGGAAAGCT GAAGTCACATCACAGAACGGGAGTGGCAACTTGTCTATGCGAGCT CCCATCAGAGAGCGAGCGTACCCACTCTAAATAGCAATTGCGCTTGAAGAG AGGCAAACCACTAGAACCTCTCATCTTGTGTTCATGGCATCG CTCCGGTGGCGCTAGTGGCAGAGCGCACATGCCACAGTCCCGAGGAGTT GGGGAGGGGGTGGCAATTGAAACGGGTGCTAGAGAAGGGTGGCGGGGTAAC GGGAAAGTGTGCTGTGACTGGCTCCGCTTTCCGAGGGTGGGGAGAACCG TATAAAGTCAGTAGTCGCCGAACCGTCTTTTCCGAAACGGGTTGGCGCAGA ACACAGCTGAGCTTGGGGCTCGCATCTCTCAGCGGCCGGCCCTAC CTGAGGCCGCGCATCACGCCGGTTGAGTCGGCTCTGCCCTCCGCTGTG GCCCTCTGAACTGCGTCCGCCGTAGGTAAAGTCACTGAGTCAGGCTGAGAC CCTGTTGCCGGCTCCCTGGACCTACAGACTCACCCGGCTCCACGCTT GCCCTGACCGCTGCTCAACTCTACGTTCTGGTTCTGTTCTGGCGCG CAGATCCAAGCTGTGACGGCGCCTACCTGAGATCACCGGCCACATGGCT TACCTGGACACCAGCATGCTCTGCTTGGACAGGCTGCCAGATCAGGGCCA CTCACACAGGAGAACCTGACCCAGAACAGCAGCAGGAACCCACTGAGG GGCCTGAGCAGAACAGTGCCAACCCCTGCTGAGGGTGTACATTGATGG ATGGGAAAGCACCCACTCACTGCTGGCACTGGGCTCCAGGGATGACAT TGTGATGTGCGTGAACGCAATGACCTACTGGAGAGTGTAGGAGCCT TTGCAACATCTACACCAACCCAGCACAGGCTGGACCCAGGGAGAAATCT GATGCTGCTGTGGTGTGACCTCTGCCAGATCACAAATGGGAATGCC GACTGATGCTGTTCTGGCTCTCACATTGGAGGAGGGCTGGCTCTCT CTCCACCTGCCCTGACCCCTGATCTTGACAGAACCCCATGCGACCC ACCCAGCAGCAAGGACTACCTCATGGGCTCCATGACCCACAGGCTGTG GTGCGCTGATCCCTCCAACCCCTCCCTGGCACCAACATTGTTCTGG TGAAGACAGACACATTGACAGGCTGGCAAAGAGGAGAGACCTGG GAGAGAGACTGGACCTGGCAATCAGAAGGGTGTATGGACTGCTGG AAACACTGT

TABLE 5 -continued

Sequences referred to in example 2.

	GAGATAACCTCCAGTGTGGAGGCTCTGGAGAGAGGACTGGGACAGCTCTGGAA CAGCACTGCCCCCTCAAGGAGCTGAGCCCCAGTCATGCTGGCCAAGACCCAC ATTGGGGACACCCCTGTCACCCCTGTCAGAGCCCCAGTCATGCTGGCTCCAACTGG AGACCTGACAATGTTGCTGGCTGGATGTTCTAGCCAAGAGGCTGAGGT CCATGCATGTTCATCCTGGACTATGACCAGTCCCCTGCTGGATGCAAGAGATGCTC TGCTGCAACTAACCTCTGGCATGGCAGACCCATGTGACCACCCCTGGCAGCCTC CCCACATCTGACCTAGCCAGAACCTTGGCAGAGATGGGAGAGGCAACTA AGGGCGCCACTCGAGCGTAGCTGGCAGACATGATAAGATAACATTGATGATTT GGACAAACCAACAATAGAATGCACTGAAAAAAATGCTTATTGTGAAATTGATGATG CTATTGCTTATTGTAAGCTGCAATAAAACAAGTAAACAACAACAAATTG ATTCACTTTATGTTGAGGTTAGGGGGGGGTGTTGGAGGTTTTAAAGCAAGTAAA ACCTCTACAAATGTGTTATGGAAGCGCCCAATTGCGCTATAGTGTGATGCTATT ACGTGCGCTACTGGCGTCGTTTACAACGTCGTGACTGGAAAACCTGGCGT TACCCAACCTTAATGCCCTTGCAAGCACATCCCCCTTCGCCAGCTGGCTAATAGCGA AGAGGCCCGCAGGAAACGCCCTTCCCAACAGTGGCAGCAGCTGAATGGCGAATG GGAGCGCCCTGTAAGGGCGCATTAAGCGGGCGGGTGTGTTACGGCAGCG TGACCGCTACACTGCCAGCGCCCTAGGCCCGCTCTTCGCTTCTCCCT TTCTGCCAGTTAGCTGCCGGTTTCCCGTCAAGCTCAAATCGGGGCTCCCTTAG GGTCTCGGATTTAGTGTGTTACGGCACCTCGACCCAAAACCTTGATTAGGGTGTG GTTGGCTGTAGTGGGCTATAGCCCTGATAGCGTTTTGCCCTTGTGACCTGG GTCACGTTCTTAAAGTGGACTCTTGTCCAACGTTGAAACAACACTCAACCCATC TCGGTCTATTCTTTGATTATAAGGGATTTCGGGCTATTGGCTATTGGTTAAAAAA TGACGTGATTAAACAAAATTAACCGAATTAAACAAAATTAACGCTTAACTT AGGTGCACTTTGCCGGAAATGTGCGGGAAACCCCTATTGTTATTCTTAATA CATTCAAATATGTATCCGCTCATGAGACAATAACCCCTGATAATGCTCAATAATT GAAAAGGAAGAGTATGAGTATTAAACATTCCGCTGCCCTTATTCCCTTTTG GGCATTTGCCCTCTGTTACGGGTTACCGCAGACGCTGGTGAAGAAGATG TGAAGATCAGTTGGTGCAGAGTGGGTTACATGCACTGGATCTCACAGCG AGATCTTGAGAGTTGCCCGAAGAACGTTTCAATGATGAGCACTTTAAAGT TCTGCTATGTCGGGGGTTATTCCGTTATGAGGCCGGCAAGAGCAACTCG GCCGATACACTATTCTCAGAAACTGTTGAGTACTCACCAGTCACAGAAAAGC ATCTTACGGATGGCATGCAAGTAAGAGAATTAGCAGTGTGCTGCCATAACCATGAGTG ATAACACTGCGGCCACTTACTCTGACAACGATCGGGAGGACCGAAGGAGCTAAC GCTTTTTGCACAACATGGGGGATCATGTAACCTGCCCTGATGCTGGGAAACGGAG CTGAATGACCCCAAACGAGCAGCGTGACACCACGATGCCGTAGCAATGCC AACAAACGTTGGCAGAACACTTAAACTGGCAGACTTACTCTAGCTTCCGGCAACA ATTAATAGACTGGATGGAGGGATAAAAGTGCAGGACCCTCTGCCCTCG TTCCGGCTGGCTGGTTATTGCTGATAATCTGGAGCGGTGAGCGTGGTCTCG GGTATCATTGAGGACTGGGCAAGATGGTAAGCCCTCCGTTCTGAGTTATCTAC ACGAGGGAGTGGCAACTATGGATGACGAAATAGACAGATCGCTGAGATAGG TGCTTCACTGATTAGCATTGGTAACTGTCAGACCAAGTTACTCATATATACTT ATTGATTTAAACTCATTAAATTAAAGGATCTAGGTGAAGATCTTTTGATAAT CTCTGAGGAAACCTTAACTGAGTTCTGCTTCAACTGAGCTGAGACCCCGTA GAAAAGATCAAAGGATCTTCTGAGATCTTTTGCTGCCGTAACTGCTGCTTGC AAACAAAAAAACACCGCTACACCGGGTGGTTGCTGCCGATCAAGAGCTACAA CTCTTTTCCGAGGTAACTGGCTTCAGCAGAGCGCAGATACAAATACTGTTCT AGTGTAGCGTAGTTAGGCCAACCTTAAGAAACTCTGAGTACCGCTTACACT CGCTCTGCTAATCTGTTACAGTGGCTGCTGCCAGTGGCGATAAGTGTGCTTAC CGGGTTGGACTCAAGACGATAGTACCGGATAAGGGCAGCGGTGGCTGAGC GGGGGTCGACACAGCCAGCTGGAGCAGACACTACACCGAAGTGAGATA CCTACAGCGTGAGTATGAGAAAACGCCAACGCTCCGAAGGGAGAAAGCGG AGGTATCCGGTAAGGGCAGGGTGGAAACAGGAGAGCGCAGGGAGCTCCAG GGGGAAACGCGCTGGTATCTTATGCTGCGGTTGCCACCTCTGACTTGAGC GTCGATTTTGCTGAGCTGTCAGGGGGGGCGAGCTATGGAAAACGCCAGAAC GCGCCTTTTACGGCTTCTGGCTTTGCTGCCCTTGTGCTCACATGGCTTCC GCGGTATCCCTGATTCTGTTGATAACCGTATTACCGCCTTGTGAGTGTGATACC GCTCGCGCAGCGAACGCGACGGCAGCGAGTCAGTGAGCAGGGAGCG AGCGCCCAATACGCAAACCGCCTCCCCGCGCTGGCGATTCTTAATGAGC TGGCAGCAGGGTTCCGACTGGAAAGGGGAGTGAAGCAGCAACGAAATTAGT GAGTTAGCTCACTGATTAGCAGGCCAGGCTTACACTTATGCTTCCGGCTGTAT GTTGAGGAAATTGAGCGATAACAAATTCAACAGGAAACAGCTATGACCATGA TTACGCCAAGCGCGTCAATTAAACCCACTAAAGGGAAACAAAGCTGTTAATTAA
65 Matrice PD1 locus IL15- 2A_sIL15Ra pCLS30513 full sequence	GACTCCCCAGACAGGCCCCCTGGAACCCCCCCCACCTCTCCCCAGCCCTGCTGGT GACCGAAGGGGACACGCCACCTTCACCTGCACTGCTGCTCAACACATCGAGAGCT TCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACAGAGCTGGCGCC TTCCCGAGGACCCAGCCAGCAGCCAGGGCTTCCGCTGTCACACAAAC TGGCAACCTACCTCTGGGGCGGTTCTGGCTGAAACAGACTTGTGATTGGACCT TCTCAAGTTGGCGGGAGACGTGGAGTCAACCCAGGGCCGGTACCGGGTCCG ACCATGGACTGGACCTGGATTCTTCTCTGCTGCTGCTCAACAGAGTGCACAG CGGCACTCATGCTCTGATTCTGGCTGTTCACTGCAAGGGCTTCTAAACACAGAAC CAACTGGGTGAATGATAAGTGTGTTGAAAAAAATTGAAGATCTTATCATTGAGC CATATTGATGCTACTTTATACCGGAAAGTGTGATGTTCAACCCAGTTGCAAAGTAACAG CAATGAAGTGTCTTCTTGTGAGTTACAAGTTGATGTTCACTTGAGTCCGGAGATGCAAG TATTGATGATACAGTAGAAAATCTGATCATCTAGCAAACAAACAGTTGTCTCTAAT GGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAACCTGGAGGAAAAAAATT AAAGAATTGGAGGAGTTGTACATATTGTCACAACTGTTACACACTTCTGGAA

TABLE 5 -continued

Sequences referred to in example 2.

GC GGAGCTACTAACCTCAGCCTGCTGAAGCAGGGTGGAGACGTGGAGGAGAACCT
 GGACCTGGGACCGCGCTGCCAACCATTGGATTGGACGTGGATCTGTTCTCGTGGC
 AGCTGCCACAAGAGTCAAGCATTCAGTATCACGTCGCCCTCCCCCATGTCGTGGAAACAG
 CAGACATCTGGTCAAAGAGCTACAGCTTGTACTCAGGGAGCGGTACATTGTAACT
 CTGGTTCAAGCGTAAAGCGGCCAGTCCAGCCTGACGGAGTGCCTGTTGAACAAG
 GCCACGAATGTCGCCCACTGGACACCCCCAGTCAAAATGCAATTAGAGACCTG
 CCTGGTTCAACAAAAGGCCAGGGCACACCTTCACAGTAACGACGGCAGGGGTGACC
 CCACAGCCAGAGGCTCTCCCTCTGGAAAAGAGCCGCAGCTTACATCTCCAG
 CTCAAAACAACAGCGGCCACAACAGCAGCTATTGTCCGGGCTCCAGCTGATGC
 CTTCAAAATCACCTCCACAGGAACACAGAGATAAGCAGTATGAGTCTCCCACG
 GCACCCCTCTCACAGAACACAGCCAAGACTGGGAACCTACAGCATCGCCTCCAC
 CAGCGCCAGGTGTGTTACACAGGGCACAGGCCACACTGAGGGCAGAGGCA
 GCCTGCTGACTGGCGCACTGCGAGGAGAACCCGGGCCCAGGGTG
 CCACGGCGCCGCGCATGGAGGGCGCTGTGCTGCTTCTGGGGGT
 GTCCCTGGAGGTGCGCAAAGGGCATGCCACAGCCTGTAACACACAGCGGT
 GAGTGTGCAAAGGCTGCAACCTGGCGAGGGTGTGGCCAGGCTTGTGGAGGCA
 ACCAGACCGTGTGTTAGGCCCTGCCTGGACAGCGTGTGACGTTCTCCGACGTGGTGA
 CGCGACCGAGCCGTCAAGCCGTGCCAGGTGGTGGGGCTCAGAGCATGTC
 GCGCGTGTGCTCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGGCCCGA
 AGGATGAGACGACTGGCGTGTGCGAGGCGTGTGCGAGGCGGGCTCG
 GCCTGTTCTCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGGCCCGA
 CGGACAGTATCCGACGAGGCACACCACGGTGGACCCGCTGCCCCGTG
 TGGAGGAGACCCGGAGCGCAGCTGGCGAGGTGCAACAGCTGGCCGACGCCAGT
 GCGAGGAGATCCCTGGCGTTGGATTACAGGTCACACCCCCAGAGGGCTCGGA
 CAGCACAGCCCCAGCACCCAGGAGCCTGAGGACACTCCAGAACAGACCATAG
 CCAGCACGGTGGCAAGTGTGTAACAGTAGTGGAGCTCCAGGCGTGTGG
 GACCCGGGACCCGACAACCTCATCCTGTCATTGCTCCATCTGGCTGCTG
 TGGTTGGGTCTTGTGGCTTACAGCTTCAAGAGGTGATCTAGAGGGCCGTTT
 AAACCCGCTGATCACCTCGACTGTGCTTCTAGTTGCCAGCATCTGTTGGCC
 CCTCCCCCGTGCCCTCTGTGACCTTGGAGGTGCCACTCCATGTCCTTCTAAT
 AAAATGAGGAATTCGATCGCATTGTCTAGTGTGTCATTCTTCTGGGGGTG
 GGGTGGGGCAGGACAGCAAGGGGAGGGATTGGGAGAACATAGCAGGATGTC
 GGATGCGGTGGCTCTATGACTAGTGGCAATTGGCGCAGATCAAAGAGGCGT
 CGGGCAGAGCTCAGGGTGACAGGTGCGGCTCGAGGGCCCGGGGAGGGTGA
 GCTGAGCGCTCCGTGGGTGGTGTCCCCCTCCCTGACAGGATCAGGAGCTCCAG
 GTCTAGGGCAGGGACCCCCAGCTCCAGTCCAGGGCTCTGTCTGCACTGGGG
 AATGGTGACCGGATCTCTGTCTCTAGTCTGAGAACCCCCAGGCCCCCTAGTCT
 GCCCTACCCCTGACCTGACCCCTCACCTGACCCGTCTAACCCCTGACCTT
 GGGATCGTCCCGTGGCGCTACTGGGAGGGCTCACAGGACATCGCCACAGTCCC
 AGAAGTTGGGGGGGGGGTGGGCAATTGAAACGGGTGCTTAGAGAAGGTGGCGGG
 GTTAACACTGGAAAGTGTGCTGTTACTGGCTCGCTTTCCGAGGGTGG
 GAGAACCGTATAAGTGCAGTAGTGCCTGAACGTTTTCGCAACGGGTTTG
 CGCGAGAGCTGGCTGGGCTGCCCCCTGAGCTGGGAGGCTCCATCTCCTCAGG
 CGCCAGAGACACAGTGAAGCTTGGAGGGCTCCATCTCCTCAGG
 CCCCTACCTGAGGGCCCATCCACCCCGTGAAGTCCGTTCTGCCCTCTCCC
 CCTGTGGTGCCTCTGAACTGCGTCGCGTCTAGGTAAGTTAAAGCTCAGTC
 AGACCGGGCTTGTCCGGCGTCCCTTGGAGCTTACCTAGACTCAGGGCTTC
 CACCGTTTGCCTGACCCCTGCTTGTGTCACAACTCAAGTGTGTTTGTGTTCT
 CGCGTTACAGATGACGGGCTTACCTGAGGAGATCACCAGGCCACCA
 TGGCTTCTTACCCCTGGACACAGCATGTTCTGCTTTGACCAAGGGCTGCCAGATCCA
 GGGCCACTCCAACAGGAGAACTGCCCTAAGACCCAGAACAGCAGGAAGGCC
 TGCTGGAGATGCTGTTGACCTCTGCCCAGATCACAATGGAAATGCC
 ATGCTGTGACTGATGCTGTTCTGCCCCCATGAGGGTGTACATTGATGAG
 CTCATGGCATGGGAAGAACCCACACTCAACTGCTGGTGGCACTGGGCTCCAG
 GATGACATTGTGATGTCCTGACCTGACGGTACTGGAGATGCTAGGAGCTCT
 GAGACCATTGGCAACATCTACACCAACCCAGCACAGGCTGGACAGGGAGAACTC
 TGTGAGGAGATGCTGTTGACCTCTGCCCCCATGAGGGTGTACATTGATGAG
 ATGCTGTGACTGATGCTGTTCTGCCCCCATGAGGGTGTACATTGATGAG
 ATGCTGTGACTGATGCTGTTCTGCCCCCATGAGGGTGTACATTGATGAG
 GAGACCATTGGCAACATCTACACCAACCCAGCACAGGCTGGACAGGGAGAACTC
 TGTGAGGAGATGCTGTTGACCTCTGCCCCCATGAGGGTGTACATTGATGAG
 AGACTGGACACTGGGCGATGCTGGCTGCAATCAGAGGGTGTATGGACTGCTGG
 CACTGTGAGATACTCCAGTGTGAGGCTTGGAGAGGGACTGGGAGCAGCT
 CTGAGACAGCAGTGGCCCTCAAGGAGCTGAGGCCCAGTCCAACTGCTGGTCAAGA
 CCCACATGGGGGACCCCCCTGGTACCCCTGGACAGGGCCCTGAGCTGGCTCC
 CAATGGAGACCTGACAATGTGTTGCTGGGCTCTGAGTGTGTTCTAGCCAAGGGCT
 GAGGGCCATGCTGTTGACCTCTGGACTATGACCGACTCCCCTGCTGGATGAG
 ATGCTGTGACTAACCTCTGGCATGGTGCAGACCCATGTCACCCCTGGC
 AGCATCCCCAACCATGTCAGGCTAGCCAGAACCTTGGCAGGGAGATGGGAGAG
 CAACTAAGGGCGCCACTCGAGCCCTAGTGGCCAGACATGATAAGATACATTGAT
 GAGTTGGACAAACCAACTAGAATGCGAGTGGAAAAATGTTTGTGAATTT
 GTGATGCTATTGCTTATTGTAACCTATAAGCTGAATAAACAACTTAACAAACAC
 AATTGCTATTCATTGTTGAGGTTGAGGGGAGGTGAGGGGAGGTTTAAAGCA
 AGTAAACCTCTACAATGTTGATGGAAGGGCGCCCAATTGCCCTATAGTGAGT
 CGTATACGTCGCGCTACTGGCGCTGTTTACACAGCTGACTGGAAAACCT
 GGCCTAACCAACTTAAATGCCCTGCAAGCACATCCCCCTTCGCCAGCTGGCTAAT
 AGCGAAGAGGCCGCCACCGAACCCCCCTCCAAAGTGGCAGCCTGAATGG
 GAATGGGAGGCGCCCTGTAGCGGCCATTAGCGCGCAGGGTGTGGTGGTTACCG
 CAGCGTACACTTGCACCGCCCTAGGCCAGGCCCTGCCCTCGCTTTCTC

TABLE 5 -continued

Sequences referred to in example 2.

	CTTCCTTCTGCCACGTTGCCCGCTTCCCGTCAAGCTAAATGGGGCTCC CTTAGGGTCCGATTAGTGCTTACGCCACCTCGACCCAAAACCTGATTAGG GTGATGGTGGCCTGAGTGGCCATAGCCCTGATAGCGGTTTCGCCCTTGAC GTTGGAGTCCACGTTTAATAGTGGACTCTGTTCCAACACTGGAACAACCTCAAC CCTATCTCGGTCTATTCTTGATTATAAGGGATTGCGATTCGGCTATTGGT TAAAAAATGAGCTATTAAACAAAATTTAACGGAAATTAAACAAAATTTAACGCTT ACAATTAGGCTGCACTTTGGGAAATGCGCGAACCCCTATTGTTTATT CTAATACATTAAATATGATCGCTCATGAGACAATAACCCGTATAATGCTCAA TAATATTGAAAAGGAAGAGTATGAGTATTCAACATTCCGTGCGCCATTCCCT TTTGGCGCATTTGCCCTCCCTTTGCTCACCCAGAAACCGTGGTGAAGTAAA AGATGCTGAGAGTCACTGGGTGACGAGTGGGTTACATGAACTGGATCTCAA GCGGTAAAGTCTTGGAGTTGCCCGAAGAACGTTTCAATGAGTGGACTT TTAAAGTCTGCTATGCGCGGTTATTCGGTATTGACGCCGGCAAGAGCAC TCGTCGCCCATACACTTCTAGAATGACTGGCGAACTACTTACTCTAGCTCCG GCAAAATTAATAGACTGGATGGGCGGATAAAGTTGAGGACCACTCTGCCT CGGCCCTCCGGCTGGCTGGTTATTGCTGATAAAATGGAGCCGGTGGCGTGGT TCTCGGGTATATTGCACTGGGCACTGGGCAAGATGTAAGCCCTCCGTATCGTAGT TATCTACACGAGGGAGTCAGGCAACTATGGATGAAACGAAATAGACAGATCGCTG AGATAGGTCTCAGTATTAGGCACTGGTCACTGTCAGACAAAGTTACTCATATAT ACTTTAGATTGATTAAACTCTATTAAATTTAAAGGATCTAGGTGAAGATCCTT TTGATAATCTGACCAAATCCCTAACGTGAGTTTCGTTCACTGAGGCTCAGA CCCCGTAGAAAGATCAAAGGATCTCTGAGATCCTTTTCTGCGCTAATCTG TGCTTCAACAAAACACCCCTACAGCGTGGTTGTTGCCGATCAAGAG CTACCAACTTTTCCGAAAGTACTGGCTCAGCAGCGCAGATAACAAATACT GTTCTCTAGTGAGCGTAGTTAGGCCACACTCAAGAACTCTGAGCACCC ACATACCTGCTCTGCTAACCTCTGAGCTGGCTGCGAGTGGCGATAAGTC TGTCTTACCGGGTGGACTCAAGACGATGTTACCGATAAGGGCAGGGTGGG CTGAACGGGGGTTGTCGACACAGCCAGCTTGGAGCGAACGACCTACACC CTGAGATACCTACAGCGTAGCTAGAGAAAGGCCACGCTCCGAAGGGAGAA GGCGACAGCTTCCGGAAGGCCAGGGCAGACAGGAGAGCGCACGGG GCTTCCAGGGGAAACGCCCTGGTATCTTATAGTCTGCGGTTGCCACCTCTG ACTTGAGCGTCGATTTTGTGATCTGTCAGGGGGCGAGCTATGGAAAACG CCAGCAACCGGCCCTTTACGGTCTGGCTTGTGCGCTTGTCACTGG TCTTCCGGTTACCCCTGATTCTGATAACCGTATTACGGCTTGTGAGTGAGC TGATCCGGCTCCGGCAGCGAACAGCGCAGCGAGTCAGTGAGCAGGAA GGCGAGAGGCCAATACGAAACCCCTCTCCCGCGGTTGCCGATTCA TGCAGCTGGCACAGGTTCCGACTGGAAAGCGGCAGTGAGCGAACGCAA TTAATGTTGAGTGTGACTCATCTAGGACCCCAGGTTACACTTTATGCTTCCGG TCGTATGTTGAGTGTGAAATTGTCAGCGGATAACAAATTACACAGGAAACAGTATGA CCATGATTACGCCAACGCGTCAATTAAACCTCACTAAAGGGAAACAAAGCTGTTAA TTAA
66 Matrice CD25 locus _IL12a_ 2A_IL12b pCLS30520 full sequence	GTTTATTATCCCTGTCACAGCTATTGTCGCCATATAAAACTTAGGCCAGGCCA GTGGCTCACACCTGTAATCCGACTTTGGAAAGGCCAGGGCAGGCAGATCACAG GTCAGGAGTCGAGACCAGCCTGGCAACATAGAAAACCCATCTACTAAAAAT ACAAAAAATAGCAGCAGCTGGTGTGCACTGGTTAGAGTGAGGACCACTT TTTGGTGGCTGTTACACATATGACCGTGTGACTTGTGTTACACACTACAGGAGGAAG AGTAGAAGAACATCGGTTCTGGCTGAACAGACTTTGAATTGACCTCTCAAGT TGGGGAGACGTTGAGTCAACCCAGGGCCATGTGGCCCTGGCTAGCCTC CCAGCACCCTGGCCACAGCTGGCTAGCATCCAGCGGCTGCCCT GTGTCCTGGCAGTGGCGGCTCAGCATGTGTCAGCGCAGCCCTCTTGTGGC TACCCCTGGCTCTGGACCCACTCAGTTGGCAGAACCTCCCGTGGCACTC CAGACCCAGGAATGTCCTCATGCCCTCACCCTCCAAAACCTGCTGAGGGCGTC AGAACATGTCAGGAAAGGCCAGAACAAACTCTAGAAATTACCCCTGCACTCTGAA GAGATTGATCATGAAAGATACAAAAGATAACCCAGCACAGTGGGGCTGTGTTA CCATTGGAAATACCAAAGAATGAGGTTGCTTAATTCCAGAGAGACCTTCTTCA CTAATGGGAGTTGCTGGCTCCAGAAAGACCTCTTTATGATGCCCTGTGCTTAA GTAGATTATGAGACTGAGTGTACCGGGAGTTCAAGACCATGTAATGCAA AGCTCTGATGGCATCTAACAGGAGATCTTCTAGATCAAACAAACTGCTGGCAGTTA TTGATGAGCTGATGCCCTGAGGCTGACTTCAACACTGAGACTGTC CCCTGAGAACCCGATTTTATAAAACTAAACGCTCTGCTACATTCTCATC TTTCAAGCTTGGGAGTCACTGGGACCTTGGGACCCAGAGCAGTGGAGGCTTGGC AAGGGGAGCTACTAACCTGAGCTGAGCTGGAGGAGACGCTGGAGGAGAAC CTGGACCTATGTCGAGCCAGCTGGTCTCATCTTGGTTTCCCTGGTTCTGG CATCTCCCTCGTGGCCATATGGAAACTGAAGAAGATGTTATGTCGAGAATTGG ATTGGTATCGGATGCCCTGGAAATGGTGGCTCACCTGACACCCCTGAA GAAGATGGTATCACCTGGGACCTTGGGACCCAGAGCAGTGGAGGCTTGGC AACCTGACCATCAGTCAAAGATTGGAGATGCTGCCAGTACACTGTC AGGAGCGAGGTTAACGGCATTGCTCTGCTGCTTCAACAAAAGGAAGATG TTGGTCCACTGATATTAAAGGACCAAGAACCCAAAATAAGACCTTCTAAG ATGCGAGGCAAGAATTATCTGAGCTTCACTGCTGGTGTGACGACAATCAG TACTGATTGACATTGAGTGTCAAAGCAGCAGAGGCTCTCTGACCCCCAAGGG GACGTGCGGAGCTGACTCTGAGAGAGTCAGGAGGACAACAGGAG

TABLE 5 -continued

Sequences referred to in example 2.

TATGAGTACTCAGTGGAGTGCCAGGAGCACGTGCCTGCCAGTGAGGAGA
 GTCGCCATTGAGCTCATGTTGATGCCGTTCAACAGCTCAAGTATGAAACTACA
 CCAGCAGCTTCTCATAGGACATCATCAAACCTGACCCACCCAAAGAACCTGAGC
 TGAAGCCATTAAAGAATTCTCGCAGGTGAGGTCAAGCTGGGAGTACCCCTGACACC
 TGGAGTACTCCACATTCTACTTCTCCCTGACATTCTGCGTTCAAGGTCCAGGGCAAG
 AGCAAGAGAAGAAAAGAAGATAGTCTCAGGACAAAGCCTAGCCACGGTCAT
 CTGCCGAAAGATGGCATCTGTGCCCTGCAGTGAGGAGCAGGGCTACTATAGCTCAT
 CTTGGAGCAGTGGCATCTGTGCCCTGCAGTGAGGAGCAGGGCTGCTGAC
 CTGCGGGAGCTCGAGGAGAACCCCGGGCATGGGGCAGGGTGCACCGGGCG
 CGCATGAGCGGGCGCTGCTGTGCTCTCTGGGGGTGTCCTTGG
 GTGAGGCAAGAGGCATGCCACAGGCGTGTACACACAGCGGTGAGTGTGCA
 AAGCTGCAACCTGGCGAGGGTGTGGCCAGGCTTGTGGAGCAACAGACCGT
 GTGTGAGGCCCTGGACAGCGTGTACGTTCTCCGACGTGGTGAAGCGGACCGAG
 CCGTCAAGCGCAGTGGCATGGCTGGGCTCAGAGCATGTCGGCGCGTGC
 TGGAGGCGATGACGCCGTGCGCTGCGCTACGGCTACTACAGGATGAGAC
 GACTGGCGTGTGGAGGCGTGGCCGTGTGCGAGGGGGCTCGGGCTGTGTT
 CTCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCACCGACGGTAC
 TCCGAGGAGGCCAACCCATGGGACCCGCTGGCTCTGCACCCGGTGGAGGACA
 CCGAGCGCAGCTGGCGAGTGCACACCGTGGGGCAGGCCGAGTGTGCGAGGAGA
 TCCCCTGGCGTTGGATTACACGGTCAACCCCCAGAGGGCTGGACAGCACAGC
 CCCAGCACCCAGGAGCCTGAGGACCTCCAGAACAAAGACCTCATAGCCAGCACG
 GTGAGGCTGTGGTACAGTGTGGGAGCTCCACGGGGTGTGACCCAG
 GCACCAACCTGACATCCCTGCTCATCTGCTGCTGCTGTTGTGG
 GTCTTGTGGCCTACATAGCCTTAAGAGGTGAAAACAAAAGAACAAAGAATTCTT
 GGTAAGAAGCGGGAAACAGAACAGAACAGAACAGTGTGAAACAGGCTCTG
 GCTAAATGGTGCAGGAGAACATCGTTGTGCTTGCTGCGTTTGGAGGCTCTG
 AAGTCACATCACAGGACACGGGAGCTGGGAAACCTTGTCTCATGGCAGCTCAGTC
 CCATCAGAGCGCAGCTACCCACTTCTAAATAGCAATTTCGCGTTGAAGAGGAA
 GGGAAACAAACACTAGAAACTCTCATCTTATTTCATGATATGTGTTATGGCATCGC
 TCCCGTGCCTGCTAGTGGGAGCAGGGCACATGCCACAGTCCCCGAGAGTGG
 GGGAGGGCTGGCAATTGAACGGGTGCTAGAGAAGGGTGGCGGGGTTAAACTG
 GGAAAGTGTGCTGTGACTTGGCTCCGCTTTTCCGAGGGTGGGGAGAACCGT
 ATATAAGTGCAGTAGTCGCGTGAACGTTCTTTCGCAACGGGTTTGCAGGAA
 CACAGCTGAAGCTGAGGGCTCGCATCTCTCCCTACCGGCCGCGCCCTACC
 TGAGGCCATCACCGCGTGGCTGAGTGGCTGGCCCTCCGCTGTGGT
 CCTCTGAATGCGCTCCGCTGCTAGGTTAAAGCTCAGGTCGAGAACGGGC
 CTTTGTCCGCGCTCCCTGGAGGCTACCTAGACTCAGCGGCTCTCACGCTTG
 CCTGACCCCTGCTGCTCACTCTACGTCTTGTGTTCTGTTCTGCGCGGTTAC
 AGATCCAAGCTGTGACCGGGCATACCTGAGATCACCGGCCACCATGGCTTCTT
 ACCCTGGACACCGACATGCTCTGCCTTGGACAGGCTGCGAGATCCAGGGGCAC
 TCCAACAGGAGAACCTGCTTAAGACCCAGAACAGACAGCAGAACCCACTGAG
 GCCTGAGCAGAGATGCCAACCCCTGCTGGGGTGTACATTGTGATGGACCTCATGGCA
 TGGCAAGAACCCACCACTCAACTGCTGGTGTGGACTCTGGCTCCAGGGATGACATT
 GTGATGCTGCGTGAACCTGACCTACTGAGAGCTGCTAGGACCTCTGAGAACCAT
 TGCAACACATCACACCACCCAGCACAGGCTGGACAGGGAGAAATCTGCTGAG
 ATGCTGCTGTTGATGACCTCTGCCAGATCACAAATGGAAATGCCCTATGCTGTA
 CTGATGCTGTTCTGCTCCATCATTGGAGGAGGGCTGGCTCTTCTCATGCCCTC
 CACCTGCCCTGACCCCTGATCTTGACAGAACCCCATGGCAGGCCCTGCTGTGCTACC
 CAGCAGCAAGTACCTCATGGCTCATGACCCACAGGCTGTCGCTGGCTTTGTG
 GCCCTGATCCTCCAACCCCTCCGGACCAACATTGTTCTGGGAGCACTGCCGA
 AGACAGACATGGACAGGCTGGCAAGAGGAGAACACTGGAGAGGAGACTGGAC
 CTGGCCATGCTGGCAATCAGAAGGGTGTATGGACTGCTGGCAAACACTGTGAG
 ATACCTCAAGTGTGGAGGCTCTGGAGAGGGACTGGGACACTCTCTGGAAACAG
 CAGTCCCCCTCAAGGAGCTGAGGCCAGTCCAAATGCTGGTCAAAGACCCACATT
 GGGAGACACTTGTGACCCCTGGTACAGAGGCCCTGAGGCTGCTGCCAAATGGAGA
 CCTGTAACATGTGTTCTGGGACTATGACCTGCTGGGACTGCTGGGAAACACTGTGCT
 GCAACTAACCTCTGGCATGGTGCAGACCCATGTGACCAACCCCTGGCAGCATCCCC
 CCATCTGTGACCTGACCAACCTTGGCAGGAGGATGGGAGAGGCCAACTAACGGC
 GCGGCACTCGAGCCATAGCTGGCAGACATGATAAGATAACATTGTGAGTTGGAC
 AAACACACATAGAATGCAAGTAAAAAATGCTTATTTGTGAAATTGTGATGCTAT
 TGCTTATTGTAACCATATAAGCTGCAATAAACAGTTAACACAAACAAATTGCAATT
 ATTATGTTGCAAGGTTCAAGGGAGGTGTTGGGGTTTTAAAGCAAGTAAACCC
 TCTACAATGTTGAGTGGCAAGGGCGCCAAATTGCGCTTATAGTGTGCTTACG
 TCGGCTCACTGGCGTGTGTTACAACTGCTGACTGGGAAACCCCTGGCTAC
 CCAACTTAATGCCCTGCGACATCCCCCTTGCCTGAGCTGGCTAATAGCGAAGA
 GGGCCGACCGAAAGGCCCTTCCAAACAGTGGCAGGCTGAAAGGGCAATGGGA
 GCGCCCTGCTAGCGCAGTAAAGCGCGGGGTGTTGCGTACGGCAGCGTGA
 CCGCTACACTTGGCAGCGCCCTAGGCCCGGCTCTTCCCTTCCCTTCC
 TCGGACAGTGTGCCGGTTTCCCGTCAAGCTCTAAATGGGGCTCCCTTGG
 TTCCGATTAGTGTGTTACGGCACCTGACCCAAAAACTTGTGTTAGGGTGTGGT
 TGGCTGAGTGGGCTGAGCCCTGATAGACGGTTTTCGCCCCCTTGACGTTGGAGT
 CCACGTTCTTAAATAGTGGACTCTGTTCAAACGGAAACAAACACTCAACCCCTATCTC
 GGCTATTCTTGTGTTATAAGGGATTGCGGATTTGCGCTTGTGTTAAAGGAA
 GAGCTGATTAAACAAAATTAAACCGGAATTAAACAAATTAACCCGTTACATTAA
 GGTGGCACTTTGGGGAAATGTGCGCGGAACCCCTATTGTTATTCTAAATAC
 ATTCAAATGATGCTCATGAGACAATAACCCGATAAAATGCTTCAATAATTGAA
 AAAAGGAAGAGTATGAGTATTCAACATTCCGTTGCGCCCTTATTCCCTTTGCGG

TABLE 5 -continued

Sequences referred to in example 2.

CATTTGCCTCCTGTTTGCTCACCCGAAACGCTGGTGAAGATAAGATGCTGA
 AGATCAGTGGTGGCACAGACTGGTTACATCGAAGCTGGATCTAACACAGGTAAAGA
 TCCTTGAGATTTCGCCCGAAGAACGTTTCAATGATGAGCACTTTAAAGCT
 GCTATGTGGCGGGTATTATCCCCTATTGACGCCGGAAAGACAACTCGGTGCC
 GCATACACTATTCTCAGAATGACTGGTTGAGTACTCACCAGTCACAGAAAAGCATCT
 TACGGATGGCATGAGTAAGAGAATTATGCAAGTGTGCTGCCATAACCCATGAGTGATAA
 CACTGCCCAACTTACTCTGAAACGATCGGAGGACCGAAGGGCTAACCGCTT
 TTTTGACACACATGGGGATCATGTAACCTGCCCTGATCGTGGGAACCGGACTG
 ATGAAGCCATACCAACGACGAGCGTACCCACAGATGCCCTGAGCAATGGCAACA
 ACGTGGCAGAACTTAACTGGCAACTTACTGAGCTTCCCGCAACAAATTAA
 TAGACTGGATGGAGGGGATAAAGTTGCAAGGACACTTCTGCGCTGGCCCTTCG
 GCTGGCTGGTTATTGCTGATAATCTGGAGCCGTGAGCTGGTTCTGCGTAT
 CATTCAGCACTGGGCCAGATGGTAAGGCTCCGTATCGTAGTTACACAGA
 CGGGAGTCAAGGCAACTATGGATAACGAAATAAGACAGATCGTGAGATAGGTGCC
 TCACTGATTAAGCATTGGTAACCTGTCAGACCAAGTTACTCATATATACCTTATTG
 TTAAACACTTCAATTAAAGGATCTAGTGAAGATCTTTTGATAATCTCAT
 GACAAAATCCCTAACGTGAGTTTCTGTTCCACTGAGCGTCAGACCCGTAGAAAA
 GATCAAAGGATCTTCTGAGATCCTTTTCTGCCGCTAATCTGCTGCTGAAACA
 AAAAACCCGCTTACAGCGGTTGGTTGGCGGATCAAGAGCTACCAACTCTT
 TTTCGAAGGTAACCTGGCTTACAGAGCCAGATAACAAATACTGTTCTTAGTG
 TAGCCGTAGTTAGGCCACACTTCAGAACACTCTGAGCACGCCATACCTCGCT
 CTGCTAATCTGTTACCTGGCTGCTGCCAGTGGCATAAGTGTGTTACCGG
 GTTGGACTCAAGCAGTAGTTACCGGATAAGGGCAGCGGTGCGTGAACCGGG
 GGTCTGACACACGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACT
 ACACGCTGAGCTATGAGAAAGGCCACGCTTCCGAAGGGAGAAAGGCCAG
 TATCCGTAAGCGCAGGGTGGAACAGGAGAGGCCAGGGAGCTTCAGGG
 GAAACGCCCTGGTATTTAGTCTGCGGTTTGCACCTCTGACTTGAGCGTC
 GATTGGTGTGATGCTGTCAGGGGGCGGAGCTATGAAAAACGCCAGCAACCG
 GCCCTTTACGGTTCTGGCTTTGCTCACAGGTCTTCTGCGT
 TATCCCCCTGATTCTGTTGATAACCTGATTACCGCTTGTGAGTGAGCTGATACCGCTC
 GCGCAGCGCAACGACCGCAGCGAGCTAGTGAGGGAGAGCG
 CCCAATACGCAACGCCCTCTCCCGCGGTTGCCGATTCAATTATGCACTGGC
 ACAGACAGGTTCCGACTGAAAGCGGCAGTGAGCGCAACGCAATTATGTGAGT
 TAGCTCACTATTAGGCACCCCAGGCTTACACTTATGCTTCCGCTGTATGTTG
 GTGGAATTGTGAGCGATAACAAATTACACAGGAAACAGCTATGACCATGATTACG
 CCAAGCGCTCAATTAAACCCCTACAAAGGAACAAAGCTGTTAATTAA

67 Matrice PD1
 locus_ IL12a_-
 2A_ IL12b
 pCL30511
 full sequence

TCGCGCTTCCGGTGTGACCGTGAACACATGCACTGCAAGCTCCGGAGACG
 GTCACAGCTGTGCTGAAACGGGATGCCGGAGGACAAAGCCCTCAGGGCGGT
 CAGCGGTGTTGGGGTGTGCCCTGGCTTAACATGCGGATCAGAGCAGAT
 TGACTGAGAGTGCACCATATGCCGTGAAATACCGCACAGATGCGTAAGGAGAA
 AATACCGCATCAGGCCATTGCCATTAGGCTGCGCAACTGTGGAGGGCA
 TCGTGCAGGCCCTTCGGTATTACCGCTGGCGAAGTGTGCTGCAA
 CGCGATTAAGTGGTAACGCCAGGTTTCCCACTCACGACCTGTAAAAACGACG
 GCCAGTGAATTGAGCTCGGTACTTCGCAATGCACTGAGACTCCCCAGACAG
 GCCCTGGAACCCCCCACCTCTCCAGCCCTGCTGTGGTACCGAAGGGGAC
 AACGCCCTTCACCTGCACTTCCAAACACATCGGAGAGCTTGTCTAAACCTGG
 TACCGCATGAGCCCCAGCAACCGACCGAAGTGGCCCTCCCGAGGAC
 GCAGCCAGCCGGGAGACTGCCCTCGTGTACACAACACTGCCAACGGGG
 TGACTTCCACATGAGCGTGGTCAAGGCCGGCGCAATGACAGCGCACCTACCT
 GTGGGGCGTTCTGGCGTAAACAGACTTGAATTGACCTTCTCAAGTTGGCG
 GGAGACGTGGAGCTTCAACCCAGGGCCATGTGGCCCTGGTCAGCCTCCAGC
 CACCGCCCTCACCTGCCGCGCACAGGTCTGCATCCAGCGCTGCCCTGTGTC
 CCTGAGTGCCTGCTAGCATGTGTCAGCGCGCAGCCTCTTGTGGCTACCC
 TGGTCTCTGGACCCACCTCAGTTGGCCAGAACCTCCAGGCTGAGGCGACTCCAGAC
 CCAGGAATTGTCCTCACCTCCAGAACACTCTAGAATTTCACCTTGCACTCTGAAGAGAT
 TGATCATGAAGATACACAAAGATAAAACCGACACAGTGGAGGCTGTTACATT
 GGAATTAAACCAAGATGAGAGTTGCTAAATTCAAGGAGACCTTCTACAACTAAT
 GGGAGTTGGCTGGCTCCAGAAAGACCTTTTATGATGGCCCTGTCCTTAGTAGT
 ATTATGAGACTGAGATGTAACCCAGGTTGGAGTCAAGACCATGAAATGCAAAGCTT
 CTGATGGATCCTAAGAGGAGATCTTAGATCAAAACATGCTGGCAGTTATTGAT
 GAGCTGATGAGGGCTGAAATTCAACAGTGGAGACTGTCACAAAAATCTCCCT
 GAAGAACCCGATTATAAAACTAAACAGCTGCAACTTCTGATGCTTCAAGGAG
 GAATTGGGAGTGAAGTGTGAGCTATCTGAATGCTTCCGGAAAGCG
 GAGCTACTAACCTAGCCTGCTGAAGCAGGCTGGAGACGTTGGAGGAGAACCTGGA
 CCTATGTCACCGCAGTGGTATCTTGTGTTTCTGGCATCT
 CCCTCGTGGCCATATGGGAACTGAGAAAGATGTTATGTCGAGAACCCCTGAAGAGAT
 ATCCGGATGCCCTGGAGAAATGTTGGTCTACCTGTCAGACACCCCTGAAGAGAT
 GGTATCACCTGGACCTGGGACAGAGCAGTGGAGGCTTGGCAAAACCT
 GACCATCCAAGTCAAGAGTTGGAGATGCTGCCAGTACACCTGTCACAAAGGAG
 GCGAGGTTCTAAGCCATTGCTCTGCTGCTTCACAAAAAGGAAGATGGAATTGGT
 CCACTGATATTAAAGGAGCAGAAAGAACCCAAAATAAGACCTTCTAAGATGCCA
 GGCAAGAATTATCTGGAGTTTACCTGCTGGTGGCTGACGACAATCAGTACTGA
 TTGACATTGAGTCAACAGCAGGAGAGCTGAGGGACAAACAGGAGTATGAG
 GCGGAGCTGACTACACTCTGCAAGAGAGCTGAGGGACAAACAGGAGTATGAG
 TACTCAGTGGAGTGCCTACAGGAGAGCTGAGGGACAAACAGGAGTATGAG
 CCATTGAGGTCACTGGTGGATGCCCTACAAAGCTCAAGTATGAAAACACCCAGCA

TABLE 5 -continued

Sequences referred to in example 2.

GCTTCTTCATCAGGGACATCATCAAACCTGACCCACCCAAGAACCTGCAGCTGAAGC
 CATTAAAGAATTCTCGCGAGGTGGAGGTAGCTGGGAGTACCCCTGACACCTGGAGT
 ACTCACCATCTCCATTCTCCGACATTCTGCTTCAAGGTCCAGGGCAAGAGCAAG
 AGAGAAAAGAAGATAGACTTCACGGACAAGACCTCAGGCCACGGTCACTCTGCCG
 CAAAAATGCCAGCATAGCTGCCGCCAGGACCGTACTATAGCTCATCTTGA
 GCGAATGGGCATCTGTGCCCTGCAGTGAGGGCAGAGGCAGCCCTGCTGACCTGCCG
 CGACGTGAGGAGAACCCGGGCCATGGGGCAGGTGCCCCGCCAT
 GGACGGGCCGCGCCCTGCTGCTGCTGCTTCTGGGGGTGCCCCCTGGAGGTGCC
 AAGGAGGAGTGCACCCACAGGCCTGTACACACACAGCGGTGAGTGTGCAAAGCCT
 GCAACCTGGGCCAGGGTGTGGCCACGGCTTGTGGAGGCAACCCAGACCGTGTGA
 GCCCTGCCCTGGACAGCGTACGTTCTCCGACGTGGTGAAGCGCACCGAGCGTGC
 AAGCGTGACCGAGTGCCTGGGCTCAGAGCATGTCGGCGCCGTGCGTGGAGG
 CCGATGACGCCGTGCGCTGCCCTACGGCTACTACAGGATGAGACGACTGG
 GCGCTGCCAGGGCTGCCGTGCGAGGGCTCGGGCTCGGGCTCGTGTCTCTGC
 CAGGACAAGCACACCGTGTGCGAGGAGTGCCTGACGGCAGGTATTCCGACG
 AGGCAACACAGTGGACCCGTGCCTGCCCTGCAACCGTGTGCGAGGACACCGAGC
 CCAGCTCCGCGAGTGCACCGCTGGGCCAGCAGGAGTGCAGGGAGATCCCTGCC
 CGTTGATTACACGGTCCACACCCCAGGGCTCGGACAGCACAGCCCCAGCA
 CCCAGGAGCTGAGGCACCTCCAGAACAGACCTCATAGCCAGCACGGTGGCAGG
 TGTGGTGACCAAGCTGATGGGAGCTCCAGGCCGTGGTGAACCGAGGACCAC
 GACAACCTCATCCCTGTCTATTGTCTCATCTGGCTGCTGTGGTGTGGTCTTGT
 GCCTACATAGCTTCAGAGGTGATCTAGAGGGCCGTTAAACCCGCTGATCAGC
 CTCGACTGTGCCCTCTAGTTGCCAGCCATCTGTTGTTGCCCTCCCCGTGCCCT
 CTGACCTGGAAAGGTGCACTCCACTGCTCTTCTTAATAAAATGAGGAATATGC
 ATTCGATTGTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGGCAGGACA
 GCAAGGGGAGGATTGGAAAGAACATAGCAGGATGCTGGGATGCGTGGCT
 TATGACTAGTGGCAATTGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGG
 GTGACAGGTGCGGCCCTGGAGGGCCGGGGCAGGGTGAAGCTGAGCCGGTCTG
 GGGTGGGTGCCCCCTCCGACAGGATCAGGGATCAGGGTCTAGGGCAGGGA
 CCCCCAGCTCAGGCTCAGGCTCTGTCACCTGGGAATGGTGAACCGCAT
 CTCTGCCCTAGGCTGAAAGCACCCAGCCCTCTAGTCTGCCCTCACCCCTGA
 CCCTGACCCCTCACCCCTGACCCCTCTAACCCCTGACCTTGTGCGATCCGG
 CCCGTGACTGCAAGGGCTGCAAGCTGGCGTAATCATGGTATAGCTGTT
 TCCGTGTAATGGTATCCGCTCACAACTCCACACATAGCGGAAAGCAT
 AAAGTGTAAAGGCTGGGGTGCCTAATGAGTAGGTAACCTCACATTAATTGCGT
 CTCAGTGCCTGTTCCAGTGGAAACCTGTCAGCTGCAAGCTTATGAG
 GCCAACCGCGGGAGAGGGGTTGCGTATTGGCGCTTCTCCGCTTCTCGCT
 CACTGACTGCTGCCCTGCGCTGCGCTGCGAGCGGTATCAGCTCACTCAA
 AGGGGTAATACGGTTACCAAGAATCAGGGATAACCCAGGAAGAACATGTGA
 GCAAAAGGCAAGCAAAAGGCAAGGAACCGTAAAAGGCCGTTGCTGGCGTT
 CCATAGGCTGCCCTGACGAGCATCACAAATGACGCTCAACTCAGAGGT
 GGGCAAACCCGACAGGACTATAAGATAACAGGCTTCCCCCTGAAAGCTCCCT
 GTGCGCTCTCTGTCCGACCTCGCGCTTACGGATAACCTGTCGCCCTTCTCC
 TCGGAAAGCTGGGCTTCTCATAGCTCACGCTGAGGTATCTAGTCCGGTGT
 GGTGCTCGCTCCAAGCTGGCTGTGCAAGCAACCCCGTTGAGCCGACCGCT
 GCGCTTATCGGTAACTATCGTTGAGTCCAACCCGTAAGACACGACTTATCG
 CACTGGCAGCAGCACTGGTAACAGGATTAGCAGAGCAGGGTATGAGCGGT
 ACAGAGTTCTGAGTGGTGGCTAAACTACGGCTACACTAGAAGAACAGTATTGG
 ATCTGCGCTGCTGAAGGCCAGTTACCTGGAAAGAGTTGGTAGCTTGTGATCC
 GGCAAAACCAACCGCTGGTAGGGTGGTTTTGTTGCAAGCAGGATACG
 CGCAGAAAAAAAGGATCTAAGAAGATCTTGTATCTACGGGTCTGACGCT
 CAGTGGAAACAAACTCACGTTAAGGGATTGGTCAAGGATTTGAGTATCAA
 TTCACCTAGATCTTTAAATTAAAAAGGTTAAATCAATCTAAAGTATATGA
 GTAAACTGGTCTGACAGTTACCATGTTAATCAGTGGGCAACTTACCGAT
 CTGCTATTCTGTCATCCAGTGTGCTGACTCCCGTGTGAGATAACTACGATA
 CGGGAGGGCTTACCATCTGCCCTCAGTGTGCAATGACCGCGAGACCCACGCT
 ACCGGCTCCAGATTATCAGCAATAAACCAAGCCAGCGGAAGGGCGAGCGAGAA
 GTGGCTCGCAACTTATCCGCTCATCAGTCTTAAATTGTCGCCGGAAAGCTA
 GAGTAAGTCTGCCAGTTAATGTTGCCAACGTTGGCTTGTGAGCTACAGGCA
 TCGTGGTGTACGCTCGTGTGGTATGGCTTATTCAAGCTCCGGTCCCAAGCAT
 CAAGGGAGGTACATGATCCCCCATGTTGCAAAAGCGGTTAGCTCTCGGTC
 CTCCGATCGTGTAGAAGTAAGTGGCCGAGTGTATCACTCATGTTATGGCAG
 CACTGCATAATTCTTACTGTCTGACCCATCCGTAAGATGCTTCTGTGACTGGT
 GTACTCAACCAAGTCTGAGAATAGTGTGAGCGGCCAGGAGTTGCTCTGCC
 GGGCTCAACAGGATAATACCGCGCCACATAGCAGAACCTTAAAGTGTCTACAT
 TGGAAAAGCTCTGGGGGAAACTCTCAAGGATCTTACCGCTGTGAGATCCAG
 TCGATGTAACCCACTGTCACCCACTGATCTTCTTCAATTGAGATCCAG
 GTTCTGGGTGAGCAAAAGGAAAGGCAAAATGCCCAAAAGGGAATAAGGC
 GACACGGAAATGTTGATCTACACTCTCCCTTTCAATATTGAGAAATAAACAA
 AGGGTATTGTCATGAGCGGATACATTTGAGTATTGAGAAATAAACAA
 TATCATGACATTAACCTATAAAATAGGCGTATCACGAGGCCCTTCGTC

TABLE 6

Preferred human endogenous gene loci responsive to T-cell activation						
symbol	description	inductionRatio12 hr	T.8Nve.Sp.OT1	T.8Eff.Sp.OT1. 12 hr.LisOva	T.8Eff.Sp.OT1. 48 hr.LisOva	T.8Eff.Sp.OT1. d6.LisOva
Il3	interleukin 21	16.4	12.8	208.9	18.4	13.6
Il2	interleukin 3	97.0	16.0	1554.4	17.7	18.1
Cc14	isopentenyl-diphosphate delta isomerase 2	2.1	16.8	35.6	17.6	19.7
Il21	granzyme C	9.2	17.4	160.5	20.4	24.9
Gp49a	chemokine (C-C motif) receptor 8	5.9	18.5	108.4	31.5	20.9
Cxcl10	interleukin 2	58.4	21.1	1229.6	32.7	17.9
Nr4a3	interleukin 1 receptor, type I	2.6	21.2	54.6	35.5	21.7
Lilrb4	tumor necrosis factor (ligand) superfamily, member 4	4.1	21.8	88.8	29.3	20.0
Cd200	neuronal calcium sensor 1	4.5	24.1	109.6	46.3	23.2
Cdkn1a	CDK5 and Abl enzyme substrate 1	3.1	26.2	80.9	49.1	32.8
Gzmc	transmembrane and tetratricopeptide repeat containing 2	2.0	26.8	53.9	26.2	29.4
Nr4a2	LON peptidase N-terminal domain and ring finger 1	3.2	28.4	90.4	50.4	28.3
Cish	glycoprotein 49 A	15.0	31.6	472.4	30.6	212.5
Nr4a1	polo-like kinase 2	3.6	31.7	114.3	39.0	32.5
Tnf	lipase, endothelial	2.1	32.4	66.7	35.9	33.3
Ccr8	cyclin-dependent kinase inhibitor 1A (P21)	9.7	34.6	335.4	54.4	71.0
Lad1	grainyhead-like 1 (<i>Drosophila</i>)	2.1	35.1	73.4	52.0	44.1
Slamf1	cellular retinoic acid binding protein II	5.3	35.4	187.2	43.3	36.3
Crabp2	adenylate kinase 4	2.2	35.9	80.4	58.5	39.8
Furin	microtubule-associated protein 1B	2.1	36.2	77.7	36.4	38.4
Gadd45g	acyl-CoA synthetase long-chain family member 6	2.0	37.2	76.0	45.2	41.3
Bcl2l1	zinc finger E-box binding homeobox 2	2.1	38.6	80.7	44.9	455.4
Ncs1	CD200 antigen	9.8	41.2	404.3	70.4	36.8
Ciatr	carboxypeptidase D	3.1	41.6	127.7	71.4	71.6
Ahr	thioredoxin reductase 3	3.6	43.4	157.8	61.7	28.8
Spry1	myosin IE	2.3	43.6	100.2	61.3	77.0
Tnfsf4	RNA binding protein with multiple splicing 2	2.1	43.6	91.5	49.8	36.5
Myo10	mitogen-activated protein kinase kinase 3, opposite strand	2.9	44.8	127.9	66.4	43.1
Dusp5	PERP, TP53 apoptosis effector	2.8	44.9	127.2	78.4	72.4
Myc	myosin X	4.1	45.5	184.9	81.6	57.5
Psrc1	immediate early response 3	2.7	45.6	121.6	63.9	66.2
St6galnac4	folliculin interacting protein 2	2.6	47.5	124.2	87.4	96.6
Nfkbid	leukocyte immunoglobulin-like receptor, subfamily B, member 4	9.9	48.9	483.3	64.5	179.1
Bst2	circadian associated repressor of transcription	4.5	50.6	225.5	100.3	33.8
Txnr3	RAR-related orphan receptor gamma	2.1	51.7	106.7	47.5	52.8
Plk2	proline-serine-rich coiled-coil 1	3.9	52.9	205.9	92.3	79.6
Gf1	cysteine rich protein 2	2.4	54.2	127.7	90.3	182.9
Pim1	cAMP responsive element modulator	2.0	55.7	112.6	54.4	57.3
Pvt1	chemokine (C-C motif) ligand 4	20.2	55.8	1125.8	103.1	89.0
Nfkbb	nuclear receptor subfamily 4, group A, member 2	7.8	58.5	457.6	78.7	72.0
Gnl2	transglutaminase 2, C polypeptide	2.3	58.7	132.1	69.8	64.7
Cd69	synapse defective 1, Rho GTPase, homolog 2 (<i>C. elegans</i>)	2.1	62.5	132.7	111.3	31.0
Dgat2	sprouty homolog 1 (<i>Drosophila</i>)	4.2	63.8	268.5	76.8	61.4
Atf3	activating transcription factor 3	3.2	65.8	210.3	88.3	75.8
Tnfrsf21	pogo transposable element with KRAB domain	2.9	68.6	196.9	91.1	293.2
Lonrfl	tumor necrosis factor receptor superfamily, member 21	3.2	70.6	224.5	126.5	72.9
Cables1	cytokine inducible SH2-containing protein	7.5	74.3	558.7	82.5	133.9
Cpd	lymphotoxin A	2.6	74.6	197.2	93.4	58.6
Qtrtd1	FBJ osteosarcoma oncogene	3.0	74.9	224.1	89.0	61.1
Polr3d	signaling lymphocytic activation molecule family member 1	5.4	75.6	412.0	108.4	190.4
Kcnq5	syndecan 3	2.4	76.0	180.0	77.2	85.3
Fos	mitochondrial ribosomal protein L47	2.1	77.2	161.7	152.0	72.3
Slc19a2	ladinin	5.5	77.3	423.2	152.5	70.4
Hif1a	E2F transcription factor 5	2.5	77.7	198.0	92.0	65.2
Il15ra	ISG15 ubiquitin-like modifier	2.8	77.9	221.0	88.9	45.1
Nfkb1	aryl-hydrocarbon receptor	4.2	78.7	333.2	145.7	91.4
Phlda3	diacylglycerol O-acyltransferase 2	3.2	81.0	259.2	150.0	84.4
Mtrr	FBJ osteosarcoma oncogene B	2.0	81.3	163.7	139.3	98.5
Pogk	pleckstrin homology-like domain, family A, member 3	2.9	84.8	244.5	126.9	83.8
Map2k3os	potassium voltage-gated channel, subfamily Q, member 5	3.0	86.3	261.0	118.1	63.4

TABLE 6-continued

Preferred human endogenous gene loci responsive to T-cell activation						
symbol	description	inductionRatio12 hr	T.8Nve.Sp.OT1	T.8Eff.Sp.OT1. 12 hr.LisOva	T.8Eff.Sp.OT1. 48 hr.LisOva	T.8Eff.Sp.OT1. d6.LisOva
Egr2	tumor necrosis factor receptor superfamily, member 10b	2.5	88.6	219.0	106.1	51.0
Isg15	Mir17 host gene 1 (non-protein coding)	2.1	90.4	190.1	120.0	51.2
Perp	glucose-fructose oxidoreductase domain containing 1	2.2	92.9	208.5	168.7	237.4
Ipo4	plexin Al	2.1	94.8	200.7	118.0	90.3
Mphosph10	heat shock factor 2	2.4	96.8	233.2	191.0	104.8
Plk3	carbohydrate sulfotransferase 11	2.4	96.8	235.1	180.8	385.7
Ifitm3	growth arrest and DNA-damage-inducible 45 gamma	4.8	104.6	504.8	109.3	95.0
Polr1b	solute carrier family 5 (sodium-dependent vitamin transporter), member 6	2.1	107.0	227.3	192.8	75.8
Usp18	interferon induced transmembrane protein 3	2.8	109.2	302.6	43.9	106.4
Top1mt	DENN/MADD domain containing 5A	2.6	109.5	279.9	102.0	517.4
Dck1	plasminogen activator, urokinase receptor	2.1	112.4	234.8	55.7	57.3
Polr1c	solute carrier family 19 (thiamine transporter), member 2	3.0	115.4	343.1	221.7	138.4
Cdk6	ubiquitin domain containing 2	2.2	117.4	255.7	198.9	122.2
Ier3	nuclear receptor subfamily 4, group A, member 3	11.8	118.0	1394.1	114.2	69.6
Lta	zinc finger protein 52	2.5	118.8	295.6	160.9	167.4
Pptrs	SH3 domain containing ring finger 1	2.4	119.3	280.9	116.5	156.5
Fnip2	dihydrouridine synthase 2	2.1	122.7	260.3	237.7	202.8
Asna1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	2.1	122.7	259.3	168.4	124.0
Mybbp1a	processing of precursor 7, ribonuclease P family, (<i>S. cerevisiae</i>)	2.1	125.9	264.9	235.7	150.6
Il1rl1	growth factor independent 1	3.5	126.8	437.7	212.0	156.6
Dennd5a	interleukin 15 receptor, alpha chain	2.9	130.9	380.1	144.3	167.8
E2f5	BCL2-like 1	4.7	133.7	627.4	257.4	231.2
Rcl1	protein tyrosine phosphatase, receptor type, S	2.6	136.6	358.8	157.5	125.0
Fosl2	plasmacytoma variant translocation 1	3.4	136.7	465.5	179.8	140.7
Atad3a	fos-like antigen 2	2.5	137.0	347.5	107.2	177.8
Bax	BCL2-associated X protein	2.5	138.0	347.3	260.1	150.2
Phf6	solute carrier family 4, sodium bicarbonate cotransporter, member 7	2.3	140.3	328.2	258.7	397.5
Zfp52	tumor necrosis factor receptor superfamily, member 4	2.2	141.7	311.1	161.7	111.6
Crtam	chemokine (C—X—C motif) ligand 10	12.7	141.7	1798.3	242.1	59.4
Nop14	polo-like kinase 3	2.8	144.8	406.3	200.1	119.9
Rel	CD3E antigen, epsilon polypeptide associated protein	2.2	158.7	350.2	260.9	111.4
Gramd1b	tumor necrosis factor (ligand) superfamily, member 11	2.1	162.4	342.1	242.1	169.7
Ifi27l2a	polymerase (RNA) III (DNA directed) polypeptide D	3.0	166.3	503.7	296.1	121.6
Tnfrsf10b	early growth response 2	2.8	173.5	494.0	136.3	68.2
Rpl7l1	DnaJ (Hsp40) homolog, subfamily C, member 2	2.1	173.6	369.4	346.2	254.3
Eif1a	DNA topoisomerase 1, mitochondrial	2.7	182.2	498.2	338.6	114.4
Nikb2	tripartite motif-containing 30D	2.3	182.6	423.4	65.8	90.6
Heatrl1	DnaJ (Hsp40) homolog, subfamily C, member 21	2.0	190.1	389.4	285.5	228.2
Utp20	SAM domain, SH3 domain and nuclear localization signals, 1	2.2	191.5	422.1	222.8	304.1
Clst11	solute carrier family 5 (inositol transporters), member 3	2.1	191.6	400.2	210.0	123.4
Ddx21	mitochondrial ribosomal protein L15	2.1	191.6	396.3	329.8	137.7
Hsf2	dual specificity phosphatase 5	4.0	203.5	818.1	307.5	560.7
Bccip	apoptosis enhancing nuclease	2.3	211.1	478.5	288.2	137.9
Tagap	ets variant 6	2.3	218.3	508.1	220.5	297.3
Scd3	DIM1 dimethyladenosine transferase 1-like (<i>S. cerevisiae</i>)	2.2	218.4	486.0	356.0	129.7
Syt13	2'-5' oligoadenylate synthetase-like 1	2.1	229.0	473.3	130.7	124.3
Gtpbp4	UTP18, small subunit (SSU) processome component, homolog (yeast)	2.1	232.0	494.3	384.9	189.5
Crip2	BRCA2 and CDKN1A interacting protein	2.4	234.6	563.3	437.5	269.8
Sh3rf1	synaptotagmin-like 3	2.4	242.4	572.9	316.7	700.7
Nsf1c	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	2.9	245.7	706.5	334.6	150.6
Gtf2f1	URB2 ribosome biogenesis 2 homolog (<i>S. cerevisiae</i>)	2.0	245.7	500.2	489.8	184.6
Slc4a7	ubiquitin-conjugating enzyme E2C binding protein	2.1	251.2	530.5	288.2	85.2

TABLE 6-continued

Preferred human endogenous gene loci responsive to T-cell activation						
symbol	description	inductionRatio12 hr	T.8Nve.Sp.OT1	T.8Eff.Sp.OT1.12 hr.LisOva	T.8Eff.Sp.OT1.48 hr.LisOva	T.8Eff.Sp.OT1.d6.LisOva
Etv6	lysine (K)-specific demethylase 2B	2.2	251.8	547.1	332.7	262.1
Trim30d	queueine tRNA-ribosyltransferase domain containing 1	3.0	260.3	788.7	358.0	75.5
Ddx27	ubiquitin specific peptidase 31	2.0	265.2	533.2	277.1	176.2
Pwp2	eukaryotic translation initiation factor 2-alpha kinase 2	2.0	267.7	540.5	260.8	244.8
Chchd2	ATPase family, AAA domain containing 3A	2.5	268.8	679.7	523.1	147.1
Myo1e	adhesion molecule, interacts with CXADR antigen 1	2.3	269.5	610.9	272.9	182.8
Eif5b	SUMO/sentrin specific peptidase 3	2.0	272.5	548.7	544.5	298.4
Stat5a	ESF1, nucleolar pre-rRNA processing protein, homolog (<i>S. cerevisiae</i>)	2.2	276.3	610.4	482.2	266.5
Cops6	deoxyribonucleotidyltransferase, terminal, interacting protein 2	2.1	282.9	600.4	359.9	326.1
D19Bwg1357e	TGFB-induced factor homeobox 1	2.1	300.5	618.9	217.5	210.6
Aatf	eukaryotic translation initiation factor 1A	2.5	300.8	738.7	597.7	262.8
Aen	interferon-stimulated protein	2.1	305.7	651.2	144.3	138.4
Amica1	pleiomorphic adenoma gene-like 2	2.1	311.5	651.9	376.2	405.9
Wdr43	PWP2 periodic tryptophan protein homolog (yeast)	2.3	321.8	743.3	586.5	189.3
Cet4	furin (paired basic amino acid cleaving enzyme)	5.2	329.7	1728.3	271.7	421.5
Nifk	tumor necrosis factor	6.6	330.7	2188.4	489.9	213.3
Tgfm2	apoptosis antagonizing transcription factor	2.3	331.4	754.8	523.1	221.5
Erol1l	interferon, alpha-inducible protein 27 like 2A	2.5	334.0	828.1	296.0	221.4
Gfod1	ST6 (alpha-N-acetyl-neuraminy1,2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4	3.9	338.4	1311.3	636.0	298.2
Ak4	methyltransferase like 1	2.2	339.4	744.7	662.8	94.5
Sdad1	notchless homolog 1 (<i>Drosophila</i>)	2.0	339.4	690.3	610.3	158.1
Dimt1	mitochondrial ribosomal protein L3	2.1	340.0	725.5	651.4	359.8
Esf1	UBX domain protein 2A	2.1	343.8	732.9	532.1	428.5
Cd3eap	guanine nucleotide binding protein-like 2 (nucleolar)	3.2	347.6	1124.7	647.4	227.5
Samsn1	programmed cell death 11	2.0	353.9	711.8	435.9	287.4
Tnfrsf4	cyclin-dependent kinase 8	2.0	364.0	731.1	702.5	346.2
Mettl1	eukaryotic translation initiation factor 5B	2.3	365.1	838.2	544.5	355.5
Cd274	RNA terminal phosphate cyclase-like 1	2.5	373.3	948.8	746.4	155.8
Ubtd2	NSFL1 (p97) cofactor (p47)	2.3	374.1	876.1	725.9	369.7
Icos	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, delta	3.9	378.5	1465.1	389.9	224.0
Kdm2b	M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein)	2.8	379.8	1069.3	738.4	290.8
Larp4	GRAM domain containing 1B	2.5	382.7	949.6	363.4	659.2
Eif3d	ERO1-like (<i>S. cerevisiae</i>)	2.2	387.7	872.3	773.0	520.9
Tnfaip3	nuclear receptor subfamily 4, group A, member 1	6.8	387.8	2639.0	343.7	220.7
Map1b	surfeit gene 2	2.1	399.8	852.2	696.3	204.0
Cdv3	N(alpha)-acetyltransferase 25, NatB auxiliary subunit	2.1	405.7	847.3	669.5	194.1
Plac8	yrdC domain containing (<i>E. coli</i>)	2.0	406.7	830.8	635.3	267.0
Mrpl3	La ribonucleoprotein domain family, member 4	2.2	408.8	887.9	586.6	358.3
Surf2	SDA1 domain containing 1	2.2	419.8	939.9	631.4	284.7
Ubxn2a	importin 4	2.8	420.3	1183.6	777.8	173.5
Utp18	inducible T cell co-stimulator	2.2	423.9	920.9	818.8	796.9
Isg20	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1	2.1	439.4	934.4	842.6	344.6
Dnajc2	arsA arsenite transporter, ATP-binding, homolog 1 (bacterial)	2.6	446.6	1165.0	717.9	963.9
Jak2	polymerase (RNA) I polypeptide C	2.7	447.8	1208.4	854.0	295.9
Slc2a1	spermatogenesis associated 5	2.0	450.8	920.2	516.0	361.6
Syde2	ubiquitin specific peptidase 18	2.7	451.8	1240.5	296.0	250.7
Slc5a6	placenta-specific 8	2.1	452.4	967.3	888.6	590.8
Dnttip2	general transcription factor IIF, polypeptide 1	2.3	454.8	1063.9	890.0	680.8
Idi2	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta	3.4	456.4	1535.5	679.1	502.7
Dus2	PHD finger protein 6	2.5	462.0	1159.5	775.8	510.4
Pitrm1	RRN3 RNA polymerase I transcription factor homolog (yeast)	2.1	462.2	948.4	913.2	388.9
Plxna1	cytotoxic and regulatory T cell molecule	2.5	473.7	1177.8	586.8	431.8
Cdk5r1	COP9 (constitutive photomorphogenic)	2.3	483.6	1101.9	947.8	560.3
Ube2cbp	homolog, subunit 6 (<i>Arabidopsis thaliana</i>) asparagine-linked glycosylation 3 (alpha-1,3-mannosyltransferase)	2.1	485.9	1006.3	758.7	339.4

TABLE 6-continued

Preferred human endogenous gene loci responsive to T-cell activation						
symbol	description	inductionRatio12 hr	T.8Nve.Sp.OT1	T.8Eff.Sp.OT1. 12 hr.LisOva	T.8Eff.Sp.OT1. 48 hr.LisOva	T.8Eff.Sp.OT1. d6.LisOva
Tnfsf11	tryptophanyl-tRNA synthetase	2.0	486.1	987.1	897.1	504.7
Pop7	hypoxia up-regulated 1	2.0	494.3	996.6	802.4	690.3
Psme3	family with sequence similarity 60, member A	2.0	500.8	1002.1	834.7	417.6
Mir17hg	bone marrow stromal cell antigen 2	3.8	502.5	1922.9	925.5	246.0
Tsr1	nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100	2.4	503.2	1231.8	494.0	341.8
Rbpms2	UTP20, small subunit (SSU) processome component, homolog (yeast)	2.4	510.5	1240.2	696.4	245.8
Mrpl47	CD274 antigen	2.2	516.6	1128.7	246.9	220.2
Rab8b	proviral integration site 1	3.4	518.4	1766.4	676.9	970.0
Plagl2	signal transducer and activator of transcription 5A	2.3	530.0	1210.4	496.6	507.8
Grib1	CD69 antigen	3.2	535.7	1725.8	289.5	153.9
Zeb2	pitrilysin metallopeptidase 1	2.1	544.9	1153.8	968.4	349.3
sept-02	cyclin-dependent kinase 6	2.7	550.3	1476.5	1064.0	642.1
Slc5a3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 27	2.3	556.2	1286.9	987.2	480.4
Naa25	polymerase (RNA) I polypeptide B	2.8	556.2	1536.0	1070.4	201.3
Plaur	tumor necrosis factor, alpha-induced protein 3	2.2	560.6	1212.2	255.5	446.0
Metap1	nodal modulator 1	2.1	563.0	1161.0	988.9	439.8
Alg3	NOP14 nucleolar protein	2.5	570.9	1418.9	925.3	398.0
Mrpl15	ribosomal protein L7-like 1	2.5	586.7	1448.7	1030.2	687.2
Oasl1	methionyl aminopeptidase 1	2.1	597.5	1244.1	1139.3	433.4
Rorc	hypoxia inducible factor 1, alpha subunit	3.0	624.2	1854.6	809.4	838.4
Nomo1	Janus kinase 2	2.1	624.5	1328.7	390.6	917.8
Tgif1	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	2.9	661.5	1913.3	713.9	720.5
Lipg	reticuloendotheliosis oncogene	2.5	678.9	1686.4	409.8	580.5
Rrn3	septin 2	2.1	687.3	1436.0	1354.1	1181.3
Dnajc21	nucleolar protein interacting with the FHA domain of MKI67	2.3	733.4	1658.2	1280.0	407.2
Yrdc	elongation factor Tu GTP binding domain containing 2	2.0	739.3	1483.5	1439.0	904.3
Acsl6	myelocytomatosis oncogene	4.0	761.0	3022.8	1064.0	211.5
Spatas5	dyskeratosis congenita 1, dyskerin	2.7	778.2	2112.0	1549.5	484.2
Urb2	camitine deficiency-associated gene expressed in ventricle 3	2.1	801.6	1718.2	1274.7	1010.3
Nlel	GTP binding protein 4	2.4	824.2	1942.6	1578.7	567.3
Wars	HEAT repeat containing 1	2.4	830.3	2020.6	1235.5	495.4
Crem	proteaseome (prosome, macropain) activator subunit 3 (PA28 gamma, Ki)	2.1	838.4	1763.5	1471.1	936.1
Larp1	La ribonucleoprotein domain family, member 1	2.0	861.7	1742.1	1250.9	854.3
Eif2ak2	DNA segment, Chr 19, Brigham & Women's Genetics 1357 expressed	2.3	868.6	1978.4	1218.0	653.4
Hyou1	eukaryotic translation initiation factor 3, subunit D	2.2	909.1	1971.6	1641.9	920.6
Senp3	TSR1 20S rRNA accumulation	2.1	913.9	1915.9	1474.6	477.2
Tmtc2	MYB binding protein (P160) 1a	2.6	1140.0	2962.9	2200.7	459.8
Fosb	T cell activation Rho GTPase activating protein	2.4	1176.7	2794.4	489.3	704.2
Pcd11	RAB8B, member RAS oncogene family	2.1	1189.5	2492.2	1671.3	2512.5
Usp31	DEAD (Asp-Glu-Ala-Asp) box polypeptide 21	2.4	1210.2	2928.0	2221.1	1098.2
Cdk8	chaperonin containing Tcp1, subunit 4 (delta)	2.3	1321.4	2989.7	2462.5	1294.8
Eftud2	coiled-coil-helix-coiled-coil-helix domain containing 2	2.3	1374.2	3171.2	2636.9	1008.9
Fam60a	WD repeat domain 43	2.3	1727.6	3912.6	2927.5	1014.9

TABLE 7

Selection of preferred endogenous genes that are constantly active during immune cell activation (dependent or independent from T-cell activation).

Symbol	Gene description
CD3G	CD3 gamma
Rn128s1	28S ribosomal RNA
Rn18s	18S ribosomal RNA
Rn7sk	RNA, 7SK, nuclear
Actg1	actin, gamma, cytoplasmic 1

TABLE 7-continued

Selection of preferred endogenous genes that are constantly active during immune cell activation (dependent or independent from T-cell activation).

Symbol	Gene description
B2m	beta-2 microglobulin
Rpl18a	ribosomal protein L18A
Pabpc1	poly(A) binding protein, cytoplasmic 1
Gapdh	glyceraldehyde-3-phosphate dehydrogenase
Rpl19	ribosomal protein L19

115

TABLE 7-continued

Selection of preferred endogenous genes that are constantly active during immune cell activation (dependent or independent from T-cell activation).

Symbol	Gene description
Rpl17	ribosomal protein L17
Rplp0	ribosomal protein, large, P0
Cfl1	cofilin 1, non-muscle
Pfn1	profilin 1

TABLE 8

Symbol	Gene description
Il3	interleukin 3
Il2	interleukin 2
Ccl4	chemokine (C-C motif) ligand 4
Il21	interleukin 21
Gp49a	glycoprotein 49 A
Nr4a3	nuclear receptor subfamily 4, group A, member 3
Lilrb4	leukocyte immunoglobulin-like receptor, subfamily B, member 4
Cd200	CD200 antigen
Cdkn1a	cyclin-dependent kinase inhibitor 1A (P21)
Gzmc	granzyme C
Nr4a2	nuclear receptor subfamily 4, group A, member 2
Cish	cytokine inducible SH2-containing protein
Ccr8	chemokine (C-C motif) receptor 8
Lad1	ladinin
Crabp2	cellular retinoic acid binding protein II

TABLE 9

Symbol	Description
Gzmb	granzyme B
Tbx21	T-box 21
Pcd1	programmed cell death 1
Plek	pleckstrin
Chek1	checkpoint kinase 1
Slamf7	SLAM family member 7
Zbtb32	zinc finger and BTB domain containing 32
Tigit	T cell immunoreceptor with Ig and ITIM domains
Lag3	lymphocyte-activation gene 3
Gzma	granzyme A
Wee1	WEE 1 homolog 1 (S. pombe)
Il12rb2	interleukin 12 receptor, beta 2
Cer5	chemokine (C-C motif) receptor 5
Eea1	early endosome antigen 1
Dtl	denticleless homolog (Drosophila)

TABLE 10

Symbol	Gene description
Spata6	spermatogenesis associated 6
Itga6	integrin alpha 6
Rcbtb2	regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2
Cd1d1	CD1d1 antigen
St8sia4	ST8 alpha-N-acetyl-neuraminate alpha-2,8-sialyltransferase 4
Itgae	integrin alpha E, epithelial-associated
Fam214a	family with sequence similarity 214, member A

116

TABLE 10-continued

Selection of genes that are down-regulated upon immune cell activation.

Symbol	Gene description
Sle6a19	solute carrier family 6 (neurotransmitter transporter), member 19
Cd55	CD55 antigen
Xkrx	X Kell blood group precursor related X linked maturin, neural progenitor differentiation regulator homolog (Xenopus)
Mturn	H2-Ob
10	Cnr2
	Itgae
	Raver2
	Zbtb20
	Arrb1
	Abca1
	Tet1
	Slc16a5
15	Trav14-1
	Ampd3
	T cell receptor alpha variable 14-1
	adenosine monophosphate deaminase 3

TABLE 11

Symbol	Gene description
Zfp640	zinc finger protein 640
LOC100038422	uncharacterized LOC100038422
Zfp600	zinc finger protein 600
Serpib3a	serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 3A
Tas2r106	taste receptor, type 2, member 106
Magea3	melanoma antigen, family A, 3
Omt2a	oocyte maturation, alpha
Cpxcr1	CPX chromosome region, candidate 1
Hsf3	heat shock transcription factor 3
Pbsn	Probasin
Sbp	spermine binding protein
Wfdc6b	WAP four-disulfide core domain 6B
Meiob	meiosis specific with OB domains
Dnm3os	dynamin 3, opposite strand
Skint11	selection and upkeep of intraepithelial T cells 11

TABLE 12

List of gene loci upregulated in tumor exhausted infiltrating lymphocytes (compiled from multiple tumors) useful for gene integration of exogenous coding sequences as per the present invention

Gene names	Uniprot ID (human)
CXCL13	O43927
TNFRSF1B	P20333
RGS2	P41220
TIGIT	Q495A1
CD27	P26842
55	TNFRSF9
	SLA
	INPP5F
	XCL2
	HLA-DMA
	FAM3C
	WARS
	EIF3L
	KCNK5
	TMBIM6
	CD200
	C3H7A
	SH2D1A
60	ATP1B3
	O60880
	O60880
	P54709
65	

TABLE 12-continued

List of gene loci upregulated in tumor exhausted infiltrating lymphocytes (compiled from multiple tumors) useful for gene integration of exogenous coding sequences as per the present invention

Gene names	Uniprot ID (human)
THADA	Q6YHU6
PARK7	Q99497
EGR2	P11161
FDFT1	P37268
CRTAM	O95727
IFL16	Q16666

TABLE 13

List of gene loci upregulated in hypoxic tumor conditions useful for gene integration of exogenous coding sequences as per the present invention

Gene names	Strategy	
CTLA-4	KO/KI	Target shown to be upregulated
LAG-3 (CD223)	KO/KI	in T-cells upon hypoxia exposure
PD1	KO/KI	and T cell exhaustion
4-1BB (CD137)	KI	
GITR	KI	
OX40	KI	
IL10	KO/KI	
ABCB1	KI	HIF target
ABCG2	KI	
ADM	KI	
ADRA1B	KI	
AK3	KI	
ALDOA	KI	
BHLHB2	KI	
BHLHB3	KI	
BNIP3	KI	
BNIP3L	KI	
CA9	KI	
CCNG2	KI	
CD99	KI	
CDKN1A	KI	
CITED2	KI	
COL5A1	KI	
CP	KI	
CTGF	KI	
CTSD	KI	
CXCL12	KI	
CXCR4	KI	
CYP2S1	KI	
DDIT4	KI	
DEC1	KI	
EDN1	KI	
EGLN1	KI	
EGLN3	KI	
ENG	KI	
ENO1	KI	
EPO	KI	
ETS1	KI	
FECH	KI	
FN1	KI	
FURIN	KI	
GAPDH	KI	
GPI	KI	
GPX3	KI	
HK1	KI	
HK2	KI	
HMOX1	KI	
HSP90B1	KI	
ID2	KI	
IGF2	KI	
IGFBP1	KI	
IGFBP2	KI	
IGFBP3	KI	
ITGB2	KI	
KRT14	KI	
KRT18	KI	
KRT19	KI	

TABLE 13-continued

List of gene loci upregulated in hypoxic tumor conditions useful for gene integration of exogenous coding sequences as per the present invention

5	Gene names	Strategy
LDHA	KI	
LEP	KI	
LOX	KI	
LRP1	KI	
10 MCL1	KI	
MET	KI	
MMP14	KI	
MMP2	KI	
MXI1	KI	
NOS2A	KI	
NOS3	KI	
15 NPM1	KI	
NR4A1	KI	
NTSE	KI	
PDGFA	KI	
PDK1	KI	
PFKFB3	KI	
20 PFKL	KI	
PGK1	KI	
PH-4	KI	
PKM2	KI	
PLAUR	KI	
PMAIP1	KI	
25 PPP5C	KI	
PROK1	KI	
SERPINE1	KI	
SLC2A1	KI	
TERT	KI	
TF	KI	
30 TFF3	KI	
TFRC	KI	
TGFA	KI	
TGFB3	KI	
TGM2	KI	
TP11	KI	
35 VEGFA	KI	
VIM	KI	
TMEM45A	KI	
AKAP12	KI	
SEC24A	KI	
40 ANKRD37	KI	
RSBN1	KI	
GOPC	KI	
SAMD12	KI	
CRKL	KI	
EDEM3	KI	
45 TRIM9	KI	
GOSR2	KI	
MIF	KI	
ASPH	KI	
WDR33	KI	
DHX40	KI	
50 KLF10	KI	
R3HDM1	KI	
RARA	KI	
LOC162073	KI	
PGRMC2	KI	
ZWILCH	KI	
55 TPCN1	KI	
WSB1	KI	
SPAG4	KI	
GYS1	KI	
RRP9	KI	
SLC25A28	KI	
60 NTRK2	KI	
NARF	KI	
ASCC1	KI	
UFM1	KI	
TXNIP	KI	
MGAT2	KI	
65 VDAC1	KI	
SEC61G	KI	

TABLE 13-continued

List of gene loci upregulated in hypoxic tumor conditions useful for gene integration of exogenous coding sequences as per the present invention

Gene names	Strategy	5
SRP19	KI	
JMJD2C	KI	
SNRPD1	KI	
RASSF4	KI	

SEQUENCE LISTING

Sequence total quantity: 80

SEQ ID NO: 1 moltype = DNA length = 1000
 FEATURE Location/Qualifiers
 misc_feature 1..1000
 note = PD1 left homology
 source 1..1000
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 1
 ccaaggccctg accctggcag gcataatgttt caggagggtcc ttgttcttggg agcccagggt 60
 cggggggcccc ctgttgttcc acatccgagt caatggccca ttcgttctt gaagcatctt 120
 tgcgtgtgacg tcttagtcccc actgttcttgc tggaaaatgt ggaggccca ctgcccactg 180
 cccaggggcag caaatggccat accacgtgtt cccagctccg agcttgcctt gaaaagggg 240
 caaagactgg accctgagcc tcggcaagggg ccacactctt cccagggtcg gggtttcatt 300
 gggcagcccc ccacccaccc agaccatgtt cacttcccttg tgccagagca gtgcagacag 360
 gaccaggcoca ggatgccccaa gggtcagggg ctggggatgg gtagccccca aacagccctt 420
 tctggggggaa ctggccctaa cggggaaagggg ggtgaaggctt cttagtagga aatcagggg 480
 acccaactgca gagccagggtt ctgtgcggaaa gtcgcagccat cacgttagaa gaagaggctc 540
 tgcgtgtggg ggcgtgttcc accccgggtt ggcagaggcc ccacgagaga cttctcaatg 600
 acatccacgc tgggggtggcc ctcccagago ctttgcgtcc cgagggatgt gaggcagggtg 660
 cccggggaggc ttgtgtgggc caccctggcc cttccctacc tctctccatc tctcagactc 720
 cccagacagg ccctggaaacc ccccccaccc tctccctggcc ctgcgtgtgg tgacccgaagg 780
 ggacaacgcg accttcacctt gcaggttcc acacacatcg gagagttcg tgctaaactg 840
 gtaccgcatg accccccaggca accagacggca caagctggcc gccttccccc aggaccgcag 900
 ccagcccccgc caggactgcc gccttccgtgt cacacaactg cccaaacgggc gtgacttcca 960
 catgagcggtt gtcaggggcc ggcgaatga cagcggcacc 1000

SEQ ID NO: 2 moltype = DNA length = 1000
 FEATURE Location/Qualifiers
 misc_feature 1..1000
 note = PD1 right homology
 source 1..1000
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 2
 ggcgtggcc agagctcagg gtgacagggtt cggccttggg ggccccgggg caggggttag 60
 ctgagccgggt cttgggggtgg gtgttccctc ctgcacaggaa tcaggagctc cagggtcgta 120
 gggcaggggac ccccccacgtc cagtcagggtt ctgtgttccg caccctgggg aaatgtgaccg 180
 gcatctctgtt ctcttagtc tggaaagcacc ccaccccttc tagtgcctt tcacccctga 240
 ccctgaccctt ccacccctgtac cccgttccaa ccctgtacc ttgttccctt ccagagagaa 300
 gggcagaagt gcccacagcc cacccttggcc ctttgcgtcc ggcacccggc cagttccaaa 360
 ccttgggtgtt ttgtgtcggtt gggggctgc tggggcgtt ggtgtcgta gtctgggtcc 420
 tggccgtcat ctgtcccccgg ggcacccgtt gtaacgtcat ccacccccc ctgcgtgtcc 480
 tgcctttaacc ctgtgtgggg cccttactcc cgcctccccc tcttccaccc ttccctcaacc 540
 ccaccccccacc tccccccatc tccccggccat gctaagtccc tggatgtggcc ccctggacta 600
 agaccccccacc ccttagggacca cgggttcagggtt tgggttcagggtt gaccccaatgt gtgtttctt 660
 gcaggggaccaa taggaggccat ggcacccggc cagcccccgtt tgatgttcac tcttttctgt 720
 catgtatccat tttttttttcc ttcctgggtt ggcacagggtt gaaaggacccat ctggggaccc 780
 acggccctgca ggacttcacat tcttattatag ccaggacccc acctccccccag ccccccaggca 840
 gcaacacctaa tcccttaaaggc catgtatccat ggcacccggc caccctgggtt ctccgggggt 900
 gcccggccca tttttttttcc ttcctgggtt cttccagggtt ggcacccggc cgggtgtggcc 960
 cgcctgggtt ctctgggggtt gcccggccca catatgtgc 1000

SEQ ID NO: 3 moltype = DNA length = 2781
 FEATURE Location/Qualifiers
 misc_feature 1..2781
 note = PD1_T3C-L2
 source 1..2781
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 3
 atggggcgtt cttttttttcc ttcctgggtt cttccagggtt ggcacccggc cgggtgtggcc 60
 tacagccaggc agcaacaggaa acgttacggcc atcgatatcg ccgtatctacg caccgtccggc 120

-continued

```

cacgaggcac tggtcggcca cgggttaca caegcgcaca tcgttgcggt aagccaacac 180
ccggcagcgt tagggaccgt cgctgtcaag tatcaggaca tgatcgacg gttccagag 240
gcgacacacg aagcgatcgt tggcgctggc aaacagtggt cggcgacacg cgctctggag 300
gccttgcata cgggtggggg agagttgaga ggtccacccgt tacagtggc cacaggccaa 360
cttctcaaga ttgcggaaaacg tggcgctgt acccgactggg aggccgtcga tgcatggcgc 420
aatgcactga cgggtggccc getcaacttg accccccggc aagtgggtgc tatecgctcc 480
aagctggggg gaaagcaggc cctggagacc gtccaggccc ttctcccaact gctttgcag 540
getcacaaggc tgaccctgt aacaggatggt gcaattgcct cacacgacgg gggcaagcag 600
gcactggaga ctgtccacggc gctgtgcgt gtctctgcg aggccccccg actcaactcc 660
gagcaggatcg tggccatcgc cagccacgt gggggcaaac aggetctggc gaccgtgcag 720
cgccctcccg cagtgtgtg ccaggctcat gggctgaccc cacagcagggt cgteccatcc 780
gccagtaacg cggggggggaa gcaggccctc gaaacagtgc agaggtgtg gcccgttgg 840
tgccaaagc acggcgatgc acccggagcc gtgtggccca tgcccttca tgacggccgc 900
aaggaggccc ttgagacatg cagagactg ttgcccgtgt tggtcaggg ccacgggttg 960
acaccccaage aggtggtcgc catggccacg aatggcgggg gaaagcaggc ctttgagacc 1020
gtgcagegggt tgcttcagt gttgtccag gCACACGGGAGC TGACGGCCGC 1080
gaaatcgccca gctacaaggc cggaaaggc gctctggaga cagtgcaggc cctctggcc 1140
gtgtgtgtc aggtcacaaggc actgcacca cagcagggtgc tgeccatcgc cagaacaggg 1200
ggccggcaaggc aggttggtaa gaccgttccg agactccctc ccgtcccttg ccaggccac 1260
gggttgacac ctgcaggggt cgtgcatttgc gcttccaaaca acggggggca gcaaggccctc 1320
gaaactgtgc agaggctgtc gcctgtgtc tgccaggctc atgggtgtc accccgacag 1380
gtgtgtggca ttgcctctaa caacggccgc aaacaggcact ggagacccgt gcaaaagggtg 1440
ctgcccgtcc ttcgtccaaacg ccacggccgc actccacacg aggttgtgc categcccta 1500
aacaatggcg ggaaggcaggc cttggagact gtccaaaggc tgctccctgt gctctggcag 1560
gcacacggac tgacccttca gcagggtgggt gcaatcgctt ccaacaaaggc gggaaaggcag 1620
gcctcgtccaa cctgtccgcg ccttcgttca gtgtgtgcg aggccatgg cctcacaccc 1680
gagcaatggc tggctatcgc cagccacgt gggggggggc aggtctggc gaccgtgcag 1740
aggtgtgtc ctgtctgtg ccaggccac gggcttactc cagageagggt cgteccatcc 1800
gccagtcatg atggggggggaa gcaggccctt gagaacgttcc acgggtgtg gccagtctt 1860
tgcagggtc acgggtgtc tccggagccgt gtgtgtggca ttgccttcaaa cattggggc 1920
aaacaggccc tggagacatg cggggccctg ctggccctgt tggtcaggg ccacggcttg 1980
acaccccaage aggtggtcgc cattgcctt aatggcgccg ggagacccgc ctttgagacc 2040
attgttgcg cgttgcgtcc ccctgtatccg cgttgcgtcc ctttgatccaa cgaccaccc 2100
gtgcgttccg cttgcgtccgg cgggggtgtc gggctggatc ctttgatccaa ctttgatcc 2160
gtatctatca gccgttccca gctgtgtggaa tccggagctgg aggagaaatgggatgggg 2220
aggcacaaggc tgaagtacgt gccccacgtg tacatcgacg tgatcgatg cggccggaaac 2280
agcacccagg accgtatccct ggagatgtaa gtgtgtggat ttttcatgaa ggtgtacggc 2340
tacaggggca cggccatggg cgggggtgtc aaggccgtgg ggcggcatctc caccgtggc 2400
tccccatctc actacggcg tgcgtggac accaaggccctt actccggccg ctacaactc 2460
cccatcgccc aggccgacgt aatgcagagg tacgtggagg agaaccagac cagaacaaag 2520
cacatcaacc ccaacagggt gttggagggtg tacccttca gctgtgaccg gttcaaggcc 2580
ctgttcgtgt cggccactt caaggccaaatc acaaggccc agtgcacccg gtcgaaccac 2640
atccaccaact gcaacggcgc cgtgtgtcc gttggagggtc ttctgtatccg cggccgatgt 2700
atcaaggccg gcaaccctgtac cttggagggtc gttggagggtc agttcaacaa cggccgatgt 2760
aacttcggcg ccgactgtata a 2781

```

SEQ ID NO: 4 moltype = DNA length = 2778
 FEATURE Location/Qualifiers
 misc_feature 1..2778
 note = PD1T3R
 source 1..2778
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 4
 atgggcgatc ctaaaaagaa acgtaaggcgt atcgatatcg ccgtatcgtc cagcgccgc 60
 tacagccaggc agcaacaggc gaagatcaaa ccgaagggtt gttcgacatg ggcgcagcac 120
 cacgaggcac tggtcggcca cgggttaca cacgcgcaca tcgttgcggt aagccaacac 180
 cccggcagcgt tagggaccgt cgctgtcaag tatcaggaca tgatcgacg gttccagag 240
 gecacacacg aagcgatcgt tgccgtggcc aacagtggt cggcgccacg cgctctggag 300
 gccttgcata cgggtggggg agagttgaga ggtccacccgt tacagtggc cacaggccaa 360
 cttctcaaga ttgcggaaaacg tggcgctgtg acccgactgg aggccgtcga tgcatggcgc 420
 aatgcactga cgggtggccctg cttccatgtc aaccccgacg aagtgtccgc aatcgccacg 480
 catgtgggg ggaaggcaggc cctcgaaacc gtcgacgggt tgcttcctgt gctgtgcac 540
 gcccacggcc ttacccctca ccgggtgggt gccatcgcaaa gtaacgggg aggaaaggca 600
 gccttggaga cagtgcaggc cttgtgtccg gtcgtgtccg aggccacccg cttcacacca 660
 gagcaggatcg tggccatgtc cttccatgtc gggggggaaa aggctctggc gaccgtccag 720
 aggtgtgtc cggccatctgtc tcaagcttccg ggcgttgcgtt cccaaacttggtccatc 780
 gcctctaaatg cggggggggaa gcaaggactgc agagactgtt ccctgtgttt 840
 tgccaaatgtc atgggtgtac cttccatgtc gtcgtgtccg ttgccttcaaa cggggggggc 900
 aagcaggccc ttggactgtt gcaaggactgt ttgcctgtcc tggtgtcaggc tcacggccctc 960
 actccacaaac aggtgtgtcgc aattggccago aacggccggc gaaacaaatc tcttggaaacc 1020
 gtgcacggcc tcctgtccgt gtcgtgtccg tgacaccaca acaagtctgt 1080
 gccatcgccca gtaataatgg cggggaaacag gtcgtgtccg gtcgtgtccca 1140
 gtgtgtgtcc accgcacacgg gtcgtgtccg gtcgtgtccg tggctatccg cagaatatt 1200
 gggggcaaggc aaggccctggc aacagtcccg gccctgtccg cagtgttccg ccaggctcac 1260
 gggctcaactc cccaggcagggt cgtggcaatc gcctccaacg gcgaggggaa gcaaggctgt 1320
 gagaccgtgc agagactgtt gcccgttccg acggactcac acctgtacac 1380
 gtgcgtccca ttgcctctca cgtatggggc aaacaaggccc ttggagacatg gcaaggccgt 1440
 ttgcctgtgt tggtccaaacg ccacggcttg actccatgtc aacgtgtccg categcccta 1500

-continued

aatggcggcg gaaaacaaga tctggagaca gtgcagagggt tgctgcccgt cctctgcca 1560
 gcccacggcc tgactccccca acaggctgctc gccattgcca gcaacaacgg agggaaacgg 1620
 gctctcgaaa ctgtgcagcg gctgtttctt gtgctgtgtc aggctcatgg gctgaccgg 1680
 gagcaagtgg tggcttattgc ctctaattggaa ggcaaggcaaa cccttgagac agtccagagg 1740
 ctgttgcagg tgctgtgcctt ggccacccggg ctccacacccc agcagggtgt cgccatcgcc 1800
 agtaacaacg ggggcaaaaca ggcattggaa accgttccage gctgtttcc agtgccttc 1860
 caggcacacg gactgacacc cgaacagggtg gtggccattt catccatga tggggggcaag 1920
 caggcccctgg agaccgtgca gagactctgtt ccagtgttgtt gccaagctca cggccctcacc 1980
 cctcagcaag tcgtggccat cgcctcaaa gggggggggcc ggcctgact ggagagcat 2040
 gttggccagttatctcgccc tgatccgggg ttggcccggt tgaccaacga ccacctcgctc 2100
 geccttggcgt gctcggccgg ggcgtctgtcg ctggatcgat tgaaaaagggtt attgggggat 2160
 cctatcagcc gttcccaagct ggtgaagttt gagctggaggaga agaagaatac cgagttgagg 2220
 cacaacgtgaa agtacgtggcc ccacggatgtc atcgatcgcc cggaaacacg 2280
 acccaggacc gatcgatggaa gatgaagggtt atggagttt tcatggatgtt gtaaggctac 2340
 agggggcaacg acctggccgg ctccggaaag cccgacggccg ccattctacac cgtgggtcc 2400
 cccatcgact acggcggtat cgtggacacc aaggctactt cggcgccctaa caacctggcc 2460
 atcggccaggcc cggacggaaat gcaaggatgtc gtggaggaga accagacccg gaacaacgac 2520
 atcaacatccaa acggatgtgtt gaaaggatgtc ccctccagcg tgacccggat ttcaatgtc 2580
 ttctgttccg gccacttcaaa gggcaactac aaggccccccgg tgacccggat gaaaccatc 2640
 accaactgca acggggccgt gctgtccgtt gaggagttcc tgatccgggg cggatgtatc 2700
 aaggccggca ccctgaccctt ggaggaggtt aggaggaaatgt tcaacaacgg cgagatcaac 2760
 ttccggccgg actgataa 2778

SEQ ID NO: 5 moltype = DNA length = 49
 FEATURE Location/Qualifiers
 misc_feature 1..49
 note = PD1-T3
 source 1..49
 mol_type = other DNA
 organism = synthetic construct
 SEQUENCE: 5
 tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagaga 49

SEQ ID NO: 6 moltype = DNA length = 60
 FEATURE Location/Qualifiers
 misc_feature 1..60
 note = 2A-element
 source 1..60
 mol_type = other DNA
 organism = synthetic construct
 SEQUENCE: 6
 tccgggtagg gcagagggaaat tcttctaaaca tgcgggtacg tggaggagaaat tccggggccc 60

SEQ ID NO: 7 moltype = DNA length = 1989
 FEATURE Location/Qualifiers
 misc_feature 1..1989
 note = apoptosis CAR
 source 1..1989
 mol_type = other DNA
 organism = synthetic construct
 SEQUENCE: 7
 gctttgcgtt tcaactgcctt gctgtttcca ctggctctgt tggtgcacgc cgcaagaccc 60
 gaggtcaagc tccaggaaag cggaccagggtt ctgggtggccc cttagtcatgc attggatgtc 120
 acttgcaccc tcaatggcggtt gtcttgcctt gattacggcg tgagctggat cagacagcccc 180
 ccaaggaaagg gacttggatgtt gctgggggtt atctggggggat ggcggactac ctactacaac 240
 agcggccctgtaa agaggatgtt gaccatcattt aaggacaactt ccaatgttcca ggttttttg 300
 aaaatgaaca gcttcggacac tgatgacactt gccatctactt acttgcggccaa gcattactac 360
 taatggggccat gatcgatctt ggactactgg gggcaggggat cctctgttccat agtgcgtcaat 420
 ggccggggggat gcaatggcggtt agggggaaat gggggccggcc gcaatggatccat ccagatggacc 480
 cagacacat ccatgttccat cgccttctgtt ggcggacaaat tgacatcgat ctggccggcc 540
 agtccggatca tcaatggatgtt taccatcgatc aaccatcgatc gacatgtaaa 600
 ttctgtatctt accacatccat caggatgttccat tcaatggatgtt ccagatgttccat 660
 ggctccggatccat caggatgttccat tcaatggatgtt ccagatgttccat 720
 taatcttgcctt accatgttccat tcaatggatgtt ccagatgttccat 780
 attactcggtt cggatccatccat cggatccatccat cggatccatccat cggatccatccat 840
 ccaggccatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 900
 ctcatgtatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 960
 cctgtggatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1020
 ccggccggggatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1080
 caggacttgcgtt tgaatggatgtt ggacttgcgtt tgaatggatgtt ccaacaaatccat cttccatccat 1140
 cccatcgatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1200
 ctggcccccattt cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1260
 ggcttttccatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1320
 tacaatgttccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1380
 accgtggatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1440
 gcccctgttccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1500
 ttgggggtggccat tttttttccatccat cggatccatccat cggatccatccat cggatccatccat 1560
 gaagttccatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1620
 acctttaatccat cggatccatccat cggatccatccat cggatccatccat cggatccatccat 1680

-continued

accactattg ctggagtcat gacactaagt caagttaaag gctttgttcg aaagaatgg 1740
 gtcaatgaag cccaaaataga tgagatcaag aatgacaatg tccaagacac agcagaacag 1800
 aaaagttcaac tgcttcgtaa ttggcatcaa cttcatggaa agaaaqaagc gtatgacaca 1860
 ttgattgcag atctcaaaaa agccaatctt tgtactctt cagagaaaaat tcagactatc 1920
 atctctcaagg acattactag tgactcgaa aattcaaact tcagaaaatga aatccagagc 1980
 ttgggtcgaa 1989

SEQ ID NO: 8 moltype = DNA length = 276
 FEATURE Location/Qualifiers
 misc_feature 1..276
 note = BGH polyA
 source 1..276
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 8
 tctagagggc ccgtttaaac ccgctgatca gcctcgactg tgccttctag ttgccagcca 60
 tctgttgtt gcccctcccc cgtgttcc ttgaccctgg aagggtccac tcccaactgtc 120
 ctttctaat aaaaatggaa aattgcatcg cattgtctga gtatgtcata ttctattctg 180
 ggggggtgggg tggggcagga cagaacgggg gaggattggg aagacaatag caggcatgtc 240
 ggggatgcgg tgggctctat gactagtggc gaattc 276

SEQ ID NO: 9 moltype = DNA length = 1000
 FEATURE Location/Qualifiers
 misc_feature 1..1000
 note = Lck left homology
 source 1..1000
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 9
 gggatagggg gtgcctctgt gtgtgtgtg gagagtgtgt gtgtgttaggg tttgtatatg 60
 tataagggtgt gtgtgagtgt gtgtgtgtg gagagtgtgt gtgtggcaga atagactgcg 120
 gaggtggatt tcatcttgat ataaagggtc tggaatgc tggatcattaa actttgggaa 180
 cagcgccttc caagcaactt gaggaggcgc ccttagagaag gaggagctgc agggactccg 240
 ggggcttcaaa agtggggcc ccactctgtc tccaggcaaaa caggcacaca ttttacactt 300
 tattctatggaa gtctctgtt atttcatcg aaaaaaaaaat tccactgtca aaacaggcaa 360
 ataaacaaaa aaaaatgtt gccaacaca gtcactgggg gggtttctgc tggggagaaag 420
 caagccctgtg tttgaaggaa ccctgtgaga tgactgtggg ctgtgtgagg ggaacagccg 480
 gggcttctgtg gtggacttgc ggacggaaag ccctttcttc acgttccatca gctagacagg 540
 ggaattataaa taggagggtgt ggcgtgcaca cccttccaggat aggggggggt ctgataagt 600
 aggtcttc caggcttggg aaatgtgtgt tcatctctag gaggtgtgtcc tcccaacaca 660
 gggtaactggc agagggagag ggaggggggca gaggcaggaa gtgggtactt agactaaca 720
 aggtgcctgtt ggcggatttgc ccatcccaagg tgggggggtt gggcttgggc tcaggggccg 780
 tttgtgtattt tacttgcatt ctggggcgc agagggagca ccgttgggaa gctggggaccc 840
 ccatttttag cttttgcatt gctgtgtt gggatccca ggatctcaca atctcaggta 900
 cttttggaaat ttccaggcc aaggccccat tatatctgtat gttggggag cagatcttgg 960
 gggagccctt tcagccccctt ctccattcc ctcaggacc 1000

SEQ ID NO: 10 moltype = AA length = 219
 FEATURE Location/Qualifiers
 REGION 1..219
 note = Interleukin-12 subunit alpha
 source 1..219
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 10
 MCOPARSLLLV ATLVLDDHLS LARNLPVATP DPGMFPCLLH SQNLLRAVSN MLQKARQTL 60
 FYPCTSEIID HEDITKDKTS TVEACLPLEL TKNESCLNSR ETSFITNGSC LASRKTSFMM 120
 ALCLSSIIYED LKMYQVEFKT MNAKLLMDPK RQIFLDQNMQL AVIDELMQAL NFNSETVPQK 180
 SSLEEPDFYK TKIKLCILLH AFRIRAVTID RVMSYLNAS 219

SEQ ID NO: 11 moltype = AA length = 328
 FEATURE Location/Qualifiers
 REGION 1..328
 note = Interleukin-12 subunit beta
 source 1..328
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 11
 MCHQQLVISW PSLVFLASPL VAIWELKKDV YVVELDWYPP APGEMVVLTG DTPEEDGITW 60
 TLDQSSEVLG SGKTLTIQVK EFGDAGQYTC HKGGEVLSHS LLLLHKKEDG IWSTDILKDQ 120
 KEPKNKTFLR CEAKNYSGRF TCWWLTTIST DLTFSVKSSR GSSDPQGVTC GAATLSAERV 180
 RGDNKEYEYS VECQEDSACP AAEESLPIEV MVDAVHKLKY ENYTSSFFIR DIIKPDPPKN 240
 LQLKPLKNSR QVEVSWEYPD TWSTPHSYFS LTFCVQVQGK SKREKKDRVF TDKTSATVIC 300
 RKNASISVRA QDRYYSSSSWS EWASVPCS 328

SEQ ID NO: 12 moltype = DNA length = 1000
 FEATURE Location/Qualifiers
 misc_feature 1..1000
 note = lck right homology

-continued

gggcggatca	cctgaggctca	ggagttaag	accagcctga	ccaacatgga	gaaacccgtc	420
tctactaaa	atacaaatt	agcttggct	gggttgtcat	gcctgtata	ccagctactc	480
gagaagctga	ggcaggagaa	ttgttgaac	ctggggaggtg	gagggtcg	tgaggccaga	540
tcgcaccatt	gcactccacg	ctgggcaaca	agagtgaat	tgcacatcaa	aaaaaaagaa	600
aaggaaataa	tctataccag	gcactccaag	tggtgtgact	gatattcaac	aagtacctc	660
agtgtgacct	taccattgat	gaagaccaag	attcttttg	attgtgtc	acactgtgcc	720
agttaaatat	tcgcacatt	accctgcct	gtgggcttc	agtgcctgac	tttgatgtcc	780
tttcacccat	caacccgtag	ggatgacca	ccgggaggtg	attcagaacc	tggagcgagg	840
ctaccgcacat	gtgcgcctg	acaactgtcc	agaggagctg	taccaactca	tgaggctgtg	900
cttggaaaggag	gcggccac	cggcccccac	cttgcactac	ctgcgcagtg	tgcgtggagga	960
cttcttcacg	gocacagagg	ggcgcacacg	gcgcacgc	gcctgcgtcc	tttgcgtcc	1000

SEQ ID NO: 15	moltype = DNA	length = 1000				
FEATURE	Location/Qualifiers					
misc_feature	1..1000					
	note = lck right homology					
source	1..1000					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 15						
gaggccttga	gaggccttgg	ggttctccc	cttctctcc	agcctgact	ggggagatgg	60
agttcttgg	ccatagtac	atggctatg	ccatatggaa	ctctgcacat	gaatccacc	120
cacatgtgc	acatatgcac	cttgcgtctg	tacacgtgtc	ctgtatgtgc	gtggactctg	180
cacatgtctt	gtacatgtgt	agcctgtgca	tgtatgtctt	ggacactgta	caaggatccc	240
cttctgcct	ctccatcc	ctggagaccac	agagagagg	gagaagctcg	ggatggacag	300
aagcttgc	ccacatactt	ttcttcctc	agatcatac	caaggttcctc	aaggggccagg	360
acttttatcc	ataccatgt	gtgttcctc	ttgggtgc	gtctggcaca	catcaggat	420
tcaataaatg	tctgttgc	actgttgc	atctttgtc	tgtccact	ttgtgggtgg	480
gcagttgggg	ttaaaaaat	ggtaatttgg	tcaccctgag	ttgggtgaa	agatggatg	540
agtggatgtc	tggggctct	gcagacccc	tcaaatgg	cagtgtct	cacccctccc	600
caaaggatcc	atgggtgactc	tacccatgg	ttccatgg	aatgggtgcg	tcaaaaggacc	660
ttctccccc	ttataaaaagg	gcaacagcat	ttttactga	ttcaaggct	atattgtacc	720
tcagatttg	ttttttttaag	gctagtcaaa	tgaagcgc	ggaatggagg	aggaacaaat	780
aaatctgtaa	ctatccat	ttttttt	tttttgcaga	ctgggttca	cttttcatc	840
caggcggag	tgcagtgcg	tgcacacgg	tactgtgac	ctcaacctc	ccagctcaaa	900
tgctccctc	gtctcagc	ccc	ggactact	ttcttgag	caggaattca	960
agaacagagt	aaatctgttgg	tctccaaaaa	aaattttaaa			1000

SEQ ID NO: 16	moltype = AA	length = 936				
FEATURE	Location/Qualifiers					
REGION	1..936					
	note = TALEN TRAC					
source	1..936					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 16						
MGDPKKKRKV	IDALPYDVPDY	AIDIADLRTL	GYSQQQQEKI	KPKVRSTVAQ	HHEALVGHGF	60
TAHIVALSQ	HPAALGTVAV	KYQDMIAALP	EATHEAIVGV	GKQWGSARAL	EALLTVAGEL	120
RGGPLQLDTG	QLLKIAKRGG	VTAVEAVHAW	RNALTGAPLN	LTPQQVVAIA	SNNGGKQALE	180
TVQRLLPVLC	QAHGLTPQQV	VAIASNNNGK	QALETVQRL	PVLQAHGLT	PQQVVAIASN	240
GGGKQALETV	QAHGLTPQVQ	IASHDGKQAA	LETVQRLLPV	LCQAHGLTPE	300	
QVVAIAHS	HDGKQALETVQ	LLPVLCQAHG	LTPEQVVAIA	SHDGGKQALE	TVQRLLPVLC	360
QAHGLTPEQV	VAIASNIGGK	QALETVQALL	PVLQAHGLT	PEQVVAIA	DGGKQALETV	420
QRLPVLQVLC	HGLTPQVQVVA	IASNINGGKQAA	LETVQALLPV	LCQAHGLTPE	QVVAIASNN	480
GKQALETVQ	LLPVLCQAHG	LTPEQVVAIA	SNIGGKQALE	TVQALLPVLC	QAHGLTPQQV	540
VAIASNNGGGK	QALETVQRL	PVLQAHGLT	PEQVVAIASN	IGGKQALETV	QALLPVLCQAA	600
HGLTPQVVAIA	IASNGGGKQAA	LETVQRLLPV	LCQAHGLTPE	QVVAIAHS	GKQALETVQ	660
LLPVLCQAHG	LTPQQVVAIA	SNGGGRPALE	SIVAQLSRPD	PALAA	LVALACLGGR	720
PALDAVKKGGL	GDPISRSQVL	KSELEKKSE	LRHKLK	YVPH	EYIELIEIAR	780
KVMFFMKVY	GYRGKHLGGG	RKDPAIYT	GSPIDYGVIV	DTKAYSGYN	LPIGOADEMQ	840
RYVEENQTRN	KHINPNEWWK	VYPSSVTEFK	FLFVSGHFKG	NYKAQLTRLN	HITNCNGAVL	900
SVEELLIGGE	MIKAGTLTLE	EVRRKFNNGE	INPAAD			936

SEQ ID NO: 17	moltype = AA	length = 942				
FEATURE	Location/Qualifiers					
REGION	1..942					
	note = TALEN TRAC					
source	1..942					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 17						
MGDPKKKRKV	IDKETAAKE	ERQHMDSIDI	ADRTLGLG	QQQEKKIKPKV	RSTVAQHHEA	60
LVGHGFTTHAH	IVALSQHPAA	LGTVAVQYQD	MIAALPEATH	EAVVGVQKQW	SGARALEALL	120
TVAGELRGPP	QLQDTQQLLE	IAKRGGVTA	EAVHAWRNAL	TGAPLNLTPE	QVVAIAHS	180
GKQALETVQ	LLPVLCQAHG	LTPQQVVAIA	SNNGGKQALE	TVQRLLPVLC	QAHGLTPQEV	240
VAIASHDGKQAA	QALETVQRL	PVLQAHGLT	PEQVVAIASN	IGGKQALETV	QALLPVLCQAA	300
HGLTPQVVAIA	IASNNNGGKQAA	LETVQRLLPV	LCQAHGLTPE	QVVAIAHS	GKQALETVQ	360
LLPVLCQAHG	LTPQQVVAIA	SNNGGKQALE	TVQRLLPVLC	QAHGLTPQPV	VAIASNNGGK	420
QALETVQRL	PVLQAHGLT	PQQVVAIASN	NGGKQALETV	QRLPVLCQAA	HGLTPQVVAIA	480

-continued

IASNNGGGKQA LETVQRLLPV LCQAHGLTP E QVVAIASNIG GKQALETVQA LLPVLCQAHG 540
 LTPEQVVAIA SHDGGKQALE TVQRLLPVLC QAHLGLTPQE V VAIASNIGGK QALETVQALL 600
 PVLCQAHGLT PEQVVAIA SHDGGKQALE TVQRLLPVLC QAHLGLTPQE V VAIASNIGGK QALETVQALL 660
 LETVQRLLPV LCQAHGLTPQ QVVAIASNGG GRPALESIVA QLSRPDPALA ALTNDHLVAL 720
 ACLGGRPALD AVKKGLGDP1 SRSVLKVS EL EEEKSSELRH K KYVPMHEYIE LIETARNSTQ 780
 DRILEMKVME FFMKVYGYRG KHLGGSRKP GAIYTVGSPI DYGVIVDTKA YSGGGYNLPIG 840
 QADEMQRVYE ENQTRNKHIN PNEWWKVYP SVTEFKFLFV SGHFKGNYKA QLTRLNHITN 900
 CNGAVLSVEE LLIGGEMIKA GTLTLEEVR KFNNNGEINF AAD 942

SEQ ID NO: 18 moltype = AA length = 913
 FEATURE Location/Qualifiers
 REGION 1..913
 note = TALEN CD25
 source 1..913
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 18
 MGDPKKKRKV IDYPYDVPDY AIDIADLRTL GYSQQQQEKI KPKVRSTVAQ HHEALVGHGF 60
 THAHIVALSQ HPAALGTVAV KYQDMIAALP EATHEAIVGV GKQWGSARAL EALLTVAGEL 120
 RGPPPLQLDTG QLLKIAKRGG VTAVEAVHAW RNALTGAPLN LTPQQVVAIA SNNGGGKQALE 180
 TVQRLLPVLC QAHLGLTPQV VAIASNNGGK QALETVQRL P VLQCAHGLT PQQVVAIASN 240
 GGGKQALETV QLLPVLQCA HGLTPEQVVA IASHDGKQAE LETVQRLLPV LCQAHGLTPQ 300
 QVVAIASNGG GKQALETVQR LLPVLCQAHG LTPQQVVAIA SNNGGGKQALE TVQRLLPVLC 360
 QAHLGLTPQV VAIASNNGGK QALETVQRL P VLQCAHGLT PQQVVAIASN GGGKQALETV 420
 QRLPVLQCA HGLTPEQVVA IASNNNGGKQAE LETVQRLLPV LCQAHGLTPQ 480
 GKQALETVQR LLPVLCQAHG LTPQQVVAIA SNNGGGKQALE TVQRLLPVLC QAHLGLTPQV 540
 VAIASNNGGK QALETVQRL P VLQCAHGLT PQQVVAIASN GGGKQALETV QRLLPVLQCA 600
 HGLTPEQVVA IASNNNGGKQAE LETVQRLLPV LCQAHGLTPE QVVAIASHDG GKQALETVQR 660
 LLPVLCQAHG LTPQQVVAIA SNNGGRPALE SIVAQLSRPD PSGSGSGCDP ISRSLVKSE 720
 LEEKKSELRH K KYVPMHEYI ELIEIARNST QDRILEMKVME E FF MVYGYR GKHLLGGSRKP 780
 DGAITYTVGSP IDYGVIVDTK AYSGGYNLPI QGADEMQRVY EENQTRNKHIN NPNEWWKVYP 840
 SSVTEFKFLF VSGHFKGNYK AQLTRLNHITN NCNGAVLSVE ELLIGGEMIK AGTLTLEEVR 900
 RKFNNNGEINF AAD 913

SEQ ID NO: 19 moltype = AA length = 913
 FEATURE Location/Qualifiers
 REGION 1..913
 note = TALEN CD25
 source 1..913
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 19
 MGDPKKKRKV IDYPYDVPDY AIDIADLRTL GYSQQQQEKI KPKVRSTVAQ HHEALVGHGF 60
 THAHIVALSQ HPAALGTVAV KYQDMIAALP EATHEAIVGV GKQWGSARAL EALLTVAGEL 120
 RGPPPLQLDTG QLLKIAKRGG VTAVEAVHAW RNALTGAPLN LTPEQVVAIA SNIGGGKQALE 180
 TVQALLPVLQCA QAHLGLTPQV VAIASHDGK QALETVQRL P VLQCAHGLT PEQVVAIASN 240
 IGGKQALETV QLLPVLQCA HGLTPEQVVA IASNNNGGKQAE LETVQRLLPV LCQAHGLTPQ 300
 QVVAIASNNG GKQALETVQR LLPVLCQAHG LTPEQVVAIA SNIGGGKQALE TVQALLPVLQCA 360
 QAHLGLTPQV VAIASNNGGK QALETVQRL P VLQCAHGLT PQQVVAIASN NGGKQALETV 420
 QRLPVLQCA HGLTPEQVVA IASNNNGGKQAE LETVQALLPVC LCQAHGLTPE QVVAIASNIG 480
 GKQALETVQR LLPVLCQAHG LTPQQVVAIA SNNGGGKQALE TVQRLLPVLC QAHLGLTPQV 540
 VAIASNNGGK QALETVQALL P VLQCAHGLT PQQVVAIASN NGGKQALETV QRLLPVLQCA 600
 HGLTPEQVVA IASNNNGGKQAE LETVQRLLPV LCQAHGLTPE QVVAIASNIG GKQALETVQA 660
 LLPVLCQAHG LTPQQVVAIA SNNGGRPALE SIVAQLSRPD PSGSGSGCDP ISRSLVKSE 720
 LEEKKSELRH K KYVPMHEYI ELIEIARNST QDRILEMKVME E FF MVYGYR GKHLLGGSRKP 780
 DGAITYTVGSP IDYGVIVDTK AYSGGYNLPI QGADEMQRVY EENQTRNKHIN NPNEWWKVYP 840
 SSVTEFKFLF VSGHFKGNYK AQLTRLNHITN NCNGAVLSVE ELLIGGEMIK AGTLTLEEVR 900
 RKFNNNGEINF AAD 913

SEQ ID NO: 20 moltype = AA length = 936
 FEATURE Location/Qualifiers
 REGION 1..936
 note = TALEN PD1
 source 1..936
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 20
 MGDPKKKRKV IDYPYDVPDY AIDIADLRTL GYSQQQQEKI KPKVRSTVAQ HHEALVGHGF 60
 THAHIVALSQ HPAALGTVAV KYQDMIAALP EATHEAIVGV GKQWGSARAL EALLTVAGEL 120
 RGPPPLQLDTG QLLKIAKRGG VTAVEAVHAW RNALTGAPLN LTPEQVVAIA SKLGGKQALE 180
 TVQALLPVLQCA QAHLGLTPQV VAIASHDGK QALETVQRL P VLQCAHGLT PEQVVAIASH 240
 DGGKQALETV QRLPVLQCA HGLTPEQVVA IASNNNGGKQAE LETVQRLLPV LCQAHGLTPE 300
 QVVAIASHDG GKQALETVQR LLPVLCQAHG LTPQQVVAIA SNNGGGKQALE TVQRLLPVLC 360
 QAHLGLTPQV VAIASNNGGK QALETVQRL P VLQCAHGLT PEQVVAIASN GGGKQALETV 420
 QRLPVLQCA HGLTPEQVVA IASNNNGGKQAE LETVQRLLPV LCQAHGLTPQ QVVAIASNNG 480
 GKQALETVQR LLPVLCQAHG LTPQQVVAIA SNNGGGKQALE TVQRLLPVLC QAHLGLTPQV 540
 VAIASNNGGK QALETVQRL P VLQCAHGLT PEQVVAIASH DGGKQALETV QRLLPVLQCA 600
 HGLTPEQVVA IASHDGKQAE LETVQRLLPV LCQAHGLTPE QVVAIASNIG GKQALETVQA 660
 LLPVLCQAHG LTPQQVVAIA SNNGGRPALE SIVAQLSRPD PALAALTNHD LVALACLGG 720

-continued

PALDAVKKGL GDPISRSQLV KSELEEKKSE LRHKLKYVPH EYIELIEIAR NSTQDRILEM	780
KVMEFFMKVY GYRGKHLGGS RKPDAIYT VSPIDYGVIV DTKAYSGGYN LPIQADEMQ	840
RVVEENQTRN KHINPNEWWK VYPSSVTEFK FLFVSGHFKG NYKAQLTRLN HITNCNGAVL	900
SVEELLIGGE MIKAGTLTLE EVRRKFNNGE INFAAD	936

SEQ ID NO: 21 moltype = AA length = 941
 FEATURE Location/Qualifiers
 REGION 1..941
 note = TALEN PD1
 source 1..941
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 21
 MGDPKKRKV IDKETAAAKF ERQHMDSDI ADLRTLGYSQ QQQEKKPKV RSTVAQHHEA 60
 LVGHGPRTTHA IVALSOHPAA LGTVAVKQD MIAALPEATH EAIVGVGKQW SGARALEALL 120
 TVAGELRGPP LQLDTGQLLK IAKRGGVTAV EAVHAWRNAL TGAPLNLPE QVVAIASHDG 180
 GKQALETVQR LLPVLCQAHG LTPQQVVAIA SNNGGKQALE TVQRLLPVLC QAHLGLTPEQV 240
 VAIASHDGGK QALETVQRLL PVLCQAHG PQQVVAIASN GGGKQALETV QRLLPVLCQA 300
 HGLTPQQVVA TASNGGGKQA LETVQRLLPV LCQAHGLTPQ QVVAIASNNGG GKQALETVQR 360
 LLPVLCQAHG LTPQQVVAIA SNNGGKQALE TVQRLLPVLC QAHLGLTPEQV VAIASNIGGK 420
 QALETVQRALL PVLCQAHGLP PQQQVVAIASN GGGKQALETV QRLLPVLCQA HGLTPEQVVA 480
 IASHDGGKQA LETVQRLLPV LCQAHGLTPQ QVVAIASNNGG GKQALETVQR LLPVLCQAHG 540
 LTPQQVVAIA SNNGGKQALE TVQRLLPVLC QAHLGLTPEQV VAIASNIGGKQ ALETVQRLLP 600
 VLCQAHGLTP QQQVVAIASNN GGKQALETVQ RLLPVLCQAH GLTPEQVVAI ASHDGGKQAL 660
 ETVQRLLPV CQAHGLTPQQ VVVAIASNNGG RPalesivaq LSRPDPLAAS LTNDHLVALA 720
 CLGGRPVALDA EKKSELRHKL KYVHEYIEL IEIARNSTD 780
 RILEMKVMEF PMKVGYRGRK HLGGSRKPDG AIYTVGSPID YGVIVDTKAY SGGYNLPQ 840
 ADEMQRYVEE NQTRRNKHINP NEWWKVYPSS VTEFKFLFV5 GHFKGNYKAQ LTRLNHITNC 900
 NGAVLVSVEEL LIIGGEMIKAG TLTLEEVRRK FNNGEINFAAD 941

SEQ ID NO: 22 moltype = DNA length = 2814
 FEATURE Location/Qualifiers
 misc_feature 1..2814
 note = TALEN TRAC pCLS11370
 source 1..2814
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 22
 atggggcgtc ctaaaaagaa acgttaaggc atcgattacc catacgatgt tccagattac 60
 gctatcgata tcgcccgtatc acgcacgctc ggctacagcc agcagaaca ggagaagatc 120
 aaaccgaaagg ttccgttcgac agtggcgcag caccacgagg cactggtcgg ccacgggttt 180
 acacacgcgc acatcggtc gttacggccaa caccggcagc cggttagggac cgtcgcgtgc 240
 aagtatcagg acatcgatgc acgcgttgcga gaggcgcacac acgaagcgtat cgttggcgtc 300
 ggc当地点 ggtccggcgc acgcgtctcg gaggccttgc tcacgggtggc gggagaggttg 360
 agagggtccac ctgttacagtt ggacacaggg caacttctca agattgcaaa acgtggccgc 420
 gtgaccgcac tggaggcgtg gcatgtatcg cgaatatcgac tgacgggtgc cccgtcaac 480
 ttgaccggcc acgagggtggt ggccatcgcc agcaatggcg tggtcaagca ggccgtggag 540
 acgggtccacgc ggctgttgcg ggtgtgtgc caggccccac gtttgacccc ccagctgggt 600
 gtggccatcg ccagcaataa ttgggtcaag caggcgttgcg agacggtcga ggggtgttg 660
 cccgtgtgtg gocagggccca cgggttgcacc cccaggcagg tggtggccat cggccagcaat 720
 ggc当地点 ggc当地点 cggaggcgtc caggcgttgcg tgccgggtgt tgccggcaggcc 780
 caccggcttgc ccccgaggca ggtgtggcc atccggccac acgtatggccg caaggcaggcg 840
 ctggagacgg tccagggcgt gttggccgtg ctgtggccagg cccacgggtt gacccggag 900
 caagggtgtgg ccatecgccag ccacgtatgc ggc当地点 cggccatggc 960
 ctgttgcggg tgcgttgcacc ggc当地点 cggccatggc tgacgggtgtt ggc当地点 1020
 agccacgatcg gggcaagca ggc当地点 cggccatggc acggttccacg ggtgttgc acc 1080
 caggcccacgc gttgtggcc gggccatcg ccagcaatat ttgggtcaag 1140
 caggcgtgtgg agacgggtca ggc当地点 cggccatcg ggc当地点 1200
 cccggaggcc tgggtggccat cggccatggc gatggccaggca acggccatggc ggc当地点 1260
 caaggcgtgtg tgcgggtgtc gttccggcc acggccatggc cccaggcaggca ggtgtggcc 1320
 atccggccatcg atattgggtgg caaggcaggcg ctggagacgg tgccaggccat gttggccgtg 1380
 ctgttgcagg cccacggccat gaccccccac cagggtggcc ccatecgccag caataatggt 1440
 ggc当地点 cggccatcg ggc当地点 cggccatcg ccagcaatat ttgggtcaag 1500
 ttgaccggcc acgagggtgtt ggc当地点 cggccatcg acgaaatattt ttgggtcaagca ggc当地点 1560
 acgggtgcagg cgctgttgc ggtgtgtgc caggcccacg gttgtggccat ccagcagggt 1620
 gtggccatcg ccagcaatggc cggccatggc acggccatggc ggc当地点 cggccatcg 1680
 cccgtgtgtg gocagggccca cggccatcg cggccatcg tggccatcgat cggccatcgat 1740
 attgggtggca acggccatcg gggccatcgat gggccatcgat tggccatcgat 1800
 cacggccatcg ccccccacgc ggtgtggccat atccggccatcg acggccatcgat 1860
 ctggagacgg tccagggcgt gttccggccat ctgtggccagg cccacggccat gacccggag 1920
 caagggtgtgg ccacatcgccat ccacgtatgc ggc当地点 cggccatcgat 1980
 ctgttgcggg tgcgttgcacc ggc当地点 cggccatcgat tggccatcgat 2040
 agcaatggcg ggc当地点 cggccatcgat acgattgttgc cccaggccat tggccatcgat 2100
 cccggccatcg cccggccatcg acggccatcgat tggccatcgat 2160
 cctggccatcg atccggccatcg acggccatcgat tggccatcgat 2220
 aagtccgagg tggaggagaa gaaatcccgat gttggccatcg acggccatcgat 2280
 gagtacatcg agctgatcg gatccggccat gacccggccat cctggccatcg 2340
 aagggtgtgg agttttcat gaaagggtgtac ggctacaggccat gcaaggccat gggccatcg 2400
 aggaaggccat cggccatcgat ctacaccgtg ggtcccccac tgcactacgg cgtgatcgat 2460

-continued

gacaccaagg	cctactccgg	cggctacaac	ctgcccacatcg	gccaggccga	cgaaatcgag	2520
aggtaacgtgg	aggagaacca	gaccaggaaac	aagcacatca	accccaacga	gtgggtggaaag	2580
gtgttaccct	ccagcgtgac	cgagttcaag	tccctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgtat	cggcgccag	atgatcaagg	ccggcacct	gaccctggag	2760
gaggtgagga	ggaagtcaa	caacggcgag	atcaacttcg	cgcccgactg	ataa	2814

SEQ ID NO: 23	moltype = DNA length = 2832					
FEATURE	Location/Qualifiers					
misc_feature	1..2832					
source	note = TALEN TRAC pCLS11369 1..2832					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 23						
atggggcata	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccc	tgccaagttc	60
gagagacacg	acatggacag	catcgatattc	gccgatctac	gcacgtccgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgttcgacag	tggcgccaga	ccacgaggca	180
cttggcgccc	acgggtttac	acacggc	acatgtcgct	taagccaaca	cccgccacqg	240
tttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgacg	cgttgcaga	ggcgacacac	300
gaaggcatacg	ttggcgatcg	caaacagtgg	tccggcgac	gcgcgttgcg	ggccttgc	360
acgggtgggg	gagagtttgag	agggtccac	ttacagttgg	acacaggcca	acttctcaag	420
attgc当地	gttggcgatcg	gaccgcgtg	gaggcgtgc	atgcgttgcg	caatgcactg	480
acgggtggcc	cgctcaactt	gaccccgag	cagggtgtgg	ccatgcacag	ccacgatggc	540
ggcaaggcagg	cgctggagac	ggtcacgggg	ctgttgcggg	tgctgtgc	ggccccacggc	600
tttgc当地	ggcgc当地	ggccatcg	ageaatggcg	tggcgacaga	ggcgctggag	660
acgggtccacg	ggctgttgc	gggtgtgc	caggccac	gettgcaccc	ggagcagggt	720
gttggccatcg	ccagccacga	tggcgcaag	caggcgctgg	agacggtcca	gcccgttgc	780
ccgggtgtgt	gcaaggccca	cggttgc	ccggagcagg	tggtggccat	cgccagcaat	840
attgtggcata	gcaaggcgt	ggagacgggt	caggcgctgt	tgccgtgt	tgccaggc	900
cacggcgttgc	ccccccacga	ttgttgc	atcgccacga	ataatggtgg	caagcaggcg	960
cttggagacgg	ttccagcggt	tttgcgggt	ctgtgc	ccacacggcc	gaccggcgg	1020
cagggtgtgg	ccatcgccag	ccacgttgc	ggcaagcagg	cgctggagac	gttccagcgg	1080
cttggcgccgg	tcgtgtgc	ggccacccgg	tttgc当地	aggcagggtt	ggccatcgcc	1140
agaatgtggc	gttggcaagca	ggcgccagg	acggtccacg	ggcttgcgg	gggtgtgtc	1200
caggccacgg	gttgc当地	ccagcagggt	gttgc当地	ccagcaataa	tggtgc当地	1260
caggcgctgg	gacacggtcca	ggcggtgtt	ccgggtgt	gccaggcc	cggttgc	1320
ccccacgggg	ttgttgc当地	ccggc当地	atatgttgc	aaatgttgc	aggcagggtt	1380
cagggtgtgg	tcgtgtgc	gttgc当地	ccggc当地	ccacggcc	ggtggtgc	1440
atcgccacg	atggcggtgg	caagcaggcg	cttgc当地	ccacggcc	tttgc当地	1500
cttgc当地	ccccacgg	gacccggag	cagggtgtgg	ccatcgccag	caatatttgc	1560
ggcaaggcagg	cgctggagac	gggttgc	ctgtgtgc	ggccacccgg	1620	
tttgc当地	ggcgc当地	ggc当地	ggc当地	ggc当地	ggc当地	1680
acgggtccacg	ggctgttgc	gggtgtgc	caggccac	gettgcaccc	ggagcagggt	1740
gttggccatcg	ccagcaat	tggtgc当地	caggcgctgg	agacggtca	ggc当地	1800
ccgggtgtgt	gcaaggccca	cggttgc	ccggagcagg	ttgttgc当地	cgccaggcc	1860
gtatggc当地	ggc当地	ggagacgggt	caggcgctgt	tgccgtgt	tgccaggc	1920
cacggcgttgc	ccccccacga	ttgttgc	atcgccacga	ataatgttgc	caagcaggcg	1980
cttggagacgg	ttccagcggt	tttgc当地	ctgtgc	ccacacggcc	gacccttc	2040
cagggtgtgg	ccatcgccag	caatcgccg	ggcaggccgg	cgctggagag	cattgttgc	2100
catttatc	ccctgttgc	ggcggttgc	ggcttgc当地	acgaccac	cgtcgctt	2160
gcgtcgctcg	gggggggtcc	tgctgtgt	gcagtgc当地	agggttggg	ggatctatc	2220
agccgttccc	agctgtgtaa	gtccgagct	gaggaga	aatccagg	gaggcacaag	2280
cttgaatcg	tcggccacac	gtatcg	ctgatcg	tgc当地	cagcacc	2340
gaccgtatcc	tggagat	gggtat	tttgc当地	agggttgc	ctacagg	2400
aaggcacc	ggcggtccag	ggagcc	ggccatct	acaccgtgg	ctccccc	2460
gactacggc	tgatcg	caccaagg	tactccgg	gttacaact	gcccac	2520
caggccacg	aatcgacag	gtatcg	gagaaccc	ccaggaa	gcacat	2580
cccaac	ggtggagg	gttacc	agcgttgc	atgttca	cttgc当地	2640
tccggccact	tcaaggcc	cttac	ggctgac	ggctgac	catcca	2700
tgc当地	ccgtgtgc	cgttgc	ggggagg	cttctgt	ggccg	2760
ggcaccc	ccctggag	ggttgc	ggggagg	aaatgtca	acggc	2820
ccgcactgat	aa					2832

SEQ ID NO: 24	moltype = DNA length = 2745					
FEATURE	Location/Qualifiers					
misc_feature	1..2745					
source	note = TALEN CD25 pCLS30480 1..2745					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 24						
atggggcata	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgatgt	tccagattac	60
gtatcgata	tcggcgatct	acgcacg	ggctacagcc	agcagcaaca	ggagaatgc	120
aaacccgaa	ttcgatcgac	agtggcg	caccacgg	cactgg	ccacgggtt	180
acacac	acatcgatgc	gttac	acccgg	cgttagg	cgctcg	240
aatgtatcg	acatcgatgc	acgcgttgc	gaggcgac	acgaagg	cggtgg	300
ggcaaac	ggtggagg	gttacc	acgcgttgc	ttac	ggggagg	360
agagg	ccgttac	ggacacagg	caacttctca	agattgc	acgtgg	420

-continued

gtgaccgcag tggaggcagt gcatgcattgg cgcaatgcac tgacgggtgc cccgctcaac	480
ttgacccccc agcagggtt ggcatacgcc agcaataatg tgggcaagca ggcgttgag	540
acggtcacgc ggctgttgcg ggtgtgtgc caggcccacg gcttgcaccc ccagcagggt	600
gtggccatcg ccagcaatgg cggtggcaag caggcgctgg agacggtcca ggggtgtt	660
ccegtgtgtt gocaggccca cggtgttgc ccccaggcgg tggtggccat cgccagcaat	720
ggcgggtggca agcaggcgct ggagacgggtc caggcgctgt tgccgggtgt gtgcagggcc	780
cacggcttga ccccgagca ggtgttgcg atggccacgc acgatggccg caagcaggcg	840
ctggagacgg tccagcggtc gttgttgcggt ctgtgtccagg cccacgggtt gaccccccag	900
caagggtgtt ccatecgccg caatggcggt ggcaggcagg egctggagac ggttccagcg	960
cttgttgcgca tgctgttgcg ggcacccccc agcagggtgt ggccatcgcc	1020
agaatggcg gttggcaagcg ggcgttggag acgggtccacg ggtgttgcg ggtgtgttgc	1080
caggccccacg gttgttgcgg ccaggcggtg gtggccatcg ccagcaatgg cgggtggcaag	1140
caggcgttgg agacggtcca ggggtgttgc ccegtgtgtt gccaggccca cgggttgcacc	1200
ccccaggcagg tgggttgcgtt ccggcaatgg ggcgggtggca agcaggcgct ggagacggc	1260
caaggcggtgt tgcgggtgtt gtcggaggcc ccccccaggca ggtgttgcgc	1320
atcgccagca ataatgggtgg caaggaggcg ctggagacgg tccagggtt gttgttgcgt	1380
ctgttgcagg cccacgggtt gaccccccgg cagggttgcgg ccatecgccg caataatgg	1440
ggcaagcgac cgctggagac ggttccagcg ctgttgcgtt tgctgtgcga gggccacggc	1500
ttgacccccc agcagggtgtt ggcatacgcc agcaatggcc ttggcaagca ggcgttgcgc	1560
acggtccacgc ggctgttgcg ggtgttgcg caggcccacg gtttgcaccc ccagcagggt	1620
gtggccatcg ccagcaatgg cggtggcaag caggcgctgg agacggtcca ggggtgttgc	1680
ccegtgtgtt gccaggccca cggtgttgcg cccaggcagg tggtggccat cgccagcaat	1740
ggcgggtggca agcaggcgct ggagacgggtc caggcgctgt tgccgggtgt gtgcaggcc	1800
cacggcttga ccccccaggca ggtgttgcgc atggccacgc atggcggttgg caaggaggcg	1860
ctggagacgg tccagcggtt gttgttgcgg ctgtgtccagg cccacgggtt gaccccccgg	1920
cagggtgtt ccatecgccg ccacgttgcg ggcaggcagg egctggagac ggttccagcg	1980
cttgttgcggc tgctgttgcg ggcacccccc ttgacccccc agcagggtgtt ggccatcgcc	2040
agaatggcg gggcaggccc ggcgttggag agcattgttgc cccagggtt tcggccgtat	2100
ccaggtggca gggggatct ataggcggtt ccaggcggtt gaagtcccgag	2160
ctggaggaga agaaatccga gttggaggca aactgtggatcg acgttgcacca cggatcacat	2220
gagctgtatcg agatcgcccg gaaacgacc caggaccgtt ttggggatg gaaggtgtat	2280
gagtttctca tgaagggtgtt cgggtacagg ggcaggcacc ttggcggcgc caggaaggcc	2340
gacggcgccca ttacaccgtt ggggtccccc atcgactacg cgggtatcggtt ggacaccagg	2400
gcctactccg cgggttacaccc cctggccatc ggcaggccggc acgaaatgtca gaggtacgt	2460
gaggagaacc agacccggaa caagcacatc aaccccaacg agtgggtggaa ggtgtacccc	2520
tccagcgtga ccagggttcaa gttctgttgc tggtccggcc acttcaaggaa caactacaag	2580
gcccaagctga ccaggctgaa ccacatcacc aactgtcaacg ggcgggtgt gtcctgttgc	2640
gagctcttgc tccggcgccg gatgtcaag gccggccacc ttggcccttgcg ggagggttgg	2700
agaagtttca acaacggcgca gatcaacttc gccggccgact gataa	2745

SEQ ID NO: 25 moltype = DNA length = 2745

FEATURE Location/Qualifiers

misc_feature 1..2745

note = TALEN CD25 pCLS30479

source 1..2745

mol_type = other DNA

organism = synthetic construct

SEQUENCE: 25

atggggcata ctaaaaagaa acgtaagggtc atcgattacc catacgatgt tccagattac	60
gtctatcgata tcggcgatct acgcacgcgc ggctacacgc acgaccaaca ggagaatgc	120
aaacccgaaagg ttctgttgcac agtggcgcaag caccaacgggg cactgggttgc ccacgggtt	180
acacacgcgc acatcggttc gttaaacccaa caccacgggg eggttagggac cgtcgctgtc	240
aagtatcgagg acatgtatcg acgcgttgcac gaggcgacac acgaaggcgat cgttgggtc	300
ggcaaaacagg gtgttgcggc acgcgtctgttggcgttgc tcacgggtgc gggaggttgc	360
agagggttccac ctgttgcgttggcgttgc acgacacggc caacccatcgca agatgtcaaa acgtggccgc	420
gtgaccgcac ttggaggcgtt gcatgcattgg cgcacatcgac ttggccgggtgc cccgtcaac	480
tttggcccccgg agcagggtgtt ggccatcgcc agcaatattg tggttgcaggca ggcgttgcgc	540
acgggtcagg cgctgttgcg ggtgttgcg cgggttgcggc gtttgcaccc ggaggcagggt	600
gtggccatcg ccaggccacga tggggccagg caggcgctgg agacgggttca ggggtgttgc	660
ccegtgtgtt gccaggccca cggtgttgcg cccaggcagg tggtggccat cgccaggcaat	720
attgggttgcg acaggcgctt ggagacgggtt caggcgctgt tgccgggtgt tgccaggcc	780
cacggcttgcg ccccccaggca ggtgttgcgc atggccacgc ataatgggttgg caaggaggcg	840
ctggagacggc tccaggcggtt gttgttgcgg ctgtgtccagg cccacgggtt gaccccccgg	900
cagggtgttgg ccatecgccg caataatggt ggcaggcgac cgggttgcgg ggttccaggcg	960
ctgttgcggc tgctgttgcg ggcacccccc ttgaccccccgg agcagggtgtt ggccatcgcc	1020
agaatatttgcg tggggcaagca ggcgttgcgg acgggttgcgg cgttgcgttgc	1080
caggccacgc gtttgcggcc ccaggcagggtt tggtggccatcc acgttgcacaa tggtggcaag	1140
caggcgctgg agacgggttca ggggttgcgtt cgggttgcgttggccat cgggttgcacc	1200
cccccaggcagg ttggggccat cggccacgtt aatgggttca acggaggcgct ggacacgggt	1260
caggcgctgt tgccgggtgtt gtgttgcggc acagggttgcg ccccgaggca ggtgttgcgc	1320
atcgccacgc atattgggttca acaggcgctt gcggaggacggc ttggaggcgct gttgttgcgt	1380
ctgtgtccagg cccacgggtt gaccccccgg cagggttgcgttgc acatcgccacg caatattgg	1440
ggcaaggcgac cgctggagac ggttgcaggc ctgtgtccggc tggttgcgc gggccacggc	1500
ttgaccccccgg agcagggtgtt ggccatcgcc agcaataatg tggttgcaggca ggcgttgcgc	1560
acggtccacgc ggctgttgcg ggtgttgcg caggcccacg gtttgcaccc ggaggcagggt	1620
gtggccatcg ccaggcaatat tggtggcaag caggcgctgg agacgggttca ggcgttgcgttgc	1680
ccegtgtgtt gccaggccca cgggttgcacc cccaggcagg tggtggccat cgccaggcaat	1740
aatgggttgcg acaggcgctt ggagacgggtt caggcgctgt tgccgggtgt tggtggcc	1800
cacggcttgcg ccccccaggca ggtgttgcgc atggccacgc atggcggttgg caaggaggcg	1860

US 12,391,933 B2

139

140

-continued

ctggagacgg	tccageggct	gttgccgggt	ctgtgcccagg	cccacggcctt	gaccggag	1920
cagggtggg	ccatcgccag	caatattgtt	ggcaagcagg	cgctggagac	ggtcagggc	1980
ctgttgcgg	tgctgtgcca	ggccccacggc	ttgacccttc	agcagggtgt	ggccatcgcc	2040
agcaatggcg	ggcgccaggcc	ggcgctggag	agcatttttg	cccagtattc	tcgccccgtat	2100
ccgagttggca	ggggaaatgg	cgggatcc	atcagccgtt	cccactgtgt	gaagtcggag	2160
ctggaggaga	agaaatccga	gttggccac	aagctgaatg	acgtgcggcc	cgagtacatc	2220
gagctgtatcg	agatcgcccg	gaacaccc	caggacccgt	tcctggagat	gaagggtatg	2280
gagttcttc	tgaagggtgt	cggttacagg	ggoaaggacc	tgggccggctc	caggaaggccc	2340
gacggcoca	tctacaccgt	gggatcccc	atcgactac	cgctgtatcgt	ggacaccaag	2400
gcctactcg	cggttacaa	cctggccat	ggccaggcc	acgaaatgc	gagggtacgt	2460
gaggagaacc	agaccaggaa	caagcacatc	aaccccaacg	agtgggtggaa	gggttacccc	2520
tccagcgtga	ccgagttcaa	gttctgttc	gttccggcc	acttcaaggg	caactacaag	2580
gcccaatgtga	ccaggatgtaa	ccatcatc	aactgcac	ggcccggtgt	gtcccggtgg	2640
gagctcttc	tccggccgca	gatgtcaag	gcccggacc	tgaccctgga	ggaggtgagg	2700
aggaaatgtta	acaacccggca	gatcaactc	gcggccgact	ataaa		2745

SEQ ID NO: 26	moltype = DNA length = 2814					
FEATURE	Location/Qualifiers					
misc_feature	1..2814					
source	note = TALEN PD1 pCLS28959 1..2814 mol_type = other DNA organism = synthetic construct					
SEQUENCE: 26						
atggggcgate	ctaaaaagaa	acgtcaaggc	atcgattac	catacgatgt	tccagattac	60
gtctatcgata	tcggcgatct	acgcacgc	ggctacagc	agcagcaaca	ggagaagatc	120
aaaccgaaagg	tgcgttcgc	agtggccag	caccacagg	cactggtcgg	ccacgggtt	180
acacacgcgc	acatcggtgc	gttaagccaa	cacccggcag	cgtagggac	cgtcgctgc	240
aagtatcagg	acatcgatgc	acgctgtgca	gaggcgcac	acgaaggat	cgttgcgc	300
ggaaaacatgt	gttccggcc	acgctgtgc	gaggccttgc	tcacgggtgc	gggagatgt	360
agagggttcc	cggttacatgt	ggacacagg	caacttctca	ataggtaaaa	acgtggccgc	420
gtgaccgcgc	tggaggcagt	gcatgcatt	cgcaatgcac	tgacgggtgc	cccgctcaac	480
tttgcacccgc	agcaagtgtt	ggctatcgct	tccaaatgcgt	ggggaaagca	ggccctggag	540
accgttccagg	cccttctccc	agtgtttgc	caggcttcgc	gactgacccc	tgaacagggt	600
gtggcaatgt	cttcacacg	cgggggca	caggcactgg	agactgtcca	ggggctgtc	660
cctgttcct	gcccaggcc	cggactcact	cctgagcagg	tcgtggocat	tgccagccac	720
gtatggggca	aacaggctt	ggagacccgt	cagccctcc	tcccagtgt	gtgccaggct	780
catggggatc	ccccacacg	ggtcgtcgc	atggccatgt	acggccgggg	gaagcaggcc	840
ctcgaaacacg	tgcagggct	gtctccgc	tttgccca	cacacggcct	gacacccgag	900
caagggtgtgg	ccatcgctc	tcatgcac	ggcaaggcag	cccttggagac	agtgcagaga	960
ctgttgcgc	tgttgtgtca	ggccacacgg	ttgacacccc	acgagggtgt	cgccatcgcc	1020
agaatgtggc	ggggaaatgc	ggcccttgc	accgtgcac	ggttgttccc	agtgtgtgc	1080
caggcacacac	gactgtggcc	tcaacagggt	gtcgcacatc	ccagttacaa	gggcggaaag	1140
caaggcttgc	agacagatgc	gcccctctg	ccctgtgtgt	gtcaggctca	cgactgac	1200
ccacacgagg	tggtcgc	cggcgttac	ggggggccg	acgaggctt	ggagaccgtc	1260
caagatcgcc	tcccccgc	ttggccagg	cacgggttgc	cacttcggca	ggtcgtcgcc	1320
attgccttca	acaacgggg	caaggccgc	ctcgaaaact	tgcagagg	gtgcctgt	1380
ctgtgcagg	tcatgggt	gacacccgg	caagggttgc	ccattgcctc	taacaacggc	1440
ggcaaaacagg	cactggagac	cggtcaaa	ctgtgcgc	tctctgc	agccacggg	1500
ctcaactcc	acgaggctgt	ggccatcgcc	tcaaaatacg	ggggaaagca	ggccctggag	1560
actgtgc	aaaggatcg	ttgtgtc	caggcactgg	gactgacccc	tcagcagggt	1620
gtggcaatcg	tttccaa	cgggggaa	caggccc	aaacctgtca	gcccctctc	1680
caaggatgtgt	ggcaggcaca	ttgcctcaca	cccgagca	ttgtggctat	cgccaggcc	1740
gacggggatc	acgaggctgt	ggagacccgt	caaggatgtc	tgccctgtc	gtgcaggcc	1800
cacggggatc	tcctcaggac	ggtctgcgc	atcgccatgc	atgtgggg	gaagcaggcc	1860
cttggacac	tccaggcgt	gtctccgc	ctttggagg	ctcacccgtt	gactcccgag	1920
caaggatgtgg	ccatcgctc	aaacattgg	ggcaaacagg	ccctggagac	agtgcaggcc	1980
ctgtgcgc	tgttgtgt	ggccacccg	ttgacacccc	acgagggtgt	cgccattgtcc	2040
tctaattggc	ggggggacc	cgccttgg	acgattgttgc	cccgatgtt	tcgeccctgt	2100
ccggcgatgg	cccggttgc	caacggcc	ctcgctgc	ttggctgc	cgccgggcgt	2160
cctgcgtgg	atgcgtgaa	aaaggatttgc	ggggatctca	tcagccgtc	ccagttgtgt	2220
aaagtccggc	tggggatgg	gaaatccg	ttgaggcaca	agctgaatgt	cggtccccc	2280
gagtcatcg	acgtgtatcg	gatcgcc	aaacgcaccc	aggaccgtat	cttggagatg	2340
aaaggatgtatcg	agtttctatcg	aaagggtgt	acgttacagg	gtcaaggact	ggccggcgtt	2400
aggaaggcccg	acggcgccat	ctacacccgt	ggtccccca	tgcactacgg	cgtgtatgt	2460
gacaccaagg	ccatactccgg	cggttacac	ctggccatcg	gccaggcc	cgaaaatgcag	2520
aggtaatcg	aggagaacca	gaccggac	aaaccaacga	gtgggtggaa		2580
gtgttccccc	ccaggatgt	cgaggatgt	tttccatgt	tttcaagg		2640
aactacaagg	cccgatgtac	cggttac	caatccacca	actgcaccc	cgccgtgt	2700
tccgtggagg	agctctgtatcg	ggggccgg	atgtcaagg	ccggccactt	gaccctggag	2760
gaggatgtgg	ggaatgttca	caacggccg	atcaactcg	cgccggact	ataaa	2814

SEQ ID NO: 27	moltype = DNA length = 2829
FEATURE	Location/Qualifiers
misc_feature	1..2829
source	note = TALEN PD1 pCLS18792 1..2829 mol_type = other DNA organism = synthetic construct

-continued

SEQUENCE: 27

atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgccc tgccaagttc 60
 gagagacacg acatggacag catcgatata gccgatctac gcacgctcg ctacagccag 120
 cagcaacagg agaagatcaa accgaagggtt cgttcgacag tggcgcagca ccacgaggca 180
 ctggcggcc acgggtttac acacgcgac atcggtcgct taagccaaca cccggcagcg 240
 tttagggacg tcgctgtcaa gtatcgac atgatcgca cgttgcaga ggcgacacac 300
 gaagcgatcg ttggcgctgg caaacagtgg tccggcgcac ggcgctcgga ggccttgctc 360
 acggtgtgggg gagagtggag aggtccacacg ttacagtggg acacaggcca acttctcaag 420
 attgcääaac gtggcgccgac gacecgactg gaggcactgc atgcatggc caatgcactg 480
 acgggtggcc cgctcaactt gggcccgag caagtcgtcg caatgcggc ccatgtatgg 540
 gggaaagcaag ccctcgaaac cgtgcagcg tggcttcgt tgctctgcga ggcctcgac 600
 cttacccctc acgagggtggt ggccatcgca agtaacggag gaggaaagca agccttgag 660
 acagtgcacg gctgtgtggc cgtgtgtgc caggcacacg gctcacacc agagcaggtc 720
 gtggccatttgc cttccatgtc cggggggaaa caggcttgcg agacgttca gaggctgtc 780
 cccgtctctc gtcaagctca cggctgact ccccaacaag tggctgcacat cgcctcta 840
 ggcggcgaaa agcaggact gggaaacagtg cagagactgc tccctgtgt ttgccaagct 900
 catgggttga ccccccaaca ggtcgctcg atggctcaaa acgggggggg caagcaggcc 960
 ctttgagactg tgcagggct gttcgacgtg ctgtgtcagg ctcacgggt cactccacaa 1020
 caagggtgtcg caatttgcac caacggccgc gggaaacaaat ctttgcacaa cgtgcacac 1080
 ctcctgcggc tgctctgtca ggctcatggc ctgacaccac aacaagtctg ggcacatcgcc 1140
 agtaataatg gggggaaaaca ggcttttag accgtccaca ggctgtccc agtgcctgc 1200
 caggcacatcc ggctgacccc cgagcaggatg tggctatcg ccagcaat tggggggcaag 1260
 caggccctgg aaacagtccca ggcctgtgtt ccagtgtttt ggcaggctca cgggctact 1320
 ccccaacggc tgctggcaat cgccttcaac ggccggggggg agcaggctt ggagaccgtg 1380
 caagagactgc tgcccgctt gtggcaggcc cacggactca caccgtaaaca ggtcgctcgcc 1440
 attgccttc acgtatggggg ccaaacaagcc ctggagacatg tggcaggatg gttgcctgt 1500
 ttgtgcaag cccacggctt gactctcaaa caatgtgtcg ccatgcctc aaatggccggc 1560
 gggaaaacaag ctctggagac agtgcagggg ttgtgtccgg tccctgtcga agccccacgc 1620
 ctgactcccc aacaggctgtc cgccatttgcg agcaacaacg gaggaaagca ggctctcgaa 1680
 actgtgcacg ggtctgttgc tggctgtgtc caggctcatg ggctgacccc cgagcagtg 1740
 gtggctatttgc cttctaatgg aggaacggaa gccccttggaa cagtccagag gctgttgc 1800
 gtgtgtgtcc aggccccacgg gctcacaccc cagcagggttgc tggccatcgcc cagaacaaac 1860
 gggggcaacaa acggcatttggaa aaccgtccagg cgccctgttcc cagtgctctg ccaggcacac 1920
 ggactggcaggc cggaaacagggtt ggtggccatttgcatccatggggcaag gcaaggccctg 1980
 gagacctgtc agagactctt cccgtgttgc tgccaaatggc acggccctac ccctcagcaa 2040
 gtgtgtggca tccgcctcaaa cggggggggc cggccctgcac tggagacat tggcccttgc 2100
 ttatctcgcc ctgatccggc gttggccgcg ttgaccaacg accacatctgt cgccttgc 2160
 tgctctcgcc ggccgtctgc gtcggatgtc gtgaaaaaaagg gattggggga tccttatcagc 2220
 cgttcccacgc tggtaagtc cggatggag gagaagaaat ccgagttgcg gcacaagctg 2280
 aagtacgtgc cccacagatc catcgatgtc atcgatgtc cccggaaacag caccggac 2340
 cgtatcttgc agatgaaggt gatggagttc ttcatgttgc tggatggcata cagggggcaag 2400
 cacctggccg gtcggaggaa gcccggacggc gccatctaca cccgtgggcctc ccccatcgac 2460
 tacggcgtca tgcgtggacac caagggcttgc tccggccgtt acaaacgtcc catggccag 2520
 gcccggacaaat tgcagggatc cgtggaggag aaccggacca ggaacaaacgca catcaacccc 2580
 aacggatgtt ggaagggttgc cccctccaggc gtgaccggat tcaagtctt gttgtgtcc 2640
 ggcacacttgc aggccacta caaggccacg ctgaccggc tgaaccacat caccacactgc 2700
 aacggcgcgg tgcgtgtccgt ggaggatgc ctgatggccg cggatgttgc caaggccggc 2760
 accctgaccc tggaggatgtt gaggaggaaat tcaacaacg cggatgttgc cttcgccggc 2820
 gactgataa 2829

SEQ ID NO: 28

moltype = DNA length = 49

Location/Qualifiers

FEATURE misc_feature

1..49

note = TALEN target TRAC

source

1..49

mol_type = other DNA

organism = synthetic construct

SEQUENCE: 28

ttgtcccaca gatataccaga accctgaccc tggcgatgtac cagctgaga

49

SEQ ID NO: 29

moltype = DNA length = 45

Location/Qualifiers

FEATURE misc_feature

1..45

note = TALEN target CD25

source

1..45

mol_type = other DNA

organism = synthetic construct

SEQUENCE: 29

tacaggagga agatgttgc aacaatctgtt aaaacccaaaaa gaaca

45

SEQ ID NO: 30

moltype = DNA length = 49

Location/Qualifiers

FEATURE misc_feature

1..49

note = TALEN target PD1

source

1..49

mol_type = other DNA

organism = synthetic construct

SEQUENCE: 30

tacactctgtg gggccatctc cctggccccc aaggcgcaga tcaaagaga

49

-continued

SEQ ID NO: 31 moltype = DNA length = 2897
 FEATURE Location/Qualifiers
 misc_feature 1..2897
 note = Matrice TRAC locus_CubiCAR CD22 pCLS30056
 source 1..2897
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 31

```

ttgctggccc ttttccat gcgtgcattt actctgcca agtttatattt ctggggtttt 60
gaagaagatc ctatataaa aaagaataag cagtattattt aagtagccct gcatttcagg 120
tttccttgag tggcaggcca ggcctggccg tgaacgttca ctgaaatcat ggcctcttgg 180
ccaaagttta tagcttgtc ctgtccctqa gtccccgttca atcacgaca gctggtttct 240
aagatgtatc ttccgttta aagcatgaga cctgtgatgg ccagccccac agagccccgc 300
ccttgcctat cactggcata tggactccag cctgggttgg ggcaaaggagg gaaatgagat 360
catgtccataa ccctgtatcc tttgtccac agatatccag tacccttacg acgtgcccg 420
ctacgcctcc ggtgaggggc gaggaaatgt tctaacatgc ggtgacgtgg aggagaatcc 480
ggggccccc tccgtctgc cctgttccat tttgtgttgc ccactggcac tggctgtcga 540
cgtgtcttgg cccggagggg gggcagatgt cccttacagc aacccccggc tggcagccg 600
aggcggggcc agcggggggag ggggttagcca ggtgcagctg cagcagacgg gccctggct 660
ggtaagccca accccagacac tgcccttgc acggccatc acggccatc ccgtgagctc 720
caactccccc gcttggggc ggttggggat ggttggggat ctttttttttggggctgggg 780
aaggacatac tategttctt aatgttccaa cgttattatgc tggctgttgc agagcagaaat 840
cacaatcaac cttgtacatc ccaaaatca gtttttttttgc cagcttataa gctgtacacc 900
agaggacatc ggcgtgtactt attggccatc ggagggttgc ggcgttccgg aggatgtct 960
tgacatctgg gggcaggggc caatgggttgc cttgttgc acggccatc ccgtgagctc 1020
aggaggaaatg gggggggggc gggttggatcc ccttggggat ctttttttttggggctgggg 1080
cggttccgtt gggcgttccat ttttttttttgc ttttttttttggggctgggg 1140
cttgcactgg tatcagcaga gggccggca gggccctttaat ctgtgtatcc acggcagaaat 1200
cttgcgttgcg agcgggtgtc catcgttgc gggccgttgc ctttttttttgc 1260
cttgcattttc ttttttttttgc ctttttttttgc ttttttttttgc 1320
tagcatcccc ctttttttttgc ttttttttttgc ttttttttttgc 1380
cgaggggggg ggcgttccat ttttttttttgc ttttttttttgc 1440
cgatgtccgc accccatggc ctttttttttgc ttttttttttgc 1500
caccacccatc ctttttttttgc ttttttttttgc 1560
tccaaggccc ctttttttttgc ttttttttttgc ttttttttttgc 1620
ggccctgttgg cccgtgtgtt gggccgttgc gtttttttttgc ttttttttttgc 1680
tattttatcc ttttttttttgc ttttttttttgc ttttttttttgc 1740
taccctgtat ttttttttttgc ttttttttttgc ttttttttttgc 1800
ggcgccatgt ctttttttttgc ttttttttttgc ttttttttttgc 1860
ggaaaggccgg ttttttttttgc ttttttttttgc ttttttttttgc 1920
acaggccgc accaaatgttca ttttttttttgc ttttttttttgc 1980
gttggataag gggggggggc gggggggggc gggggggggc gggggggggc 2040
tcaggaggccc ttgttacatc agtgcgttgc gggggggggc ttttttttttgc 2100
cgggatgaag gggggggggc gggggggggc gggggggggc ttttttttttgc 2160
cacagccaca aaggacatc acggccatc gtttttttttgc ttttttttttgc 2220
gtttagggggcc cccgttgc ttttttttttgc ttttttttttgc 2280
atttgggtt ttttttttttgc ttttttttttgc ttttttttttgc 2340
cctttccataa taaaatgggg ttttttttttgc ttttttttttgc ttttttttttgc 2400
ggggggggggg gggggggggc gggggggggc gggggggggc ttttttttttgc 2460
tggggatgtcg ttttttttttgc ttttttttttgc ttttttttttgc 2520
aaatccatgtt ctttttttttgc ttttttttttgc ttttttttttgc 2580
caaaggtaagg atttctgtt ttttttttttgc ttttttttttgc ttttttttttgc 2640
gacttcaaga gcaacatgtc ttttttttttgc ttttttttttgc ttttttttttgc 2700
gccttcaaaac acaggatgtc ttttttttttgc ttttttttttgc ttttttttttgc 2760
tttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 2820
tggtaatgtt ttttttttttgc ttttttttttgc ttttttttttgc 2880
aaccctttt ttactaa ttttttttttgc ttttttttttgc ttttttttttgc 2897

```

SEQ ID NO: 32 moltype = DNA length = 2688
 FEATURE Location/Qualifiers
 misc_feature 1..2688
 note = Matrice CD25 locus_IL15_2A_sIL15Ra pCLS30519
 source 1..2688
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 32

```

gttttattttt cctgttccat agtatttttttgc tgccatataaa aaacttaggc caggcacatgt 60
ggctcacacc ttttttttttgc gtttttttttgc ttttttttttgc ttttttttttgc 120
agttcgatc ctttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 180
agccaggatc gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 240
gttacacatca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 300
ggtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 360
tccaacccatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 420
gttggctgtgtt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 480
cgaggccatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 540
gaagatctta ttcaatcttat gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 600
cccaatgttca aatgttcaatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 660
gttccggatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 720

```

-continued

```

agtttgtctt ctaatggaa tggtaacagaa tctggatgca aagaatgtga ggaactggag 780
gaaaaaaaaata tttaagaatt ttgcagagt ttgtacata ttgtccaaat gttcatcaac 840
acttctggaa gcggagctac taacttcago ctgctgaacg aggctggaga cgtggaggag 900
aacccctggac ctgggaccgg ctctgcaacc atggattggg cgtggatcct gtttctcg 960
gcagctgcca caagagttca cagatctacg tgccctcccc ccattgtccgt ggaacacgca 1020
gacatctggg tcaagageta cagttgtac tccaggggc ggtacatttg taactctgg 1080
ttcaagcgta aagccggcac gtccagctg acggagtgcc tggtaaccaa ggccacgaa 1140
gtcgcccact ggacaacccc cagttcaaa tggatttagag accctgcct ggttaccaa 1200
aggccagcgc caccctccac agtaacgcg gcagggttgca ccccacaggc agagagctc 1260
tcccttctg gaaaaggcc cgcagatcc tctcccaatgtaaacaac acggccacac 1320
acacgagota ttgtccccc ctcggatctg atgccttcaaa aatcaccttc cacaggaacc 1380
acagagataa gcaatgtca gtcctccac ggcacccccc ctcagacaaac agccaagaac 1440
tgggaaactca cagatccgc ctcggccac ccggccagggt tgtagtccaca gggccacagc 1500
gacaccactg aggccaggg cagctgtcg acctggggcc acgtcgagga gaacccccc 1560
cccatggggg cagggtccac cgccggccgct atggacggcc cgcgcgtgt gctgtgtc 1620
cttctggggg tggcccttgg aggtgccaag gaggcatgc ccacaggct gtacacacac 1680
agcggtgagt ggtgcaaaacg ctgcaacccg ggcgggggtg tggccccaggc ttgtggagcc 1740
aaccagaccc tgggtgagcc ctgctggac agcggtgacgt ttcctcgact ggtgagcgc 1800
accggccgtg gcaaggccgtg caccggatgc gtgggtccctc agagatgtc ggcgggtgc 1860
gtggaggccg atgacggcgt gtcggcgtc gcttacggc actaccaggta tgagacgact 1920
gggcgcgtcc aggcgtccg cgtgtgcgag gggggctgg gctctgtt ctccgtccag 1980
gacaaggccgta ctagatccgc caccgtggca gggggccggc cgttcccaac 2040
cacgtggacc cgtgtccgtcc ctgcaccctg tggaggacca cggggccca gtcggccg 2100
tgcacacgcg gggccgacgc cgagtgcgag gagatccctg ggcgttggat tacacgtcc 2160
acaaccccccaggccaggc caccacggcc cccagccaccaggcgttgc ggcacccctca 2220
gaacaagacc tcatatggc caccgtggca ggtgtgggtt ccacagtgtt gggcgcgtcc 2280
cagccctgttgg tggccggagg caccacggcc acccttcatcc ctggatcttgc 2340
gtgtgtgtgg ttgtgggtct tgggtcttca atgccttca agaggtgaaa aaccaaaga 2400
acaagaattt ctgtttaaga agccgggaa acacaaacaga agtcatgtaa cccaaatgaa 2460
atcaaagggtt ctaatggc gccaggaga catccgttgc gtttgcgtc gttttggaa 2520
ctctgtggact acatcacaggc acacggggca ttggcaaccc tttctatgg ccagctcgt 2580
cccatcagag agcgagccgt accactctt aaatagcaat ttgcggccgt gggggagg 2640
gaaaaaccac tagaactctc catttttt tcatgtatat gtgttcat 2688

```

SEQ ID NO: 33 moltype = DNA length = 2964
 FEATURE Location/Qualifiers
 misc_feature 1..2964
 note = Matrice PD1 locus_IL15_2A_sIL15Ra pCLS30513
 source 1..2964
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 33
 gactcccccac agaggccctg gaacccccc accttctccc cagccctgtc cgtgggacc 60
 gaaggggaca acgcacccctt caccgtcago ttctccaaaca catcgaggag cttcgctcta 120
 aactggtacc gcatgagccc cagcaaccag acggacaacg tggccgcctt ccccgaggac 180
 cggagccaggc cccggccaggc ctggcgctc cgtgtcacac aactgcccac ccgggggtgac 240
 ttcacacatgaa cgtgtgtcg ggcggccggc aatgacagccg gcacactact ctgtggggcc 300
 ggttctggcc tggaaacagac ttgttattt gaccccttca agttgggggg agacgtggag 360
 tccaaccccg gggccggatc cgggtccggcc accatggact ggacctggat tctgttctc 420
 gtgtgtgtcg ctacaagatg gcacagccg attcatgttc tcatatgtgg ctgtttcgt 480
 gcagggttc tttaaacaga agccaaatgg gttaaatgttta taatgttattt gaaaaaaatt 540
 gaagatcttta tttaaatctat gcatatgtt gttactttat atacggaaat tgatgttcc 600
 cccagttgtca aagtaacagc aatgaagtgc tttcttctgg agtttacaatg tatttcactt 660
 gagtccggag atgcaatgtt tcatgtatca gtagaaaaat ttgtatcatctt agcaacaaac 720
 agtttgtctt ctaatggaa ttgttgcgatgca aatggatgtt gggaaactggag 780
 gaaaaaaata ttaaaatgtt ttttgcgatg tttgttacata ttgttccaaat gttcatcaac 840
 acttctggaa gggggactac taacttcago ctgctgaacg aggctggaga cgtggaggag 900
 aaccctggac ctgggaccgg ctctgcaacc atggattggg cgtggatcct gtttctcg 960
 gcagctgcca caagagttca cagatctacg tgcctccccc ccattgtccgt ggaacacgca 1020
 gacatctggg tcaagagctt cagttgtac tccaggggc ggttacatttg taactctgg 1080
 ttcaagcgta aagccggcac gtccagctg acggagtgcc tggtaaccaa ggccacgaa 1140
 gtggccactt ggacacccccc cgttccaaat tgcatatggact accctgcctt ggttccacaa 1200
 aggccagccg caccctccac agtaacgcg gcagggttgca cccacaggcc agagagctc 1260
 tcccttctg gaaaaggcc cgcacccgttca tttcccaatgtaaacaac acggccacac 1320
 acagcagcta ttgtccccc ctcggatctg atgccttcaaa aatcaccttc cacaggaacc 1380
 acagagataa gcaatgtca gtcctccac ggcacccccc ctcagacaaac agccaagaac 1440
 tgggaaactca cagatccgc ctcggccac ccggccagggt tgtagtccaca gggccacagc 1500
 gacaccactg aggccaggc caccgtgtcg acctgtggcc acgtcgaggaa gaacccccc 1560
 cccatggggg cagggtccac cgccggccgctt atggacggcc cgcgcgtgt gctgtgtc 1620
 cttctggggg tggcccttgg aggtgccaag gaggcatgc ccacaggct gtacacacac 1680
 agcggtgagt ggtgcaaaacg ctgcaacccgtt ggcagggttg tggccccaggc ttgtggagcc 1740
 aaccagaccc tgggtgagcc ctggctggcc agcggtgacgt ttcctcgact ggtgagcgc 1800
 acccgagccgt gcaaggccgtt caccgtgtgc gttggggctcc agacatgtc ggcggccgtc 1860
 gtggaggccg atgacggccgt gtcggcgtc gcttacggc actaccaggta tgagacgact 1920
 gggccgtccg aggccgtccg cgtgtgcgag gggggctgg gctctgtt ctccgtccag 1980
 gacaaggccgta acaccgtgtt cggaggatgc cccgacggca cgttcccaac acggccacac 2040
 cacgtggacc cgtgtccgtcc ctgcaccctg tggaggacca cccggccgag 2100
 tgcacacgtt gggccggccgc cggatgtccg gggatccctg ggcgttggat tacacgtcc 2160
 acaccccccaggccaggc caccacggcc cccagccaccaggcgttgc ggcacccctca 2220

-continued

```

gaacaagacc tcatacgccag cacgggtggca ggtgtggtga ccacagtat gggcagtc 2280
cagcccgtag tgacccgagg caccaccgac aacctcatcc ctgtcttatg ctccatctg 2340
gtctgtgttgg ttgtgggtct tttgtggctac atagccttca agaggtgtatc tagagggcc 2400
gtttaaaccc gtcgtatcgc ctcgactgtg cttctatgtt gccagccatc ttgtgttgc 2460
ccctccccccg tgccttcctt gaccctggaa gggtggccactc ccactgtctt ttccatataa 2520
aatgaggaaa ttgcacatcga tttgtgtatc aggtgtatc ttattctggg ggggtgggtg 2580
gggcaggaca gcaaggggga ggatggggaa gacaataga ggcatgtgg ggttgccgtg 2640
ggctctatga ctatgtggcga attcgccgca gatcaaagag agctcgccgg cagagctc 2700
ggtgacaggt gggccctggg agggcccccggg gcagggttga gtcggccggg ttctgggtg 2760
ggtgtccctt ctgcacagg atcaggatc ccagggtctg agggcaggga ccccccaact 2820
ccatgtccagg gtctgttctt gcaactgggg aatggtacc ggcatctctg ttcttagt 2880
cttggaaagcac cccagccctt ctatgtctcc ctcaccctctg accctgaccc tccaccctga 2940
ccccgtctta accccctgacc ttg 2964

```

```

SEQ ID NO: 34 moltype = DNA length = 3363
FEATURE Location/Qualifiers
misc_feature 1..3363
note = Matrice CD25 locus_IL12a_2A_IL12b pCLS30520
source 1..3363
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 34

```

```

gtttattttt cctgttccac agtatttgc tgccatataa aaacttaggc cagggcacagt 60
ggctcacacc tgtaatccca gcacccatgg aggccgaggc aggccatca caagggtcagg 120
agttcgagac cagccgtggc aacatagca aaccccatctt ctactaaaaa tacaaaaatt 180
agccaggcat ggtggcgtgt gcactgtgtt agatgtgggg ccacatttt ttgggtgcgt 240
gttacacata tggaccgtac tttgttacac cactacggg ggaaggtatc aagaacatc 300
ggttctggc tgaaacagac tttgaattttt gacccatctca agttgggggg agacgtggag 360
tccaacccag ggcctatgtg gccccctggg tcagccctccc agccacccggc ctcacccgtc 420
ggggccacag gtctgtatcc acggccgtcc cctgtgtccc tgcaatgtccg gtcagcatg 480
tgtccacgcgc gcaactccctt ccttgggtt accctgttcc ttctggccca ccttcgttt 540
ggccggaaacc tccctgtggc cactccatc ccaggatgtt ccctcatgtt tcaccactcc 600
caaaaacctgc tgagggccgt cagcaacatc ctccagaagg ccagacaaac tctagaattt 660
tacccttgcg ctccatgtt gattgtatc gaagatataa aaccacgaca 720
gttggaggcgt gtttacccat gggatataacc aagaatgaga gttgcataaa ttccagagag 780
acctcttca taactaatgg gagttgcctg gcctccaaagaa agacctttt tatgtggcc 840
ctgtgccta ttagtattta tgaagacttg aagatgtacc aggtggggat caagaccatg 900
aatgcacaaac ttctgtggg tccttgcgtt tagatcaaaa catgtggca 960
gttattgtat agctgtatc ggcctgtat ttcaacatgtt agactgtgcc acaaaaatcc 1020
tcccttgcg aaccggatcc ttataaaact aaaaatcaacg tctgcataact tcttcatgt 1080
ttcagaattc gggcactgtac tattgtatca gttgtatcgtt atctgtatgc ttccggaaagc 1140
ggagactaca attcgcgtt gctgtgggg ggtggggggaa ccctggaccc 1200
atgtgttccatc acggatgtgtt catcttgcgtt tttttctggc atctccctcc 1260
gtggccatata gggaaatgtt tagtgcgtt aattggatgtt gttatccggat 1320
gcccctggg aatgtgtgtt cctcacccgtt gacacccctgtt aagaagatgg tatcacctgg 1380
acccctggacc agagcgtgtt ggtgttgcgtt tctggcaaaa ccctgcacat ccaacttccaa 1440
gagttttggat atgtggccca gtacacccgtt cccaaaggagg ggggggttcc aaggccatcg 1500
cttctgtgtc ttccaaaaaa gggaaatgttcc atttgggttca ctgtatattt aaaggacccat 1560
aaagaaccca aaaataagac cttttcaaga tgccggccca agaatttttcc tggacgtttc 1620
acccctggaccatc ggtgtgtgtt ggtgttgcgtt tttttccgtt aatccatcc 1680
gggtttttccg aaccccaagg ggtgtgtgtt ccacttgcgtt agagagatgt 1740
agaggggaca acaaggatgtt tgtagtactca tggtgtgtcc aggaggaccc tgccctggcc 1800
gctgtgtgggg agagttgtcc cattgggttcc atgggtggat ccgttccaa gtcgttat 1860
gaaaactaca ccacgtgtt ctccatgttcc gacatcatca aaccctgttcc acccaacaaac 1920
ttgcagttgtt gggccatataa gaatttccgtt cgggtgggg tcaatgtggg gttaccctgac 1980
acccctggatca ctccacatcc tcaatgttcc ctgtatccatcc ggtttccgtt ccaggccaaag 2040
agcaagagag aaaagaaga tagatgttcc acggacaaga ccttcacccac ggttcatctgc 2100
cgcaaaaatcc ccacgttccatcc cttgtggggcc cggggccgtt actatgttcc atcttggggc 2160
gaatggggcat ctgtggccgtt cagtggggcc agggccatcc tggtgtgttcc cggccatcc 2220
ggggggggccatc cggggccatcc gggggccatcc gggggccatcc cggggccatcc 2280
ctgtgtgtgtt tgggtgttcc ttttttttttcc gggggggggatcc atggggggggatcc 2340
ggccctgtaca cacacagccg gttgtgtgttcc aaacccctgttcc acctggggcc ggggtgtggcc 2400
cggccctgtgtt gggccatcc gggccatcc gggccatcc gggccatcc gggccatcc 2460
gacgtgtgtgtt gggccatcc gggccatcc gggccatcc gggccatcc gggccatcc 2520
atgtcggtccatcc ggtgtgtgttcc gggccatcc gggccatcc gggccatcc 2580
caggatgaga gggccatcc gggccatcc gggccatcc gggccatcc 2640
gtgtgtgtgtt gggccatcc gggccatcc gggccatcc gggccatcc 2700
tccgtggccatcc gggccatcc gggccatcc gggccatcc gggccatcc 2760
cgccatcc gggccatcc gggccatcc gggccatcc gggccatcc 2820
tggattacac gggccatcc gggccatcc gggccatcc gggccatcc 2880
cctggggccatcc gggccatcc gggccatcc gggccatcc 2940
gtgtgtgtgtt gggccatcc gggccatcc gggccatcc gggccatcc 3000
tattgtgttccatcc ttttttttttcc gggccatcc gggccatcc gggccatcc 3060
tggatccatcc gggccatcc gggccatcc gggccatcc gggccatcc 3120
tggatccatcc gggccatcc gggccatcc gggccatcc gggccatcc 3180
cctggggccatcc gggccatcc gggccatcc gggccatcc gggccatcc 3240
ctatgtgtgttccatcc gggccatcc gggccatcc gggccatcc gggccatcc 3300
cggtgtgtgtt gggccatcc gggccatcc gggccatcc gggccatcc 3360
cat 3363

```

-continued

SEQ ID NO: 35 moltype = DNA length = 3639
 FEATURE Location/Qualifiers
 misc_feature 1..3639
 note = Matrice PD1 locus_IL12a_2A_IL12b pCLS30511
 source 1..3639
 mol_type = other DNA
 organism = synthetic construct
 SEQUENCE: 35
 gactccccag acaggccctg gaacccccc accttctccc cagccctgct cgtggtgacc 60
 gaaggggaca acggcacctt cacctgcago ttcccaaca catcgaggag ctccgtgcta 120
 aactggtacc gcatgagccc cagaaccag acggacaagg tgccgcctt ccccgaggac 180
 cgcagccaggc cggccaggag ctgcgtctt cgtgtcacac aactgccc aaaggcggtgac 240
 ttccacatga cgtgttcgaa gggccggc aatgacagcc gcaactactt ctgtggggcc 300
 ggttctggcg tggaaacagac tttaattttt gaccccttca agttgggggg agacgtggag 360
 tccaaccagg gggccatgtg gccccctggg tcagccctcc agccaccggc ctcacctgccc 420
 gggggccacat gctgtccatcc aegggctcgc cctgtgtccc tgcagtgcgg gctcagcatg 480
 tggccagccgc cagcccttcc ctttgcgttgc cccctggcc tccctggacca cctcagtttgc 540
 gccagaaaacc tcccccgtgc cactccagac ccaggatgt tcccatgtct tcaccactcc 600
 caaaaacctgc tgagggccgt cagcaacatg ctccagaagg ccagacaac tctagaatttt 660
 tacccttgcga cttctgaa gattgtatcga aaaaagataa aaccaggcaca 720
 gtggaggccgt gtttaccatt ggaattaacc aagaatgtgg gttgcctaaa ttccagagag 780
 acctcttca taactaatgg gagttgcgtg gcctcccgaa agacccctt tatgtggcc 840
 ctgtgcctta gtatgtttt tgaagacttg aagatgtacc aggtggagtt caagaccatg 900
 aatgcaaaacg ttctgtatggc ttccaaaggagg cagatctttt tagatcaaaa catgtggca 960
 gttattgtatcgtgc gggccatgtt ttcacacatgg agactgtggc aaaaaaaatcc 1020
 tcccttgcgg aaccggattt ttatataactt aaaaatcaacg tctgcataactt tcttcatgt 1080
 ttcagaattc gggcgtgtac tattgtataga gtgtatggcgt atctgtatgc ttccggaaage 1140
 ggagctacta acttcagccgt gtcgaaggag gtcggagacg tggaggagaaa ccctggaccc 1200
 atgtgtcacc agcgatgtgtt catcttctggg ttttttgcg atctccctc 1260
 gtggccatata gggaaactgaa aaaaatgtt tttatgtcgtag aattttggatg gtatccggat 1320
 gccccctgggg aatatgtgggt cctcacctgt gacaccctgg aagaagatgg tattcacctgg 1380
 accttggacc agagcgtgt ggtttaggc tctggcaaaa ccctggaccc ccaagtcaaa 1440
 gagtttggggat atgtgtccca gtacacatgtt cacaaggagg gcgagggttca aaggccatcg 1500
 ctctctgtgc ttccaaaaaa gggaaatgtt atttgggttca ctgtatattt aaaggacccag 1560
 aaagaacccca aaaataagac ctttcaaga tggaggccca aqaattattt tggacgttcc 1620
 acctgtgtgtt ggctgtgcac aatcgtactt gattgtatcgtt tcagtcgttca aagcagccaga 1680
 gggttcttcg acccccaagg ggtgtgtgc gggacgtgtca cacttcgtc agagagatgc 1740
 agagggggaca acaaggatgtt tgatgtactca acgggtgtcc tggaggatcc agggaggacg tggctgtccca 1800
 gctgtgtgggg agagatgtgttcc catttggatgtt ccgttccaaa gctcaagttt 1860
 gaaaactaca ccagcgtt ctttcatcagg gacatcatca aacctgtaccc acccaagaac 1920
 ttgcgtgtca accccataaa gaaatcttcggg cagggtggagg tcagctggg gtaccctgtac 1980
 accttggatca cttccatcc tcatttcgtt ctgcatttcgtt ccagggttcc 2040
 agcaagagag aaaaagaaaatg tagatgttcc acggacaaga ccttcacccatcc ggtcatctgc 2100
 cgcaaaaaatg ccagcattag cgtgtggggcc caggaccgtt actatagtc acctttggacc 2160
 gaatgtggcat ctgtgtccgtt cagttggggcc agaggccatgtc tgctgtgtcc cggccgtcc 2220
 gaggagaatggccccc gggggccatgtt gccacccggcc gegeccatggg cggggccgcgc 2280
 ctgtgtgtgtt ggggggttcc ctgggggttcc ccaaggaggcc atggcccccaca 2340
 ggccctgtaca cacacacggg tgatgtgtccaa aaacgtgtccaa acctggggcc ggggtgtggcc 2400
 cagccctgtgtt gggccacccatgtt gggccgtgttcc tggggccgtcc gacgttctcc 2460
 gagctgtgtgttcc gggccgtccaa gggccgtgttcc cggccgtcc gggccgtcc 2520
 atgttggccgc cggccgtgttcc gggccgtgttcc gggccgtcc gggccgtcc 2580
 caggatgaga cggccgtccaa gggccgtccaa gggccgtcc gggccgtcc 2640
 gtgttcttcgttcc gggccgtccaa gggccgtccaa gggccgtcc gggccgtcc 2700
 tccgacggggcccaaccatgtt gggccgtccaa gggccgtccaa gggccgtcc 2760
 cggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 2820
 tggattacac gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 2880
 ctgtgtgtgttcc gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 2940
 gtgtgtgtgttcc gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3000
 tattgtgttccaa tttttttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3060
 tgatgtgtgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3120
 ccatctgtgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3180
 gtcttccatgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3240
 ctgtgtgtgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3300
 gctggggatgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3360
 gggggccatgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3420
 gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3480
 agggccatgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3540
 ctgtgtgtgttccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3600
 gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtccaa gggccgtcc 3639

SEQ ID NO: 36 moltype = DNA length = 3017
 FEATURE Location/Qualifiers
 misc_feature 1..3017
 note = Inserted matrice TRAC locus_CubiCAR CD22 (60 nucleotides upstream and downstream)
 source 1..3017
 mol_type = other DNA
 organism = synthetic construct

-continued

SEQUENCE: 36

```

atgagatcat gtcctaaccct tgatecctt gtcccacaga tatccagaac cctgaccctg 60
ttgctggcc tttttccat gcctgcctt actctgcca agtttatattg ctgggtttt 120
gaagaagata ctattaaata aaagaataag cagtattatt aagttagccct gcatttcagg 180
ttcccttgag tggcaggcca ggccctggcg tgaacgttca ctgaaatcat ggcctctgg 240
ccaagatgta tagcttgcg ctgtccctga gtcccaggctc atcacgagca gctggttct 300
aagatgtat ttccctgtata aagatgaga ccgtgacttgc ccagccccac agagccccgc 360
ccttgtccat cactggcatc tggactccag cctgggttgg ggcaaagagg gaaatgagat 420
catgtcttaa cctgtccatc ctgtccctac agatatccag tacccttacg acgtgcccga 480
ctacgcctcc ggtgaggggca gggaaatgtct tctaacaatgc ggtgaetgg aggagaatcc 540
ggggccccgggaa tccgtctgc ccgttcccgcc tctgtctgtc ccactggcac tgctgtgca 600
cgctgtctgg cccggggggg gggcagctg ccctacagc aaccccaagcc tgcagccgg 660
aggccggccggc aecgggggggg ggggttggca ggttggccatc cagcagccgg gcccggcc 720
gttggaaaggca ggccaggcaac tgcgtccatc ctggccatc acggccgatt ccgtgagctc 780
caactccccc ggcgttgcattt ggttggccatc gtcccttctt cggggcttgg agtggcttgg 840
aaggacatac tatacggttata agtggtacaa cgattatgcg gtgtctgtgaa agagcagaat 900
cacaatcaac cctgttgcattt ccaagaatca gtttctctgtc cagctgaaata gctgtgacacc 960
agaggacacc gccgtgtactt attcggccatc ggggttggccatc ggcgacccctgg aggtgcctt 1020
tgacatctgg gggccaggca caatggatc ctgttgcattt ccgttggccatc gatctggccg 1080
aggaggaagt gggggggggc gggttgcattt ccagatgaca cagtcctccat ccttcgttgc 1140
cgccctccgtg ggcgttgcattt tgacatcactt ctgttggccatc tcccttgcattt 1200
ctctgtactgg tatacgccatc gggccggcaatc gggcccttataat ctgttgcattt acgcagcc 1260
ctccctgtccatc aecggggatgc catccatgttgc ctgttggccatc ggcgttggccatc 1320
cctgttgcattt ttttttttttttccatc agggccggatc ctgttggccatc tactatttgc 1380
tagcatcccc cagatccatc ggcaggccatc caagctggatc atcaatgttgc 1440
cgagggggggaa ggcgttgcattt ccttcgttgcattt ccccaatgttgc tgcagccggatc gggccggcc 1500
cgagctgtcc accccaggccatc ctttttttttttccatc ctgttggccatc aacgttgcattt 1560
caccaccacc ggcgttgcattt attcacatc ttccctgtgttgc gtcgttgcattt 1620
tccaaggccatc ctttttttttttccatc ccaactatc tgccctccatc ccacttcac tgccggccatc 1680
ggccgttgcattt cccgttgcattt gggccggatc gtcgttgcattt 1740
tattttatccatc tggccatccatc tcgcggccatc ctggggggatc ctttttttttttccatc 1800
taccctgtat tgcagacccggg gcccggaaatc gtttccatc atttttatc acgttgcattt 1860
ggccggccatc cccgttgcattt attcacatc ttccctgtgttgc gtcgttgcattt 1920
ggaaaggccatc tgcgttgcattt gggccggatc gtcgttgcattt 1980
acaggccatc aaccatgttgc atcaacatc taacccatc gggccggatc aatccatc 2040
gttggataag agaaggggggc gggcccccgcgatggggatc aagcccccgcgatggggatc 2100
tcaggaggccatc tgcgttgcattt acgttgcattt 2160
cggttgcattt gggggggccgatggccatc gggccggatc gggccgttgcattt 2220
cacaatccatc aaggacatc acgttgcattt 2280
gttccatc aaccatgttgc atcaacatc taacccatc gggccggatc aatccatc 2340
atctgttgcattt tgcgttgcattt 2400
ccttttttttttccatc taaaatgttgcattt 2460
gggggggttggggatc tggggggatc acgttgcattt 2520
tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 2580
aaatccatc aaccatgttgc atcaacatc taacccatc gggccggatc aatccatc 2640
caaaatggatc ttttttttttttccatc aaaaaatgttgcattt 2700
gacttcaatc gcaacatgttgc tggggatgcgttgc acgttgcattt 2760
gttccatc aaccatgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 2820
tttgggttgcgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 2880
tgggttgcgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 2940
aaccccttttccatc aaccatgttgc atcaacatc taacccatc gggccggatc aatccatc 3000
aaaaaaatgttgcgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 3017

```

SEQ ID NO: 37

```

moltype = DNA length = 2808
FEATURE Location/Qualifiers
misc_feature 1..2808
note = Inserted matrice CD25 locus_IL15_2A_sIL15Ra (60
        nucleotides upstream and downstream)
source 1..2808
mol_type = other DNA
organism = synthetic construct

```

SEQUENCE: 37

```

agtgtggctt aaaaaatgttgcgttgc tggggatgcgttgc tggggatgcgttgc 60
gttttatttccatc aaccatgttgc tggggatgcgttgc tggggatgcgttgc 120
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 180
agtttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 240
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 300
gttccatc aaccatgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 360
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 420
tccaaaccatc aaccatgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 480
gttccatc aaccatgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 540
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 600
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 660
cccaatgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 720
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 780
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 840
ggccgttgcattt tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 900
acttctgttgc tggggatgcgttgc tggggatgcgttgc tggggatgcgttgc 960
aaccccttttccatc aaccatgttgc atcaacatc taacccatc gggccggatc aatccatc 1020

```

-continued

gcagctgcca	caagagttca	cagtatca	cg	tgc	ccccc	ccatgtccgt	ggAACACGCA	1080
gacatctggg	tcaagagcta	cagttgtac	tccaggagc	gg	tacatttg	taactcttgt	1140	
ttaaagcgta	aagccggcac	gtccagctg	acggagtgc	tgtt	aaaaaa	ggccacaa	1200	
gtcgccccact	ggacaacccc	cagttcaaa	tgcatttaga	accctgc	ccctgtcc	ggttcaccaa	1260	
aggcccgacg	caccctccac	agtaa	cg	gggggtga	ccccacagcc	agagagctc	1320	
tcccttctg	gaaaagagcc	cgcagttca	tctcc	ccagct	aaaacaa	acac	1380	
acacgagota	tttgc	ccccagctg	atgc	cttca	aatcac	cacaggaa	1440	
acagagataa	gcagtc	atc	gttcc	ccac	ccatc	cacaggaa	1500	
tggttgc	actca	ccatccc	gtc	ctc	ccccc	ctcagaca	1560	
gacaccactg	aggggc	agg	ctgc	ccccc	ccatc	gggcccacagc	1620	
cccatgggg	cagg	ttcc	ccac	gggg	ccatc	ggggcc	1680	
cttctgggg	tgt	ccctt	gg	gg	ccatc	ggggc	1740	
agcggtg	act	gg	cc	gg	ccatc	ggggc	1800	
ggttgc	aa	cc	cc	gg	ccatc	ggggc	1860	
aacc	cc	cc	cc	gg	ccatc	ggggc	1920	
gtggaggcc	atg	cc	cc	gg	ccatc	ggggc	1980	
gggcgc	gg	cc	cc	gg	ccatc	ggggc	2040	
gaca	cc	cc	cc	gg	ccatc	ggggc	2100	
cacgtt	acc	cc	cc	gg	ccatc	ggggc	2160	
tgcac	ac	cc	cc	gg	ccatc	ggggc	2220	
acac	cc	cc	cc	gg	ccatc	ggggc	2280	
gaaca	cc	cc	cc	gg	ccatc	ggggc	2340	
cacgg	cc	cc	cc	gg	ccatc	ggggc	2400	
gtgt	cc	cc	cc	gg	ccatc	ggggc	2460	
aca	cc	cc	cc	gg	ccatc	ggggc	2520	
atca	cc	cc	cc	gg	ccatc	ggggc	2580	
ctt	cc	cc	cc	gg	ccatc	ggggc	2640	
ccca	cc	cc	cc	gg	ccatc	ggggc	2700	
gcaaa	cc	cc	cc	gg	ccatc	ggggc	2760	
gg	cc	cc	cc	gg	ccatc	ggggc	2808	

SEQ ID NO: 38 moltype = DNA length = 3084
 FEATURE Location/Qualifiers
 misc_feature 1..3084
 note = Inserted matrice PD1 locus_ IL15_2A_sIL15Ra (60
 nucleotides upstream and downstream)
 source 1..3084
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 38
 gggtggccggg gaggcttgc gggccaccc agccccttc tcacctcttc ccatctctca 60
 gactccccag acaggccctg gaacccccc accttctccc cagccctgc ctgtgtgacc 120
 gaaggggaca acggccaccc taccgtcago ttctccaaca catcgagag cttcgtgtca 180
 aactggtacc gcatgagccc cagaacccag acggacaacg tggccgcctt ccccgaggac 240
 cgcagccagc ccggccagga ctggccgttc cgtgtcacac aactgccccaa cgggcgtgac 300
 tttccacatga gggtggtcgac ggccggcgcc aatgacagcc gcacccactt ctgtggggcc 360
 gggttctggcc tggaaacagac ttgttctca aatggccgggg agacgtggag 420
 tccaaccccg gggccggatc cgggtccggc accatggact ggacccgttat tctgttcttc 480
 gtggctgtct ctacaagagt gcacagccgc attcatgtct tcattttggg ctgttctact 540
 gcaggccgtt ctaaaacaga agccaaactgg gtgtatgtaa taatgtattt gaaaaaaatt 600
 gaagatctta tcaatcttat gcatatgtat gtcattttat atacggaaag tgatgttccac 660
 cccagttgca aatgaaacgc aatgaaatgc tttctcttgg agtttacagt tatttcactt 720
 gagtccggatc atgcaatgtat tcatatataca gtagaaaatc tgatcatctt agcaaaacaac 780
 agtttgcattt ctaatggaa tggtaacagaa tctggatgc aagaatgtga ggaactggag 840
 gaaaaaaaaata tttaaagaaatt tttgcagatg ttgttacata ttgtccaaat gttcatcaac 900
 acttctggaa gggggatc tcaatcttgc ctgttgcggc aggctggaga cgtggaggag 960
 aaccctggac ctgggaccgg ctctgcaccc atggattggg cgtggatctt gtttctctg 1020
 gcagctgcca caagagttca cagtttcacgc tgccttcccccc ccatgtccgtt ggaacacgc 1080
 gacatctggg tcaagagttca cagttgtac tccaggggatc ggttacatttgc taactcttgtt 1140
 ttaaagcgta aagccggcac gtccagctg acggagtgc tggtaaaaaaa ggccacaaat 1200
 gtcgccccact ggacaacccc cagttcaaa tgcatttaga accctgcctt ggttaccaa 1260
 aggcccgacg caccctccac agtaa

-continued

```
cagcccggtgg tgaccggagg caccacccgac aacccatcatcc ctgtcttattt ctccatcttg 2400
gctgctgtgg ttgtgggtct tggccatcac atagccttca agagggtatc tagaggggccc 2460
gtttaaaccc gtcgtatcgc ctcgactgtg ctttctatgtt gccagccatc tgggtttgtc 2520
ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtctt ttcataataa 2580
aatggggaaa ttgcatcgc tttgtgttgtt aggtgttcatc tttttctggg gggtgggtgt 2640
ggcaggaca gcaaggggggaa gacaatagca ggcatgtggg ggatgcgggtg 2700
ggctctatga ctatgtggca attcggcga gatcaaagag acgctgggg cagagcttag 2760
ggtgacaggt gggccctggg aggccccggg gcaggggtga gctgagccgg tccctgggtg 2820
gggtgtccccc ctgcacagg atcaggagct ccagggtcggtt agggcaggga ccccccagct 2880
ccagtccagg gtctgtggg gcaatgtggg aatgggtgacc ggcatctcg tcccttagct 2940
cttggaaoccc cccagccctt ctatgtgtcc ctcacccttgc accctgaccc tccaccctga 3000
ccccgttcta accccctgacc tttgtgtcc tccagagaga agggcagaag tgcccacagc 3060
ccaccccaagc ccctcaccca ggcc 3084
```

SEQ ID NO: 39 moltype = DNA length = 3475
 FEATURE Location/Qualifiers
 misc_feature 1..3475
 note = Inserted matrice CD25 locus_IL12a_2A_IL12b (60
 nucleotides upstream and downstream)
 source 1..3475
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 39
 agtgctggct agaaaccaag tgctttactg catgcacatc atttagcaca gtttagttgtc 60
 gtttattttt ctgttccac agcttatttgc tgccatataaa aaacttaggc caggcacagt 120
 ggctcacacc tggtaatccca gcaacttggg aggccggggc aggccatca caaggctcagg 180
 agttcggagac cagccgtggc aacatagcaaa aaccccatctt ctactaaaaaa tacaaaaattt 240
 agccaggcgtt ggtgggtgtt gcaacttgggtt agagtggagga ccacatttt ttgggtgcgt 300
 gtttacacata tgaccgtgac ttgtttatcac cactacagga ggaagagtag aagaacaatc 360
 ggttctggcg tggaaacagac ttgttattttt gacccatgtca agttgggggg agacgtggag 420
 tccaaaccccg gggccatgtg gccccctggg tcagccctcc accccacggcc ctcaccctgccc 480
 gggggccacac gtctgtatcc accgggctcg cctgtgtccc tgcagtgcgg gtcagcatg 540
 tggccagggc gcaatgtggc tccctgtgggtt accctgtggc tccctggacca cctcaatgg 600
 gccagaaaaaccc tcccccgtggc cactccagaccc ccaggaaatgt tcccatgtgttcc tccaccactcc 660
 caaaacccgtc tgaggccgtt gcaacatcgatccaaagg ccagacaaac tcttagattttt 720
 tacccttgca cttctgttca gattgtatcat gaagatataa caaaagataaa aaccacgacaca 780
 gtggaggccgt gtttaccattt ggaattaacc aagaatgaga gttgcctaaa ttccagagag 840
 accctcttca taactaatgg gatgtgtccg gcttcccaaaaa agacccctttt tatgtgtggcc 900
 ctgtgtcccttta ttagtattttt gtaaagatgg aatgtgtacc aggtgggtt caagaccatg 960
 aatgcacaaaccc ttctgtatggc ttcttgcaggatccatcttttccatgtgtggca 1020
 gtttattgtat gactgtatgc gggccatgtt ttcaacatgtt agactgtgtcc acaaaaatcc 1080
 tcccttgcgg aaccggatattt ttataaaaatcc aaaaatcaacg tctgtatcaact tctttatgtgt 1140
 ttcagaatcc gggcgtgtatc tattttatgtat gatgtgtatcc tcttccggaaacg 1200
 ggagctacta acttcggccat gcttgcggccat gtcggagaccc tggaggagaaa ccctggaccc 1260
 atgtgttacc accgtgttgcgatccatcttttccatgtgtggc ttttttgcgttccatctcc 1320
 gtggccatattt gggaaatgttgcgatccatgtgtggatccatgtgtggatccatgtgtggatcc 1380
 gcccctgggg aatgtgtgttgcgatccatgtgtggatccatgtgtggatccatgtgtggatcc 1440
 accttggacc accggcgttgcgatccatgtgtggatccatgtgtggatccatgtgtggatcc 1500
 gagttttgggg atgtgtggccat gtcggccat gtcggccatccatgtgtggatccatgtgtggatcc 1560
 ctctgtgtcc ttcacaaaaaa ggaatgtatccatgtgtggatccatgtgtggatccatgtgtggatcc 1620
 aaagaacacca aaaaatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 1680
 acctgtgttgcgatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 1740
 ggcttcttcg acccccaagg ggtgtatccatgtgtggatccatgtgtggatccatgtgtggatcc 1800
 agaggggacca acaaggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 1860
 gctgtgtccat gatgtgtccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 1920
 gaaaacttccat ccaggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 1980
 ttgcagttccat gacccatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2040
 accttggatccat cttccatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2100
 agcaagggatccat aaaaatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2160
 cggccatccat ccaggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2220
 gaatggccat ctgtgtccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2280
 gagggggaccc cccggggccat gggggccatgtgtggatccatgtgtggatccatgtgtggatcc 2340
 ctgtgtgtgttccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2400
 ggccctgttccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2460
 cagccctgttccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2520
 gacgtgtgtccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2580
 atgttggccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2640
 caggatgtatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2700
 gtgttcttcgttccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2760
 tccggacggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2820
 cgccagatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2880
 tggatttccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 2940
 cctggggccatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3000
 gtgtatggccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3060
 tattgttccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3120
 tgaaaaaatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3180
 tgaagccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3240
 cctggccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3300
 ctatgtgtccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatccatgtgtggatcc 3360

-continued

cgttgaagag gaaggccaaa accactagaa ctctccatct tattttcatg tatatgttgtt 3420
 catgaatgtt atggaactct ctccacccta tatgttagtat aaagaaaagt aggtt 3475

SEQ ID NO: 40 moltype = DNA length = 3759
 FEATURE Location/Qualifiers
 misc_feature 1..3759
 note = Inserted matrice PD1 locus_IL12a_2A_IL12b (60
 nucleotides upstream and downstream)
 source 1..3759
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 40
 gtggccggg gaggcttgc gggccaccc agccccttcc tcacctcttc ccatctcca 60
 gactccccag acaggccctg gaaccccccc accttctccc cagccctgtc cgtgggacc 120
 gaaggggaca acggcacccctt cacctgcago ttctcaaca catcgagag cttcgctcta 180
 aactggtacc gcatgagccc cagaaccag acggacaage tggccgcctt ccccgaggac 240
 cgccggccagg ccggccaggta ctggccctc cgtgtcacac aactgcccac cggcgctgac 300
 ttccacatga cgtgttgtcgc ggccggcgc aatgacagcg gcacactact ctgtggggcc 360
 ggttctggcg tggaaacagac tttgaatttt gaccccttcga agttgggggg agacgtggag 420
 tccaaaccagg gggccatgtg gccccctggg tcaagctccc agccacccggc ctcacctgcc 480
 gggccggccacag gtctgcattcc aegggctcgc cctgtgtccc tgcagtgccg gctcagcatg 540
 tggccggccgc gcaagcttcc ctttgcgttgc accctgggttcc tcttggacca cctcagtttgc 600
 gccggaaacc tcccccgtgc caactccagac ccagggatgt tccctgcgt tcaccactcc 660
 caaaacatgc tgaggccgt cagcaacatg ctccagaagg ccagacaaac tctagaatttt 720
 tacccttgca ttctgttca gattgtatcga aaaaagataa aaccaggcaca 780
 gtggggccctt gtttaccatt ggaatgttacc aagaatgttacc gtttgcctaa ttcccgagag 840
 acctctttca taactaatgg gatggccctg gcctcccgaa agaccccttt tatgtggcc 900
 ctgtgcctta ttagtattt tgaagacttg aagatgttacc aggtggagtt caagaccatg 960
 aatgcaaaacg ttctgtatggc ttctaaaggagg cagatctttc tagatcaaaa catgtggca 1020
 gtttattgtatcgtgtc gggccctgtat gtttgcctgtat gtttgcctgtat gtttgcctgtat 1080
 tcccttgaa aaccggattt ttatataact aaaaatcaacg tctgcatact tcttcatgtct 1140
 ttcagaattc gggcaatgtac tattgtataga gtgtatgtatcgt atctgtatgc ttccggaaagc 1200
 gggagctacta acttcagccct gctgaagcag gctggagac tggaggagaa ccctggacct 1260
 atgtgttccacc agcaggatgttgc cttccatgttgc ttttccctgg atctcccttc 1320
 gtggccatata gggaaacttgc gaaatgttgc tatgtcgat aattttgttgc gttatccggat 1380
 gcccctggag aaatgttgc gtttgcctgt gacacccctt gaaagatgg tatcacctgg 1440
 accttggacc agagcagtga ggtttaggc tctggccaaa ccctgaccat ccaagtcaaa 1500
 gagtttggaggg atgttgcgc gtttgcctgt cacaaggaggac gcgagggttca aggccatcg 1560
 ctccctgtgc tttccatgttgc gtttgcctgtat ttttgcctgtat aaaggaccatg 1620
 aaagaaccca aaaataagac ctttcaaga tggaggccca agaatttttc tggacgttcc 1680
 acctgtgttgc ggttgcgc gatgttgc gtttgcctgtat ttttgcctgtat ttttgcctgtat 1740
 ggttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 1800
 agcaaggatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 1860
 gtttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 1920
 gaaaactaca ccaggcgtt cttcatcagg gacatcatca aacccgttcc acccaagaac 1980
 ttgcagctgtc accccatataa gtttgcctgtat ttttgcctgtat ttttgcctgtat 2040
 accttggatc tcccacattc ttttgcctgtat ttttgcctgtat ttttgcctgtat 2100
 agcaaggatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2160
 cgccaaaatgc ccaggcatttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat 2220
 gaatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2280
 gaggatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2340
 ctgtgtgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2400
 ggcctgtaca cacacagccgg ttttgcctgtat ttttgcctgtat ttttgcctgtat 2460
 cagcctgtgc gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat 2520
 gacgttgcgc gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat 2580
 atgttgcgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2640
 caggatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2700
 gtgttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2760
 tccgacggg ccaaccatgc gggccatgttgc ttttgcctgtat ttttgcctgtat 2820
 cggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 2880
 tggattacac gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat 2940
 cctgaggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3000
 gtgttgcgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3060
 ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3120
 tgatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3180
 ccatctgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3240
 gtgttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3300
 ctgggggggttgc gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat 3360
 gtttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3420
 gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3480
 gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3540
 agggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3600
 ctctgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3660
 gggccatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3720
 agaaatgttgc ttttgcctgtat ttttgcctgtat ttttgcctgtat ttttgcctgtat 3780

SEQ ID NO: 41 moltype = DNA length = 60
 FEATURE Location/Qualifiers
 misc_feature 1..60

-continued

```

source          note = upstream TRAC locus polynucleotide sequence
1..60
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 41
atgagatcat gtcctaacc tgatcctt gtcccacaga tatccagaac cctgaccctg 60

SEQ ID NO: 42      moltype = DNA length = 60
FEATURE
misc_feature       Location/Qualifiers
1..60
note = downstream TRAC locus polynucleotide sequence
source          1..60
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 42
gaaacagtga gccttggtct ggcagttcc agaatgacac gggaaaaaag cagatgaaga 60

SEQ ID NO: 43      moltype = DNA length = 60
FEATURE
misc_feature       Location/Qualifiers
1..60
note = upstream CD25 locus polynucleotide sequence
source          1..60
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 43
agtgcgtggct agaaaaccaag tgctttactg catgcacatc atttagoaca gtttagttgtc 60

SEQ ID NO: 44      moltype = DNA length = 52
FEATURE
misc_feature       Location/Qualifiers
1..52
note = downstream CD25 locus polynucleotide sequence
source          1..52
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 44
gaatggatg gaactctctc caccctatat gtatgtataaa gaaaaggtagg tt           52

SEQ ID NO: 45      moltype = DNA length = 60
FEATURE
misc_feature       Location/Qualifiers
1..60
note = upstream PD1 locus polynucleotide sequence
source          1..60
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 45
ggtgccgggg gaggctttgt gggccaccc agccccctcc tcacctctct ccatctctca 60

SEQ ID NO: 46      moltype = DNA length = 60
FEATURE
misc_feature       Location/Qualifiers
1..60
note = downstream PD1 locus polynucleotide sequence
source          1..60
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 46
tgccttcga gagagaaggg cagaagtgcg cacagccac cccagccct caccaggcc 60

SEQ ID NO: 47      moltype = DNA length = 759
FEATURE
misc_feature       Location/Qualifiers
1..759
note = IL-12a polynucleotide
source          1..759
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 47
atgtggcccc ctgggtcagc ctcccagcca cccgcctcac ctggcgccgc cacaggtctg 60
catccagccg ctcgcctgt gtcctgcag tgccgcgtcc gcatgtgtcc agccggcagc 120
ctccctccttg tggctaccgg gtcctcctgt gaccacctca gttggccag aaacctcccc 180
gtggccactc cagacccagg aatgttcca tgccctcacc actcccaaaa cctgtgagg 240
gcggcagca acatgttcca gaaggccaga caaactctag aattttaccc ttgcacttct 300
gaagagatgt atcatgaaga tatcacaaaa gataaaacca gcacagtgga ggcctgtta 360
ccattggat taaccaagaat tgagagtgc ctaaattcca gagagacctc ttctataact 420
aatgggatgt gcctggcctc cagaaagacc tcttttatga tggccatgtg ctttagtagt 480
attttatgaat acttgaaat gtaccagggt gatgtcaaga ccatgaatgc aaagcttctg 540
atggatctta agggcagat ctttctatgat caaaacatgc tggcagttat tgatgagctg 600
atgcaggccc tgaattcaa cagtgagact gtgccacaaa aatcctccct tgaagaacccg 660
gatttttata aactaaat caagctctgc atacttcttc atgctttcag aattcgggca 720
gtgactattg atagagtgtat gagctatctg aatgcttcc 759

```

-continued

SEQ ID NO: 48 moltype = DNA length = 984
 FEATURE Location/Qualifiers
 misc_feature 1..984
 note = IL12b polynucleotide
 source 1..984
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 48
 atgtgtcacc agcagtggat cacttctgg ttttccctgg tttttctggc atctccctc 60
 gtggccatat gggaaatggaa aaaaatggat tatgtcgtag aattggatgg gtatccggat 120
 gccccctggag aaatgggtt ctcacccctgt gacacccctgg aagaagatgg tataccctgg 180
 accttggacc agagcagtga ggtttaggc tctggcaaaa ccctgaccat ccaagtcaaa 240
 gagtttggggat atgtggccca gtacacctgt cacaaggaggac gggagggttct aagccatcg 300
 ctccctgtgc ttccacaaaaaa ggaagatggaa atttggtcca etgatatttt aaaggacac 360
 aaagaaccca aaaataagac ctttcaaga tgccggccca agaatttttc tggacgttcc 420
 acctgtgtt ggctgacgac aatcgtact gatttgacat tcagtgtcaa aagcagcaga 480
 ggctcttcg acccccaagg ggtgacgtgc ggagctgtca cactcttcg agagagatc 540
 agagggggaca acaaggatgtat gtagtactca gtggagtgcgg aggaggacag tgcctgc 600
 gctgctgtgggg agagtctgc catttggatc atggatggatc cggttcacaa qctcaagtat 660
 gaaaactaca ccagcagctt ctcatcagg gacatcatca aacccgtaccc acccaagaa 720
 ttgcagtcga accccataaa gaattctggg cagggtggggat tcagctggatc gtaccctgac 780
 acctggatgtt ctcccacatttc ctacttcttc ctgcacatttc ggtttcgatcc ccaggggcaag 840
 agcaagaagag aaaagaaaaa tagatgttcc acggacaaaga cctcggccac ggtcatctc 900
 cgcaaaaaatg ccagcattag cgtggggccc caggaccgc actatagctc atcttggagc 960
 gaatgggcat ctgtgccttg cagt 984

SEQ ID NO: 49 moltype = DNA length = 399
 FEATURE Location/Qualifiers
 misc_feature 1..399
 note = IL15 polynucleotide
 source 1..399
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 49
 ggatttcatat ttttcatttt gggctgttcc agtgcaggggc ttccctaaaac agaaggccaa 60
 tgggtgaatg taataatgttta ttggaaaaaaa attgaagatc ttatcaatc tatgcatttt 120
 gatgtcaactt tatatacgga aagtgtatgtt caccctggat gcaaatgtaa acgtatggaa 180
 tgctttctctt tggagtttaca agtttttca ctggatgtccg gagatgoaag tattcatgtat 240
 acatgtatggaa atctgtatcat ccttagaaac aacatgttgc ttctcaatgg gaatgtaa 300
 gaatctggat gcaaaaatgt tgaggaaactg gaggaaaaaaa atttaaaaatgttgc 360
 agttttgtatc atattgttcca aatgttcatc aacacttctt 399

SEQ ID NO: 50 moltype = DNA length = 525
 FEATURE Location/Qualifiers
 misc_feature 1..525
 note = sIL15ra polynucleotide
 source 1..525
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 50
 atcaacgtgcc ctccccccat gtcgtggaa cacgcagacata ctcgggtcaaa gagctacac 60
 ttgttacttca gggagggttgc cattttgtaaat tctgggttca agcgttaaagc cggccatgtcc 120
 agcctgacgg agtgcgtgtt gaacaaggcc acgaatgtcc cccactggac aaccccccgt 180
 ctcaaatgtca ttagagaccc ttccctggttt caccaaaggcc cagcgcaccc ctccacacgt 240
 acgacggcgg ggggtgacccc acagccatgttcc agcgttcccttcttggaaa agagccgc 300
 gtttcatcttcc caagctcaaa cacacacgcg gccacaacacag cagctatttttgc 360
 cagctgtatgc cttcaaaatc accttccaca ggaaccacag agataagcag tcatgatgtcc 420
 tccccacggca cccctctca gacaacacgc aagaactggg aactcacacgc atccgcctcc 480
 caccacccgc cagggtgtgttca tccacaggcc cacacgcgacca ccactt 525

SEQ ID NO: 51 moltype = DNA length = 1818
 FEATURE Location/Qualifiers
 misc_feature 1..1818
 note = soluble GP130 polynucleotide
 source 1..1818
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 51
 atgtgtacac tgccatgttg gctgtgtcc gcaactgtttt tttttctgtac tactgaatca 60
 actggcgaaac tgctggaccctt tgggtgttca atcagccctggt agtccccatgtt ggtgcagctg 120
 cacagcaact tcaccggccgt gtgcgtgtca aaggagaatgt gtatggactt ctttcacgtt 180
 aacggccaaat atatcgatgtt gaaaaaccaac cacttcacaaat tcccccaaggaa gcgttacacc 240
 attcatcaata ggacagccatgttccctt gggccatgttca tggccctccat gaaatccatgtt 300
 ctgacactgtca atatctgtcc attcggccatgttccctt gggccatgttca tggccctccat 360
 attcgttcccttca tggccctccat gggccatgttca tggccctccat gggccatgttca tggccctccat 420
 aagatgtccatgttcc gggccatgttca tggccctccat gggccatgttca tggccctccat 480
 aagtccatgttcc gggccatgttca tggccctccat gggccatgttca tggccctccat 540
 tccctgttccatgttcc tggccctccat gggccatgttca tggccctccat gggccatgttca tggccctccat 600
 gagaatgtccatgttcc gggccatgttca tggccctccat gggccatgttca tggccctccat 660

-continued

```
aagcctaacc caccacaa tctgagcgta atcaattccg aggagctgtc tagcatctg 720
aagctgacct ggacaaaccc atctatcaag agcgtgatca tcctgaagta caaatccag 780
tatcgacca aggacgcctc cacatggago cagatccctc cagaggatac cgccagcaca 840
agatccttcc tcaccgtgca ggacactgaag cccttcacagc agtacgtgtt tcggatcaga 900
tgtatgaagg aggacggca gggctactgg aggatgggtt ccgaggaggc cagcgcatac 960
acatcgagg acaggccttc taaggcccccc agcttctggt acaagatcga tccatccac 1020
acccaggcgt atcgacacagt gcagctgggt tgaaaacc cttccccc ttccggccac 1080
ggcaagatcc tggactacga ggtgaccctg acacggtgaa agtccccactt gcagaactat 1140
accgtgaatg ccaccaacgt gacagtgaad ctgacacaatg atccgtactt ggccaccctg 1200
acagttagaa accttggggg caagtctgac ggcggctgtc tgccatccc tgccctgcat 1260
tttcaggcoca cacacccatg gatggacctg aaggcccttc ccaaggatata tatgtgtgg 1320
gtggagtgga ccacacctag agagtccgtg aagaagtaca tcctggagtg gtgcgtgtg 1380
tctgacaaagg ccccatgtat caccgtggg cagcaggagg atggcacctg gcacaggaca 1440
tatctgccc gcaacccatg cggatcttgc tggttacatgtg tcacccgtgac accccgttat 1500
gcagacggac caggcttcc tgagagatc aaggccctacc tgaaggaggc accaccaac 1560
aaggggacaa ccgtgcccac aaagaagggtc ggcaagaatg aggccgtgtt ggagtgggac 1620
cagctgcctt tggatgtgca gaacccgttcc atcaggatata acaccatcc ttatcgacaa 1680
atcatcgcca acgagacacgt cgtgaatgtg gagacgtccce acacccgatc tacactgtct 1740
agcctgacct ccgatcactt gtatctgggtt aggtatggccctt cttatcaga cgaggccggc 1800
aaggatggcc ccgatgtt 1818
```

SEQ ID NO: 52 moltype = DNA length = 72
 FEATURE Location/Qualifiers
 misc_feature 1..72
 note = IgE signal sequence
 source 1..72
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 52
 gtatccgggtt cggccaccat ggactggacc tggattctgt tcctcggtc tgctgtaca 60
 agagtgcaca gc 72

SEQ ID NO: 53 moltype = DNA length = 75
 FEATURE Location/Qualifiers
 misc_feature 1..75
 note = F2A
 source 1..75
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 53
 ggttctggcg tgaaacacagac tttgaatttt gaccttctca agttggcgaa agacgtggag 60
 tccaaacccatg gggcc 75

SEQ ID NO: 54 moltype = DNA length = 66
 FEATURE Location/Qualifiers
 misc_feature 1..66
 note = P2A
 source 1..66
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 54
 ggaaggcggg ctactaactt cagectgctg aaggaggctg gagacgtgga ggagaaccctt 60
 ggacctt 66

SEQ ID NO: 55 moltype = DNA length = 54
 FEATURE Location/Qualifiers
 misc_feature 1..54
 note = T2A
 source 1..54
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 55
 gagggcagag gcagcctgtt gacctgcggc gacgtcgagg agaaccggcc gccc 54

SEQ ID NO: 56 moltype = DNA length = 825
 FEATURE Location/Qualifiers
 misc_feature 1..825
 note = LNGFR
 source 1..825
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 56
 atggggggcag gtgccaccgg ccgcgcctatg gacggggccgc gctgtgtgtt gttgtgtctt 60
 ctgggggtgtt cccttggagg tgccaaggag gcatggccca caggctgtt cacacacac 120
 ggtggatgtgtt gcaaaaggctg caacccggcc gagggtgtgg cccagectt tgagccaaac 180
 cagaccgtgtt gtgagccctg cttggacago gtgacgttcc cccacgtgtt gagcgcgacc 240
 gagccgtgtca agccgtgtc acgactgtgtt ccgtgtgtt cccgtgtt accaggatga gacgactggg 300
 gagggccatgtt acggccgtgtt ccgtgtgtt tacggatgtt accaggatgtt gacgactggg 360
 cgctgcgagg cgtgcggcgtt gtgcggaggcg ggctggccctc ctggccaggac 420

-continued

aagcagaaca ccgtgtgcga ggagtgcggg gacggcacgt atccgcacga ggccaaccac 480
 gtggaccctg gcctgcctg caccgtgtgc gaggacccg agcgcacgt ccgcgactgc 540
 acacgcgtgg cccgacgcccga gtgcgaggag atccctggcc gttggattac acggccaca 600
 cccccagagg gtcggacag cacagcccc agcacccagg agcctgaggc acctccagaa 660
 caagaccta tagccagac ggtggcaggat gtggatggc cagtatggg cagtcggcag 720
 cccgtggta cccgaggcac caccgacaaat ctcatccctg tctattgtc catctggct 780
 gctgtgggtt tgggtcttgt ggcctacata gcctcaaga ggtga 825

SEQ ID NO: 57 moltype = AA length = 253
 FEATURE Location/Qualifiers
 REGION 1..253
 note = IL-12a polypeptide
 source 1..253
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 57
 MWPPGASQP PPPAAATGL HPAARPVSLQ CRLSMCPARS LLLVATLVL DHLSLARNLP 60
 VATPDPMFP CLHHSQNLLR AVSNMLQKAR QTLEFYPCTS EEDIDHETIK DKTSTVEACL 120
 PLELTKNESC LNSRETSFIT NGSCLASRKTF SFMMALCLSS IYEDLKMVQV EFKTMNAKLL 180
 MDPKRQIFLD QNMLAVIDEL MQALNFNSET VPQKSSLEEP DFYKTKIKLC ILLHAFRIRA 240
 VTIDRVMSYL NAS 253

SEQ ID NO: 58 moltype = AA length = 328
 FEATURE Location/Qualifiers
 REGION 1..328
 note = IL12b polypeptide
 source 1..328
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 58
 MCQQQLVISW FSLVFLASPL VAIWELKKDV YVVELDWYPD APGELEVLTIC DTPEEDGITW 60
 TLDQSSEVLG SGKTLTIQVK EFGDAGQYTC HKGGEVLSHS LLLLHKKEDG IWSTDILKDQ 120
 KEPKNKTFLR CEAKNYSGRF TCWWLTTIST DLTFSVKSRR GSSDPQGVTC GAATLSAERV 180
 RGDNPKKEYEV VECQEDSACP AAAELSPIEV MVDAVHKLKY ENYTSSFFIR DIIKPDPPKN 240
 LQLKPLKNSR QVEVSWEYPD TWSTPHSYF LTFCVQVQGK SKREKKDRVF TDKTSATVIC 300
 RNNASISVRQ QDRYYSSSSWS EWASVPCS 328

SEQ ID NO: 59 moltype = AA length = 133
 FEATURE Location/Qualifiers
 REGION 1..133
 note = IL15 polypeptide
 source 1..133
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 59
 GIHVFIILGCF SAGLPKTEAN WVNVISDLKK IEDLIQSMHI DATLYTESDV HPCKVTAMK 60
 CFLLELQVIS LESGDAIHD TVENLIIILAN NSLSSNGNVT ESGCKECEEL EEKNIKEFLQ 120
 SFVHIVQMFN NTS 133

SEQ ID NO: 60 moltype = AA length = 175
 FEATURE Location/Qualifiers
 REGION 1..175
 note = sIL15ra polypeptide
 source 1..175
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 60
 ITCPPPMPSVE HADIWKYSY LYSRERYICN SGFKRKAGTS SLTECVLNKA TNVAHWTPS 60
 LKCIRDPAV HQRAPPSTV TTAGVTPQPE SLSPSGKEPA ASSPSSNTA ATTAIAVPGS 120
 QLMPSKSPST GTTEISSHES SHGTPSQTTA KNWELTASAS HQPPGVYPQG HSDTT 175

SEQ ID NO: 61 moltype = AA length = 606
 FEATURE Location/Qualifiers
 REGION 1..606
 note = soluble gp130
 source 1..606
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 61
 MLTLQTWLQ ALFIFLTTE TGELLDPCGY ISPESPVVQL HSNFTAVCWL KEKCMDYFHV 60
 NANYIVWKTN HFTIPKEQYT IIINRTASSVT FTDIASLNIQ LTCNILTFGQ LEQNVYGITI 120
 ISGLPPEKPK NLSCIVNEGK KMRCEWGDGR ETHLETNFTL KSEWATHKFA DCKAKRDPT 180
 SCTVDYSTVY FVNIEVVWEA ENALGKVTSN HINFDPVYKV KPNPPHNLSV INSEELSSIL 240
 KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PTTEYVFRIR 300
 CMKEDGKGWY SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360
 GKILDYEVTL TRWKSHLQNY TVNATKLTWN LTNDRYLATL TVRNVLGKSD AAVLTIPACD 420
 FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCWL SDKAPCITDW QQEDGTVHRT 480
 YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKVK GKNEAVLEWD 540
 QLPVDVQNGF IRNYTYFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600

-continued

KDGP EF

606

SEQ ID NO: 62 moltype = AA length = 836
 FEATURE Location/Qualifiers
 REGION 1..836
 note = soluble gp130 fused to a Fc
 source 1..836
 mol_type = protein
 organism = synthetic construct
 SEQUENCE: 62
 MTLTQTLVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDFYFHV 60
 NANYIVWKTN HTFTIPKEQYT IINRTASSVT FTDIASLNQI LTCNIITFGQ LEQN VY GITI 120
 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180
 SCTVDYSTVY FVNIEVVVEA ENALGKVTSD HINFDPVVKY KPNNPHNL SV INSEELSSIL 240
 KLTWTNPNSIK SVIILKYNIQ YRTK DASTWS QIPPEDTAST RSSFTVQDLK PT EYVFRIR 300
 CMKEDGKGWY SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360
 GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLLVGKSD AAVLTIPACD 420
 FQATHPVMDL KAPPKDMLW VEWTTPRESV KYKILEWCVL SDKAPCITDW QQEDGTVHRT 480
 YLRGNLAE SK CYLITVTPVY ADGPGSPESI KAYLKQAPS KGPVTRTKV GKNEAVLEWD 540
 QLPVDVQNGF IRNYTIIFYRT IIGNETAVNV DSSHTEYTLS SLTS DTDLYMV RMAAYTDEGG 600
 KDGP EF RSCD KTHTCPCPA PEAEGPSVLF PP KPKDML MISRTPEVTC VVVDVSHEDP 660
 EVKFNWYV DGE VEVHNKA TPREEQYNTK PREEQYNTK VVS VLTVLHQ DWLNGKEYKC KVS NKALPAP 720
 IEKTISAKAG QPREPOVYTL PPSREEMTKN QVSLTCLVKG FYP PSDIAV EWSNGOPENNY 780
 KTT PPLVLDSD GSFFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 836

SEQ ID NO: 63 moltype = DNA length = 7711
 FEATURE Location/Qualifiers
 misc_feature 1..7711
 note = Matrice TRAC locus_CubicAR CD22 pCLS30056 full
 sequence
 source 1..7711
 mol_type = other DNA
 organism = synthetic construct
 SEQUENCE: 63

gtggcactt tcgggaaat gtgcgcggaa cccctatttt tttat ttttc taaaat acatt 60
 caaatatgtt ccgcgtcatg agacaataac cctgataat gcttcaat aa tattgaaaaa 120
 ggaagagttt gaggat tcaaa catttccgtg tcgc ccttat tccctttt gcggcatttt 180
 gccttcctgt ttttgcgtcc ccgaaacgcg tggtaaaatg aaaatgctt gaagatcagt 240
 tgggtgcacg aatgggttac atcgaacttgc atcgaacag cggtaatgc cttgagat 300
 ttccgcggca agaacgtttt ccaatgtatgc gcaactttaa agttctgc tttggcgcgg 360
 tattatcccg tatttgcgc gggcaagago aactcggcgc cccgcatacac tatttcaga 420
 atgacttgcgt tttgtacttgc ccaggatcag aaaaatgcgt tacggatggc atgacatgaa 480
 gagaattatg cagtgcgtcc ataaccatgc ggtataacac tggcccaac ttacttcgt 540
 caacgcgtcc aggacccaag gagttacccg ctttttgc caacatggg gatcatgtaa 600
 ctgcgccttgc tcgttggaa ccggagctga atgaagccat accaaacgac gagcgtgaca 660
 ccacgcgtcc ttgtatgc gcaacacgt tgccaaatctt attaacttgc gaaactactt 720
 ctctatgttcc cccggcaacaa ttaatagactt ggttggggcc ggataaaatggt gcaaggaccac 780
 ttctgcgtcc ggccttcgc gctggctgtt tttatgc ttaatatgc ggcggtgac 840
 gtgggttcgc cggatcatttgc gcaatgcgg tggccatgg taaggccccc cgtatcgttag 900
 ttatctacac gacggggatgc caggacacta tggatgaacg aaatagacag atcgttgc 960
 taggtgcgtc actgatcaag catttttttgc ttttttttgc ttttttttgc ttttttttgc 1020
 agatgttattt aaaaatccat ttttttttgc aaaaatgc ttttttttgc ttttttttgc 1080
 atctcatgac caaaatccct taatgcgtt ttttttttgc ttttttttgc ttttttttgc 1140
 aaaaatgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 1200
 caaaaaatcccttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 1260
 ttccgcggatgt aacttgcgttcc aacggatcgcg agatccaaat ttttttttgc ttttttttgc 1320
 cgtatgttgcgttcc aacggatcgcg agatccaaat ttttttttgc ttttttttgc ttttttttgc 1380
 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 1440
 gacgatgttcc aacggatcgcg agatccaaat ttttttttgc ttttttttgc ttttttttgc 1500
 ccacgcgtcc gcaacgcacc tacaccgcac ttttttttgc ttttttttgc ttttttttgc 1560
 ggcgcacgcgttcc gcaacgcacc tacaccgcac ttttttttgc ttttttttgc ttttttttgc 1620
 caggagacgc caggacgcgttcc gcaacgcacc tacaccgcac ttttttttgc ttttttttgc 1680
 ggttttcgccttcc cctctgtacttgc gacgttgcgttcc gtttttttgc ttttttttgc 1740
 tatggaaaaaa ccggccgttcc gggcccttttgc ttttttttgc ttttttttgc ttttttttgc 1800
 ctcacatgttcc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 1860
 agtgagatgttcc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 1920
 aacggatcgc gcaacgcacc tacaccgcac ttttttttgc ttttttttgc ttttttttgc 1980
 cagctggccac gacggatcgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 2040
 gagttgttgcgttcc aacggatcgc gtttttttgc ttttttttgc ttttttttgc ttttttttgc 2100
 gtgttgcgttcc aacggatcgc gtttttttgc ttttttttgc ttttttttgc ttttttttgc 2160
 caagcgcgttcc aacggatcgc gtttttttgc ttttttttgc ttttttttgc ttttttttgc 2220
 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 2280
 tatttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 2340
 ggcaggccgcgttcc gacgttgcgttcc gtttttttgc ttttttttgc ttttttttgc ttttttttgc 2400
 agttgttgcgttcc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 2460
 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 2520
 actggcatcttcc gacttgcgttcc gtttttttgc ttttttttgc ttttttttgc ttttttttgc 2580
 cctgtatgttcc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc 2640
 gtgaggccgcgttcc gacgttgcgttcc gtttttttgc ttttttttgc ttttttttgc ttttttttgc 2700

-continued

ccgtctcgcc	cgtcacccgt	ctgctgtgc	cactggcact	gctgctgcac	gctgctaggc	2760
ccggaggggg	aggcagctgc	ccctacagca	accccagcct	gtgcagcgg	ggcggcggca	2820
gccccggagg	gggttagccag	gtgcagctgc	agcagagcgg	ccctggactg	gtgaagccaa	2880
gccagacact	gtccctgacc	tgcgcacatca	gccccggattc	cgtgagctcc	aactccggcg	2940
cctggatttgc	gtcagggcag	tccccccttc	ggggccctgg	gtggctgg	aggacatact	3000
atcggcttaa	gtggtaacaac	gattatgcgg	tgtctgtgaa	gagcagaatc	acaatcaacc	3060
ctgacaccc	caagaatcag	ttctctgtgc	agtgtaatag	cgtgacacca	gaggacaccc	3120
ccgtgtacta	ttgcgcagg	gaggtgaccc	gcccacccgt	ggatgectt	gacatctggg	3180
cccgaggac	aatggtgacc	gtgagctccg	gaggcgggg	atctggcgg	ggaggaaagt	3240
ggggcgggg	gagtgtatc	cagatgacac	agtcggccat	ctctgtgac	gcctccgtgg	3300
ggcgacagat	gacaatcacc	tgtggccct	ccccagccat	cgtgtttiac	ctgaacttgtt	3360
atcagcagag	gccccggcaag	gccectaata	tgtgtatcta	cgcageaagc	tccctgcaga	3420
gccccggcc	atccagatcc	tctgcggcagg	gtctccggc	agacttcacc	ctgaccat	3480
ctagctgc	ggccggagac	ttgcgcacat	actatggcca	gcaatgttat	agcatcccc	3540
agacatttgg	ccaggccacc	aagctggaga	tcaagtcgg	tcccgaaagc	ggagggggag	3600
gcagctgcc	ctacagcaac	cccagctgt	gcagcggagg	ccggcggc	gagctgcaca	3660
cccgaggac	cttctccaa	gtgtccacca	acgtgagccc	agccaaagcc	accaccaccc	3720
cctgtccctt	ttccaatcc	ttctctgtg	ctcccaaccc	aaccacccgt	ccaaggcccc	3780
ctacccccc	accactatt	gcctccagg	cacttcact	gcccgttgg	gcctgtcg	3840
ccgctgtgg	aggcgcagtg	catacaaggg	gcctcgattt	cgccctcgat	atttacatct	3900
gggcacccct	ccggcggacc	tgcgggttgc	ttctcccttc	cctgggtatt	accctgtatt	3960
gcagacgggg	ccggagaag	ctccctctaca	tttttaagca	gcctttcatg	cgcccgatgt	4020
agacaaccca	agaggagat	gggttcttgc	gcagattccc	tgaggaagag	gaaggcgggt	4080
gcgagctgag	agtgaatttc	tccaggagcg	cagatgcccc	cgccatataa	cagggccaga	4140
accagcttca	caacgcgtt	aacccgggaa	ggcgcgaaga	atacgacgt	ttggataaga	4200
gaagggggcg	ggacccggag	atgggaggaa	ageccccggag	gaagaaccc	caggaggccc	4260
tgtacaacga	gttgcagaag	gataagatgg	ccggggctta	ctcagatgc	ggggatgaagg	4320
ggggagccgg	ccggggaaag	ggggcagatg	ggtctacc	ggggctgag	acagccacaa	4380
aggacacata	ccacgccttgc	cacatgcagg	cccttccacc	ccggaaatag	tctagaggcc	4440
ccgtttaaac	cgtgtatca	gccttgcactg	tgcttcttc	ttggcagcc	tctgttgtt	4500
ggccctcccc	cgtgccttc	ttgaccctgg	ttggccaccc	tcccactgtc	ctttcttaat	4560
aaaatgagga	aattgtatcg	cattgtctga	gtaggtgtca	ttcttattctg	gggggtgggg	4620
tggggcgggg	cagcaagggg	gaggattttgg	aagacaata	caggcatgt	ggggatgcgg	4680
tgggctctat	gactgtggc	gaattcccttgc	gttgcagatgt	agagactcta	aatccatgt	4740
caagtgttc	ttccattatca	ccgttggat	ttcttcaaaa	aatgtgtc	aaagtaagg	4800
ttctgtatgt	tatatcacag	acaaaaactgt	gttagacat	aggtctatgg	acttcaagag	4860
caacagtgc	gtggccttgc	gcaacaaatc	tgactttca	tgtcaaaac	ccttcaacaa	4920
caggcattt	ccagaaacaca	ccttccat	caggccatgt	aaggccatgt	ttggtgctt	4980
cgcaggctgt	ttccctgttgc	caggatggc	cagggttgc	ccagatct	ggtcaatgt	5040
gtctaaact	cctctgatttgc	gttgccttgc	cctttatccat	tgccacaaa	accctcttt	5100
tactaagcga	tcgtctcggt	gccccgt	ggcagagcg	cacatcgccc	acagtcccc	5160
agaagttgg	ggggggggc	ggcaatttgc	cgggtgc	gagaagggttgg	cgccggggtaa	5220
acttggggaa	tgatgtgtgc	tactgtgtcc	gcctttttcc	cgagggttgg	ggagaacccgt	5280
atataatgtc	agtagtcgc	gtgaacgttgc	tttttcgaa	ccgggttgg	gcccaaacac	5340
agctgaagct	tcgaggggct	cgcatcttc	cttcacgc	ccggccgcct	acctgaggcc	5400
ggccatccac	ccgggttgg	cgccgttgc	cgccctccgc	ctgtgttgc	tcctgtact	5460
cgtccggcgt	cgttggatgt	ttaaatgtca	ggtcagac	ggggcccttgc	ccggccgttcc	5520
cttggagct	acccatgtc	acccggctt	ccacgttgc	cctgtccctg	cttgcataac	5580
tctacgttt	tttttgc	tctgttgc	ccgttgc	atccaaatgt	tgaccggcgc	5640
ctacactgaga	tcacccggc	caccatgttgc	tcttacccttgc	gacaccaga	tgcttgc	5700
tttgaccagg	tcggcggat	caggggccac	tccaaacagg	gaactgcct	aagaccacaa	5760
agacagcagg	aaggccatgt	ggttggcc	ggcggaa	tgcacccct	gctgagggt	5820
tacattgtat	gacccatgt	catgggcaag	accaccacca	ctcaactgt	ggtggact	5880
ggctccagg	atgacatgttgc	gtatgtgtcc	gagccatgt	cctactgtgg	agtgttagg	5940
gcctctgaga	ccattgttgc	catctacacc	accacgcaca	ggctggacca	gggagaatac	6000
tctgtgtgg	atgctgtgt	ggtgttgc	tctgtccca	tccaaatgg	aatccctt	6060
gtctgtact	atgctgttgc	ggcttctca	atggaggag	aggctggc	tttctatgc	6120
cctccaccc	ccctgttgc	gatctttgc	agacacccca	ttgcagccct	gctgtgtc	6180
ccaggcagca	ggtacccat	gggttccat	acccacccagg	ctgtgttgc	ttttgtggcc	6240
ctgtatccct	caacccctcc	tggccacaa	attgttgc	gagcactgg	tgaagacaga	6300
cacattgaca	ggctggccaa	gaggcagaga	cctggagaga	gactggact	ggccatgt	6360
gtgtcaatca	gaagggtgt	tggatgtgt	gcaaaactgt	tgagatact	ccagtgtgg	6420
ggcttggaa	gagggatgt	ggggacgt	tctggaaagg	cagtgc	cccccc	6480
gagccccccgt	ccaaatgttgc	tccaaaccc	cacattgggg	acaccctgtt	caccctgtt	6540
agagccccct	agctgtgtgc	tcccaatgttgc	gacctgtaca	atgtgttgc	ctgggtctg	6600
gtatgttgc	ccaaagggct	gagggttgc	catgtgtca	tcctggacta	tgaccatgt	6660
cctgtgtgt	ccggatgt	tctgttgc	ctaacccctgc	gcatgtgtca	gaccctgttgc	6720
accacccttc	ccggatgt	caccatgttgc	gacccatgttgc	ggggatgt	cttgc	6780
ggagaggcc	actaaaggcc	gcccacccgt	cgatgtgttgc	ccagacatgt	taagatata	6840
tgatgtgttgc	ggacaaacca	caactgtat	gcatgtgttgc	ttttgttgc	ttttgttgc	6900
tttgtatgt	attgtttat	ttgttgc	tataagctgc	aataaaacaa	ttaacaacaa	6960
caattgtt	cattttatgt	ttcagggttca	ggggggatgtt	ttttttgtt	ttttttgtt	7020
gtaaaaaccc	tacaaatgttgc	gtatgttgc	ggggcccaat	tcgcgcctata	gtgatgttgc	7080
ttacgttgc	ttcacttgc	gtcttttgc	aacgttgc	ctggaaaac	cctggcgtt	7140
cccaacttac	tcgttgc	gcacatcc	cttgc	ccggcgtt	atgcgttgc	7200
cccgccacc	aaaccccttc	ccaaacgttgc	cgccgttgc	atggcgttgc	ggagccct	7260
gtacggccgc	attaaggcc	gccccgttgc	cagcgttgc	gctacacttgc	7320	
ccaggccccc	agcggcccccgt	ccttcccttc	tttttgc	acgttgc	cccgccct	7380
gtttccccc	tcaagatgttca	aatggggcc	tttttttgc	tttttttgc	tttttttgc	7440

-continued

```
ggcacctcga ccccaaaaaa cttgatttagg gtgtatggtt gcctgttagt ggcatagcc 7500
ctgatagacg gttttcgcc ctttgacgtt ggagtccacg ttctttaata gtggacttt 7560
gttccaaact ggaacaacac tcaaccctat ctgggtctat tcttttgatt tataaggat 7620
tttgcgatt tcggcattt ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa 7680
tttaacaaa atattaacgc ttacaattt a 7711
```

```
SEQ ID NO: 64 moltype = DNA length = 7502
FEATURE Location/Qualifiers
misc_feature 1..7502
note = Matrice CD25 locus_IL15_2A_sIL15Ra pCLS30519 full
sequence
source 1..7502
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 64
gttattatt cctgttccac agctattgtc tgccatataa aaacttaggc caggcacagt 60
ggctcacacc tgtaatccca gcacatttgg aggccgaggc aggcatca caaggtcagg 120
agtctcgagac cagcgtggcc aacatgcac aacccatct ctactaaaaa taaaaat 180
agccaggccat ggtggcgtgt gcactgggtt agagtgaggaa ccacatttt ttggtcgt 240
gttacacata tgaccgtgac tttgttacac cactacaggaa ggaagagttag aagaacaatc 300
ggttctggcc tgaaacagac ttgaaatttt gaccccttcac agttggcggg agacgtggag 360
tccaaccagg cgcccggtac accatgggat ggacctggat tctgttctc 420
gtgctgtgt ctacaaggt gcacacggc attcatgtct tcattttttt ctgtttcagt 480
gcagggttc ctaaaacaga agccaactgg gtgaatgtaa taagtgattt gaaaaaatt 540
gaagatctta ttcaatctat gcataattgtt gactacttat atacggaaag tgatgttac 600
cccagggtca aagtaacagc aatggatgtt tttcttgggg agttacaagt ttttcaact 660
gagtccggag atgcaagttt tcatgatataa gtaaaaatc tgatcatctt agcaaacaac 720
agtttgctt ctaatggaa tgtaacagaa tctggatgca aagaatgtga ggaactggag 780
gaaaaaaaata ttaaagaatt ttgcagatgtt ttgtatataa ttgtccaaat gttcatcaac 840
acttctggaa gggggatgtac taacttcacgc ctgctgaagc aggctggaga cgtggggagg 900
aaccctggac ctggggaccc ctctgcacatc atggattggc cgtggatctt gtttctgt 960
gcagctcoca caagaggatca cagttatcag tgccctcccccc ccattgtccgtt ggaacacgc 1020
gacatctggg tcaagagctt cagttgtac tccaggggggc ggtacattttt taactctgg 1080
ttcaagegtt aaggccggcact gtccggcttcc acggagttggc tggtgaacaa ggccacgaaat 1140
gtggcccaactt ggacacccccc cagtttcaaa tgcatggatgg accctgcctt ggttcaccaa 1200
agggccagcgc caccctccac agtaacgcgcg gcagggttgc ccccacagcc agagagcttc 1260
tccccttctg gaaaagagcc cgcagcttca tctcccttgcgtt caaaacaacac agccggccaca 1320
acagcagtcgtt ttgtccccggg ctccggatccatc atgccttcac cacaggaaac 1380
acagagatcaa cagtcgtatgcg tccctccaccc ggacccccccttccacaaac agccaaagaac 1440
tgggaactca cagcatccgc ctccccccac ccgcacgggtt tgatccaca gggccacagc 1500
gacaccactg aggggcagagg cagctgtgtt acctgcggcc acgtcgaggaa gaaccccccgg 1560
cccatggggg caggtggccac cggggccggcc atggacgggc cgcgcctgtt gctgttgcgt 1620
cttctggggg ttgtccctgg aggttccaaag gaggcatgtt ccacaggctt gtacacacac 1680
agcgggtttagt gtcgtcaaggc ctgtcaacttggt ggggggggg tggccggatc ttgttgagcc 1740
aaccagaccc tttgttgagcc ctgcgttgcgtt acgtgttgcgt tttccgttgcgtt ggttgcgt 1800
accggccgtt gcaagacgtt caccggatgtt gttggggctcc acggatgttc ggcgcctgtc 1860
gtggaggccgtt atgacggccgtt gtgcgcgttgc gcttacgggtt actaccaggaa tgagacgtact 1920
ggggcgtcgc agggcgtccgc cgttgcgcgcggggccgttgc gcttgcgtt ccctgtccag 1980
gacaaggaga acaccgtgtt cggagggtgttgc cccgcggccatcgttccgcgcggccaaac 2040
caacgtggacc ctgcgttgcgcgcgttgcggggccatcgttccgcgcggccaaac 2100
tgcaacgtt gggccggccgc cggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 2160
acaccccccggg agggttccggc cagcagacccccc cccagcccccaggatgttgcggatgttgc 2220
gaacaagacc tcatagccatc caccgtggca ggtgtggatc ccacaggatgttgcggatgttgc 2280
cagccctgttgg tgaccggggatc caccgttgcgttgcggatgttgcggatgttgcggatgttgc 2340
gtctgttgcgtt ttgtgggttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 2400
acaagaattt ttgtgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 2460
atcaaagggtt cttaatggtc gcccaggaga catccgttgcgttgcggatgttgcggatgttgc 2520
ctctgtggatc acatccacagg acacggggcaatcgttgcggatgttgcggatgttgcggatgttgc 2580
cccatcgtatc agcggatgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 2640
gcaaaaccac tagacttccatc tcatgttgcgttgcggatgttgcggatgttgcggatgttgc 2700
gtggccgtca gtggggcagatc cgcacatgcgttgcggatgttgcggatgttgcggatgttgc 2760
tcggcaattt aacgggggttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 2820
tgtactgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 2880
ccctgtggatc ttttttttttccggatgttgcggatgttgcggatgttgcggatgttgc 2940
ctcgcatctc tcccttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3000
gtcgccgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3060
gtttaaactt ctttttttttccggatgttgcggatgttgcggatgttgcggatgttgc 3120
tcagccggatc tcccttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3180
tttctgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3240
ggccaccatgg ctcttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3300
tccaggggccatcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3360
gaggttggccatcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3420
ggcatggccatcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3480
gtgtatgttcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3540
aacatctaca ccacccaggatcgttgcgttgcggatgttgcggatgttgcggatgttgc 3600
gtgtgttgcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3660
ctggcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3720
ctgtatcttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3780
atggggccatcgttgcgttgcggatgttgcggatgttgcggatgttgcggatgttgc 3840
```

-continued

cctggcacca	acattgttct	ggggactg	cctgaagaca	gacacattga	caggctggca	3900
aaggcaga	gacctggaga	gagactggac	ctggccatgc	tggctgcaat	cagaagggtg	3960
atggactgc	tggcaaacac	tgtgagatac	ctccagtgt	gaggcttgc	gagagaggac	4020
tggggacagc	tctctggaaac	agcagtgcgc	cctcaaggag	ctgagcccc	gtccaatgt	4080
ggtccaagac	ccccatgg	ggcacccctg	tccaccctgt	tcagagccc	tgagctgt	4140
gtctccaatg	gagacctgt	aatgtgtt	gctggggct	tggatgtt	agccaagagg	4200
ctgagggtca	tgcatgtgtt	catctggac	tatgaccagt	ccccctgtgg	atcgagagat	4260
gtctctgtgc	aactaacctc	tggcatgtgt	cagacccatg	tgaccacccc	tggcagcata	4320
cccacccatct	gtgacccatge	cagaacccctt	gccaggagaga	ttggagaggc	caactaaaggc	4380
gcccacatcg	agcgcgtatgc	ggccagacat	gataagatac	attgtgtgt	ttggacaaac	4440
cacaactaga	atgcgtgtaa	aaaaatgttt	tatttgtgaa	atttgtgtat	ctatgtgtt	4500
attttaacc	attataagct	gcaataaaaca	agttacaac	aacaattgtca	ttcattttat	4560
gtttcagggt	cagggggggg	tgtgggggtt	tttttaaaggc	aagttaaaacc	tctacaatgt	4620
tgttatggaa	ggcgcgcccc	attgcctta	tagtgagtgc	tattacgtcg	cgctcactgg	4680
cgctcggttt	acaacgtcg	gactggggaa	accctggcg	tacccaaattt	aatgcgcctt	4740
cagcacatcc	cccttcgc	agctggcgta	atagcgaaga	ggccgcacc	gaaacgcct	4800
tcoccaacagt	tgcgcagcgt	gaatggccaa	tgggagcgcc	ctgttagggc	gcattaagcg	4860
cggcgggtgt	ggtggttacg	cgcagcgt	cgctacact	tgccageggc	ctagcgcccc	4920
ctcccttcct	tttcttcct	tcctttctcg	ccacgttccg	cggtttcccc	cgtcaagctc	4980
taaatcgccc	gtccccctta	gggttccgt	ttagtgttctt	acggcaccc	gaccccaaaa	5040
aacttggat	gggtatgtgt	tggctgttag	tggccatata	ccctgtataga	cggttttctg	5100
ccctttgacg	tttggatcca	cgttggat	tagtgactt	ttgttccaaa	ctggaaacaac	5160
actccacccct	atctcggtct	attttttgt	tattataaggg	atttttgcga	tttgcgccta	5220
tttggtaaaa	aatgagctga	ttaaacaaaa	attnaacgcg	aattttaaaca	aaatattaaac	5280
gcttcaatt	tagtgggc	tttttgggaa	aatgtgcgcg	gaacccctat	ttgttttattt	5340
tttctaaat	atccaaat	gtatccgtc	atagacata	aaccctgtata	aatgttttca	5400
taatattggaa	aaaggaaagag	tagtgattt	caacatttc	gtgtcgccct	tattccctt	5460
tttgcggat	tttgccttcc	tgtttttgt	cacccagaaa	cgctggtgaa	agttaaagat	5520
gctgaagata	atgtgggtgc	acgagtgggt	tacatcgac	tggatctcaa	cagcgttaag	5580
atcttggaga	gttttgcgc	cgaagaacgt	ttttcaatgt	tgagacttct	taaagtctcg	5640
ctatgtggcg	cggttattatc	ccgttattgc	gccggggca	agcaacttgc	tcgcccata	5700
cactatttc	agaatgactt	ggtttggatc	tcaccaggta	cagaaaagca	tcttacggat	5760
ggcatgacag	taagagaatt	atgcgtgtct	gccataacc	tgagtgat	taactgcggcc	5820
aacttggat	tgacacgcgt	cggggaccc	aaggagatc	ccgctttttt	gcacaacatgc	5880
ggggatcatg	taactcgcc	tgatgtgttgc	gaacccggac	tgaatgaagc	cataaaaaac	5940
gacggcgctg	acaccacgt	gcctgttagc	atgcacaa	cggtggccaa	actattaaact	6000
ggcgaactac	ttactcttagc	ttcccgccaa	caattaatag	actggatgga	ggcggataaa	6060
gttgcaggac	cactctgc	ctcgccctt	ccggctggct	gggttatttgc	tgataaattt	6120
ggagccgggt	atgcgtgttc	tcggcgat	attgcagcac	tggggccaga	tggtaagccc	6180
tcccgtatcg	tagttatcta	cacgacgggg	agtcaggca	cstatggat	acgaaataga	6240
catatcgctg	agatagggtc	ctcaactgatt	aagcattgtt	aactgtcaga	ccaaagttttac	6300
tcatataata	tttagatgtt	tttttttat	ttaaaaaggat	ctagggtt	ctagggtt	6360
atcccttttt	ataatctcat	gaccaaaatc	ccttaatgtt	agtttttgc	ccactgtatcg	6420
tcagaccccg	tagaaaaat	caaaaggatc	tcttggat	ctttttttt	gcgcgtat	6480
tgctgtgtgc	aaacaaaaaa	accaccgt	ccagcgggttgc	tttgttgc	ggatcaagag	6540
ctaccacatc	tttttccgaa	ggtaacttgc	ttcagcagat	cgccagatacc	aaatactgtt	6600
tttcttagtgt	atgcgtatgtt	atggccacc	ttaaagaact	ctgtgtcc	gcctacata	6660
ctcgctctgc	taatctgtt	accagggt	gtgtccatgt	gcgtatgtc	gtgttttacc	6720
gggttggact	caagacgata	gttaccggat	aaggcgc	ggtcgggtgt	aacgggggtt	6780
tcgtgcacac	accccgat	ggagcgtac	acctacacc	aacttagat	cctacagcgt	6840
gagctatggat	aaaggccac	gtttccgaa	ggggagaaagg	cggttttttgc	tccgttgc	6900
ggcagggtcg	gaacaggaga	gcgcacgg	gggtttcc	ggggaaacgc	ctgggtatctt	6960
tatagtctg	tcgggtttcg	ccacccatgc	tttgagcgtc	gatttttgtt	atgtctgtca	7020
ggggggcggaa	gctatggaa	aaacccgc	acgcggcc	ttttacgg	cttggccctt	7080
tgctgtgtt	tgctgtat	ggtttttct	cggttattcc	ctgttgc	ggataaccgt	7140
attaccgtt	tttgcgtat	tgatccgt	cgccgcac	aaacgtatgc	gcgcgtat	7200
tcagtgtgc	aggaaagcg	gagcgtccaa	tacgcaacc	gcctctccc	gcgcgttggc	7260
cgattcat	atgcgtatgc	cacgcacgt	ttcccgact	gaaagcgggc	agtgtacgc	7320
acgcaat	tgtgtatgtt	ctcaactt	aggcacc	ccgttacac	tttgcgtt	7380
cggtctgtat	tttgcgttgc	atttgatgttgc	gataaaat	tcacacagg	aacagctatgc	7440
accatgatta	cgccaaacgc	gtcaat	cctcaactaa	gggaacaaa	gctgttaatt	7500
						7502

SEQ ID NO: 65 moltype = DNA length = 7778
 FEATURE Location/Qualifiers
 misc_feature 1..7778
 note = Matrice PDI locus_IL15_2A_SIL15Ra pCLS30513 full
 sequence
 source 1..7778
 mol_type = other DNA
 organism = synthetic construct
 SEQUENCE: 65
 gactccccag acaggccctg gaacccccc accttctccc cagccctgtc cgtgggttgc 60
 gaaggggaca acggccacctt cacctgcac ttttccaaaca catcgagag ctccgtgtca 120
 aactgggtacc gcatgagccc cagcaaccag acggacaacgc tggccgcctt ccccgaggac 180
 cgcagccacgc cggcccgatggc ctggccgttc cgtgttgcacac aactggccaa cggccgtgtac 240
 ttccacatgc gcgtggatcag ggccggccgc aatgacacgc gcacccatct ctgtggggcc 300
 gggttctggcg tgaaacacgc tttgtatggat gacccatccaa ggtttatccatc tttatgttttgc 360
 tccaaacccatgc ggcccgatgc accatggact ggacccatgc tctgttgc 420

-continued

gtggctgctg	ctacaagagt	gcacagccgc	attcatgtc	tcattttgg	ctgtttcagt	480
cgagggttc	ctaaaacaga	agccaactgg	gtaatgtaa	taatgttattt	aaaaaaattt	540
gaagatcta	tcaatctat	gcatattgt	gctactttat	atacggaaag	tgatgttac	600
cccagttca	aagtaacagc	aatgaagtgc	tttcttctgg	agtttacaat	tatcttactt	660
gagtccggag	atgcaagtt	tcatacata	gtagaaaaat	tgatcatct	agcaacaaac	720
agtttgc	ctaatggaa	tgtatcata	tctggatgca	aagaatgtga	ggaactggag	780
aaaaaaaaata	ttaaagaatt	tttgcagat	ttttatcata	ttgtccaaat	gttcatcaac	840
acttctggaa	gccccggctac	taacttcago	ctgtgtaa	aggctggaga	cgtggaggag	900
aaccctggac	ctgggacccgg	ctctgcacaa	atggatgg	ctgtgttct	gtttctcg	960
cgagctccca	caagaggatca	cgtatc	tgcccttcc	tgcccttcc	ggaacacgca	1020
gacatctgg	tcaagactca	cagggtgt	tcctaggag	ggtagatctt	taactctgg	1080
ttcaagegt	aaggccgcac	gttccagctg	acggatgtcg	tgttgaacaa	ggccacgaat	1140
gtgcggccact	ggacaaacccc	cagtcttcaa	tgatcata	accctgcct	gttccacaa	1200
aggccagcc	cacccttccac	agtaacgac	cgagggttg	ccccacaggc	agagagctc	1260
tcccttc	gaaaagagcc	cgccgttca	tctcccgat	caaacacac	agccggccaca	1320
acagcagct	ttgtcccccgg	ctccca	atgccttca	aatcacctt	cacaggaaacc	1380
acagagataa	gcagtgatca	gttccccc	ggcacccccc	ctcagacaaac	agccaagaac	1440
tgggaaactca	cagcatccgc	ctccca	cgccggat	tgtatcata	gggcccacagc	1500
gacaccactg	aggccagagg	caggctgt	acccgcgg	acgtcgagg	qaaccccccgg	1560
ccatgggggg	cagggtccac	cgccgcgc	atggacgggc	cgccgttct	gtctgttgc	1620
cttctggggg	tgcccttgg	agggttccaa	ggggcatg	ccacaggctt	gtacacacac	1680
agegggtgat	gctgaaacag	ctgcaac	ggggatgg	ttggcccg	ttgtggagcc	1740
aaccaggacc	tgttgagcc	ctgcgttca	acgtgtac	tctccgac	gttgcggcgg	1800
accgagccgt	gcaagcgt	caccgat	gtgggg	ttccat	agagcatgtc	1860
gtggaggccg	atgacggccgt	gtgcgttgc	gcctacgg	actaccagg	tgagacgact	1920
ggggcgttgc	aggcgttgc	cgtgt	ggggatgg	ggctgttgc	ctccctgcag	1980
gacaaggaga	acaccgtgt	cgaggat	ccggacggca	cgatcc	cgaggccaaac	2040
caagtggacc	ctgtgttgc	ctgcacccgt	tgccggat	ccgat	gtcccgag	2100
tgacacacgt	ggggcgacgc	cgatgtcg	gagatcc	ccgttgcgt	tacacgg	2160
acacccccc	agggttgcgg	caggac	ccca	aggatcgt	ggccgcgtc	2220
gaacaagacc	tcatagcc	cacgggttca	gggttgg	ccacat	gggcgcgtc	2280
cacccctgtt	tgacccgg	cacccac	aaaccttac	ctgttattt	ctccatctcg	2340
gtctgttgc	ttgtgggtt	ttgtggctt	atgccttca	agaggttac	tagaggccc	2400
gtttaaaaccc	gtgttgc	ctgcgttgc	ccttgcgt	ccat	ttgtgttgc	2460
ccttccccc	tgcccttctt	gaccctt	gggttgc	ccactt	ttccataata	2520
aatgaggaaa	ttgcacat	ttgtgttgc	agggttcat	ctatttctt	gggttgggttgc	2580
gggcaggaca	gcaaggggg	ggattggaa	gacaatgca	ggcatgtt	ggatgtcg	2640
ggctctatgt	ctagtgcgc	atccggc	gatcaaa	aggcttgcgg	cagatctcag	2700
gggtacagg	gcccgttgc	aggcccccgg	cgagggttgc	gttgcgg	ttctgggttgc	2760
ggtgtccccc	ctgcacagg	atcaggat	ccagggttgc	agggcagg	ccccccagat	2820
ccagtccagg	gtctgttgc	gcaccttgg	aatggtacc	ggcatcttgc	ttctctag	2880
ctggaagcc	ccacccccc	ctatgttgc	ctcaccccttgc	accctgtac	ttccacccctg	2940
ccccgttca	acccttgc	tttggc	gtcccggttgc	ccgttgcgttgc	ccagatcg	3000
catcgcccc	atcccccg	aatgggggg	ggggatgg	caatgttac	gttgccttgc	3060
gaagggttgc	ggggtaaa	tggaaatgt	atgtgttgc	ctggcttccgc	tttttccgc	3120
agggttgggg	agaacgtat	ataatgttgc	tgatgttgc	tgatgttgc	ggacgttctt	3180
ggtttgc	cagaacacag	ctgatgttgc	ggggatgttgc	catacttct	tcacgcggcc	3240
ggccgcctac	ctgaggccgc	catccac	gggttgcgt	cttcccg	ccatccgcct	3300
gtgtgttgc	ctgactgtc	tcgcgtt	aggttgcgt	aaatgttac	tcgagatcg	3360
gccttgc	ggcgccccc	tggatgttgc	ctagacttgc	ccggcttcc	acgttttgc	3420
tgaccgttgc	tgctcaact	taatgttgc	tttgcgttgc	tttgcgttgc	cgatcagat	3480
ccaaatgttgc	accggccct	acctgtat	accggccca	ccatgttgc	ttacccttgc	3540
caccatgt	tttgcgttgc	tgaccat	ggccat	ggggccactc	caacaggaga	3600
actgcctt	gaccccgaa	acacatgg	ccactgttgc	tgatgttgc	ccatgttgc	3660
ccaatgttgc	tgagggttgc	cattgtat	ctccatgttgc	ttggcaaa	caccacact	3720
caactgttgc	ttggactgttgc	ctccaggat	gatcatgttgc	atgtgttgc	ccaaatgttgc	3780
tactggag	tgcttaggt	ctctgtat	attgttgc	ccatgttgc	ccagatcagg	3840
ctggaccagg	gagaaatctc	tgatgttgc	gtgtgttgc	tgatgttgc	ttccatgttgc	3900
acaatggaa	tgccctatgc	tgtgtat	gtgtgttgc	ctccat	tggaggatgc	3960
gtctggctt	ctcatgttgc	tccaccttgc	ctgacccat	tctttgcac	acacccat	4020
gcagccgtc	tgtgttgc	agcagat	tacctgttgc	gttgcacat	ccacaggat	4080
gtgtgttgc	ttgtggccat	gatcccttca	acccttccat	tgttgcgttgc	tttttgc	4140
geactgttgc	aaagacagaca	cattgtat	ctggcaaa	ggcagat	ttggatggaga	4200
ctggaccat	ttgtgttgc	agggttgcgt	agatgttgc	tgatgttgc	aaacactgttgc	4260
agatacttcc	atgtgttgc	ctcttgcgttgc	gaggacttgc	gacatgttgc	tggaaacagca	4320
gtgtgttgc	aaaggatgttgc	aatgttgc	ccatgttgc	caagacccca	cattggggac	4380
accctgttca	ccctgttgc	agccccat	ccatgttgc	ccatgttgc	ccacaggat	4440
gtgtttgc	gggttgc	tgttgcgttgc	ttttatgttgc	ggtgcacat	tgttgc	4500
ctggactat	accatgttgc	tgatgttgc	agatgttgc	tgatgttgc	tttttgc	4560
atgtgttgc	ccatgttgc	cacccatgttgc	agatgttgc	tttttgc	ccatgttgc	4620
accttgc	ggggatgttgc	agggatgttgc	taaggccgc	cactcgat	ctagatgttgc	4680
agacatgttgc	atgtgttgc	ataatgttgc	ccatgttgc	ccatgttgc	tttttgc	4740
atgttttattt	tgtgttgc	tgttgcgttgc	ttttatgttgc	ttttatgttgc	tttttgc	4800
taaaacaatgttgc	aaacaacaa	atgttgc	ttttatgttgc	ttttatgttgc	tttttgc	4860
ggagggtttt	taaagatgttgc	aaaacatgttgc	caatgttgc	ttttatgttgc	tttttgc	4920
gcccttatgt	tgatgttgc	acgtgttgc	cactgttgc	ttttatgttgc	tttttgc	4980
ggaaaaaccc	tggcgat	caacttgc	ccatgttgc	ttttatgttgc	tttttgc	5040
ggcgat	taaagatgttgc	ccatgttgc	ccatgttgc	ttttatgttgc	tttttgc	5100
ggcgat	ggggatgttgc	agcgccat	taaggccgc	gggttgcgttgc	ttttatgttgc	5160

-continued

```

gctgtggcc tacacttgcg agcgccctag cgccccgtc tttcgcttcc ttcccttc 5220
tttcgccc gttcgccgc ttcccccgtc aagctctaaa tcgggggtc ccttaggg 5280
tccgatttag tgcttacgg cacctcgacc ccaaaaaact tgatttaggt gatggttgc 5340
ctgttagtggg ccataccct gatagacgg tttcgccct ttgacgttgg agtccacgt 5400
ctttaatagt ggactcttg tccaaactgg aacaacactc aaccctatc cggcttattc 5460
tttgattta taaggattt tgccgattt ggcttattgg taaaaaatg agctgattta 5520
acaaaaattt aacgcgaaattt ttaaaaaattt attaacgc tacaatttgg tggacttt 5580
cgggggaaatg tgcgcggaac cccttattgt ttatccctt aaatacatc aaataatgtat 5640
ccgctcatg gacaataacc ctgataatcc ctccataataat attgaaaaag gaagagtt 5700
agtattcaac atttccgtgt cgcccttattt cccttttttgc cggcttatttgc 5760
tttgctcacc cagaaacgcg ggttaaagta aaagatctg aagatcggtt ggggtgcacga 5820
gtgggttaca tgcactggg tctcaacago ggttaagatcc ttgagatgtt tcgccttgc 5880
gaacgttttta caatgtatgg cactttttaa gttctgtatc gtggcgccgtt attatccctgt 5940
attgacgcggc ggcgaagcga actcggtcg cgcataactt atttccggaa tgacttgg 6000
gagtaatcc acgtcacaacaa aacgatctt acggatggca tgacatcgaa agaattatgc 6060
agtgtctcca taaccatcgat tgataacact gcccggcaact tacttctgac aacgatcgga 6120
ggaccgaaggc agctaaccgc tttttgcac aacatggggg atcatgtatc tcgccttgc 6180
cggtggggcc cggagatgg ttaaggccata ccaaaacgcg acgcgtgacac cacgatgcct 6240
gtacatgg caacaaacgtt ggcggaaacta ttaacttgcg aactatctac tctatcttc 6300
cgccaaacaat taatagactg gatggaggg gataaaatgg caggaccact tctcgctcg 6360
ggcccttccggg ctggctgtt tatttgcgtt aaatctgggg cccgggtggcg tgggttctgc 6420
ggatcttgcgtt cggactggg gccagatgtt aaggcccttc gtatctgtat tatctacacg 6480
acggggggcc accgaactat ggttgcacaa aatagacaga tcgctgatgg aggtgcctca 6540
ctgattaatgg attggtaact gtcagaccaa gtttactcat atataacttta gattgat 6600
aaacttcttta aaggatctgg gttgaagatcc tttttgcataa tctcatgacc 6660
aaatcccttta aacgtggatg ttcgttccac tgagcgatcg aaccctgtaa aaagatccaa 6720
ggatcttgcgtt gagatctttt tttttgcgtt gtaatctgtt gtttgcacaa aaaaaacc 6780
ccgcttccac cgggtgtttt ttttgcggat caagatcttcc tccggaggtt 6840
actggcttca gcaagagcgca gataccaaat actgtttttc tagtgcggcc gtagtgcgg 6900
caccatccaa aagaactctgg aacatccctgg ctctgtatc cctgttacca 6960
gtggctgtgtt ccaggcgccgca taagtgcgtt cttaaccgggtt tgacttcaag acgataggta 7020
ccggataaagg cgcaggccgtt gggctgaacg ggggggttgcgtt gcacacagcc cagttggag 7080
cgaacgacctt acaccgaactt gagatcttca cagcgtgacg tatgagaacag cggccacgtt 7140
cccgaggaggcggc cgggttgcgtt gtaaggccggca ggttgcggaaaggagagcgc 7200
acggggggcc ttcccgaggggg aaacgcttggg ttttttttttgcgtt gtttgcgcac 7260
ctctgacttgc acgtgttttttgcgtt ttttttttttgcgtt gggccggactt atggaaaaac 7320
gccagcaacg cggcccttttgcgtt acgggttccgtt gccttttgcgtt ggccttttgcgtt tcacatgttc 7380
tttcgtgtt ttttttttttgcgtt acgggttccgtt acgggttccgtt gtttgcgtt gtttgcgtt 7440
accgctcgcc gcaaggccgtt gacccggccgca acgggttccgtt acgggttccgtt gtttgcgtt 7500
ggccaaatccgcaaaacccttcccccggcgtt gtttgcgtt tcattaaatgc acgtggccac 7560
acagggttccgactggaaa gccccggccgtt acgggttccgtt acgggttccgtt gtttgcgtt 7620
ctcattaggcc accccggccgtt ttacacttca ttttttttttgcgtt gtttgcgtt 7680
tgagcggatcc acaatttccatc acaggaaaca gctatgcggcc ttttttttttgcgtt 7740
attaacccttca actaaaggga acaaaaggctg ttttttttttgcgtt 7778

```

```

SEQ ID NO: 66 moltype = DNA length = 8177
FEATURE Location/Qualifiers
misc_feature
1..8177 note = Matrice CD25 locus_IL12a_2A_IL12b pCLS30520 full
sequence
source 1..8177
mol_type = other DNA
organism = synthetic construct

```

```

SEQUENCE: 66
gttattttt cctgttccac agctattgtc tgccatataa aaacttaggc caggcacagt 60
ggctcacacc tggatccca gcaatttggg aggccgaggc aggcagatca caagggtcagg 120
agtgcgacac cagcgtggcc aacatagca aaccccatctt ctactaaaaaa tacaaaaatt 180
agccaggcat ggttggctgtt gcaacttgcgtt agagtgggg ccacatctttt ttgggtgcgt 240
gttacatatac tgacgttgcac ttgttgcacat cactacaggaa ggaagagtt aagaacaaatc 300
ggttctggcg tggaaatggt gaccccttcac agtttttttttgcgtt gtttgcgtt 360
tccaaccctgg gccccatgtt gccccctggg tccatccccc acggccacccgc ctcacccgtt 420
ggccggccacac gtctgtatcc acgggttccgtt cctgtgtcccg tgcactgtcccg gctcggccatg 480
tgtcccgccgc cggccctccctt ccttgggttccgtt acccctgggttcccttgcgtt 540
ggccggccaccc tcccccgttgcgtt acggccatggcc ccggatgtt tccctgcgtt tcacccatcc 600
caaaacccatgc tgaggccgtt cggccatgtt ctccggccatgg ccagacaaac tcttggat 660
tacccttgcac ttctgtatcc gattgtatcc gaaatgtatcc caaaagatcc aaccggccaca 720
gttggaggccgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt 780
accccttgcgtt taactatgg gatgttccgtt gcttccggccatgg agacccatcc ttttttttttgcgtt 840
ctgtgcgttta gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt 900
aatgcggatcc ttctgtatcc gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt 960
gttatttttttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt 1020
tcccttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt 1080
ttccggccatgg acggccatggcc ttttttttttgcgtt gtttgcgtt gtttgcgtt 1140
ggccggccatgg acggccatggcc ttttttttttgcgtt gtttgcgtt gtttgcgtt 1200
atgtgtccatgg acggccatggcc ttttttttttgcgtt gtttgcgtt gtttgcgtt 1260
gttggccatgg acggccatggcc ttttttttttgcgtt gtttgcgtt gtttgcgtt 1320
ggccggccatgg acggccatggcc ttttttttttgcgtt gtttgcgtt gtttgcgtt 1380
accccttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt gtttgcgtt 1440
gatgtgtccatgg acggccatggcc ttttttttttgcgtt gtttgcgtt gtttgcgtt 1500

```

-continued

ctcctgctgc	ttcacaaaaa	ggaagatgga	atttggtcca	ctgatattt	aaaggacca	1560
aaaagaacca	aaaataagac	ctttctaaga	tgcgaggcca	agaattatc	tggacgttc	1620
acctgcttgt	ggctgacgac	aatcagact	gatttgacat	tcagtgtcaa	aagcagcaga	1680
ggcttctcg	accccaagg	ggtgcgtgc	ggagctgcta	cactctctgc	agagagagtc	1740
agaggggaca	acaaggagta	tgatgtacta	gtggagtgcc	aggaggacag	tgcctgcca	1800
gctgctgagg	agagtctgc	cattggggc	atggggatg	cgttccaa	gctcaagtt	1860
gaaaactaca	ccagcagctt	cttcatcagg	gacatcatca	aacctgaccc	acccaagaac	1920
ttgcagctga	agccattaaa	gaattctcg	cagggtgggg	tcagctggg	gtaccctgac	1980
acctggagta	ctccacatc	ctactctcc	ctgacattct	cgcttcagg	ccaggccaa	2040
agcaagagag	aaaagaaaaga	tagatcttc	acggacaaga	cctcagccac	ggtcatctgc	2100
cgcggaaatcg	ccagcattag	cgtggggcc	caggaccgc	actatgc	atcttggagc	2160
gaatgggcat	ctgtgcctg	cagtggggc	aggggcagcc	tgctgaccc	cggegacgtc	2220
gaggggaaacc	cggggccat	ggggggcagg	ggccacggg	ggccatgga	cgggccggc	2280
ctgctgtgt	tgcgttct	gggggtgtcc	cttggagggt	ccaaggaggc	atgccccaca	2340
ggcctgtaca	cacacagccg	tgatgtgc	aaaggctgca	acctggggc	gggtgtggcc	2400
cagcctgtg	gagccaacca	gaccgtgt	gagccctgc	tgacagcgt	gacgttctcc	2460
gacgtgtgt	ggcgacccg	ggcgtgcac	ccgtgcaccc	agtgcgtgg	gtctccagagc	2520
atgtcgccgc	cgtgcgtgg	ggccgtatgc	ggcgtgtgc	gtctgcgecta	cggtactac	2580
caggatgaga	cgactggcg	ctgcgaggcg	tgccgcgt	cgagggccgg	ctcgccctc	2640
gtgttctct	gccaggacaa	gcagaacacc	gtgtgcgagg	agtgcggccg	cggecactat	2700
tcggcaggg	ccaaacacgt	gggcccgtg	ctggccctgc	cggtgtgc	ggacaccgg	2760
cgcacgtcc	cgcgtgcac	acgctggggc	gacgcccagg	gagggagat	ccctggccgt	2820
tggattacac	ggccacacc	cccaagggg	tcggacagca	cagcccccc	cacccaggag	2880
cctgaggac	ctccagaaca	agacccata	gccagcacgg	ttggcagggt	gttgaccaca	2940
gtgatggc	gtccccagcc	cgtgtgac	cgaggcacca	ccgacaaact	catecctgtc	3000
tattgtc	tcctggctc	tgtgtgtgt	gggtttgtgg	cctacatagc	cttcaagagg	3060
tgaaaaacca	aaagaacaag	aattttctgg	taagaagccg	ggaaacagaca	acagaagtc	3120
tgaagccaa	gtgaaatcaa	agggtctaa	ttggtcgccc	ggagacatcc	gttgcgttg	3180
cctgcgttt	ggaacgtctg	aagtccacat	acaggacacg	gggcgtgtc	aacccgtct	3240
ctatgcgc	tcagtcacat	cagagacgc	gegctaccca	tttccaaata	gcaatttcgc	3300
cgttgaagag	gaaggggcaaa	accactaa	cttccatctt	tattttcatg	tataatgtgtt	3360
catgcgtatc	ctcccggtgc	cgteagtg	cagagcgcac	atcgccccca	gtccccgaga	3420
agttgggggg	aggggtcgcc	aatttgcacgg	gtgccttag	aaagggtggc	ggggtaaact	3480
ggggaaatgt	tgcgtgtac	tggctccgg	ttttccgg	gggtggggg	gaaccgtata	3540
taagtgcagt	agtcgcgtt	aacgttctt	ttcgcacgg	ttttccgg	agaacacagc	3600
tgaagcttcg	aggggtcgc	atcttcctt	cacggccccc	ccgccttacc	tgaggccg	3660
atccacgcgc	gttgcgtcgc	gttctgcgc	ctcccgctg	ttgtgcctcc	tgaactgcgt	3720
ccggccgttca	ggttaatgttca	aaggttcagg	cgagacccgg	ccttgcgtc	cggtccctt	3780
ggagccctacc	tagactcgc	cggtcttca	cggttgc	gaccctgtt	gtcaactct	3840
acgtctttgt	ttcggtttct	gttctgcgc	gttacagatc	caagctgt	ccggccctca	3900
cctgagatca	ccggccac	catggcttct	taccctggac	accagcatc	tttgcctt	3960
gaccaggcgt	ccagatcccg	ggggccactc	aacaggagaa	ctggccctaa	acccagaaga	4020
cagcaggg	ccactcgagg	gaggttcgt	cagaagatgc	caacccctgt	gagggtgtac	4080
attgtgcac	ttcatgcat	gggcacggcc	accacactc	aactgtgt	ggcactggc	4140
tccaggatgt	acattgtgt	tgtgcctgt	ccaatgcac	actggagat	gtctaggagc	4200
tctgagacca	ttgcacacat	ctacaccacc	cagcacaggc	ttggcaggagg	agaaatctt	4260
gctggatgt	tcgtgtgtt	gtgtgtgt	gcccagatct	caatgggt	ggccctatgt	4320
gtgactgtat	tcgtgtgttgc	tcctcacat	ggaggagggt	ctggcttctc	tcatgcctt	4380
ccacctgtcc	tgaccctgtat	cttgcacaga	caccccttgc	cagccctgt	tggtcaccca	4440
gcagcaaggt	acctctgtgg	ctccatgtac	ccacagggt	tgctgggtt	tgtggccctg	4500
atccctccaa	cctccctgg	caccaacatt	gttttgggg	cactgtctg	agacagacac	4560
atttgacaggc	ttggcaaaagag	gcagagaccc	ggagagagac	ttggacgtgc	catgtggc	4620
gcaatcagaa	gggtgtatgg	actgtgtca	aaactgt	gataccctca	gttggaggg	4680
tcttggagag	aggactgggg	acagtc	ttgtgttca	ggggatgt	4740	
ccccagtc	atgtgttcc	aagggccac	tttggggaca	ccctgttcc	gttgcgttca	4800
gcccctgc	tgctggctcc	atgtgttgc	ctgtacatg	ttttgcgt	ggctctgtt	4860
gttctagcca	agagggtgag	gttcatgt	gttgcatttc	ttggactatg	ccagccctt	4920
gtctggatgt	gagatgtctt	gtgtgttca	acccctggca	ttgtgcac	ccatgtgtac	4980
acccctggca	gcateccccac	catgtgtac	ctggccatgg	ttttgccttgc	ggggatgtt	5040
gaggccaaatc	aaggccgc	actcgacgc	tgatgttgc	gacatgttac	gatacatatg	5100
tgagtttgg	caaaccacaa	ctagaatgc	gtaaaaaaa	tgctttat	gtgaaattt	5160
tgtgtctt	gttttttttgc	taaccattat	aagctgt	aaacaatgt	acaacaacaa	5220
tttgcattat	tttatgttgc	agggttcagg	gggggtgtgg	gagggtttt	aaagcaagta	5280
aaacccctatc	aatgtgttgc	ttggggccgc	ggcccaatttc	ccctatgt	agtctgttta	5340
cgtcgccgtc	actggccgtc	gttttacaac	gtctgtact	ggaaaaccc	ggcttaccc	5400
aacttataatcg	cottgcac	cateccccctt	tcgcacgt	gcgtatagc	gaagaggccc	5460
gcaccgaaatc	ccctccca	acagttgcgc	agectgt	gcaatggg	ggccctgtt	5520
ggggccat	aagcgcggcg	gggtgggtgg	ttacgcgt	cggtacccgt	acacttgc	5580
ggcccttgc	ggccgttctt	ttcggttctt	ttcccttctt	tctgcaccc	ttgcgggt	5640
ttccccgtca	agctctaaat	ctgggggttcc	ctttaggggt	ccgatattgt	gtcttaccc	5700
acctcgaccc	aaaaaaactt	gattaggggt	atgggttgc	tgtgtgttgc	catagccct	5760
atagacgtt	tttcgcctt	tgacgttgc	gtccacgtt	tttaatgt	gactcttgc	5820
ccaaacttgc	acaacactca	accctatctc	ggtcttattt	tttgattat	aagggtttt	5880
ggccat	gcttatttgc	aaaaatgt	tgcttattt	aaaaattt	acgcgttatt	5940
taacaaaata	ttaacgtt	caatgttgc	ggcactttt	ggggaaatgt	gcgcggaaacc	6000
ccttatttgc	tattttctt	aatacattca	aatatgttac	cgctcatg	acaataaccc	6060
tgataatgc	ttcaataata	ttgaaaaagg	aaagatgt	tttcaaca	tttccgttgc	6120
gccttatttgc	ccttttttgc	ggcattttgc	tttgcaccc	agaaacgt	6180	
gtgaaatgt	aaagatgt	tgatgttgc	ggtgcac	tggttacat	cgtactgt	6240

-continued

ctcaacagcg gtaagatcct tgagagttt cgccccgaag aacggtttcc aatgatgagc 6300
 acttttaaag ttctgtatg tggcgcgta ttatcccgtt ttgacgcgg gcaagagcaa 6360
 ctccggcgcc gcatacacta ttctcagaat gacttggtt agtactcacc agtcacagaa 6420
 aagcatcta cggatggcat gacagtaaga gaattatgca gtgtcgccat aaccatgagt 6480
 gataaacactg cggccaaactt accttgcata acgatcgagg gaccgaagg gctaaccgct 6540
 tttttgcaca acatggggga tcatgttaact cgccttgatc gttggaaacc ggagctgaat 6600
 gaagccatac caaacgacga gcgtgacacc acgatgcctg tagcaatggc aacaacgttg 6660
 cgcaaaactat taactggcga actacttact ctagttccc ggcaacaatt aatagactgg 6720
 atggaggcgg ataaagtgc aggacttctt cccttcggc tggctgggtt 6780
 attgtcgata aatctggcgc cggtgcgtt ggttctcgcc gtatcatgc agcactgggg 6840
 ccagatgtta accgccttccg tatecgtagt atctacacga cggggagtc ggcacactat 6900
 gatgaacgaa atagacagat cgctgagata ggtgcctcac tgattaagca ttggtaactg 6960
 tcagaccaag ttatctcata tatactttatg attgatttaa aacttcattt ttaatttaaa 7020
 aggatcttactt tgaatgttctt tttgtataat ctcatgacca aaatccctta acgtgagttt 7080
 tcgttccatc gagcgtcaga ccccgtagaa aagatcaaaag gatcttttgc agatctttt 7140
 tttctgecgcg taatctgtt cttgcaaaaca aaaaaaccac cgctaccacg ggtggttgt 7200
 ttggccggata aagagctacc aacttttttcc cccaaggtaa ctggcttcag cagagcgcag 7260
 ataccaaaaata ctgtttttctt agtgtagccg tagttaggcc accacttcaa gaactctgtta 7320
 gcaccgccta catacctcgc tctgtcaatc ctgttaccag tggctgtgc cagtgcgcgt 7380
 aagtcgtgtc ttacegggtt ggactcaaga cgatagttac cggataaggc gcagcggtcg 7440
 ggctgaaacgg ggggttcgtg cacacagccc agcttggagc gaacgacta caccgaactg 7500
 agataacctac agcgttgatc atgagaaacg cccacgttcc cccaaggaggg aaaggcggac 7560
 aggtatccggg taageggcag ggtcgaaaca ggagacgcga cgaggaggt tccaggggga 7620
 aacgcctgtt atctttatag tctgtcggtt ttgcgcacc ctgtacttga gcgtcgattt 7680
 ttgtgtatgtc ctgtcaggggg gggggccctt tggaaaaaaccc ccagcaacgc ggcctttta 7740
 cgggttcctgg ctttttgcgtt gcctttttgtt cacaatgttctt ttccctgtat 7800
 tctgtggata accgttattac cgcctttagtgc tgatgttgc cgcctcgcc cagccgaacg 7860
 accgagcgcga cgcgttcgtt gagegaggaa gggagagcgc cccaaatagc aaaccgcctc 7920
 tccccccgcg ttggccgatt cataatgtca gctggcaca caggttccc gactgaaag 7980
 cgggcgttgc ggcacacgcga attaatgttgc gtttagtcac tcatttagca ccccaggctt 8040
 tacactttat tttcccgctt cgtatgttgc tgatgttgc gggggatataa caatttcaca 8100
 caggaaacacg ctatgacccat gattacgcca agcgcgtca ttaaccctca ctaaaggaa 8160
 caaaagctgt taattaa 8177

SEQ ID NO: 67 moltype = DNA length = 6349
 FEATURE Location/Qualifiers
 misc_feature 1..6349
 note = Matrice PD1 locus_IL12a_2A_IL12b pCLS30511 full
 sequence
 source 1..6349
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 67
 tcgcgcgttt cgggtgtatgc ggtaaaaacc tctgacacat gcagctcccg gagaeggtca 60
 cagcttgcgt gtaagcggtt gcccggagca gacaaggccg tcagggcgcg tcagcggtt 120
 ttggcgggtt tcggggctgg cttatctatgc cggcatcaga gcatgttgc ctgatgtgc 180
 accatatgcgt tggtggaaata cgcacagatc gctgttggggg aaaataccgc atcaggcgcc 240
 attcgccatt caggctgcgc aactgttggg aaggccgttcc ggttgcggggc ttcttgcgtt 300
 tacggccatgtt ggcggaaagggg ggatgtgttgc caaggccattt aagttgggtt acgcccagggt 360
 ttcccccgttcc accgttgcgtt aaaaacgcgg ccagtgttgcgat cgatgttgcgtt accttgcgaa 420
 tgcattctaga tgactttccca gacaggccctt ggaaccccccc cacccttcc ccagccctgc 480
 tcgttgcgttcc cgaaggggggc aacgcacccatc tcaaccttgcgat cttcttccaaac acatcgagaa 540
 gettcgtgttcc aactatgttgc cgcgttgcgttcc ccaatcgccca caccatgcgttcc 600
 tccccccggggcc cccggccatc cccggccagg actggccgtt ccgtgttccaa caccatgcgttcc 660
 acggccgttgc ctcccatgttcc acgtgttgcgttcc gggccggccggc caatgttgcgttcc 720
 tctgtggggggcc cgggttgcgttcc gttggatattt tgatcttcgc aatgttgcgttcc 780
 gagacgttgc gttccaaaccctt gggcccatgtt gggccctgg gtcgttgcgttcc caccatgcgttcc 840
 cttccacccgttcc cccggccatc ggttgcgttcc cccggccagg actggccgtt ccgtgttgcgttcc 900
 gggttgcgttcc gttggatattt tgatcttcgc aatgttgcgttcc 960
 accttcgttcc gggccatc cccggccatc cccggccagg actggccgtt ccgtgttgcgttcc 1020
 ttccaccatc cccaaaccctt ctggggccgc tcaatgttgcgttcc gttccatgcgttcc 1080
 ctcttagatccatc tttcccttgc actcttgcgttcc agatgttgcgttcc tttccatgcgttcc 1140
 aaaccacccatc agtggggccatc tttcccttgc actcttgcgttcc tttccatgcgttcc 1200
 attccatgcgttcc gacccatc tttccatgcgttcc tttccatgcgttcc 1260
 ttatgttgcgttcc ctttgcgttcc agttagtattt tgatcttcgc aatgttgcgttcc 1320
 tcaagaccatc gaaatgttgcgttcc tttccatgcgttcc 1380
 acatgttgcgttcc agttagtattt tgatcttcgc aatgttgcgttcc 1440
 cacaatccatc tttccatgcgttcc gaaatgttgcgttcc tttccatgcgttcc 1500
 ttcttcatgcgttcc tttccatgcgttcc tttccatgcgttcc 1560
 ctccggccatc cggccatc tttccatgcgttcc tttccatgcgttcc 1620
 accccctggacc tttccatgcgttcc tttccatgcgttcc 1680
 catctccatc tttccatgcgttcc tttccatgcgttcc 1740
 ggttccatgcgttcc tttccatgcgttcc tttccatgcgttcc 1800
 gtatcatgcgttcc gacccatc tttccatgcgttcc tttccatgcgttcc 1860
 tccaaatgttgcgttcc gaaatgttgcgttcc tttccatgcgttcc 1920
 taagccatc tttccatgcgttcc tttccatgcgttcc 1980
 taaaggccatc gaaatgttgcgttcc tttccatgcgttcc 2040
 ctggacgttcc tttccatgcgttcc tttccatgcgttcc 2100
 aaacccatc gaaatgttgcgttcc tttccatgcgttcc 2160

-continued

cagagagagt	cagaggggac	aacaaggagt	atgagtaactc	agtggagtgc	caggaggaca	2220
gtgcctgcc	agctgtgag	gagagtctgc	ccatttaggtt	catgggttat	gccgttcaca	2280
agctcaagta	tgaaaactac	accacgacgt	tcttcatca	ggacatcatc	aaacctgacc	2340
cacccaagaa	cttcgcgtg	aagccattaa	agaattctcg	gcagggtggag	gtcagctggg	2400
agtacccctga	cacccgtgt	actccacat	cctacttctc	cctgacatc	tgcggttcagg	2460
tccaggggcaa	gagcaagaga	gaaaagaaag	ataagatctt	cacggacaag	acctcaggcca	2520
cggtcatctg	ccgaaaaaat	gccgcattt	gcgtgcgggc	ccaggacgc	tactataag	2580
catcttggag	cgaaatggca	tctgtgcct	gcagtggggg	cagaggcagc	ctgtgtaccc	2640
ggggcgcgt	cgaggagaac	ccccggccca	tggggcagg	tgccacccggc	cgccgcattgg	2700
acggggcgc	cgtgtgtgt	ttgtgttcc	tgggggtgtc	ccttgggggt	gccaaggagg	2760
catgccccac	aggccgtgtac	acacacageg	gtgagtgctg	caaagectgc	aacctgggg	2820
agggtgtggc	ccagccgtgt	ggagccaacc	agaccgtgt	tgagccctgc	ctggacacgc	2880
tjacgttttc	cgacgtgtgt	agcgacacgg	agccgtgtca	gcccgtcacc	gagtgcgtgg	2940
gtgtccagag	atgtgcggc	ccgtgtgtgt	aggccgtatg	cgccgtgtgc	cgctggccct	3000
acggctacta	ccaggatgt	acgactgggc	gtgcgtggc	gtgcgcgtg	tgcgaggcgg	3060
getcgccgc	ctgttctcc	tgccaggaca	agcagaacac	ctgtgtcgag	gagtgcggcc	3120
acggcacgt	ttccgacgg	gccaaccgc	tggacccgtg	ctgcgcctgc	accgtgtgcg	3180
aggacacccg	gcgcgcgg	cgcgatgtca	cacgctgggc	cgacgcggag	tgcgaggaga	3240
tccttggccg	ttggattaca	cggttccac	ccccagggg	ctggacacgc	acagccccca	3300
gcacccagga	gcctgaggca	cctccagaac	aagacctcat	agccagacag	gtggcagggt	3360
tggtgaccac	agtgtgtggc	agctcccg	ccgtgtgtac	ccggggcacc	accgacaacc	3420
tcatccctat	ctattgttcc	atccgtgtc	ctgtgtgtgt	gggttgggt	gcttacatag	3480
ccttcaagag	gtgtatgtca	ggggccgtt	aaacccctgt	atcagcttgc	actgtgcctt	3540
ctagttgc	ccatctgtt	gtttggccc	ccccctgtgc	ttcttgcacc	ctggaaagggt	3600
caactccac	tgtcctttcc	taataaaatg	aggaaattgc	atcgattgt	ctgagtaggt	3660
gtcattctat	tcttgggggt	gggggtgggg	aggacagca	ggggggggat	tggaaagaca	3720
atagcaggca	tgctggggat	gggggtgggt	ctatgtacta	tgccgaatc	ggcgacatc	3780
aaagagagcc	tgccccccaga	gctcagggtgt	acaggtgcgg	ctcggaggc	ccccggggcag	3840
gggtgagctg	agccggctct	gggggtgggt	tcccctctc	cacaggatca	ggagtcctag	3900
gtgtcgtaggg	caggggacccc	ccagotccg	tccagggtgtc	tgtctctgcac	ctggggaaatg	3960
gtgaccggca	tctctgttcc	ctagcttgc	aagcacccca	gccccctctag	tctgccttc	4020
cocctgaccc	tgacccttcc	ccctgacccc	gtcttaacc	ctgacettgc	atcgatccc	4080
ggggccgtcg	atgcagagg	cctgatca	agcttggcg	aatcatggtc	atagctgtt	4140
cctgtgtgaa	attgttattcc	gctcaacat	ccacacaacaa	tacgagccgg	aagcataaag	4200
tgtaaagcct	gggggtgcct	atagtgatgc	taacttacat	taattgggt	gctgtactg	4260
cccgctttcc	agtccggaaa	cctgtcg	caagtcatt	aatgaatcgg	ccaaacgcgc	4320
ggggagaggcg	gtttgcgtat	tggggctct	tccgcttcc	cgctcaactg	ctcgctgcgc	4380
tcggtcgtgc	gtctcgccgg	agcgttatac	gctcaactca	aggcggtat	acggttatcc	4440
acagaatcag	gggataaacgc	agggaaagaa	atgtgagca	aaaggccacca	aaaggccagg	4500
aaccgtaaaa	aggccgcgtt	gctggcg	ttccataggc	tccgc	ccccccccc	4560
cacaaaaatac	gacgctcaag	tcagagggtg	cgaaacccga	caggactata	aagataccag	4620
gcgttccccc	ctggacgtc	cctcg	tctctgtgt	cgaccctggc	gttaccgg	4680
tacctgttcc	ccttccccc	tcctgtgt	tcgggg	gtggcg	ctatagtc	4740
tatctcgtt	cggtgttagt	cggtcg	aaagctgggt	gtgtgac	acccttgcgt	4800
cagccgacc	gctgcgcctt	atccgttac	tatcg	tcttgc	agtccaa	4860
gacttacgtc	cactggc	agccactgtt	aacaggat	gcagagcgg	gtatgttag	4920
ggtgtctacag	atgttctgt	gtggggct	aactacgg	acactagaag	aacagtatt	4980
ggtatctcg	ctctgtgt	gccgttacc	tccggggaaa	gagttgggt	ctcttgatcc	5040
ggcaaaacaaa	ccacccgtgg	taggggtgt	ttttttgtt	gcaagcagca	gattacgcgc	5100
agaaaaaaag	gatcttcaaga	agatcttctt	atctttcta	cggggttgc	cgctcgtgg	5160
aacggaaaact	cacgtttaagg	gattttgtc	ataggtt	aaaaaggat	tttacccat	5220
atcttttaa	ataaaaatg	aagtttaaa	tcaatctaa	gtatata	gtaaacttgc	5280
tctgacatgtt	accaatgtt	aatca	gtgtgt	gcacccat	cagcgatctg	5340
tcatccatag	ttgcgtgt	ccccgtgt	tagataacta	cgataccgg	gggttacc	5400
tctggccca	gtgtgttca	gataccgc	gaccgcac	ccgggttcc	agatttata	5460
gcaataaacc	agccacccgg	aaggccc	cgacgtt	gttctgc	tttatccgc	5520
tccatccagt	ctattaattt	ttggggaa	gctagagta	gtatgt	ccgttacccat	5580
tttgcgttac	tttgcgtt	tgatc	atcggtgt	cacgttgc	gttgggtat	5640
gettcatat	gtccgggtt	ccaaacgtat	aggcggtat	catgttgc	atcggtgt	5700
aaaaaaacgg	ttatgttcc	ccgttctcc	atcggtgtca	gaaatgtt	ggccgcgt	5760
ttatctacta	ttgttgc	agcaactgt	aattcttca	ctgtcat	ccatcgat	5820
tgttttctg	tgactgtgt	gtactca	aagtcttac	gagaatgt	tatgcggc	5880
cccgatgtgt	tttgcgtt	gttcc	atcggtgt	cacgttgc	gttgggtat	5940
aaagtgtca	tcattttggaa	acgttgc	ggggcggaaa	tctca	aggatgttgc	6000
tttgcgtt	ttatgttcc	gttcc	atcggtgt	gcacccaa	gtatcttgc	6060
tttgcgtt	tttgcgtt	gttcc	atcggtgt	gatcttgc	atctttact	6120
tttgcgtt	tttgcgtt	gttcc	agcaaaaaca	gttcc	aaaggaaata	6180
agggcgtac	ggaaatgtt	aatactata	cttcc	ttcaatata	ttgaagcatt	6240
tatcagggtt	atgttctat	gagcgatata	atatttga	gtatgtt	aaataaaacaa	6240
atagggtt	ccgcgcacatt	tccccc	gtccac	acgttca	aaccattt	6300
atcatgacat	taacctataa	aaataggcgt	atcac	gaggc	cotttcgt	6349

SEQ ID NO: 68 moltype = AA length = 14
 FEATURE Location/Qualifiers
 VARIANT 5
 note = MISC_FEATURE - Xaa is Ile or Val
 VARIANT 13
 note = MISC_FEATURE - Xaa is Lys, Arg, or Gln
 source 1..14
 mol_type = protein

-continued

```

organism = Human immunodeficiency virus 1
SEQUENCE: 68
LQARXLAYER YLXD                                         14

SEQ ID NO: 69      moltype = AA length = 14
FEATURE          Location/Qualifiers
VARIANT          13
note = MISC_FEATURE - Xaa is Lys, Ala, or Gln
VARIANT          14
note = MISC_FEATURE - Xaa is Asp or His
source           1..14
mol_type = protein
organism = Human immunodeficiency virus 2

SEQUENCE: 69
LQARVTAIEK YLXX                                         14

SEQ ID NO: 70      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = Simian immunodeficiency virus

SEQUENCE: 70
LQARLLAVER YLKD                                         14

SEQ ID NO: 71      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = unidentified
note = Moloney murine leukemia virus

SEQUENCE: 71
LQNRRGLDLL FLKE                                         14

SEQ ID NO: 72      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = unidentified
note = Human T-cell lymphotropic virus

SEQUENCE: 72
AQNRRGLDLL FWEQ                                         14

SEQ ID NO: 73      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = Mason-Pfizer monkey virus

SEQUENCE: 73
LQNRRGLDLL TAEQ                                         14

SEQ ID NO: 74      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = Homo sapiens

SEQUENCE: 74
LQNRRALDLL TAER                                         14

SEQ ID NO: 75      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = Homo sapiens

SEQUENCE: 75
LQNRRGLDML TAAQ                                         14

SEQ ID NO: 76      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein
organism = unidentified
note = Human endogenous retrovirus K

SEQUENCE: 76
LANQINDLRQ TVIW                                         14

SEQ ID NO: 77      moltype = AA length = 14
FEATURE          Location/Qualifiers
source           1..14
mol_type = protein

```

-continued

```

organism = Feline leukemia virus
SEQUENCE: 77
LQNRRGLDIL FLQE

SEQ ID NO: 78      moltype = AA length = 9
FEATURE
source
1..9
mol_type = protein
organism = Human immunodeficiency virus 1
SEQUENCE: 78
GALFLGFLG

9

SEQ ID NO: 79      moltype = AA length = 9
FEATURE
REGION
1..9
note = Synthetic peptide
1..9
mol_type = protein
organism = synthetic construct
SEQUENCE: 79
AGFGLLLGF

9

SEQ ID NO: 80      moltype = AA length = 9
FEATURE
REGION
1..9
note = Synthetic peptide
1..9
mol_type = protein
organism = synthetic construct
SEQUENCE: 80
AGLFLGFLG

```

The invention claimed is:

1. A method for preparing a population of engineered primary human NK or T cells for immunotherapy comprising:
 - providing primary human NK or T cells;
 - introducing an exogenous coding sequence encoding an interleukin selected from IL-15, IL-12, or IL-2 with a sequence-specific endonuclease targeting an endogenous gene into the primary human NK or T cells;
 - cleaving the endogenous gene and inserting the exogenous coding sequence into the endogenous gene such that said interleukin is under transcriptional control of the promoter of the endogenous gene, while disrupting the coding sequence of the endogenous gene,
 - wherein the endogenous gene encodes PD1; and
 - introducing an exogenous coding sequence encoding a chimeric antigen receptor (CAR) or a recombinant TCR into the primary human NK or T cells;
 - wherein said engineered primary human NK or T cells secrete a level of the interleukin sufficient to enhance the antitumor activity of the cells.
2. The method of claim 1, wherein said interleukin is IL-2.
3. The method of claim 1, wherein said interleukin is IL-12.
4. The method of claim 1, wherein said interleukin is IL-15.
5. The method of claim 1, wherein more than 50% of said engineered primary human NK or T cells are TCR negative T-cells and/or more than 50% of said engineered primary human NK or T cells are CAR positive cells.

- 30 6. The method of claim 1, wherein the CAR is an antiCD22 CAR.
7. The method of claim 2, wherein the CAR is an antiCD22 CAR.
8. The method of claim 3, wherein the CAR is an antiCD22 CAR.
- 35 9. The method of claim 4, wherein the CAR is an antiCD22 CAR.
10. The method of claim 5, wherein the CAR is an antiCD22 CAR.
- 40 11. The method of claim 1, wherein the exogenous coding sequence encoding an interleukin is inserted into the middle of the PD1 open reading frame using TALENS having the sequence of SEQ ID NO:20 and 21.
12. The method of claim 2, wherein the exogenous coding sequence encoding an interleukin is inserted into the middle of the PD1 open reading frame using TALENS having the sequence of SEQ ID NO:20 and 21.
- 45 13. The method of claim 3, wherein the exogenous coding sequence encoding an interleukin is inserted into the middle of the PD1 open reading frame using TALENS having the sequence of SEQ ID NO:20 and 21.
14. The method of claim 4, wherein the exogenous coding sequence encoding an interleukin is inserted into the middle of the PD1 open reading frame using TALENS having the sequence of SEQ ID NO:20 and 21.
- 50 15. The method of claim 5, wherein the exogenous coding sequence encoding an interleukin is inserted into the middle of the PD1 open reading frame using TALENS having the sequence of SEQ ID NO:20 and 21.

* * * * *